Republic of the Philippines
Department of Health

Philippines COVID-19 Emergency Response Project (P173877) and Additional Financing Project (P175953)

ENVIRONMENTAL AND SOCIAL MANAGEMENT FRAMEWORK (ESMF)

17 MARCH 2021
Table of Contents

Executive Summary ........................................................................................................................................... 1

1 Introduction and Background ......................................................................................................................... 6
  1.1 Purpose of this Document ......................................................................................................................... 6
  1.2 COVID-19 World Bank Program ............................................................................................................... 7
  1.3 World Bank Programming in the Country Health Sector ......................................................................... 8

2 Project Description ........................................................................................................................................ 9
  2.1 Development Objectives .......................................................................................................................... 9
  2.2 COVID-19 Project Components and Activities ....................................................................................... 9
  2.3 Subcomponent Typology ......................................................................................................................... 10
  2.4 Prohibited/Negative List ......................................................................................................................... 14

3 Policy, Legal and Regulatory Framework ..................................................................................................... 15
  3.1 Philippines Legal Framework relevant to the ESF ................................................................................... 15
    3.1.1 Philippine Environmental Impact Assessment System of 1978 ......................................................... 15
    3.1.2 Republic Act (RA) 6969 —Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990 .................................................................................................................................... 16
    3.1.3 DENR Administrative Order (DAO) 1992-29 established the Implementing Rules and Regulations (IRR) of Republic Act 6969 or Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990 .................................................................................................................................... 16
    3.1.4 Republic Act (RA) 9003 — Ecological Waste Management Act and DENR AO 2001-34 (Implementing Rules and Regulations) ........................................................................................................ 16
    3.1.5 Joint DOH-DENR DAO Order No. 2005-02 – Policies and guidelines on effective and proper handling, collection, transport, treatment, storage and disposal of health care waste ......................................................................................................................... 16
    3.1.6 DAO 2014-02 – Revised Guidelines for Pollution Control Officer Accreditation ............................ 17
    3.1.7 DAO 2013-22 – Revised Procedures and Standards for the Management of Hazardous Wastes 17
    3.1.8 DENR Memorandum Circular (MC) 2020-16 – Amendment of the Interim Guidelines on Issuance of Special Permit to Transport (SPTT) for the Transportation of Hazardous Wastes within the Community Quarantine Period ........................................................................................................ 17
    3.1.9 Memorandum Circular (MC) 2020-20 – Provisional Guidelines on the Hazardous Wastes Management within the Extended Enhanced Community Quarantine ........................................................................................................ 18
    3.1.10 Philippine Clean Air Act of 1999 ........................................................................................................ 18
    3.1.11 Chemical Control Order on Ozone-Depleting Substances ............................................................ 19
    3.1.12 Department of Energy Administrative Order 110 – Procurement of Energy- Consuming Equipment ........................................................................................................................................ 20
    3.1.14 Climate Change Act of 2009 and Relevant DOH Policy Issuances .............................................. 20
3.1.15 Disaster Risk Reduction and Management and Relevant DOH Policies ........................................ 21
3.1.16 DOH Administrative Orders – Hospitals and Other Health Facilities and Clinical Laboratories ................................................................................................................................. 27
3.1.18 Department of Health COVID-19 Interim Guidelines ......................................................... 28
3.1.19 National Policy Issuances on the Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines (NDVP) ............................................................................................................. 29
3.1.20 Issuances on the National Strategic Policy Framework for COVID-19 Vaccine Deployment and Immunization ......................................................................................................................... 29
3.1.21 Other National and DOH Issuances on COVID-19 Vaccination ........................................ 29
3.1.22 Guidelines on Adverse Events Following Immunization (AEFI) .................................... 30
3.1.23 Executive Order no. 121 series of 2020 .............................................................................. 30
3.1.25 Bureau of Food and Drug (BFAD) Circular 16, series of 1999 – Amending BFAD MC No. 22 dated September 8, 1994, regarding Inventory, Proper Disposal, and/or Destruction of Used Vials or Bottles ....................................................................................................................... 31
3.1.27 FDA Circular No. 2020-028 || Reissuance of the Guidelines for the Registration of Drug Products under Emergency Use (DEU) for the Coronavirus Disease 2019 (COVID-19) .................. 32
3.1.28 Guidelines on Adverse Events Following Immunization (AEFI) .................................... 32
3.1.29 Greening and Energy-Efficiency Guidelines of the Department of Health ......................... 32
3.1.30 Labor Legislation .................................................................................................................... 33
3.1.31 Persons with Disabilities (PWDs) ....................................................................................... 37

Occupational Health and Safety .................................................................................................................. 35
Republic Act 11058 – The Occupational Safety and Health Standards Act ........................................ 35
Department of Labor and Employment (DOLE) Department Order no. 13 series of 1998 – Guidelines Governing Occupational Safety and Health in the Construction Industry ................................................................. 35

3.1.32
Republic Act 7277 – An Act Providing For The Rehabilitation, Self-Development And Self-Reliance Of Disabled Person And Their Integration Into The Mainstream Of Society And For Other Purposes 37

Republic Act 11106 – An Act Declaring the Filipino Sign Language as the National Sign Language of the Filipino Deaf and the Official Sign Language of Government in All Transactions Involving the Deaf, and Mandating its Use in Schools, Broadcast Media, and Workplaces 38

Batas Pambansa (BP) bilang 344 – An Act to Enhance the Mobility of Disabled Persons by Requiring Certain Buildings, Institutions, Establishments and Public Utilities to Install Facilities and Other Devices 38

3.1.32 Indigenous Peoples 38

3.1.33 Republic Act 9184 – An Act Providing for the Modernization, Standardization and Regulation of the Procurement Activities of the Government and for other Purposes 39

3.1.34 Executive Order 301 series of 2004 – Establishment of a Green Procurement Program in all Government Agencies 40

3.1.35 GPPB Resolution No. 15, series of 2013 – Approval to Support the Implementation of Sustainable and/or Green Public Procurement Regime in Government 40

3.2 World Bank Environmental and Social Policies 40

3.2.1 ESS1 Assessment and Management of Environmental and Social Risks and Impacts 40

3.2.2 ESS2 Labor and Working Conditions 42

3.2.3 ESS3 Resource Efficiency and Pollution Prevention and Management 43

3.2.4 ESS4 Community Health and Safety 44

3.2.5 ESS7 Indigenous Peoples/Sub-Saharan African Historically Underserved Traditional Local Communities 45

3.2.6 ESS10 Stakeholder Engagement and Information Disclosure 47

3.3 International and Regional Regulations and Guidance 48

3.3.1 Vaccine Introduction Readiness Assessment Tool (VIRAT)/Vaccine Readiness Assessment Framework (VRAF) Integrated Tool 48

3.3.2 World Health Organization 48

3.3.3 Stockholm Convention 50

3.3.4 Kigali Amendment to the Montreal Protocol on Substances that Deplete the Ozone Layer 50

3.3.5 Doha Declaration on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and Public Health 51

4 Environmental and Social Baseline 51

4.1 Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines 52

4.1.1 Shipment and Storage 52

4.1.2 Distribution and Deployment 56

4.1.3 Implementation of Nationwide Vaccination 61

4.1.4 Assessment, Monitoring, and Evaluation 79
4.2 Health Care Waste Management of Infectious Wastes Related to COVID-19 .................85
4.3 Health Care Waste Transporters and Treatment, Storage, and Disposal Facilities (TSDs) ...88
4.4 Training for Implementers on the COVID-19 Vaccination Activities .................................90
4.5 Air Quality and Healthcare Waste Incineration ...........................................................91
4.6 Indigenous Peoples ..................................................................................................91
4.7 Disadvantaged and Vulnerable Groups ......................................................................92
  4.7.1 Persons with Disabilities ......................................................................................92
  4.7.2 Disability-Inclusion in the World Bank’s COVID-19 Response ..............................94
  4.7.3 Gender and Gender-based Violence ...................................................................96
4.8 National Immunization Context ...............................................................................97
4.9 Social and Behavioral Issues on Immunization .......................................................97
4.10 Lessons Learned on the Immunization Roll-out of a Novel Vaccine .......................99
5 Potential Environmental and Social Impacts and Mitigation Measures ..................100
  5.1 Methodology for Assessing Risk and Impacts .........................................................100
  5.2 Risk Summary .......................................................................................................101
    5.2.1 Environmental Risks ..........................................................................................101
    5.2.2 Social Risks ......................................................................................................102
  5.3 Construction Stage .................................................................................................104
    5.3.1 Environmental Risks ........................................................................................104
    5.3.2 Occupational Health and Safety ......................................................................104
  5.4 Operational Stage ..................................................................................................106
    5.4.1 Occupational Health and Safety ......................................................................106
    5.4.2 Healthcare Waste Management at Healthcare Facilities ................................110
    5.4.3 Wastes from COVID-19 Vaccination ...............................................................113
    5.4.4 Labor Rights and Gender .................................................................................113
    5.4.5 Community Health and Safety .......................................................................115
    5.4.6 Social Exclusion ..............................................................................................118
    5.4.7 Gender-Based Violence (GBV) and/or Violence Against Children (VAC) ........119
    5.4.8 Social Stigma ..................................................................................................121
    5.4.9 Cold Chain Operation ......................................................................................123
    5.4.10 Climate-Change Related Risks ......................................................................124
6 Procedures to Address Environmental and Social Issues ........................................127
  6.1 Screening Process ..................................................................................................127
  6.2 Environmental and Social Management Plans ......................................................128
  6.3 Health-care Waste Management ............................................................................129
  6.4 Indigenous Peoples ...............................................................................................129
7 Stakeholder Engagement, Consultation and Disclosure .......................................................... 132
  7.1 Stakeholder Consultations on the Parent Project ................................................................. 133
  7.2 Stakeholder Consultations on the Additional Financing .................................................... 143
  7.3 Priority Eligible Populations for the COVID-19 Vaccination .............................................. 153
  7.4 Monitoring of Adverse Events Following Immunization (AEFI) ......................................... 160
  7.5 National Demand Generation and Communications Plan for COVID-19 Vaccines ............... 162
  7.6 DOH COVID-19 Hotline ........................................................................................................ 168
8 Project Implementation Arrangements, Responsibilities, and Capacity Building ................. 170
  8.1 Implementation Arrangements .............................................................................................. 170
  8.2 Security/ Uniformed Personnel Engagement in COVID-19 Vaccine Delivery and Deployment 176
  8.3 Capacity Building .................................................................................................................. 178
  8.4 Estimated Budget .................................................................................................................... 179
A Abbreviations and Acronyms .................................................................................................... 180
B Labor Management Procedures (LMP) ......................................................................................... 181
C. Labor Management Procedures (LMP) Monitoring Form Template ........................................ 200
D. Code of Conduct and Ethical Standards for Public Officials and Employees ......................... 209
E. Code of Conduct of Public Health Workers ............................................................................. 216
F. Code of Conduct and Ethical Standards for Military Personnel ................................................ 220
G. Philippine National Police (PNP) Ethical Doctrine ................................................................. 222
H. Screening Form for Potential Environmental and Social Risk ................................................... 225
I. Environmental and Social Management Plan Template .............................................................. 235
J. Environmental and Social Management Plan Monitoring Report Template ............................. 242
K. Environmental Codes of Practice (ECOP) Checklist ............................................................... 243
L. Environmental Codes of Practice (ECOP) Monitoring Form Template .................................... 250
M. Infection Control and Waste Management Plan (ICWMP) ...................................................... 251
N DENR- Accredited M501 and M503 Waste Transporters ......................................................... 257
O DENR- Accredited M501 and M503 Waste Treatment, Storage, and Disposal (TSD) Facilities .... 263
P Vaccine Introduction Readiness Assessment Tool (VIRAT)/ Vaccine Readiness Assessment Framework (VRAF) Tool ................................................................................................. 267
Q Resource List: COVID-19 Guidance .......................................................................................... 271
Executive Summary

The Project Development Objective of the COVID-19 Emergency Response Project is to strengthen the Philippines’ capacity to prevent, detect, and respond to the threat posed by COVID-19 and to strengthen national systems for public health preparedness.

The Environmental and Social Management Framework (ESMF). The Project consists of a number of different activities and/or investments (subprojects) for which the risks and impacts cannot be determined until implementation. The ESMF describes the principles, processes, and technical guidance for the Project implementing agencies and their consultants to assess the environmental and social risks and impacts of the Project activities.

This ESMF assists the Department of Health (DOH) in identifying the type of environmental and social assessment that should be carried out for the project activities that involve the construction, expansion, rehabilitation and/or operation of healthcare facilities, and the deployment of a safe and effective vaccine in response to COVID-19, and in developing the environmental and social (E&S) management plans in accordance with the World Bank’s Environmental and Social Framework (ESF).

The ESMF is applicable to all investments under the Project. It aims to (a) assess the potential environmental and social (E&S) risks and impacts of the Project and propose mitigation measures which will effectively address these risks/impacts; (b) establish clear procedures for the E&S screening, review, approval, and implementation of activities; (c) specify appropriate roles and responsibilities, and outline the necessary reporting procedures, for managing and monitoring E&S issues related to eligible activities; (d) identify the training and capacity building needed to successfully implement the provisions of the ESMF; (e) address mechanisms for public consultation and disclosure of project documents as well as redress of possible grievances; and (f) establish the budget requirement for implementation of the ESMF.

Eligible Project Activities. The Project will be national in coverage and scope, and would finance a number of activities that focus on the (i) provision of medical supplies, including personal protective equipment for ICUs, medicines, and ambulance in existing hospitals at national, provincial and local government levels; (ii) provisions to address capacity building needs of the medical service providers and supporting staff training related to COVID-19 emergency preparedness, infection control and medical waste management; (iii) civil works that involve retrofitting existing hospital buildings to include isolation/negative pressure wards; (iv) establishment of point-of-entry quarantine and decontamination facilities; (v) strengthening laboratory capacity at national and sub-national levels; and (vi) procurement and administration of COVID-19 vaccines. The Project will include the Bangsamoro Autonomous Region in Muslim Mindanao (BARMM) and possibly, areas with indigenous peoples.

Potential Environmental Impacts and Risks. Overall, the environmental risk is expected to be moderate due to the nature of associated activities and works and the duration of construction period (less than 12 months). The direct and indirect environmental impacts that may arise due to the project activities are:

---

1 Approximately ten percent of the population in the Philippines is considered indigenous peoples.
(i) **Occupational safety and health risks (OSH).** The profiling and screening of patients prior to vaccination, the administration of the vaccine, and the operation of medical facilities and laboratories involved in COVID-19 response might expose the health care workers to a higher risk of contracting the virus, if infection prevention and control measures are not implemented, and cause unsafe environment. There are also OSH risks to the workers/laborers due to the possible exposure during the construction activities in the health facilities and laboratories. Occupational safety and health risks for cleaners and waste handlers in health facilities and the waste service providers are present due to the possible exposure to infectious health care wastes during the collection, storage, treatment, and disposal stages.

(ii) **Risks from infectious healthcare wastes.** The wastes generated from the COVID-19 testing, other diagnostic procedures, clinical management of patients, and vaccination activities, including waste collection from the health care facility by the facility’s waste handlers and cleaners and by the contracted waste service providers, as well as community health and safety issues related to the handling, transport, treatment, and disposal of the healthcare wastes are present.

(iii) **Logistics and distribution risks of the vaccine.** The COVID-19 vaccines require specific temperatures during storage and distribution to maintain efficacy and safety. Hence, the contraindications and storage and transport condition requirements of the vaccine may pose risks. The availability of cold storage and refrigerated transportation suitable to the temperature needs of the vaccine and in the location of vaccine administration is a potential risk to the Project’s implementation. Relatedly, the cold storage to be procured or rented may contain refrigerants which do not conform to the requirements of the Montreal Protocol, Kigali Agreement, and the chemical control order on ozone-depleting substances (ODS) and contribute to the generation of greenhouse gases (GHG). Other refrigerants are also toxic and flammable and can pose risk to people’s health and safety. Cold storage systems also require huge amount of energy to operate that may have an impact on climate change. The compliance with biosafety protocols during the transport of the vaccines is also a risk, as breakage of the vials and spillage of the vaccine might occur. Similarly, natural disasters such as earthquake, landslide, flooding, storm surge and other climate change-related risks as well as unstable power supply resulting to power outages exist in some areas in the country which may affect the security of the delivery and distribution of the vaccines. The possible hot weather in the country may also have an effect on the efficacy of low temperature-requiring vaccines.

(iv) The small construction activities which are part of the project components, such as the expansion or rehabilitation of existing buildings and facilities, pose occupational health and safety risks to the workers. The project will include limited civil works such as small retrofitting activities on existing premises and there will be no land acquisition and involuntary resettlement involved.
Potential Social Impacts and Risks. There are substantial risks related to the direct and indirect social impacts of the eligible activities. These risks can be mainly classified as (i) biosafety issues, (ii) case management of population for vaccination, (iii) regulatory measures, (iv) community health and safety, (v) affordability, social inequity, and risk of exclusion, (vi) stigma, discrimination, and vaccine acceptance; and (vii) misinformation, lack of information, and disinformation:

i. **Biosafety Issues of the vaccine.** Due to the novelty and relatively shorter timeframe of the development and clinical trials of the COVID-19 vaccine, the communities may have fear and apprehension on its scientific integrity, efficacy, and safety. The contraindications and storage and transport condition requirements of the vaccine may pose risk. Transparency on the vaccine information and manufacturer credibility are important considerations for the public. Misinformation on the adverse health effects of vaccine is also a risk which should be addressed through an effective risk communication strategy.

ii. **Case management of population for vaccination.** There are risks of contraindications and adverse health effects as result of improper or inadequate profiling and screening of individuals prior to vaccination. There is also a risk of not completing the vaccine dose/shots due to the individual's apprehension and/or schedule mismanagement. The data management of the vaccination program, including the establishment of good surveillance system and schedule monitoring, are also risks. With the use of more than one vaccine during the immunization period, close monitoring of adverse events in vaccinated individuals using information technology, i.e., digital tracking system should be conducted. As the possibility of adverse effects of the vaccine is a risk, tracking of health effects in vaccinated individuals and follow-up assessments should be conducted. Moreover, since there will be collection of information of the vaccinees, and the data will be subject to various processing and storage procedure, considering as well as the authorized access and the data users, information security and data privacy are risks.

iii. **Regulatory measures.** Due to the global demand for the vaccine and the limited vaccine production, access to the COVID-19 vaccines is a risk. The conduct of strict regulatory measures should be ensured in view of the novelty of the vaccine. Regulation and access concerns should be equally taken into consideration. Moreover, the work of relevant bodies such as the Food and Drug Administration (FDA), the National Immunization Technical Advisory Group (NITAG), and the Health Technology Assessment Committee (HTAC) should be continually aligned and synchronized to ensure the expeditious national approval of the vaccines.

iv. **Community health and safety.** The vaccine administration may also lead to crowding and violation of physical distancing measures, increasing the risk of exposure of the health workers, the vaccinees, and the community, especially the residents within the vicinity of the immunization site. Thus, compliance to minimum public health standards is strongly advised. Infectious health care wastes generated from the vaccination and other COVID-19-related responses pose risk to community health and safety if not handled, transported, treated,
and disposed of according to the proper health care waste management practices. Hospital visitors and other non-COVID-19 patients may also be exposed to the virus as well as the workers when establishing or upgrading health facilities. There is also a risk of not completing the vaccine dose/shots due to the individual’s apprehension and/or schedule mismanagement.

v. **Affordability, social inequity, and risk of exclusion.** The accessibility of COVID-19 vaccines due to its price is a risk. Due to the novelty and urgent need of the vaccine, there is a risk in price regulation and compliance with fair trade guidelines. Although the national government has already identified its eligible population to be immunized from 2021 – 2023, strict adherence to this list to ensure that the most-at-risk are the ones vaccinated first is a risk. There is an indirect risk of social exclusion, in particular, the most vulnerable and marginalized groups such as the indigenous peoples in remote areas from access to the COVID-19 information, treatment, and vaccines, and also the sexual and gender minorities (especially transgender people) or refugees. The elderly, those with underlying medical conditions, and people living with disability, though included in the priority populations to be vaccinated as identified in the WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply², may have limited access to the vaccines due to reduced mobility. The vulnerable groups may also be excluded from coverage of the national program and local responses to COVID-19. The vaccine distribution and deployment may also exclude populations based on geographical distribution, i.e., those in far-flung areas, and on socioeconomic status, such as less access for the marginalized.

vi. **Stigma, discrimination, and vaccine acceptance.** The fear and apprehension of individuals and communities on the scientific integrity, efficacy, and safety of the COVID-19 vaccines may lead to people refusing vaccination. The vaccine acceptance may also be affected by the country’s previous experience with the Dengvaxia vaccination. The possibility of having COVID-19 may also cause individuals to hide symptoms, avoid getting tested, and reject hygiene measures, which could lead to further spread of the virus. The health workers involved in the vaccine administration activities may face discrimination and harassment when going back to their communities due to people’s fear in contracting the virus, frustrations over medical care, or misinformation.

vii. **Misinformation, lack of information, and disinformation.** Misinformation and disinformation on COVID-19 and the adverse health effects of vaccines and hearsays on the conspiracy theories and underlying political agenda on the vaccines are widespread. The information materials on COVID-19 and the vaccine to be developed could exclude the most vulnerable or be developed in a way that is not sensitive to the needs and access of these different groups. Messages on COVID-19 and the vaccine may also not be in the language appropriate and may

---

Procedures to Address Environmental and Social Issues. The ESMF provides a screening tool for potential project activities to allow determination of potential environmental and social issues. The screening process identifies possible instruments, e.g., Environmental and Social Management Plan (ESMP), Environmental Codes of Practice (ECOP), to be applied during Project implementation, based on subproject typology. These issues will also be addressed through relevant capacity building activities, observance of the labor management procedures and environmental and social management plans for project sites, conduct of community consultations, and active observance of the Grievance Redress Mechanism. The Stakeholder Engagement Plan includes provisions for engaging affected and interested stakeholders throughout the project implementation. Measures to address concerns of vulnerable groups, including persons with disabilities and indigenous peoples, are included in the ESMF and SEP.

The National Health Care Waste Management Program in healthcare facilities (HCF) considers the HCF staff and waste management service providers and the community health and safety issues related to the handling, transport, and disposal of healthcare wastes, which are addressed through the ESMF. To ensure the safety of the vaccines to be procured, the vaccine regulatory approval of the Stringent Regulatory Authorities (SRAs) identified by the World Health Organization will be required. Appropriate messages are being developed under the risk communication plan to address the vaccine safety and identification of priority population concerns of communities.

The DOH Health Promotion Bureau (HPB) has developed key messages on COVID-19 information, prevention, and treatment through its BIDA Solusyon Campaign. A Communications Campaign Plan will also be developed by the DOH-HPB for the COVID-19 immunization program. It will have a whole-of-government, whole-of-system, and whole-of-society approach which will encompass general information on (i) COVID-19 and the need for sanitation and hygiene practices, (ii) COVID-19 vaccine basic information, (iii) trials results and procurement, and (iv) vaccine program roll-out. The WHO Risk communication and community engagement readiness and response to coronavirus disease (COVID-19) released on 19 March 2020 will also be used as reference in the development of messages and planning of risk communication and community engagement (RCCE) activities.

Serial obtaining of informed consent from the identified vaccinees and counselling shall be conducted prior to the administration of the COVID-19 vaccine. The profiling and screening of candidate individuals to be vaccinated should be performed so as to avoid the risk of vaccine contraindications. A comprehensive data management system is also needed to support the profiling, screening, and scheduling to address the risk of individuals not completing the required shots/doses of the vaccine. Coordination with the local government units as well as the uniformed personnel will be done to assist in crowd management and for the successful conduct of the National Deployment and Vaccination Program.

Institutional Arrangement for ESMF implementation. The Department of Health (DOH) shall be responsible for the coordination, management, and implementation of the project at the national

---

and sub-national levels including financial management, procurement, and environmental and social management. The Project’s implementation shall be mainstreamed in the DOH processes and shall involve a Project Management Unit headed by the Bureau of International Health Cooperation (BIHC) under the Office of the Undersecretary for Health Policy and Systems Development Team (HPSDT). This has been strengthened by the recruitment of additional staff responsible for environmental and social management.

The COVID-19 vaccination activities will also be implemented in accordance with the directives of the COVID-19 Vaccine Cluster Organizational Structure. The Inter-Agency Task Force on the Management of Emerging Diseases is Chaired by Secretary Francisco Duque III of the DOH while the National Task Force Against COVID-19 is Chaired by Secretary Delfin Lorenzana of the Department of Defense. Secretary Carlito Galvez, Jr., Presidential Adviser on the Peace Process, is the Chairperson of the National Incident Command and COVID-19 Vaccine Cluster (Philippine National Vaccine Roadmap or PNVR). Undersecretary Leopoldo Vega of the DOH is the Chairperson of the Response Cluster while the National Economic and Development Authority (NEDA) is the Chair of the Recovery Cluster. Task Groups and Sub-Task Groups were also created for the various aspects of the vaccination activities, as detailed in Chapters 7 and 8.

1 Introduction and Background

1.1 Purpose of this Document

This Environmental and Social Management Framework (ESMF) has been prepared to assess and manage the environmental and social risks and impacts of the Philippine COVID-19 Emergency Response Project. A framework approach is chosen as the specific locations and details of the sub-projects will not be known until implementation. The ESMF assists the DOH in identifying the type of environmental and social assessment that should be carried out for projects that involve the construction, expansion, rehabilitation and/or operation of healthcare facilities, and the deployment of a safe and effective vaccine in response to COVID-19, to the extent possible and based on existing information, the environmental and social management approach that should be taken at the subproject level and the E&S management plans to be developed, in accordance with the World Bank Environmental and Social Framework (ESF).

The purpose of the ESMF is to guide DOH and other proponents on the environmental and social screening, assessment, and management of specific project activities during implementation. The document also provides guidance on the preparation of location specific Environmental and Social Management Plans (ESMPs), when needed, in accordance with the ESF.

Additional financing will be provided to support the costs of expanding activities of the Philippines COVID-19 Emergency Response Project (P173877, the parent project) to enable affordable and equitable access to COVID-19 vaccines and help ensure effective vaccine deployment in the country through enhanced vaccination system and to further strengthen preparedness and response activities under the parent project for additional US $ 300 million. The Parent Project

---

ESMF have been updated to reflect the activities under the Additional Financing and the identified issues related to COVID-19 response based on guidance provided by the Bank.

1.2 COVID-19 World Bank Program

An outbreak of the coronavirus disease (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) has been spreading rapidly across the world since December 2019, following the diagnosis of the initial cases in Wuhan, Hubei Province, China. Since the beginning of March 2020, the number of cases outside China has increased thirteenfold and the number of affected countries has tripled. On March 11, 2020, the World Health Organization (WHO) declared a global pandemic as the coronavirus rapidly spreads across the world. As of March 26, 2020, the outbreak has resulted in an estimated 416,686 cases and 18,589 deaths in 197 countries and territories. COVID-19 is one of several emerging infectious disease (EID) outbreaks in recent decades that have emerged from animals in contact with humans, resulting in major outbreaks with significant public health and economic impacts. The last moderately severe influenza pandemics were in 1957 and 1968; each killed more than a million people around the world. Although countries are now far more prepared than in the past, the world is also far more interconnected, and many more people today have behavior risk factors such as tobacco use and pre-existing chronic health problems that make viral respiratory infections particularly dangerous.

With COVID-19, scientists are still trying to understand the full picture of the disease symptoms and severity. Reported symptoms in patients have varied from mild to severe, and can include fever, cough, and shortness of breath. In general, studies of hospitalized patients have found that about 83% to 98% of patients develop a fever, 76% to 82% develop a dry cough and 11% to 44% develop fatigue or muscle aches. Other symptoms, including headache, sore throat, abdominal pain, and diarrhea, have been reported, but are less common. While 3.7% of the people worldwide confirmed as having been infected have died, WHO has been careful not to describe that as a mortality rate or death rate. This is because in an unfolding epidemic it can be misleading to look simply at the estimate of deaths divided by known cases so far. Hence, given that the actual prevalence of COVID-19 infection remains unknown in most countries, it poses unparalleled challenges with respect to global containment and mitigation. These issues reinforce the need to strengthen the response to COVID-19 across all IDA/IBRD countries to minimize the national and global risks and impacts posed by this disease.

The World Bank is providing support to Governments for preparedness planning to provide optimal medical care, maintain essential health services and to minimize risks for patients and health personnel (including training health facilities staff and front-line workers on risk mitigation measures and providing them with the appropriate protective equipment and hygiene materials). As COVID-19 places a substantial burden on inpatient and outpatient health care services, support will be provided for a number of different activities, all aimed at strengthening national health care systems, including systems for the deployment of safe and effective COVID-19 vaccine.

---

5 https://www.who.int/emergencies/diseases/novel-coronavirus-2019
1.3 World Bank Programming in the Country Health Sector

The project is aligned with the World Bank Group strategic priorities, particularly the WBG’s mission to end extreme poverty and boost shared prosperity. The Program is focused on preparedness which is also critical to achieving Universal Health Coverage. It is also aligned with the World Bank’s support to national plans and global commitments to strengthen pandemic preparedness through three key actions under Preparedness: (i) improving national preparedness plans including organizational structure of the government; (ii) promoting adherence to the International Health Regulations (IHR); and (iii) utilizing international framework for monitoring and evaluation of IHR.

The economic rationale for investing in the MPA interventions is strong, given that success can reduce the economic burden suffered both by individuals and countries. The project complements both WBG and development partner investments in health systems strengthening, disease control and surveillance, attention to changing individual and institutional behaviour, and citizen engagement. The project contributes to the implementation of IHR (2005), Integrated Disease Surveillance and Response (IDSR), and the World Organisation for Animal Health (OIE) international standards, the Global Health Security Agenda, the Paris Climate Agreement, the attainment of Universal Health Coverage and of the Sustainable Development Goals (SDG), and the promotion of a One Health approach.

The Project supports Specific Objective #4 in the Philippines’ National Objectives for Health 2017-2022 that strives to increase access to quality essential health products and services. This includes working toward a resilient health system that has the capacity to absorb, adapt, and transform when exposed to a shock such as pandemics, natural disasters or armed conflict and still retain the same control on its structure and functions. The objective is to enable local government units (LGUs) to mobilise communities to implement Disaster Risk Reduction and Management in Health (DRRM-H), which will be institutionalized in all levels of governance by: (1) developing and implementing DRRM-H plans, (2) organizing trained and equipped health emergency response teams, (3) ensuring availability and accessibility of health emergency commodities, and (4) ensuring functionality of Operation Centers (OPCEN).
2 Project Description

2.1 Development Objectives

The Project objectives are aligned with the results chain of the COVID-19 Strategic Preparedness and Response Program (SPRP). The project development objective (PDO) is to strengthen the Philippines' capacity to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. Three PDO level indicators are proposed:

- Percentage of hospitals with personal protective equipment and infection control products and supplies according to DOH requirements, without stock-outs in preceding one month;
- Percentage of designated laboratories with COVID-19 diagnostic equipment, test kits, and reagents, without stock-outs in preceding one month;
- Number of acute healthcare facilities with isolation capacity according to DOH established standards;
- Percentage of health workers received COVID vaccine as per government’s plan;
- Percentage of project- targeted population given full dose of COVID-19 vaccination;
- Percentage of hospitals designated as vaccination sites in project areas having adequate and functioning cold chain equipment (CCE) maintaining the temperature required for the COVID-19 vaccine assigned;
- Percentage of project-targeted vaccinated population who rated as satisfactory the COVID-19 vaccination services received;
- Percentage of project-targeted population reporting adverse event following immunization (AEFI) having received additional care and free treatment; and
- Eligibility for vaccination criteria include barangay health workers (BHWs) among priority group (yes/no).

The risk profiling for the vaccinees will include data collection and disaggregation based on sex, age, indigent status (per DSWD guidelines), indigenous group or community (IP), and presence of any disability.

Additional financing will be provided to support the costs of expanding activities of the Philippines COVID-19 Emergency Response Project (P173877, the parent project)\(^9\) to enable affordable and equitable access to COVID-19 vaccines and help ensure effective vaccine deployment in the country through enhanced vaccination system and to further strengthen preparedness and response activities under the parent project for additional US $ 300 million.

2.2 COVID-19 Project Components and Activities

The Project will finance a broad range of both immediate and near-term priority health sector activities which will include the medical facilities refurbishment and procurement of health care

equipment and ambulances, personal protective equipment (PPE), COVID-19 vaccines, and medical consumables that constitute priorities of the Government of the Philippines (GoP) national response to the COVID-19 pandemic. In particular, this will include establishing testing and quarantine facilities at six major international airports in Luzon, Visayas and Mindanao administrations, 21 first-line decontamination facilities at international airports, strengthening the national reference laboratories as well as sub-national and public health laboratories for COVID-19 analysis, refurbishing and establishing negative pressure isolation rooms in about 70 DoH and 30 UHC implementation site public hospitals, extensive provision and training on use of PPE, about 150 land and 10 sea ambulances, COVID-19 test kits, and an array of diagnostic and life support equipment (ventilators, oxygen machines, cardiac monitors, infusion pumps, portable x-ray machines, PCR equipment, dialysis machines).

The Project will be national in scope, supporting the existing network of the health care facilities and services in the Philippines, and providing support to immediate response, e.g., testing, quarantine, decontamination and treatment, and immunization, as well as mid-term activities such as completion of construction of the national reference laboratory complex. The Project will include the Bangsamoro Autonomous Region in Muslim Mindanao (BARM) and possibly, areas with indigenous peoples. Approximately ten percent of the population in the Philippines is considered indigenous peoples. They live in several regions but are particularly concentrated in the mountains of Northern and Central Luzon as well as in the islands of Mindanao.

Refurbishment and civil works are expected to be of small scale, distributed throughout the health care network providing COVID-19 response, and will take place within the existing compounds of the health care facilities or as designated by the DOH or the National Task Force Against COVID-19.

Despite recent progress, the Philippines remains one of the countries most affected by the COVID-19 in East Asia and Pacific, rendering vaccine purchase and deployment a national priority. With the availability of vaccines, the Philippines has now an opportunity to add a significant new layer to its COVID-19 emergency response. Procuring and administering vaccines is critical to reducing mortality from COVID, opening the economy in earnest and arresting the decline in GDP, employment and incomes. Hence, Additional Financing (AF) was sought by the country.

The AF will form part of an expanded health sector response to the COVID-19 pandemic. AF is envisioned to enable affordable and equitable access to COVID-19 vaccines and help ensure effective vaccine deployment in the country through an enhanced vaccination system and to further strengthen preparedness and response activities under the parent project for additional US $ 500 million.

2.3 Subcomponent Typology

The project involves two distinct phases: a COVID-19 emergency response (Component 1); and a mid-term initiative to strengthen laboratory capacity to support emerging infectious diseases (EIDs) (Component 2). In addition, the project includes a Management/Monitoring and Evaluation component (Component 3), and Contingent Emergency Response Component or CERC (Component 4).

The environmental and social management approaches to Component 1 and 2 will be governed by the urgency of the interventions. Activities under Component 1 will be undertaken in an unpredictable environment determined by the extent of the COVID-19 outbreak in the
Philippines, the capacity of the health system and the duration of the pandemic. Environmental and social management measures for Component 1 will need to be adaptable to the circumstances, with the priority necessarily being the public health risks of the virus. Component 2 activities will be undertaken in an orderly and predictable manner, allowing environmental and social management measures to be better calibrated.

The proposed additional US$500 million IBRD loan will support the scale-up of activities for vaccination. The changes proposed for the AF entail expanding the scope and scale of activities under the PCERP, and there will be no changes to the overall design. However, there will be changes to sub-components under Component 1 to include activities on deployment of vaccines. The PDO will remain unchanged as the proposed activities to be funded under the AF are aligned with the original PDO. The closing date of the AF will remain aligned with the closing date of the parent project, i.e., December 29, 2023.

**Component 1: Strengthening Emergency COVID-19 Health Care Response (Total US$ 581,000,000):** The aim of this component is to strengthen essential health care service delivery system to be able to respond to a surge in demand as a result of anticipated rise in the number of COVID-19 cases in the coming months. As COVID-19 will place a substantial burden on inpatient and outpatient health care services, support will be provided to equip selected health facilities prioritized by DOH for the delivery of critical medical services and to cope with increased demand.

Health system strengthening efforts will therefore focus on provision of medical and laboratory equipment, PPE, medical supplies as well as essential inputs for treatment such as oxygen delivery systems and medicines to selected hospitals and health facilities. Local containment will be supported through the establishment of local temporary isolation units. The component will also finance requirements of infrastructure of quarantine facilities. It is anticipated that any construction involved under this component will be conducted at existing facilities; activities requiring land acquisition or involuntary resettlement are not eligible.

This component also supports the Department of Health in preparing a guidance note on standard design for hospital isolation and treatment centers to manage Severe Acute Respiratory Infections (SARI) patients that will be used in health facilities across the country to ensure standard and quality of COVID-19 health care services. The component has three sub-components. The scope of Component 1: Strengthening Emergency COVID-19 Health Care Response (current allocation: US$95.5 million; revised allocation: US$581 million) will be scaled up to support COVID-19 vaccines purchase. Component 1 will be revised as follows:

(a) **Sub-component 1.1. Provision of medical and laboratory equipment and reagents**

(current allocation: US$34.3 million; revised allocation: US$ 34.5 million): This sub-component will support selected DOH hospitals and provincial hospitals with laboratory equipment (e.g. Polymerase Chain Reaction machines), test kits, reagents, as well as to upgrade diagnostics and treatment of COVID-19 infection capacity through procurement of such intensive care unit equipment and devices as mechanical ventilators, cardiac monitors, portable x-ray, extracorporeal membrane oxygenation (ECMO) machine, portable oxygen generator machine, and continuous positive airway pressure (CPAP). The sub-component will also support provision of oxygen, emergency beds, laboratory

---

10 Laboratory support under Sub-Component 1.1 is short-term and includes PCR machines and test kits for selected DOH hospitals and provincial hospitals. Component 2 supports strengthening of reference laboratories at both national and sub-national levels to address EIDs in the short and medium term.
reagents, and waste management facilities. This subcomponent will also support short trainings on the use of equipment, devices, and tests for health providers and technicians; and to support the necessary logistics and supply chain to ensure that the equipment will reach frontline health facilities without delays. No new additional activities are proposed but the amount has been revised to be aligned with updated costing of activities by the DOH.

(b) **Sub-component 1.2. Provision of medical supplies, including Personal Protective Equipment (PPE), COVID-19 vaccines, medicines, and ambulance (current allocation: US$46.6 million; revised allocation: US$21.3 million)**: This subcomponent will support the health system with supplies including PPE such as masks, goggles, gloves, gowns, etc. It will also support medical counter measures and medical supplies for case management and infection prevention, through the procurement of COVID-19 vaccines, drugs such as antivirals, antibiotics, and essential medicines for patients with co-morbidity and complications such as CVDs and diabetes, as well as assistance to support the Borrower’s advance purchase mechanisms. This subcomponent will also support short trainings on the use of medical supplies for health providers and technicians as needed; and support to the necessary logistics and supply chain to ensure that the medical supplies and PPE will reach frontline health facilities without delays. Small part of this sub-component may also support ambulance vehicles to address COVID-19 response, as needed. The AF supports COVID-19 vaccines purchase through this sub-component.

(c) **Sub-component 1.3. Enhancing isolation/quarantine facilities (current allocation: US$14.5 million; revised allocation: US$25.2 million)**: This subcomponent will support the establishment, construction, retrofitting/refurbishment of quarantine facilities in major points of entry, increase number of regular isolation rooms in DOH and provincial hospitals as well as establishment of negative pressure isolation rooms in DOH and provincial hospitals. It will also support setting up of first line decontamination facilities in international airports (holding areas) as well as establishing isolation tents for triaging in health facilities. The increased amount for the component restores financing which had been re-allocated to sub-component 1.2 to finance COVID-19 vaccines during the December 2020 restructuring.

(d) **Sub-component 1.4. Deployment of COVID-19 vaccines** (new sub-component, financed by counterpart funding from the GOP: US$155.5 million). The sub-component is financed primarily through the GOP’s counterpart funding to support the deployment of World Bank-financed and eligible COVID-19 vaccines. The sub-component will finance planning and management of the COVID-19 vaccines procured by loan proceeds from the AF and deemed eligible by the World Bank, as part of the national COVID-19 vaccination campaign, through enhancing systems and capacity for planning, regulation, and M&E. In addition, the sub-component will finance safe and effective deployment of COVID-19 vaccines procured by loan proceeds from the AF and deemed eligible by the World Bank, including delivery, cold chain and logistics system, disposal of healthcare wastes, risk and communication, as well as surveillance and adverse events monitoring.
Component 2: Strengthening laboratory capacity at national and sub-national level to support Emerging Infectious Diseases (EIDs) Prevention, Preparedness, and Response (Total US$ 11,500,000): The component will support the establishment of national reference laboratories as well as selected subnational and public health laboratories. It will include improving, retrofitting, and refurbishing national reference laboratory – Research Institute for Tropical Medicine (RITM) as well as six sub-national and public health laboratories in Baguio, Cebu, Davao, Surigao City, and Manila. The sub-component may also support constructing and expanding laboratory capacity in priority regions that currently do not have necessary laboratory capacity. The sub-component will also support necessary laboratory equipment, laboratory supplies, reagents, as well as capacity building for relevant laboratory staff. It is anticipated that any construction involved under this component will be conducted at existing facilities, and that no new land acquisition or involuntary resettlement are expected.

Component 3: Implementation Management and Monitoring and Evaluation (Total US$ 7,500,000):

Project Management. The component will support the Department of Health (DOH) as the implementing agency of the project. DOH will be responsible for the coordination, management, and implementation of the project at the national and sub-national levels, financial management and procurement. The project will be implemented through mainstream DOH processes and will not involve a parallel project implementation unit or secretariat. This will be strengthened by the recruitment of additional staff/consultants responsible for overall administration, procurement, and financial management under country specific projects. To this end, the Project would support costs associated with project coordination, management, and implementation. This component will also support costs related to the management of environmental and social risks under the Bank’s ESF, including the implementation of this ESMF and Stakeholder Engagement Plan (SEP).

The implementation arrangements of the Parent Project will be adjusted to enhance the capacity of DOH for implementation related to vaccine procurement, cold chain strengthening, and vaccination delivery support, as well as human resource strengthening in risk communication and community mobilization and M&E. Additional expertise and capacity will also be added as required by the additional financing. Specifically, the COVID-19 vaccination initiatives will be strengthened by the development of the Vaccine Delivery and Distribution Manual and National Deployment and Vaccination Plan (NDVP) and the hiring of a (i) Vaccine Specialist, (ii) M&E Specialist, and a (iii) second Procurement Specialist.

Monitoring and Evaluation (M&E). This component would also support monitoring and evaluation of project implementation, prevention and preparedness, building capacity for clinical and public health research, and joint learning across and within countries. Furthermore, the M&E includes a mechanism to review the capacity of the national health systems to deploy vaccines universally and to reach isolated and marginalized communities and those difficult to reach. It will include the maintenance of daily records documenting who received the vaccine from which vial as well records of any adverse vaccination effects. The M&E system will include data and information disaggregated by gender, demography, race-ethnicity, location-residence, socioeconomic status, and disability. As may be needed, this component will also support third-party monitoring of progress and efficient utilization of project investments.

11 Subnational and public health laboratories include (i) Lung Center of the Philippines (QC); (ii) San Lazaro Hospital (Manila); (iii) Baguio General Hospital (Baguio); (iv) Vicente Sotto Memorial Medical Center (Cebu); (v) Caraga Regional Hospital (Surigao City); (vi) Southern Philippines Medical Center (Davao).
Component 4: Contingent Emergency Response Component (CERC) (US$0): In the event of an Eligible Crisis or Emergency, the project will contribute to providing immediate and effective response to said crisis or emergency. A zero-value component has been included to ensure funds can be deployed through the project depending on the specific needs that may arise.

Project Activities: Table 1 lists the goods, services, and works that will be financed under the project which will be deployed variously to Department of Health (DOH) hospitals, provincial hospitals, and local government unit (LGU) hospitals as specified.

**Table 1.1. List of Goods, Services and Works**

<table>
<thead>
<tr>
<th>Goods*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive Care Unit (ICU) equipment - mechanical ventilator, cardiac monitor, closed-circuit apparatus, suction pump, portable x-ray, dialysis machine (70 DOH hospitals)</td>
</tr>
<tr>
<td>Polymerase Chain Reaction (PCR) Machines (70 DOH hospitals; 85 Provincial Hospitals)</td>
</tr>
<tr>
<td>Real Time (RT-PCR) Nucleic Acid Detection Kits</td>
</tr>
<tr>
<td>Personal protective equipment (300,000 sets)</td>
</tr>
<tr>
<td>Ambulances (approximately 180 vehicles plus 10 water ambulances)</td>
</tr>
<tr>
<td>COVID-19 vaccines</td>
</tr>
<tr>
<td>Cold storage and refrigerated transportation of the COVID-19 vaccines***</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Services**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community outreach</td>
</tr>
<tr>
<td>Training and capacity building for health care personnel and relevant workers</td>
</tr>
<tr>
<td>Support to project implementation and monitoring</td>
</tr>
<tr>
<td>Waste collection, treatment, and disposal of the health care wastes generated from the vaccination***</td>
</tr>
<tr>
<td>Rental of cold storage and refrigerated transportation of the COVID-19 vaccines***</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Works*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strengthen capacity of sub-national and public health laboratories (6 facilities)</td>
</tr>
<tr>
<td>Research Institute for Tropical Medicine (RITM) Biosafety Level (BSL) 3 Lab and National Reference Laboratory (NRL) Complex</td>
</tr>
<tr>
<td>Point-of-Entry Quarantine Facilities (Luzon (1), Visayas (2) and Mindanao (3))</td>
</tr>
<tr>
<td>First line decontamination facilities at International Airports (Manila (Pasay), Clark, Bicol, Cebu, Kalibo, Cagayan de Oro, Davao)</td>
</tr>
<tr>
<td>Regular isolation rooms in DOH and Provincial hospitals</td>
</tr>
<tr>
<td>Negative pressure isolation rooms in DOH and Provincial hospitals</td>
</tr>
<tr>
<td>Construction of warehouse facilities for the storage of the COVID-19 vaccines***</td>
</tr>
</tbody>
</table>

Source:  
*Philippines COVID-19 Emergency Response Project Procurement Plan (May 2020)  
**Project Appraisal Document (April 23, 2020)  
*** For Discussion/Confirmation

2.4 Prohibited/Negative List

The Project will not involve activities with high potential environmental and social risks. Such activities which are not eligible for financing include but are not limited to the following:

- Activities that have potential to cause any significant loss or degradation of critical natural habitats whether directly or indirectly.
- Activities that could adversely affect forest and forest health.
• Activities that could affect sites with archaeological, paleontological, historical, religious, or unique natural values.
• Activities that will result in the involuntary taking of land, relocation of households, loss of assets or access to assets that leads to loss of income sources or other means of livelihoods, and interference with households’ use of land and livelihoods.
• Use of goods and equipment on lands abandoned due to social tension/conflict, or the ownership of the land is disputed or cannot be ascertained.
• Use of goods and equipment to demolish or remove assets, unless the ownership of the assets can be ascertained, and the owners were consulted and had concurred
• Use of goods and equipment involving forced labor, child labor, or other harmful or exploitative forms of labor.
• Use of goods and equipment for activities that would adversely affect indigenous peoples.
• Use of goods and equipment for military or paramilitary purposes aside from vaccination activities involving these personnel

3 Policy, Legal and Regulatory Framework

3.1 Philippines Legal Framework relevant to the ESF

3.1.1 Philippine Environmental Impact Assessment System of 1978

The Philippine Environmental Impact Assessment System of 1978 which was set forth by Presidential Decree (PD) 1586 is the primary law that establishes the Philippine Environmental Impact Statement (EIS) System. This is one of the series of decrees promulgated in the late 1970s to address emerging environmental issues and concerns. The Philippine EIS System was established to facilitate the attainment and maintenance of a rational and orderly balance between socio-economic growth and environmental protection. This policy provides that "no person, partnership, or corporation shall undertake or operate any such declared ECP or project within an ECA without first securing an Environmental Compliance Certificate (ECC)" which requires the submission of an Environmental Impact Statement. The latest implementing rules for this law is the DENR Administrative Order 30-2003 (DAO 30-2003) which provides criteria for and detailed lists of ECAs and ECPs.

The other related laws are PD 1151 — The Philippine Environmental Policy and PD 1152 — The Philippine Environment Code. The PD 1151 stressed the urgent need to formulate an intensive, integrated program of environmental protection through EIA, requiring all agencies and instrumentalities of the national government, the government-owned and -controlled corporations, the private corporations, firms, and entities, to prepare and submit an Environmental Impact Statement (EIS) for every action, project or undertaking which significantly affects the environment.
3.1.2 Republic Act (RA) 6969 — Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990

The Philippine Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990 was enacted to regulate, restrict, or prohibit the importation, manufacture, processing, sale, distribution, use and disposal of chemical substances and mixtures that present unreasonable risk and/or injury to health or the environment; to prohibit the entry, even in transit, of hazardous and nuclear wastes and their disposal into the Philippine territorial limits for whatever purpose; and to provide advancement and facilitate research and studies on toxic chemicals.

3.1.3 DENR Administrative Order (DAO) 1992-29 established the Implementing Rules and Regulations (IRR) of Republic Act 6969 or Toxic Substances and Hazardous and Nuclear Wastes Control Act of 1990

The DENR DAO 1992-29 requires hazardous waste generators to register with the DENR-EMB, properly manage, and dispose of hazardous wastes generated in its facility. The hazardous wastes must be segregated, labelled, kept in proper storage facility, transported, treated/recycled and disposed of through DENR-accredited firms. In compliance with the Section 27 of the IRR, a transporter of health care wastes is required to register and obtain a Transport Permit from the DENR-EMB.

3.1.4 Republic Act (RA) 9003 – Ecological Waste Management Act and DENR AO 2001-34 (Implementing Rules and Regulations)

The law seeks to ensure the protection of public health and the environment through the utilization of environmentally sound methods for treating, handling, and disposing of solid wastes and encourages waste minimization and segregation at source.

Article 4, Section 27 of RA 9003 mandates the Department of Trade and Industry (DTI) to formulate and implement a coding system for packaging materials and products to facilitate waste recycling and reuse.

3.1.5 Joint DOH-DENR DAO Order No. 2005-02 – Policies and guidelines on effective and proper handling, collection, transport, treatment, storage and disposal of health care waste

The Joint DOH-DENR Administrative Order (JAO) 2005-02 dated August 24, 2005 provides definition and classification of health care wastes. The classification includes general waste, infectious waste, pathological waste, sharps, pharmaceutical wastes, genotoxic waste, chemical waste, waste with high heavy metals content, pressurized containers, and radioactive waste. The DENR-DOH JAO clarified the roles and responsibilities of DOH and DENR in regulating the activities of HCFs. All onsite activities are to be managed and supervised by the DOH while movement of hazardous healthcare wastes are required to comply with the requirements of the DENR in accordance with RA 6969 and its implementing rules and regulations.
3.1.6 DAO 2014-02 – Revised Guidelines for Pollution Control Officer Accreditation

The Revised Guidelines for Pollution Control Officer (PCO) Accreditation issued by DENR on February 3, 2014 requires industrial, commercial, and manufacturing establishments and private entities whose activities are potential and actual sources of pollution to designate a PCO. The PCO shall secure accreditation from the DENR in accordance with this DAO.

3.1.7 DAO 2013-22 – Revised Procedures and Standards for the Management of Hazardous Wastes

The DENR AO 2013-22 is a revision of the DAO 2004-36. This policy aims to further streamline the procedures for generation and compliance to the legal and technical requirements of hazardous waste management, including guidelines for waste generators, transporters, and treatment, storage, and disposal facilities.

Under this law, healthcare wastes from hospitals, medical centers, and clinics containing pathological, pathogenic, and infectious wastes, sharps and others are categorized as M501 or pathological or infectious wastes. Meanwhile, pharmaceuticals and drugs (M503) include expired pharmaceuticals and drugs stocked at producers and retailers’ facilities which contain hazardous constituents harmful to the environment such as antibiotics, veterinary, and phytopharmaceutical and others.

The COVID-19 vaccine vials are categorized under pharmaceutical and drugs (M503) while the syringes, cottons, and other materials used in the vaccination which had contact to the patient will be considered as infectious wastes (M501).

The policy mandates waste generators to avail services of waste transporters and TSD facilities duly registered by the EMB Central Office and whose permits are valid within the period that the wastes are being transported and treated, stored, or disposed of.

3.1.8 DENR Memorandum Circular (MC) 2020-16 – Amendment of the Interim Guidelines on Issuance of Special Permit to Transport (SPTT) for the Transportation of Hazardous Wastes within the Community Quarantine Period

This policy covers registered transporters and registered TSD facilities which respectively haul, treat, and/or dispose healthcare wastes nationwide. The transporters with existing valid regular permit to transport (PTT) for M501 shall continue to collect/haul hazardous COVID-19 wastes and other pathological and infectious wastes from healthcare facilities and are allowed to pass through checkpoints for delivery at designated TSD facility during the community quarantine period. If the PTT will expire during the period, an SPTT is to be secured online. Similarly, TSD facilities with TSD Registration Certificates and transporters with Transporter Registration Certificate (TRC) handling M501 with certificates expiring during the Enhanced Community Quarantine are automatically extended for 60 days and the Application for Renewal shall be immediately processed within 5 days upon lifting of ECQ.
3.1.9 Memorandum Circular (MC) 2020-20 – Provisional Guidelines on the Hazardous Wastes Management within the Extended Enhanced Community Quarantine

DENR MC 2020-20 dated April 30, 2020 provides the guidelines that waste transporters and treatment, storage, and disposal (TSD) facilities need to comply during the extended enhanced community quarantine. It upholds the policy of the government to continuously monitor the transport, treatment, storage, and disposal of hazardous wastes in order to prevent or avoid the likelihood of environmental disaster and contamination and provide temporary protocols for waste handlers, transporters, treaters, local government units, law enforcement authorities, and other stakeholders in the smooth implementation of proper hazardous waste management. It describes the coverage and simplification of existing procedures for the issuance of the Permit to Transport to registered transporters and registered TSD facilities during the extended enhanced community quarantine period to enable them to haul, treat and dispose healthcare wastes and related hazardous wastes. The transporters and TSD facilities are required to follow safety protocols as outlined in the health, safety, and environmental (HSE) plan. The safety protocols should include the preparation and submission of reports such as the report of compliance and completion of transport or the manifest and the Certificate of Treatment (COT) after each completed transport and treatment of the transporter and TSD, respectively. The manifest of the registered transported waste shall be attested by the duly designated representative or PCO of the health care facility or hazardous waste generator and the TSD, within 24 hours for M501 wastes and 7 days for other hazardous wastes after delivery to the TSD facility. The TSD facility shall also submit a report of compliance and completion of treatment or the COT to be attested by their PCO within 7 days after M501 wastes and 21 days for other types of hazardous wastes, after completion of treatment.

3.1.10 Philippine Clean Air Act of 1999

The Philippine Clean Air Act of 1999 (Republic Act 8749) provided for a comprehensive air pollution control policy and recognizes the rights of Philippine citizens to breathe clean air. RA 8749 applies to the project due to the potential for emissions from healthcare waste incineration. Section 20 of RA 8749 states:

*Ban on Incineration* - Incineration, hereby defined as the burning of municipal, bio-medical and hazardous wastes, which process emits poisonous and toxic fumes, is hereby prohibited: Provided, however, that the prohibition shall not apply to traditional small-scale method of community/neighborhood sanitation "siga", traditional, agricultural, cultural, health, and food preparation and crematoria: Provided, further, That existing incinerators dealing with bio-medical wastes shall be phased out within three (3) years after the effectivity of this Act: Provided, finally, That in the interim, such units shall be limited to the burning of pathological and infectious wastes, and subject to close monitoring by the Department.

With due concern on the effects of climate change, the Department shall promote the use of state-of-the-art, environmentally-sound, and safe non-burn technologies for the handling, treatment, thermal destruction, utilization, and disposal of sorted, unrecycled, uncomposted municipal, bio-medical and hazardous wastes.
These provisions of RA 8749 were clarified by a Department of Environment and Natural Resources Memorandum Circular (DMC-2002-05), which:

- states that RA 8749 does not prohibit incineration of wastes except those burning processes which emit poisonous and toxic fumes;
- recognises that appropriate disposal techniques for medical and bio-medical wastes are limited; and
- incineration of these wastes is only permitted in state-of-the-art facilities which are proven to emit minimal air pollutants with concentrations meeting RA 8749 criteria.

The phasing out of bio-medical incinerators contemplated under RA 8749 was deemed impracticable due to lack of affordable best available technology (BAT).

3.1.11 Chemical Control Order on Ozone-Depleting Substances

The Philippines ratified the Montreal Protocol on Substances that Deplete the Ozone Layer on March 21, 1991. The country agreed to phase-out its consumption of all ODS, based on the agreed timetable for Article 5 developing countries. Since the Philippines is neither a producer nor an exporter of ODS, the phaseout involves the reduction of importation and consumption of ODS following the schedule for Article 5 countries. The Montreal Protocol was amended during the 28th Meeting of the Parties through the implementation of the Kigali Agreement that also established the phase-down of hydrofluorocarbon (HFC) with developed countries taking the lead on phasing down HFCs, starting with a 10% reduction in 2019 and delivering an 85% cut in 2036 (compared to the 2011-2013 baseline).

The DENR issued DENR Administrative Order No. 2013-05, also known as the “Revised Regulations on the Chemical Control Order (CCO) for Ozone Depleting Substances” which is the legal basis of the country for the phaseout of ODS. This second revision of the CCO updates the phase-out status of controlled substances covered by the Montreal Protocol and reflects the accelerated phase-out schedule for hydrochlorofluorocarbons (HCFCs) in accordance with the Decision XIX/6 of the 19th meeting of the parties to the Montreal Protocol.

In accordance with the CCO, any importer of ODS must register with the Environmental Management Bureau (EMB) of the DENR. An importer of ODS must secure annually a certificate of registration from EMB and a Pre-Shipment Importation Clearance (PSIC) prior to the entry of each ODS shipment and that importers must follow the updated phase-out schedule for HCFCs. There is a quota allocation for HCFCs that should conform to the “one-shipment, one clearance” policy.

The dealers, resellers, and retailers of ODS that are registered with the EMB and accredited by the Department of Trade and Industry (DTI) are allowed to purchase, re-sell, distribute, and utilize allowable uses of ODS. The dealers and retailers should adhere to the Code of Practice for Refrigeration and Airconditioning (2013 update). Servicing of ODS-using equipment such as air-conditioners and refrigeration equipment must secure a certificate of registration from the DENR to assess their capability to take measures in the handling of ODS to control and minimize

---

12 Only HCFCs are allowed to be imported until January 2040 among the ODS. From 2030-204, an annual HCFC importation of 2.5% of the baseline consumption shall be allowed for use in the servicing sector. Other ODS, including chlorofluorocarbon (CFC), halons, and carbon tetrachloride (CTCs) have been banned for importation since January 1, 2010.
emissions and ultimately, phasing out their use by replacing with substitutes or alternatives recognized and certified by the DENR-EMB.

All importation of HCFC-22 for the manufacture of refrigeration and air-conditioning has been prohibited since January 1, 2020 to encourage companies to shift to alternative technologies. Importation of HCFC-123 for as cooling agent for chillers (also as fire-extinguishing agent) will be prohibited by January 1, 2025. Importation of HCFC blends for all sectors will be prohibited by January 1, 2030 to reduce HCFC imports by 97.5% in 2030 based in recorded baseline consumption. The Philippines, as an Article 5 country, has to reduce HFC consumption to 50% of baseline consumption in 2040-2044 based on the Kigali Agreement.

3.1.12 Department of Energy Administrative Order 110 – Procurement of Energy-Consuming Equipment

The order aims to reduce the monthly consumption of electricity and petroleum products by at least 10% through the implementation of the Government Energy Management Program.


The circular prohibits the selling of energy-inefficient products and provides incentives for the judicious and efficient use of energy. For chillers and air-conditioning units and other energy consuming devices and equipment, the DOE circular applies the highest Minimum Energy Performance Standards (MEPS).

3.1.14 Climate Change Act of 2009 and Relevant DOH Policy Issuances

National Framework Strategy on Climate Change (NFSCC) is the roadmap for addressing climate change. It identified adaptation as the anchor strategy and considered mitigation as a function of adaptation. The DOH is one of the first government agency in the country to prepare its sector strategy for climate change adaptation pursuant to the NFSCC 2010-2022. The Health Sector Strategy for Climate Change Adaptation (Department Circular No. 2010-0187) became part of the Philippine Strategy on Climate Change Adaptation. The National Climate Change Action Plan similarly identified health as one of the thematic priorities under Human Security with the intended outcome of health and social protection delivery systems that are responsive to climate change risks. Targets include health personnel and community’s capacity on climate change health adaptation and risk reduction developed; public health surveillance system is developed and implemented in all provinces; and health emergency response, preparedness and post-disaster management implemented at the national and local levels.

The DOH issued Administrative Order No. 2012-005 "National Policy on Climate Change Adaptation for the Health Sector" to set the overall policy directions on addressing the impact of climate change on health and to create an enabling environment for capacity strengthening of health systems, engagement of key partners in supporting comprehensive actions, and in protecting the health of all Filipinos from the impact of climate change. The scope of the order includes all units and instrumentalities of the Department, including its attached agencies, local government units, NGO, professional organizations, private sector and other relevant partners involved in the implementation of climate change adaptation for health programs. Administrative Order No. 2012-0018 was issued as its operational guidelines for strategies on policy, plans and partnerships;
service provision, capacity and infrastructure enhancement; health promotion, research, surveillance and monitoring; strengthening organizational structure for climate change at different levels of governance. The AO similarly outlines the organizational structure, roles and responsibilities, and budget and funding for its implementation.

In 2015, DPO No. 2015-5342 created the DOH Climate Change Executive Committee. Since then, the DOH has conducted 5 trainings on Health Vulnerability and Capacity Assessment (HVACA) nationwide with priority to the top 20 provinces identified to be most vulnerable and at risk to climate change. The objectives of the training are to provide LGUs and Centers for Health and Development (CHDs) a clearer view of climate change and health so that better assessment, planning and programming of health interventions toward climate change risk reduction can be accomplished; and to improve the capacity of the CHDs and LGUs on the use of the Climate Change Adaptation Tools (CCAT) for Health. The HVAVA and M&E tools were developed in partnership with the National Economic and Development Authority. Various trainings were also conducted on the use of Climate Change Adaptation Tools for Health from 2013 to 2015.

The DOH continues with its actions to increase the adaptive capacity of the Philippine health sector. Some of the ongoing activities relevant to the ESMF include: Finalization of the standards for green health care facilities and promote green hospitals (DC No. 2019-0059 dated 14 Feb 2019 - Green Certification of Government Healthcare Facility Projects); Implementation of the safe hospitals initiative; Promotion of the greening of hospitals and health facilities through improving energy and water efficiency and conservation, sustainable cooling system and sustainable healthcare waste management in hospitals (Section 37 of the GAA for 2019 General Provisions - RA No. 11260); Assessment of HVACA trained provinces and status of their Local Climate Change Action Plans (LCCAPs); Coordination meeting with Health Promotion and Communication Services (HPCS) for advocacy and health promotion (in line with Climate Sensitive Diseases, Water and Sanitation Related Diseases, Food and Waterborne Diseases and Emerging and Re-emerging Infectious Disease Program Communication Plan); and Technical Assistance to the HVACA trained provinces.

3.1.15 Disaster Risk Reduction and Management and Relevant DOH Policies

The Republic Act 10121 or Philippine Disaster Risk Reduction and Management Act of 2010 provides guidelines on the development of policies and plans and the implementation of actions and measures pertaining to all aspects of disaster risk reduction and management, including governance, risk assessment and early warning, knowledge building and awareness raising, reducing underlying risk factors, and preparedness for effective response and early recovery. Through this policy, the National Disaster Risk Reduction and Management Council (NDRRMC) was institutionalized.

The National Disaster Risk Reduction and Management Council, headed by the Secretary of the Department of the National Defense (DND) as the Chairperson, is the overall responsible Office for disaster response and management, with the Secretary of Department of the Interior and Local Government (DILG) as Vice-Chairperson for Disaster Preparedness, the Secretary of Department of Social Welfare and Development (DSWD) as Vice-Chairperson for Disaster Response, the Secretary of the Department of Science and Technology (DOST) as Vice-Chairperson for Disaster Prevention and Mitigation, and the Director-General of the National Economic and Development Authority (NEDA) as Vice Chairperson for Disaster Rehabilitation and Recovery, as set forth in the Implementing Rules and Regulations of the Republic Act no. 10121.
The NDRRMC shall provide guidelines on the selection and screening of the civil society organizations (CSOs) and private sector representatives. The NDRRMC, empowered with policy-making, coordination, integration, supervision, monitoring, and evaluation functions, shall have the following responsibilities:

a) Develop a NDRRM Framework which shall provide for comprehensive, all-hazards, multi-sectoral, inter-agency and community-based approach to disaster risk reduction and management. The Framework shall serve as the principal guide to disaster risk reduction and management efforts in the country and shall be reviewed on a five (5) year interval, or as may be deemed necessary, in order to ensure its relevance to the times;

b) Ensure that the NDRRM Plan is consistent with the NDRRM Framework;

c) Advise the President on the status of disaster preparedness, prevention, mitigation, response and rehabilitation operations being undertaken by the government, CSOs, private sector, and volunteers; recommend to the President the declaration of a state of calamity in areas extensively damaged; and submit proposals to restore normalcy in the affected areas, to include calamity fund allocation;

d) Ensure a multi-stakeholder participation in the development, updating, and sharing of a Disaster Risk Reduction and Management Information System and Geographic Information System-based national risk map as policy, planning and decision-making tools;

e) Establish and/or strengthen a comprehensive, all hazards national early warning and emergency alert system to provide accurate and timely advice to national or local emergency response organizations and to the general public through diverse mass media to include digital and analog broadcast, cable, satellite television and radio, wireless communications, and landline communications;

f) Develop appropriate risk transfer mechanisms that shall guarantee social and economic protection and increase resiliency in the face of disaster;

g) Monitor the development and enforcement by agencies and organizations of the various laws, guidelines, codes or technical standards required by the Act;

h) Manage and mobilize resources for disaster risk reduction and management including the National Disaster Risk Reduction and Management Fund;

i) Provide necessary guidelines and procedures, and monitor the Local Disaster Risk Reduction and Management Fund (LDRRMRF) releases as well as utilization, accounting, and auditing thereof;

j) Develop assessment tools on the existing and potential hazards and risks brought about by climate change to vulnerable areas and ecosystems in coordination with the Climate Change Commission;

k) Develop vertical and horizontal coordination mechanisms for a more coherent implementation of disaster risk reduction and management policies and programs by sectoral agencies and LGUs;

l) Formulate a national institutional capability building program for disaster risk reduction and management to address the specific weaknesses of various government agencies and LGUs, based on the results of a biennial baseline assessment and studies.

m) Formulate, harmonize, and translate into policies a national agenda for research and technology development on disaster risk reduction and management;

n) In coordination with the Climate Change Commission, formulate and implement a framework for climate change adaptation and disaster risk reduction and management from which all policies, programs, and projects shall be based;

o) Constitute a technical management group composed of representatives of the abovementioned departments, offices, and organizations, that shall coordinate and meet as
often as necessary to effectively manage and sustain national efforts on disaster risk reduction and management;
p) Task the OCD to conduct periodic assessment and performance monitoring of the member-agencies of the NDRRMC, and the Regional Disaster Risk Reduction and Management Councils (RDRRMCs), as defined in the NDRRMP;
q) Coordinate or oversee the implementation of the country's obligations with disaster management treaties to which it is a party and see to it that the country's disaster management treaty obligations be incorporated in its disaster risk reduction and management frameworks, policies, plans, programs and projects; and
r) Coordinate or oversee the implementation of the country's obligations with disaster management treaties to which it is a party such as the ASEAN Agreement on Disaster Management and Emergency Response (AADMER), which came into force on 24 December 2009, and see to it that the country's disaster management treaty obligations be incorporated in its disaster risk reduction and management frameworks, policies, plans, programs and projects.

The DND as the Chair of the NDRRMC, is the government organization established to lead, administer, and coordinate all disaster management activities. The DND is the central entity responsible for coordinating risk reduction and emergency management in the country. In the event of a National Declaration of a State of Calamity by the Office of the President of the Republic of the Philippines or the Local Declaration by the Local Government Unit, the NDRRMC and the Local Disaster Risk Reduction and Management Council (LDRRMC), respectively, have the responsibility to administer a comprehensive national civil defense and disaster risk reduction and management program by providing leadership in the continuous development of strategic and systematic approaches as well as measures to reduce the vulnerabilities and risks to hazards and manage the consequences of disasters.

The DOH is mandated to work in close collaboration with the DND as Chairperson of the NDRRMC, the OCD as the implementing arm of the NDRRMC, and other relevant inter-ministerial committees, where relevant support on the technical discussions on DRR and other related activities of the Project, which may include the activation of the Contingency Emergency Response Component (CERC). Moreover, the DOH including other member agencies, is mandated by the Republic Act to (i) establish a disaster office, (ii) maintain a functional operations center, (iii) mainstream disaster risk reduction management (DRRM) in all planning activities, and (iv) orient all their employees on DRRM.

The Republic Act 7160 or the Local Government Code of 1991 mandates DOH to have the following authorities and roles in emergency and disaster risk response and management:

a. Enhance and strengthen the capabilities of LGUs to provide health services and facilities to their constituents;
b. Have the final decision in determining the presence of ‘widespread public dangers’ in a particular area or region [Section 44 (b) and (c)] including situations in calamity areas and in relation to a displaced population [Section 43 (a)];
c. Recommend to the President the issuance of an appropriate order directing the DOH to assume direct supervision and control over local health operations in affected areas; and
d. Prepare, implement, and monitor plans of action in such circumstances, and of evaluation of the local health situation [Section 45, (c) and (f)].
The Local Government Code of 1991 institutionalized a devolved health care system where the responsibility of delivering health care services in the local level are assigned to the local government units (LGUs) and not the DOH Central Office. The LGUs have the primary responsibility of providing immediate and direct response to disasters, but in cases where disasters have reached proportions beyond the capability of the LGUs, the national government takes control as stipulated under Section 105 of the Code. Relatedly, Executive Order no. 102 s. 1999 – ‘Redirecting the Functions and Operations of the DOH’ provides that the DOH shall (1) serve as the lead agency in health emergency response services, including referral and networking systems for trauma, injuries and catastrophic events, (2) promote health and well-being through public information and provide the public with timely and relevant information on health risks and hazards, and (3) assume leadership in health in times of emergencies, calamities and disasters, and system failures.

The Health Emergency Management Bureau (HEMB) as the focal unit of the DOH in emergency response, has the following roles and responsibilities:

a) Act as the DOH Coordinating unit and Operation Center for all health emergencies and disasters, as well as incidents with the potential of becoming an emergency, and coordinate the mobilization and sharing of resources;

b) Provide communication linkage among DOH Central Office and other concerned agencies, including the hospitals and the regions, during emergencies and disasters;

c) Maintain updated information of all health emergencies and disasters (except epidemiological investigation reports) and provide such information to other offices and agencies in accordance with existing protocols;

d) Maintain a database of all health emergency personnel, technical experts, and resource speakers. Together with the Health Facilities Development Bureau (HFDB) and the Health Facilities Enhancement Program Management Office (HFEPMO), HEMB shall maintain a database of capabilities of health facilities;

e) Lead in the development of Disaster Risk Reduction & Management in Health (DRRMH) Plan and the development of protocols, guidelines and standards for health emergency management;

f) Provide technical assistance in the development of programs and planning activities for HEM for other government and non-government organizations;

g) Lead advocacy activities, including simulation exercises;

h) Develop and implement an Integrated Human Resource Training Agenda for the Health Sector for emergencies and disasters;

i) Lead in the networking of hospitals and health sector organizations responding to emergencies and disasters; and

j) Monitor and evaluate the enforcement of compliance to policies and recommend the formulation or amendment of policies related to health emergency management.

Given the crucial role of the DOH in DRRM, the Manual of Operations on Health Emergency and Disaster Response Management was developed in 2015. The Manual provides guidelines on the health emergency and disaster response framework and the management of the event/incident, victims, service providers, information system, and non-human resources.

The development and implementation of a national policy framework for emergencies and disasters in the health sector was established by the DOH Administrative Order no. 168 series of
2004 entitled National Policy on Health Emergencies and Disasters. It aims to decrease mortality and promote physical and mental health, as well as prevent injury and disability on the part of both victims and responders specifically through the (i) development of goals, strategies, plans and policies for ensuring an efficient system for managing emergencies and disasters in the health sector, (ii) improvement of the effectiveness of DOH systems, structures, capacities and mechanisms, and (iii) building up of the preparedness and response activities of both the public and private health facilities for administering mass casualty events, and (iv) strengthening the links between partner agencies and stakeholders in responding to and managing emergencies and disasters in the country.

The DOH Administrative Order no. 0024 s. 2008 – ‘Adoption and Institutionalization of an Integrated Code Alert System Within the Health Sector’ provides that there should be a Code Alert System in the mobilization and deployment of resources, including the expected levels of preparation and the most appropriate response by all facilities in emergencies and disasters. Previously, DOH AO no. 182 s. 2001 was issued for the Adoption and Implementation of the Code Alert System for DOH Hospitals During Emergencies and Disasters.

The DOH Policies and Guidelines on the Establishment of Operations Center for Emergencies and Disasters (DOH AO no. 29 s. 2010) describes the policies and guidelines in the establishment of Operations Center (OpCen) at all levels from the national to the local government to ensure a well-coordinated response of the health sector. Its objectives include to i) develop policies and guidelines on the establishment and management of an Operations Center, (ii) identify the functions of the OpCen at the different levels, (iii) set the minimum specification for the design of an OpCen and minimum standards for logistical requirements, human resource requirements, coordination mechanisms, and relationship among Operations Centers, and (iv) provide funds to sustain its functionality. The DOH also issued the Guidelines on Health Emergency Management (HEM): Manual for Operations Center, 2nd edition, in 2008 outlining the (1) requirements and standards for health emergency management staff, (2) the element, physical attributes, standard operating procedures, information management, human resource development, evaluation of operation centers, and the (3) guidelines for operation centers in DOH CHDs and hospitals. The first volume of the Information Management Manual for Coordinating and Monitoring Health Emergency and Disaster Response: Manual of Guidelines and Procedures on Information Management for Selected Functions of the Health Emergency Management Staff of the Department of Health was issued in 2007 To provide guidance on the information needs of key players in HEM at the national level, information sources and data collection tools, data collection flow and reporting mechanisms, assuring quality of information, and data processing (collation, information dissemination, and storage).

To provide guidance in ensuring an effective and efficient reporting mechanism to yield a responsive evidence-based decision-making process during emergencies and disasters, the DOH released AO no. 14 series of 2012 – Policy and Implementing Guidelines on Reporting in Emergencies and Disasters. The AO required the reporting of units at all levels of the health sector to submit timely, reliable, and continuous reports of all health-related events with standardized reporting mechanisms at all levels for emergencies/disasters. It has the objective of ensuring consistency and compliance of all reporting units with the reporting mechanisms in emergencies and disasters.

With the aim of further improving disaster surveillance, the DOH issued AO 2014- 011 – Policies and Guidelines on the Implementation of Surveillance in Post Extreme Emergencies and Disasters.
(SPEED). The AO aims to institutionalize SPEED, an early warning system is vital in detecting health conditions or diseases with outbreak potential and in accessing real-time information for prompt and appropriate response, in all levels of health emergency and management response.

The DOH AO no. 13 series of 2012 entitled Policy and Guidelines on Logistics Management in Emergencies and Disasters provides guidelines on the effective and efficient management of logistics support at all levels of the health system in emergency or disaster situations. It mandates the DOH to lead in formulating policies and plans for logistics management in emergencies and disasters and, in coordination with members of the health sector, formulate guidelines, standards, procedures and protocols in relation to logistics management in emergencies and disasters with corresponding reporting systems and tools. The Guidelines on the Acceptance and Processing of Foreign and Local Donations During Emergency and Disaster Situations (DOH AO no. 17 series of 2007) was issued in relation to this to set a rational and systematic procedure for the acceptance, processing and distribution of foreign and local donations that are exclusively for unforeseen, impending, occurring and experienced emergency and disaster situations. Similarly, the Food and Drug Administration has issued the FDA Circular no. 2020-009 or the Guidelines on the Identification, Notification, Evaluation, Regulatory Enforcement Action, and Review and Monitoring of Donated Health Products Solely Intended to Address COVID-19 Public Health Emergency. The Bureau of Customs also issued in 2014 the Guidelines and Procedures on Customs Clearance of International Donations Availing of Duty and/or Tax Exemption During Calamities.

In 2004, the Implementing Guidelines for Managing Mass Casualty Incidents (MCI) During Emergencies and Disasters (AO no. 155 series of 2004) was issued by the DOH. It states that the DOH is the lead in implementing a mass casualty system and procedures for resource mobilization, field management, and hospital reception to a comprehensive and well-coordinated response in MCI.

The DOH AO no. 2013-004 – Policies and Guidelines on Hospitals Safe from Disasters was issued with the goal of reducing disaster risks to ensure protection and continuous operation of hospitals and other health facilities and save lives during emergencies and disasters. It prepares hospitals to address operation challenges during disasters and emergencies with the vision of remaining as the last building standing and functioning, specifically through (i) strictly enforcing national and local government safety regulations and codes in the construction, expansion, renovation, repair and rehabilitation of hospitals, (ii) inclusion in the hospital licensure requirements of a program for regular maintenance consistent with the most current Hospitals Safe from Disasters indicators, (iii) subjecting hospitals to yearly self-assessments and action planning to address their structural, non-structural, and functional vulnerabilities and capacities using the most current assessment tool, (iv) ensure surge capacity to be able to manage increased demand, and (v) utilize, build and strengthen partnerships and networks and develop corresponding mechanisms in times of emergencies and disasters. The Safe Hospitals in Emergencies and Disasters released by the DOH in 2009 lists the Philippine Indicators for monitoring and evaluation.

The NDRRMC has developed the National Disaster Response Plan outlining the policies, key strategies, guidelines. And roles and responsibilities of agencies in DRR response management. The DOH was the lead in health services including in the areas of water, sanitation, and hygiene (WASH), nutrition, and psychosocial services. As such, the DOH issued the Guidelines in the Provision of the Essential Health Service Packages in Emergencies and Disasters in 2017 (AO 2017-0007). It aims to set the standards for the effective, efficient, and timely delivery of essential health services.
services in emergencies and disasters. Specifically, it (i) sets the guidelines in the delivery of essential health services in emergencies and disasters, (ii) define the essential service components for health, nutrition, water and sanitation hygiene, and mental health and psychosocial support that need to be available and accessible before, during, and after emergencies and disasters, and (iii) delineate the roles and responsibilities of concerned offices, stakeholders, and partners in the delivery of essential health service packages. Moreover, the DOH is currently developing the WASH in Emergencies (WiE) Technical Guidelines and the Green and Safe Health Care Facility Manual.

3.1.16 DOH Administrative Orders – Hospitals and Other Health Facilities and Clinical Laboratories

Joint DOH-DENR Administrative Order No. 2005-02 dated August 24, 2005 defines health care wastes as all wastes generated as a result of the following: 1) diagnosis, treatment, management, and immunization of humans or animals, 2) research pertaining to the above activities, 3) producing or testing of biological products, 4) wastes originating from minor or scattered sources (e.g. dental clinics, alternative medicine clinics, etc.). The DAO also identifies its hazards to people and the strategies to manage these wastes.


Department of Health Administrative Order (AO) No. 2007-0027 “Revised Rules and Regulations Governing the Licensure and Regulation of Clinical Laboratories in the Philippines” prescribes “...a revised minimum standard for clinical laboratories [to]...ensure accuracy and precision of laboratory examinations in order to safeguard public health and safety.” The AO requires all clinical laboratories, government or private, to have written policies and procedures for the provision of laboratory services and for the operation and maintenance of the laboratory, including proper disposal of waste and hazardous substances, as well as biosafety and biosecurity. This AO applies directly to activities under the project, most specifically under Component 2.


The DoH issued the DC 2020-0191 last 23 April 2020 institutionalizing the use of the 4th Edition of the Health Care Waste Management Manual. It is intended to serve as the most comprehensive set of guidelines on the safe management of wastes generated from heath care activities in the country. It incorporates the requirements of all Philippine laws and regulations governing HCWM and considers the recommendations of the World Health Organization (WHO) and stakeholders, including end-users.

This edition is intended and designed for the use of individuals, establishments, and other entities involved in the segregation, collection, handling, storage, treatment, and disposal of waste generated.
The DOH Health Care Waste Management (HCWM) Manual 4th edition classifies discarded items used in handling of vaccines, such as vials, or boxes with residues, gloves, and masks, as pharmaceutical wastes.

3.1.18 Department of Health COVID-19 Interim Guidelines

DoH has developed a series of Interim Guidelines specifically targeted at COVID-19 response (https://www.doh.gov.ph/2019-nCov/interim-guidelines?page=1). Relevant guidelines include:

- Department Memorandum No. 2020-0072 - Interim Guidelines For 2019 Novel Coronavirus Acute Respiratory Disease Response In Hospitals And Other Health Facilities https://drive.google.com/file/d/1zmXeJt_3kmiOzyJyt9iaVXTfk6JKJsT/preview
The application of these Guidelines should be considered in comparison with evolving WHO guidance to ensure that contemporary good practice is adopted.

3.1.19 National Policy Issuances on the Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines (NDVP)

The National Task Force Against COVID-19 (NTF) has issued last 26 January 2021 the Memorandum Circular No. 5 series of 2021 – ‘Adaptation and Implementation of the Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines’ (NDVP) with reference to the IATF Resolution no. 95 series of 2021 (January 21, 2021) which approved and ratified the NDVP. The NTF DM mandates all regional and local COVID-19 Task Forces and Vaccination Operations Centers to implement the NDVP.

3.1.20 Issuances on the National Strategic Policy Framework for COVID-19 Vaccine Deployment and Immunization

The DOH issued Administrative Order no. 2021-0005 – ‘National Strategic Policy Framework for COVID-19 Vaccine Deployment and Immunization’ dated 12 January 2021 which aims to provide strategic policy guidance and direction on the selection, access, deployment of the COVID-19 vaccine and the COVID-19 immunization program. Specifically, it aims to (a) provide guidance on vaccine delivery strategies, vaccine acceptance, human resource management and training, supply chain, and management of health care waste, safety and surveillance, and immunization monitoring systems, (b) guide the implementation and provision of a free, safe, and effective, high-quality vaccine/s against SARS-CoV2, prioritizing the most-at-risk and most-vulnerable populations, and (c) ensure implementation of risk communication, health education and community engagement activities utilizing diverse platforms, and the conduct of strategies and interventions addressing vaccine hesitancy. The National Strategic Policy Framework is further disseminated through the DOH Department Circular 2021-0009 dated 14 January 2021, circulated together with the DOH’s Strategic Plan for COVID-19 Vaccination 2021-2023.

3.1.21 Other National and DOH Issuances on COVID-19 Vaccination

The Department Memorandum (DM) no. 2021-0031 – Interim Guidelines on the Management of Health Care Wastes Generated from COVID-19 Vaccination aims to provide guidance on the proper management of health care wastes generated from the COVID-19 vaccination activities in all health care facilities (HCFs) involved.

In order to prepare the country for the COVID-19 vaccination program of the DOH, the creation and maintenance of a masterlist of priority sectors is necessary to: (a) provide basis for identification of target eligible groups for vaccination and identification of priority areas for registration of eligible individuals; (b) ensure uniqueness of individuals in the vaccine administration plan; and (c) provide input to operational planning especially for costing and allocation of resources. Hence, the DM no. 2021-0047 – Interim Guidelines on Masterlisting for the COVID-19 Electronic Immunization Registry (CEIR) - Phase 1 was developed.

Moreover, to establish the processes/activities to be followed as soon as the COVID-19 vaccines has been procured from the pre-shipment, during delivery and the acceptance of the vaccines and
ancillary immunization commodities to the Central Cold Storage Facility and Warehouses, the DM
no. 2021-0053 was issued last 28 January 2021.

- DOH Department Memorandum 2021-0099 - Interim Omnibus Guidelines for the
  Implementation of the National Vaccine Deployment Plan for COVID-19
- DOH Department Circular 2021-055 - Interim Guidelines on the Prioritization Framework
  for the Philippine National Deployment and Vaccination Plan and its Initial Roll-out of the
  First Tranche of Pfizer-BioNTech COVID-19 Vaccines
- DOH Department Personnel Order no. 2021-0105 - Creation of a Committee for the
  Review of Documents Relative to the Acquisition of COVID-19 Vaccines
- DOH Department Memorandum 2021-0053 - Interim Guidelines on the Shipment and
  Acceptance of the COVID-19 Vaccines and Ancillary Immunization Commodities
- National Task Force (NTF) Against COVID-19 Memorandum dated 8 February 2021 - DICT
  as the Lead Agency for All COVID-19 Vaccine- Related Data Collection, Storage,
  Processing, and Analysis’
- Republic Act no. 11525 - COVID-19 Vaccination Program Act of 2021
- Memorandum Order no. 51 - Granting Authority to Make Advance Payments for the
  Procurement of COVID-19 Vaccines, Prescribing Conditions Therefor, and for Other
  Purposes

3.1.22 Guidelines on Adverse Events Following Immunization (AEFI)

The following are the guidelines and standards which will be used by the DOH in monitoring and
responding AEFIs:

  following immunization
- Department of Health – National Epidemiology Center. (2014). Adverse events following
  immunization (AEFI): A manual of procedure for surveillance and response to AEFI
- DOH Administrative Order no. 2016-0006: Revised Guidelines on Surveillance and
  Response to Adverse Events Following Immunization
- National Deployment and Vaccination Plan
- Standard Operating Procedures in Handling Serious AEFI Cases in the Region
- DOH Department Memorandum 2021-0099 - Interim Omnibus Guidelines for the
  Implementation of the National Vaccine Deployment Plan for COVID-19

3.1.23 Executive Order no. 121 series of 2020

The Executive Order no. 121 s. of 2020 grants the Director General of the Food and Drug
Administration to issue emergency use authorization for COVID-19 drugs and vaccines.

of Emergency Use Authorization for Drugs and Vaccines for COVID-19

This Circular shall apply to the pharmaceutical industry and government entities such as the
national procurer or health program implementors intending to apply for an emergency use
authorization (EUA) for drugs and vaccines for COVID-19, and shall pertain only to unregistered
(anywhere in the world) drugs and vaccines for prevention, diagnosis and treatment of COVID-19
and granted an EUA by the National Regulatory Authority (NRA) of the country of origin or any
other mature and established NRA as identified by FDA.
The EUA is defined as an authorization issued for unregistered drugs and vaccines in a public health emergency. The EUA is not a Certificate of Product Registration (CPR) or a marketing authorization. The evaluation process of the product may be facilitated by reliance and recognition principles, but stricter conditions on the use and monitoring following authorization shall be imposed.

The EUA shall only be issued and remain valid only when all of the following circumstances are present: (1) based on the totality of evidence available, including data from adequate and well-known controlled trials, it is reasonable to believe that the drug or vaccine may be effective to prevent, diagnose, or treat COVID-19; (2) the known and potential benefits of the drug or vaccine, when used to diagnose, prevent, treat COVID-19, outweigh the known and potential risks of the drug or vaccine, if any; and (3) there is no adequate, approved and available alternative to the product for diagnosing, preventing or treating COVID-19. The last condition is deemed present when there exists no registered drug or vaccine in the country for diagnosing, preventing, or treating COVID-19.

3.1.25 Bureau of Food and Drug (BFAD) Circular 16, series of 1999 – Amending BFAD MC No. 22 dated September 8, 1994, regarding Inventory, Proper Disposal, and/or Destruction of Used Vials or Bottles

The BFAD circulars were released to prevent the proliferation of adulterated, misbranded, and counterfeit drugs brought about by the recycling of used pharmaceutical bottles and vials. The circular contains the guidelines on the proper inventory and destruction of bottles and vials. The Chief Pharmacists of government and private hospitals are required to conduct at least, a semestral inventory of the proper disposal and destruction of used vials or bottles. The inventory is to be submitted to the BFAD within five days from the date of the inventory. The nurse administering the drugs must be under strict instruction to return all empty vials to the hospital pharmacy for destruction on a quarterly basis. All inventories and/or destruction shall be done under the supervision of duly authorized representative of BFAD.


In line with DOH Administrative Order No. 2007-0017 – Guidelines on the Acceptance and Processing of Foreign and Local Donations during Emergencies and Disaster Situations, the FDA released Circular no. 2020-009 which covers the identification, notification, evaluation, review and monitoring and other regulatory or enforcement action of FDA covering foreign or locally donated health products solely intended to address the COVID-19 public health emergency. This Circular is applicable to the following: (a) face masks including N-95 masks, (b) shoe covers, (c) gloves, (d) head covers, (e) gowns, (f) goggles/ face shields, (g) COVID-19 diagnostic test kits, (h) alcohol, hand sanitizers, etc., and (i) other health products that may hereinafter be identified and listed by the FDA. The Food and Drug Action Center (FDAC), Center for Drug Regulation and Research (CDRR), Center for Device Regulation, Radiation Health, and Research (CDRRHR), Center for Cosmetics Regulation and Research (CCRR), Center for Food Regulation and Research (CFRR),
Field Regulatory Operations Office (FROO), and Testing Laboratories are the focal units for the implementation of the Circular.

3.1.27 FDA Circular No. 2020-028 || Reissuance of the Guidelines for the Registration of Drug Products under Emergency Use (DEU) for the Coronavirus Disease 2019 (COVID-19)

This Circular was issued to amend FDA Circular Nos. 2020-012, -A, and -B with the aim of providing streamlined requirements and application process for the registration of Drug Products under Emergency Use (DEU) for COVID-19, covering all Marketing Authorization Holders (MAH) intending to manufacture and import/distribute the drug products listed in the PSMID Interim Guidelines on the Clinical Management of Adult Patients with Suspected or Confirmed COVID-19 Infection.

3.1.28 Guidelines on Adverse Events Following Immunization (AEFI)

In 2014, the Department of Health, with the lead of the National Epidemiology Center, now referred to as the Epidemiology Bureau, has developed the Adverse Events Following Immunization (AEFI): A Manual of Procedure for Surveillance and Response to AEFI. This Manual of Procedure or MOP provides guidelines for health professionals from the public and private sectors who are providing vaccination nationwide which include the DOH-concerned offices and attached agencies, epidemiology and surveillance units, private and government health facilities, local government units, and the community involved in the surveillance and management of AEFIs to properly respond to these cases and maintain public confidence with the immunization program of the DOH. Specifically, it provided guidelines on the following: principles of immunization and vaccine, adverse event following immunization, AEFI surveillance, case detection and notification, case investigation, causality assessment, data management and utilization, feedback, response and follow-up activities, risk communication, and monitoring and evaluation.

The Revised Guidelines on Surveillance and Response to Adverse Events Following Immunization has been issued by the DOH on February 2016 through Administrative Order (AO) 2016-0006. It aims to provide guidelines for concerned stakeholders on the early detection, reporting, investigation, and appropriate response to adverse events following immunization and to establish mechanisms for collaboration between and among Epidemiology Bureau, Food and Drug Administration, Family Health Office and other stakeholders involved in AEFI surveillance and response. This Administrative Order supplements the Manual of Procedure issued in 2014.

3.1.29 Greening and Energy- Efficiency Guidelines of the Department of Health

The DOH is currently developing the Green and Safe Health Care Facilities Manual. The following are existing guidelines circulated to various offices on the greening and energy- efficiency of health care facilities:

- Department Memorandum 2020-0240. Submission of hospital energy consumption and generated health care waste (28 May 2020)
Department Memorandum 2020-0051. Designation of energy efficiency and conservation officer (EECO) (3 February 2020)
Department Memorandum 2019-0280. Establishment of green public procurement (GPP) system in the health care facility (4 July 2019)
Department Circular 2019-0059. Green certification of government health care facility projects (14 February 2019)
Department Memorandum 2018-0151. Accomplishment and submission of the green healthcare facility components survey questionnaires (3 April 2018)
Department Memorandum 2018-0035. Submission of energy consumption information of DOH hospitals to establish energy efficiency standards as part of the green healthcare facilities standards (25 January 2018)
Department Memorandum 2017-0118. Accomplishment and submission of the green healthcare facility self-assessment checklist (20 March 2017)
Administrative Order 2012-0005. National policy on climate change adaptation for the health sector (13 March 2012)

3.1.30 Labor Legislation

Labor Code of the Philippines

Presidential Decree No. 44, as amended by RA 6715, known as the “Labor Code of the Philippines”, governs all employment practices and relations in the country. Provisions of the Code are aligned with international good practice on decent work and shall be strictly implemented. These provisions include:

Wage and Welfare

1. Employees shall receive their wages by means of legal tender, at least once every two weeks or twice a month at intervals not exceeding sixteen (16) days.

2. In a contracted work, employees of the contractor and of the latter’s subcontractor, shall also be paid in accordance with the labor code.

3. The wage paid by the employers to the workers shall not be lower than the prescribed minimum wage set by the Regional Tripartite Wages and Productivity Boards.

Working Time, Rest Days and Holidays

1. The normal work hours for every employee shall not exceed eight (8) hours a day. If all or any part of the employee’s working hours falls on 10:00 PM to 6:00 AM, he/she shall be entitled to a night shift pay in addition to the regular wage. If the worked performed exceeds the normal working hours, he/she shall be given overtime pay.

2. It is the right of every employee for a rest period not less than twenty-four (24) consecutive hours after every six (6) consecutive normal workdays.

3. Compensation shall be given for work performed during holidays and Sundays.

Equal Rights
1. Workers shall have the right to self-organization and to form, join, or assist labor organizations of their own choosing for purposes of collective bargaining.

2. Minimum employable age is 18 years old.

3. Gender discrimination in employment and labor relations shall be prohibited. Male and female employees are entitled to equal compensation for work of equal value and access to promotion and training opportunities.

**International Labour Organisation**

The Philippines became a member of the International Labor Organization (ILO) on 15 June 1948. It was the first country in Asia to participate in a pilot programme on decent work in 2002. The Philippines has ratified thirty-eight (38) ILO Conventions including all of the eight (8) Fundamental Conventions, as follows:

- C.29 Forced Labour Convention, 1930
- C.87 Freedom of Association and Protection of the Right to Organise Convention, 1948
- C.98 Right to Organise and Collective Bargaining Convention, 1949
- C.100 Equal Remuneration Convention, 1951
- C.105 Abolition of Forced Labour Convention, 1957
- C.111 Discrimination (Employment and Occupation) Convention, 1958
- C.138 Minimum Age Convention, 1973
- C.182 Worst Forms of Child Labour Convention, 1999

The 1987 Constitution of the Republic of the Philippines provide the following relevant provisions as legislative framework for labor concerns:

- Sec. 3, Art. XIII – The State shall afford full protection to labor, local and overseas, organized and unorganized, and promote full employment and equality of employment opportunities for all. It shall guarantee the right of all workers to self-organization, collective bargaining and negotiations, and peaceful concerted activities, including the right to strike in accordance with the law. They shall be entitled to security of tenure, humane conditions of work, and a living wage. They shall also participate in policy and decision-making processes affecting their rights and benefits as may be provided by law. The State shall promote the principle of shared responsibility between workers and employers and the preferential use of voluntary modes in settling disputes, including conciliation, and shall enforce their mutual compliance therewith to foster industrial peace. The State shall regulate the relations between workers and employers, recognizing the right of labor to its just share in the fruits of production and the right of enterprises to reasonable returns to investments, and to expansion and growth.
- Sec. 11, Art. II – The State values the dignity of every human person and guarantees full respect for human rights.
- Sec 13, Art. II – The State recognizes the vital role of the youth in nation-building and shall promote and protect their physical, moral, spiritual, intellectual, and social well-being. It shall inculcate in the youth patriotism and nationalism, and encourage their involvement in public and civic affairs.
- Sec. 14, Art. II – The State recognizes the role of women in nation-building, and shall ensure the fundamental equality before the law of women and men.
• Sec. 1, Art III – No person shall be deprived of life, liberty, or property without due process of law, nor shall any person be denied equal protection of the laws.
• Sec. 4, Art. III – No law shall be passed abridging the freedom of speech, of expression, or of the press, or the right of the people to peaceably assemble and petition the government for redress of grievances.
• Sec. 14, Art. XIII – The State shall protect working women by providing safe and healthful working conditions, taking into account their maternal functions, and such facilities and opportunities that will enhance their welfare and enable them to realize their full potential in the service of the nation.

Occupational Health and Safety

The protection against OHS risk to the workers embodied in various international laws, national laws and administrative issuances governing the public sector, shall be observed.

Republic Act 11058 – The Occupational Safety and Health Standards Act

This law strengthens the compliance with Occupational Safety and Health Standards to ensure a safe and healthful workplace for all working people by affording them full protection against all hazards in their work environment. To ensure that the provisions of the Labor Code of the Philippines, all domestic laws, and internationally recognized standards on occupational safety and health are being fully enforced and complied with by the employers. And to protect every worker against injury, sickness or death through safe and healthful working conditions thereby assuring the conservation of valuable manpower resources and prevention of loss or damage to lives and properties. DOLE Department Order No. 198-2018 sets out the implementing rules and regulations of this act.

Department of Labor and Employment (DOLE) Department Order no. 13 series of 1998 – Guidelines Governing Occupational Safety and Health in the Construction Industry

This Department Order was issued to ensure the protection and welfare of workers employed in the construction industry, ensure the protection and welfare of the general public within and around the immediate vicinity of any construction worksite as well as the promotion of harmonious employer-employee relationships, and consider the relevant industry practices and applicable government requirements. This guideline will apply to all construction activities, including demolition, regardless whether private or public property. The Department Order sets forth the inclusion of a ‘Construction Safety and Health Program’ prior to the onset of the construction where in the construction project manager is required to submit a comprehensive plan for the said program to the respective DOLE Regional Office. The said program includes the creation of a Safety and Health Committee, safety policies, penalties and sanction, orientation, instruction and training, and waste disposal. The DO also highlights the need for the use of personal protective equipment, designation of a safety personnel, use of construction safety signages, observance of safety and health information, and the practice of safety inspection and tool box meeting.

The DPWH DO 39 was issued on May 19, 2020 to provide guidelines on the allowed construction activities during the COVID-19 pandemic and the corresponding safety protocols for the workers in the said period. It covers all allowed government and private construction projects as stated in the Inter-Agency Task Force (IATF)- issued Revised Omnibus Guidelines dated 15 May 2020 for areas under enhanced community quarantine (ECQ), modified enhanced community quarantine (MECQ), general community quarantine (GCQ), and modified general community quarantine (MGCQ).


The JMC 20-04-A of DTI and DOLE issued last August 15, 2020 provides guidelines on workplace safety and health during the COVID-19 pandemic which covers all private establishments regardless of economic activity, including those located inside special economic zones and other areas under the jurisdiction of Investment Promotion Agencies (e.g. Philippine Economic Zone Authority (PEZA), Clark Development Corporation (CDC), Authority of the Freeport Area of Bataan (AFAB), Aurora Pacific Economic Zone and Freeport (APECO, etc.).) It describes measures on increasing physical and mental resilience, reducing virus transmission, management of symptomatic and asymptomatic employees in the workplace, COVID-19 testing, notification and reporting, OSH Committees, disinfection and closure of buildings/workplaces, and leave of absences and entitlements.


This convention will enter into force for Philippines on 17 June 2020 which is well within the period of implementation of the Project. The following are National Policy under Section 3:

1. Each Member shall promote a safe and healthy working environment by formulating a national policy;
2. Each Member shall promote and advance, at all relevant levels, the right of workers to a safe and healthy working environment;
3. In formulating its national policy, each Member, in light of national conditions and practice and in consultation with the most representative organizations of employers and workers, shall promote basic principles such as assessing occupational risks or hazards; combating occupational risks or hazards at source; and developing a national preventative safety and health culture that includes information, consultation and training.

1987 Constitution of the Republic of the Philippines

The relevant provisions of the Constitution as regards OHS are as follows:

- Sec. 3, Art. XIII – The State shall afford full protection to labor, local and overseas, organized and unorganized, and promote full employment and equality of employment
opportunities for all. It shall guarantee the right of all workers to self-organization, collective bargaining and negotiations, and peaceful concerted activities, including the right to strike in accordance with the law. They shall be entitled to security of tenure, humane conditions of work, and a living wage. They shall also participate in policy and decision-making processes affecting their rights and benefits as may be provided by law.

- **Sec 13, Art. II** – The State recognizes the vital role of the youth in nation-building and shall promote and protect their physical, moral, spiritual, intellectual, and social well-being. It shall inculcate in the youth patriotism and nationalism, and encourage their involvement in public and civic affairs.
- **Sec. 14, Art. XIII** – The State shall protect working women by providing safe and healthful working conditions, taking into account their maternal functions, and such facilities and opportunities that will enhance their welfare and enable them to realize their full potential in the service of the nation.
- **Sec. 11, Art. II** – The State values the dignity of every human person and guarantees full respect for human rights.

**Civil Service Commission Administrative Issuances**

- Memorandum Circular No. 33, Series of 1997 (Policy on Working Conditions at the Workplace) – all government offices shall provide adequate office ventilation and lighting, clean and adequate comfort room facilities, potable drinking water, First Aid Kit facilities, and all government offices should be non-smoking areas.
- Memorandum Circular No. 08, Series of 2011 (Reiteration of the Physical Fitness Program “Great Filipino Workout”) – requiring all agencies to adopt “The Great Filipino Workout” in order to develop a healthy and alert workforce.
- Memorandum Circular No. 04, Series of 2003 (Promotion of Good Nutrition in the Bureaucracy) – promotion of good nutrition of workers as an effective strategy to achieve and sustain increased organizational productivity.

3.1.31 **Persons with Disabilities (PWDs)**

**Republic Act 7277 – An Act Providing For The Rehabilitation, Self-Development And Self-Reliance Of Disabled Person And Their Integration Into The Mainstream Of Society And For Other Purposes**

The RA 7277 or the Magna Carta for Disabled Persons highlights the rights and privileges of disabled persons, such as equal opportunity for employment, access to quality education, inclusion in the national health program, provision of rehabilitation centers, provision of auxiliary social services, access to telecommunications, provision of sign language inset or subtitles, political and civil rights, and accessibility. Accessibility includes a barrier-free environment, mobility, and access to public transport facilities. To ensure the attainment of a barrier-free environment, disabled persons will be provided access to public and private buildings and establishments and such other places mentioned in Batas Pambansa 344 or the Accessibility Law. Related discrimination and corresponding penalties such as in employment, transportation, use of public accommodations and services, and use of government recreational or sports centers were described.
Republic Act 11106 – An Act Declaring the Filipino Sign Language as the National Sign Language of the Filipino Deaf and the Official Sign Language of Government in All Transactions Involving the Deaf, and Mandating its Use in Schools, Broadcast Media, and Workplaces

The RA 11106 or the Filipino Sign Language Act, in compliance with the United Nations Convention on the Rights of Persons with Disabilities, aims to eliminate discrimination in public communications and to promote inclusion through the use of Filipino sign language for the deaf. This RA is also in line with the Early Years Act (Republic Act No. 10410) and the Enhanced Basic Education Act (Republic Act No. 10533), which have recognized Filipino Sign Language in the education of the deaf learners from early childhood up to the secondary level. The Section 8 of this RA or the Filipino Sign Language in the Health System mandates all public health facilities to provide access of health services to the deaf through the free provision of FSL interpreters and accessible materials upon request of deaf patients, or individuals who have family members who are deaf. Meanwhile, private health care facilities are encouraged to provide access to health services to all deaf patients and their family members as part of their corporate social responsibility.

Batas Pambansa (BP) bilang 344 – An Act to Enhance the Mobility of Disabled Persons by Requiring Certain Buildings, Institutions, Establishments and Public Utilities to Install Facilities and Other Devices

The BP 344 or the Accessibility Law mandates the provision of architectural facilities or structural features which will provide access to the PWDs such as ramps, railings, sidewalks and the like in all facilities, establishments, and public utilities, such as educational institutions, airports, sports and recreation centers and complexes, shopping centers, public parking places, and workplaces. Posters and similar signages will also be displayed in prominent areas to generate public awareness on the rights and needs of the PWDs.

3.1.32 Indigenous Peoples

The Republic Act 8371 entitled ‘An Act to recognize, protect and promote the rights of indigenous cultural communities/indigenous peoples, creating a national commission on indigenous peoples, establishing implementing mechanisms, appropriating funds therefor, and for other purposes,’ or the Indigenous Peoples’ Rights Act of 1997 (IPRA), is a landmark legislation that recognizes and respects the rights of indigenous communities in the Philippines, including rights of control of their ancestral lands and right to self-determination. The law requires, among others, that development undertakings within the declared ancestral domains of the ICC/IPs shall be subject to their free, prior informed consent (FPIC) following different procedures depending on the character of activities. The IPRA, inter alia, declares that the State shall recognize and promote the rights of ICCs/IPs to government’s basic health services. The National Commission for Indigenous Peoples (NCIP) is responsible for implementing the IPRA. Likewise, the Joint Memorandum Circular 2013-01 entitled “Guidelines on the Delivery of Basic Health Services for Indigenous Cultural Communities / Indigenous Peoples” will also be considered.

The Department Circular 2020-0192 - Ensuring that people in GIDAs, Indigenous Cultural Communities/Indigenous Peoples are well-informed on COVID-19 and have access to Temporary Treatment and Monitoring Facilities and Referral Hospitals was issued by the Department of Health led by the Bureau of Local Health Systems Development (BLHSD) last April 2020. The
Centers for Health Development (CHDs) and the Ministry of Health - Bangsamoro Autonomous Region in Muslim Mindanao (MOH-BARMM) were tasked to coordinate with the local government units (LGUs) to ensure that the people in geographically isolated and disadvantaged areas (GIDAs) and the indigenous cultural communities/indigenous peoples (ICCs/IPs) are well informed on COVID-19 and have access to temporary treatment and monitoring facilities (TTMF), whether national- or LGU-managed, and COVID-19 referral hospitals.

3.1.14 Gender- Based Violence (GBV) and Violence Against Women and Their Children (VAWC)

The Republic Act 9262 or the Anti-Violence Against Women and Their Children Act of 2004 upholds the dignity and rights of women and children cognizant of the need to protect the family and its members particularly women and children, from violence and threats to their personal safety and security. This is in accordance with the Constitution and the Provisions of the Universal Declaration of Human Rights, the convention on the Elimination of all forms of discrimination Against Women, Convention on the Rights of the Child and other international human rights instruments of which the Philippines is a party. This law covers the acts of violence against women and their children, penalties, and protection orders.

The Special Protection of Children Against Abuse, Exploitation and Discrimination Act or Republic Act 7610 aims to protect and rehabilitate children gravely threatened or endangered by circumstances which affect or will affect their survival and normal development and over which they have no control. It provides special protection to children from all forms of abuse, neglect, cruelty exploitation and discrimination and other conditions, prejudicial their development; and provide prevention and deterrence of and crisis intervention in situations of child abuse, exploitation and discrimination. The Republic Act 10354, the Responsible Parenthood and Reproductive Health Act of 2012, also highlights the elimination of violence against women and children and other forms of sexual and gender-based violence. In addition, the DOH Administrative Order 1-B entitled “Establishment of a Women and Children Protection Unit in All Department of Health (DOH) Hospitals” was promulgated in response to the increasing number of women and children who consult due to violence, rape, incest, and other related cases.

3.1.33 Republic Act 9184 – An Act Providing for the Modernization, Standardization and Regulation of the Procurement Activities of the Government and for other Purposes

Republic Act 9184 or the Government Procurement Reform Act and its implementing rules and regulations outline the legal framework of the public procurement from procurement planning up to contract implementation. The public procurement process refers to the Generic Procurement Manuals and standard Philippine Bidding Documents (PBDs) for mandatory use by all government procuring entities. The PBDs define the objective, scope, and expected outputs of the proposed contract, the eligibility requirements of the bidders, the expected contract duration and the obligations, duties, and functions of the winning bidder. The technical specifications of goods and infrastructure projects are defined in the PBDs including any green criteria or green technical specifications.
3.1.34 Executive Order 301 series of 2004 – Establishment of a Green Procurement Program in all Government Agencies

Executive Order 301 s. of 2004 establishes a Green Procurement Program for all departments, bureaus, offices, and agencies of the executive branch of government. It promotes the culture of making environmentally-informed decisions in government during the purchase and use of different products and in including environmental criteria in public tenders, whenever possible and practicable. The order also requires the establishment of specifications and requirements for products and services to be considered as environmentally advantageous and incentive programs for suppliers of environmentally sound products and services. The Philippines has a Green Public Procurement Roadmap.

3.1.35 GPPB Resolution No. 15, series of 2013 – Approval to Support the Implementation of Sustainable and/or Green Public Procurement Regime in Government

The resolution was issued by the Government Procurement Policy Board (GPPB) which recognizes that sustainable public procurement (SPP) or GPP must be included in the public procurement system, rules and procedures in line with sustainable consumption and production, green economy, and sustainable development strategies. The GPPB oversees the implementation of the public procurement reform agenda. It is an independent inter-agency body with government and private sector representation that was established by virtue of Section 63 of RA 9184.

3.2 World Bank Environmental and Social Policies

Key aspects of the Philippines legal framework relevant to the Project are described in the previous section. A high-level comparison has been made with the Bank’s ESF, consistent with the template for COVID-19 health projects provided by the World Bank. There are no significant gaps between the national framework and the ESF. However, the Project will apply both the relevant ESSs of the ESF and national legislation relevant to the Project and its E&S risks.

3.2.1 ESS1 Assessment and Management of Environmental and Social Risks and Impacts

ESS1 is relevant given the environmental and social risks to assess and manage. The Philippine environmental regulations, particularly the Philippine Environmental Impact Statement System (PEISS) reflects the spirit of ESS1 and the key elements are covered mostly under its implementing rules and regulations. The PEISS functions as a regulatory and approval tool of projects aside from its intent as a planning tool to ensure environmental, social, and economic sustainability. The process of EIA and decision-making and balancing environment protection and development is reflected as one of DENR’s focus areas of mandate in ensuring implementation of the principles of sustainable development. The ESMF is prepared consistent with both the national legislation and the Bank’s ESF.

The main environmental risks associated are: (i) occupational health and safety risks resulting from the operation of medical facilities and laboratories involved in COVID-19 response and the vaccination activities which inherently expose staff to infection risk; (ii) health care waste management and disposal and community health and safety issues related to the handling,
transportation and disposal of healthcare wastes generated from the vaccine administration; and (iii) possible environmental and safety risks associated with small scale civil works for warehousing of the COVID-19 vaccine, medical facilities refurbishment, or completion of ongoing construction. Occupational health and safety and medical waste management are of particular concern.

Healthcare-associated infections due to inadequate adherence to occupational health and safety standards can lead to illness and death among healthcare and laboratory workers and exposed communities. The laboratories, relevant healthcare facilities, and community settings which will be used for the COVID-19 vaccine administration will generate infectious wastes such as sharps, used vials, syringes, cotton swabs, gloves, PPEs, and masks as well as non-hazardous solid wastes such as packaging materials, syringe wrappers, and syringe capping. Effective management and control measures will have to be in place to avoid and minimize risks of the infectious wastes from contaminating the environment and causing harm to the people. Measures to avoid risks and impacts can be implemented through proper management, treatment, and disposal of healthcare wastes, use of appropriate disinfectants, implementation of quarantine procedure for COVID-19, implementation of occupational health and safety protocols, ensuring proper use of chemicals in the laboratory, use of non-ODS refrigerants in the cold chain, and implementation of environmentally-sound construction practices for any civil works, as documented in this ESMF and in line with guidelines from WHO and applicable GoP regulations. The ESMF includes guidelines for assessing adequacy of the existing Health Care Waste Management system for handling increased quantities of waste and identifying measures for strengthening capacity of the DOH, hospitals and its regional health units, if needed. Direct and indirect social risks include potential exclusion of or inadequate response measures for marginalized and vulnerable social groups, such as persons with disabilities and indigenous peoples, risk of panic/conflicts resulting from false rumors and social unrest (for instance at quarantine and isolation facilities not welcomed by local communities), the social stigma associated with COVID-19, and Sexual Exploitation and Abuse (SEA) and Sexual Harassment (SH), Gender-Based Violence (GBV) and/or Violence Against Children (VAC) for workers (except VAC) and patients.

The Project’s ESMF also provides environmental and social risk management for the Contingent Emergency Response Component (CERC)\textsuperscript{13} should it be activated during project implementation. The CERC may be activated for another health-related emergency with similar needs and eligible activities and within the scope of the Project Development Objective. However, since activation of the CERC for emergency activities outside of the health sector cannot be ruled out, the applicability of the risk management measures of the ESMF will be assessed before activation of the CERC. For eligible emergencies outside of the health sector, e.g., earthquakes, typhoons, and volcanic eruptions, where the measures included in this ESMF do not fit the activities of the activated CERC, an ESMF for the CERC would be prepared with the situation-specific environmental and social risk assessment and management measures. This CERC ESMF will be prepared prior to CERC activation and will cover all activities financed by the CERC in line with the Emergency Action Plan prepared for the CERC. In all circumstances, the ESMF provisions will be reflected in the CERC Operations Manual that will be prepared to guide CERC implementation, including a description of the type of activities eligible for support in response to the emergency

\textsuperscript{13} The CERC is a project component that is designed to provide swift response in the event of an eligible crisis or emergency, defined as “an event that has caused, or is likely to imminently cause, a major adverse economic and/or social impact associated with natural or man-made crises or disasters.” Project funds may be transferred to respond to such emergencies at the request of the government.
and their environmental and social risks and management measures as well as a negative list of activities categorically excluded from support under the activated CERC.

3.2.2 ESS2 Labor and Working Conditions

The Labor Code of the Philippines is the main legislation that protects workers’ rights including security of tenure, self-organization, collective bargaining, and humane working conditions. The Labor Code provides a competent system that allows for speedy resolution of labor disputes and includes a provision on grievance machinery and voluntary arbitration. The Labor Code together with RA 11058 on occupational health and safety plus other Philippine laws prohibiting forced and child labor and sexual harassment provide a suite of national legislation that is relatively aligned with the provisions of ESS 2.

Most activities supported by the Project will be conducted by health and laboratory workers, i.e. civil servants employed by the Government of the Philippines and professional consultants and contractors (hired as contracted workers). Activities encompass the provision of quarantine and isolation rooms, proper storage for medicines, PPEs, laboratory equipment necessary for the proper care of COVID-19 patients which may require minor expansion that would involve small-scale civil works for medical facilities refurbishment or completion of ongoing construction. There is a risk that health care workers are exposed to COVID-19 during the initial screening and vaccine administration in the health facility or community setting. There is also a risk that the cleaners and waste collectors of the health care facilities and waste service providers are exposed to infectious wastes generated from the immunization activities. The key risk is the contamination with COVID-19 (or other contagious illnesses as patients taken seriously ill with COVID-19 are likely to suffer from illnesses which compromise the immune system), which can lead to illness and death of workers.

The project will ensure the application of OHS measures as outlined in the ESMF’s Labor Management Procedures (LMP) (Annex B), the Philippine Labor Code, the Philippine Occupational Health and Safety Act and the International Labor Office Occupational health and safety management systems (ILO- OSH 2001). These laws and guidelines provide basis for the procedures for entry into health care facilities, including minimizing visitors and undergoing strict checks before entering; procedures for the protection of workers in relation to infection control precautions; provision of immediate and ongoing training on the procedures to all categories of workers, and post signage in all public spaces mandating hand hygiene and PPE; ensuring adequate supplies of PPE (particularly facemask, gowns, gloves, handwashing soap, and sanitizer); and overall ensuring adequate OHS protections in accordance with General EHSGs and industry-specific EHSGs and follow evolving international best practice in relation to protection from COVID-19. Also, the project will regularly integrate the latest guidance by WHO as it develops over time and experience addressing COVID-19 globally.

The project’s LMP incorporates issues for the DOH staff and contracted workers: working conditions and management of worker relationships, protecting the workforce and ensuring proper OHS, and a grievance mechanism for project workers whether direct or contracted workers hired for the small-scale civil works. Child labor is forbidden in accordance with ESS2 and Philippines law, and due to the hazardous work situation, no person under the age of 18 will be hired by the Project.
To prevent risks of Sexual Exploitation and Abuse (SEA) and Sexual Harassment (SH), Gender-Based Violence (GBV) and/or Violence Against Children (VAC) from interactions within work forces and between workers and patients and other community members, the LMP includes provisions for training on community interaction and SEA/SH/GBV/SEA to all teams, staff (civil servants and outsources staff/contractors) to ensure the teams respect local communities and their culture and will not engage in misconduct, including Codes of Conduct (CoC). Other relevant documents, such as letter of DOH’s staff appointment and contracts for contracted workers in line with relevant national laws and legislation to be adopted and applied under the project, will also include the CoC. The LMP includes similar provisions for security personnel that will be involved in project activities, for instance in providing security at health facilities.

3.2.3 ESS3 Resource Efficiency and Pollution Prevention and Management

The Philippines has very comprehensive regulatory mechanism for regulating hazardous wastes. The challenge exists in relation to the availability of hazardous waste transporter and treatment and disposal facilities in various parts of the country. Title III of DAO 29 of RA 6969 defines the legal and technical requirements of hazardous waste management. The requirements for hazardous waste generators, transporters, and treaters are outlined in DAO 2013-22 including the procedures to follow to comply with the provisions of the law. The DENR EMB MC 2020-20 specify the health and safety protocols for compliance of the transporters and TSD facilities to ensure the proper handling of infectious COVID-19 wastes. The safety protocols include the preparation and submission of reports such as the report of compliance and completion of transport or the manifest and the certificate of treatment (COT) after each completed transport and treatment of the transporter and TSD, respectively. The ESMF is prepared based on national legislation as well as ESS3.

Wastes generated by healthcare facilities, laboratories, quarantine and isolation centers, and screening posts may include infectious wastes such as pathological wastes, sharps, pharmaceutical wastes, and chemical wastes (including water, reagents, infected materials, etc.) from the laboratory testing. The COVID-19 immunization activities may also generate infectious wastes in the form of sharps, syringes, vials, cotton swabs and PPEs used by healthcare workers during administration of the vaccine. These types of wastes are classified as hazardous wastes which may have substantial impact on the environment and human health when handled and disposed inappropriately. All facilities will follow the requirements of the ESMF and the national standards and regulations in place such as the DOH Healthcare Waste Management Manual (4th edition). The DENR also sets the requirements for the registration of healthcare facilities as hazardous waste generators and the commissioning of DENR-registered transporters and treaters in cases when the health care wastes are treated and disposed offsite.

Disposal of health care waste will not be permitted at sites which threaten human or environmental health including natural habitats. It similarly includes measures to ensure that standards relevant to the provision and protection of water resources and the effective management of wastewater from the facilities are observed. Measures related to transportation and management of samples and medical goods or expired medications and chemicals are also included in the Infection Control and Waste Management Plan (ICWMP). The project, as documented in the ESMF, will ensure the use of resources (water, air, etc.) in quarantine facilities and laboratories and that standards and measures consistent with the US- Center for Disease Control (CDC), and the WHO environmental infection control guidelines for medical facilities will be followed. As indicated, there is no major physical works planned yet.
In support to the ESMF, the Project developed healthcare waste management self-assessment audit tools for the adoption and regular use of the project recipient hospitals. The tools aim to monitor the waste management of hospitals, particularly on COVID-19 vaccination and other related infectious wastes, to ensure the safety of the staff, community, and the environment. Through the self-assessment, hospitals would be able to identify the gaps and barriers in proper infectious waste management. The results of the assessment would also aid the Project to provide informed support to the project recipients such as through capacity building.

3.2.4 ESS4 Community Health and Safety

A variety of national legislations exist that are at par with the provisions of ESS 4. The Philippine EIA review process ensures that assessments of health and safety impacts of projects in the community are conducted. Public health issues are referred to the Department of Health.

The communities may have fear and apprehension on COVID-19 vaccination due to its efficacy and safety. Misinformation on the adverse health effects of vaccines and other rumors remain widespread and add to the fears on vaccine safety. To ensure the safety of the COVID-19 vaccines, the approval of the vaccine by the WHO-identified SRAs as well as the proper storage and transport conditions will be observed. The profiling and screening of candidate individuals to be vaccinated as well as the data management system should done to avoid the risk of vaccine contraindications. Risk communications for the populations will also be done together with counselling and prior informed consent. Ensure existence of protocols regarding consent to vaccinations, process for agreeing to or refusing to be vaccinated, and measures to protect those that refuse to be vaccinated would be in place at regional and local levels.

Health care wastes generated from vaccine administration have a potential of carrying microorganisms that can infect the community at large if they are not properly collected, stored, treated, and disposed of. There is a possibility for the infectious microorganism to be introduced into the environment if not well contained within the health care facility or laboratory or due to accidents or emergencies, such as a fire response or natural phenomena event (e.g., seismic). The health care facilities and possible community settings involved in the vaccine administration, laboratories, quarantine and isolation centers, and screening posts will have to follow appropriate COVID-19 prevention and control protocol, procedures, and guidelines applicable infection prevention and control and health care waste management procedures prescribed by the DOH, DENR and the LGUs where the facilities are located. The operation of quarantine and isolation centers needs to be implemented in a way that staff, patients, and the wider public follow and are treated in line with the international good practices for patient handling and treatment as outlined in the WHO guidance for COVID-19 response.

The Magna Carta for Disabled Persons and the Accessibility Law ensure that persons with disabilities are granted universal access. In 1995, RA 7877 was signed into law which prohibits sexual harassment in the workplace and in educational settings including training. In 2019, the Safe Spaces Act expanded the coverage to include online work, all public spaces, and gender-based violence among peers. Payment for ecosystem benefits is a known concept in the country but so far there is no legislation to support its use and is not relevant to the Project at hand. Moreover, the vulnerable groups are considered in the vaccine population prioritization.
The Project’s Stakeholder Engagement Plan (SEP) also ensures engagement with communities in order to disseminate information related to project activities, particularly with communities in the vicinity of health facilities, such as screening and quarantine facilities.

The project will need to mitigate potential risks of Sexual Exploitation and Abuse by applying the WHO Code of Ethics and Professional Conduct for all workers in the quarantine facilities as well as the provision of gender-sensitive infrastructures, such as segregated toilets and enough lighting in quarantine and isolation centers. As noted under ESS2, the LMP includes provisions to prevent SEA/GBV/SEA through training and Codes of Conduct (CoC) to ensure workers respect local communities and their culture and will not be involved in misconduct.

Crowd management in vaccination sites will also be observed. Crowd management for the COVID-19 vaccination sites is to use some uniformed or security personnel to ensure the observance of social distancing and peace and order. In relation to security of the vaccines, supplies, and equipment during delivery, DOH’s freight service provider ensures that all vaccines are delivered intact and safe onsite with the proper storage and transport conditions. DOH reports that security has not been an issue in the delivery of equipment in different areas nationwide. However, as COVID-19 may develop in unpredictable ways and due to potential concerns among the public, the use of additional government security personnel from the local or national police, or in some instances possibly the military, may be directed to implement measures to ensure peace and order in affected areas, including in vaccine administration sites, quarantine, isolation, decontamination, and other health facilities.

The potential scope of such security measures, and potential risks surrounding them, have been assessed as part of preparing the ESMF to manage environmental and social risks concerning project activities and monitored during project implementation. In cases where project activities are supported by private or government security personnel, it will be ensured that the security personnel follow a strict code of conduct and avoid any escalation, taking into consideration protocols consistent with ESS4 and best practice international guidance as outlined in IFC Good Practice Handbook on the Use of Security Forces: Assessing and Managing Risks and Impacts."14 Likewise, any incident involving security personnel will need to be recorded in the Grievance Mechanism, described under ESS10, following WB incident classification: indicative, serious and severe. Any severe incident involving security personnel will need to be reported to the World Bank no later than 48 hours with basic information and a detailed incident report within 10 workings days. Details about incident classification and incident reporting are included under Annex B – Labour Management Procedure (LMP).

3.2.5 ESS7 Indigenous Peoples/Sub-Saharan African Historically Underserved Traditional Local Communities

The Bank’s ESS 7 on Indigenous Peoples/Sub-Saharan African Historically Underserved Traditional Local Communities (IPs or Indigenous Cultural Communities/ Indigenous Peoples (ICC/IPs) in the Philippines context) aims to:

- ensure that the development process fosters full respect for the human rights, dignity, aspirations, identity, culture, and natural resource-based livelihoods of IPs;

---

• avoid adverse impacts of projects on IPs, or when avoidance is not possible, to minimize, mitigate and/or compensate for such impacts;
• promote sustainable development benefits and opportunities for IPs in a manner that is accessible, culturally appropriate and inclusive;
• improve project design and promote local support by establishing and maintaining an ongoing relationship based on meaningful consultation with IPs affected by a project throughout the project’s life cycle;
• obtain the Free, Prior and Informed Consent (FPIC) of affected IPs in the three circumstances described in ESS7; and
• recognize, respect and preserve the culture, knowledge, and practices of IPs, and to provide them with an opportunity to adapt to changing conditions in a manner and in a timeframe acceptable to them.

When indigenous peoples are present in, or have collective attachment to, a project area ESS7 requires that:

• The IPs should be fully consulted about, and have opportunities to actively participate in, the project design and the determination of project implementation arrangements.
• There should be an assessment of the nature and degree of the expected direct and indirect economic, social, cultural (including cultural heritage), and environmental impacts on them.
• The borrower should develop a consultation strategy and means by which affected IPs will participate in project design and implementation and adopt measures and actions in consultation with the affected IPs to be contained in a time-bound plan (IP Plan) which will be proportionate to the potential risks and impacts of the project.
• Adverse impacts on the IPs should be avoided by exploring alternatives to the project and where adverse impacts are unavoidable, the Borrower will minimize, mitigate and/or compensate for these impacts in a culturally appropriate manner. The mitigation and compensation measures shall include culturally appropriate and sustainable development benefits whether delivered through the community or individually.

The standard requires free, prior, and informed consent (FPIC) when a project may have adverse impacts on the land and natural resources, cause relocation or have significant impacts on IPs’ cultural heritage. None of these circumstances are present in this project.

There are a few differences between the national framework and ESS7. These concern the requirements for FPIC, the scope of undertaking a social assessment, preparing an Indigenous Peoples Plans (IPP), and disclosure and monitoring of such plans. However, given the nature of the project’s activities, these differences do not have material effects and the project would not require free, prior and informed consent under ESS7 or IPRA, nor require the preparation of IPPs. Sections 4.2 and 6.2 of this ESMF describes the measures for engagement with indigenous peoples at health facilities supported by the Project and measures to address particular issues concerning indigenous peoples, including through working with traditional health practitioners and local experts to ensure that affected members of indigenous communities are able to access appropriate health services.
3.2.6 ESS10 Stakeholder Engagement and Information Disclosure

The PEISS provides for information dissemination and the conduct of consultations as required under ESS 10. The DENR Guidelines on Public Participation under the PEISS provides that for the entire EIA process, public participation should be conducted with the stakeholders during the early and various stages of the process. The stakeholders should be involved in the assessment, management, and monitoring of environmental impacts of a project. Public information/disclosure is required, especially to the stakeholders to enable them to understand and appreciate their participation in the whole process. The PEISS also has provisions on grievance redress but these are limited to environmental issues and not for all project concerns as required in ESS 10. However, government agencies including DOH have set up their own hotlines and systems for dealing with complaints from the public. These hotlines and systems will be redesigned and reviewed to ensure a mechanism with multiple intake points for feedback and grievances in relation to the vaccine program. As a result, PEISS and DOH will establish an Emergency Operations Center with complete data management systems and tools particularly for the COVID-19 deployment nationwide.

The SEP has been prepared based on ESS10 and PEISS. The project recognizes the need for effective and inclusive risk communication and engagement with all relevant stakeholders and the population at large. Considering the serious challenges associated with COVID-19 pandemic and the COVID-19 vaccines, dissemination of clear messages around physical distancing, high-risk demographics, self-quarantine, and when necessary, mandatory quarantine is critical. Meaningful consultation, particularly when public meetings are counter to local and national advisories on physical distancing, means that meaningful disclosure of appropriate information and innovative and virtual stakeholder engagement assume huge significance for ensuring public health and safety from all perspectives social, environmental, economic, and medical/health. To address these challenges a Stakeholder Engagement Plan (SEP) has been prepared. The SEP defines a program for stakeholder engagement, including public information disclosure and consultation, throughout the entire project cycle. It outlines the ways in which the DoH and partners will communicate with stakeholders and includes a grievance redress mechanism by which people can raise concerns, provide feedback, or make complaints about the project and any activities related to the project. Provisions have been included to reach and meaningfully engage vulnerable and disadvantaged groups (e.g., elderly, children, poor households, vulnerable groups, people with disabilities and indigenous peoples), including in rural areas with little access to the internet.

Under the parent project, a preliminary vaccine allocation for priority eligible groups as well as mapping of stakeholders was included. Individuals and groups likely to be affected (direct beneficiaries) have been identified. Mapping of other interested parties such as government agencies/authorities, at regional and local levels, NGOs and CSOs, and other international agencies have also been done. The additional financing will support the costs of expanding activities of the Philippines COVID-19 Emergency Response Project (P173877, the parent project)\(^\text{15}\) to enable affordable and equitable access to COVID-19 vaccines and help ensure effective vaccine deployment in the country through enhanced vaccination system and to further strengthen preparedness and response activities under the parent project for additional US $ 300 million. As a result, the SEP will be revised to strengthen social mobilization, information awareness and risk communication and engagement strategy for the COVID – 19 vaccine

deployment nationwide. The strategy will ensure to generate confidence, acceptance, and demand for COVID-19 vaccines.

As a result, the draft SEP will be re-disclosed publicly by DOH and at the World Bank’s external website. The SEP will be updated during implementation and publicly re-disclosed as needed.

3.3 International and Regional Regulations and Guidance

3.3.1 Vaccine Introduction Readiness Assessment Tool (VIRAT)/Vaccine Readiness Assessment Framework (VRAF) Integrated Tool

The Vaccine Introduction Readiness Assessment Tool (VIRAT)/Vaccine Readiness Assessment Framework (VRAF) Integrated Tool was developed by WHO, UNICEF and the World Bank. The introduction of the integrated tool or Readiness Assessment Tool is a national level instrument which aims to assist countries assess readiness to deliver COVID-19 vaccines when they become available; identify gaps and prioritize opportunities for enhanced readiness; and identify opportunities for financial support.

The VIRAT/VRAF tool measures countries’ readiness to administer the COVID-19 vaccine across ten categories namely: a) Planning and Coordination, b) Budgeting, c) Regulatory, d) Prioritization, Targeting and COVID19 Surveillance, e) Service Delivery, f) Training and Supervision, g) Monitoring and Evaluation, h) Vaccine, Cold Chain, Logistics, and Infrastructure, i) Safety Surveillance, j) Demand Generation and Communication. Within these categories are assessment/activity areas. The tool is designed to provide information necessary for identifying gaps in readiness across the various activities, listing actions necessary to meet the gaps and generating financial implications of those actions.

3.3.2 World Health Organization

WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply

The Strategic Advisory Group of Experts (SAGE) on Immunization of the World Health Organization (WHO) has released guidelines on 13 November 2020 on the implementation of national vaccination programs against COVID-19 which include the values framework, prioritization roadmap, and vaccine- specific recommendations. It outlines vaccine allocation, prioritization, and administration recommendations.

WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination

The WHO SAGE published the Values Framework for the Allocation and Prioritization of COVID-19 Vaccination on 14 September 2020 to provide guidance for countries on national prioritization and allocation of COVID-19 vaccines considering the limited supply. The main goal is for the COVID-19 vaccines to contribute significantly to the equitable protection and promotion of human well-being among all people of the world. The guiding principles include the (a) human well-being, (b) equal respect, (c) global equity, (d) national equity, (e) reciprocity, and (f) legitimacy.

Under national equity, the goals include to (1) ensure that vaccine prioritization within countries takes into account the vulnerabilities, risks and needs of groups who, because of underlying societal, geographic or biomedical factors, are at risk of experiencing greater burdens from the COVID-19 pandemic; and to (2) develop the immunization delivery systems and infrastructure
required to ensure COVID-19 vaccines access to priority populations and take proactive action to ensure equal access to everyone who qualifies under a priority group, particularly socially disadvantaged populations.

Hence, priority groups and others which need to be consider include the following:

- People living in poverty, especially extreme poverty
- Homeless people and those living in informal settlements or urban slums
- Disadvantaged or persecuted ethnic, racial, gender, and religious groups, and sexual minorities and people living with disabilities
- Low-income migrant workers, refugees, internally displaced persons, asylum seekers, populations in conflict setting or those affected by humanitarian emergencies, vulnerable migrants in irregular situations, nomadic populations
- Hard to reach population groups

Risk communication and community engagement readiness and response to coronavirus disease (COVID-19)

This guideline release by WHO on 19 March 2020 provides checklists for risk communication and community engagement (RCCE) readiness and initial responses to the COVID-19 outbreak for countries in preparation for the pandemic as adopted from the adapted from the WHO’s RCCE guidance and training materials. It describes steps on the implementation of effective RCCE strategies which contribute to public health protection. It fosters proactive public communication of experts and authorities and gauges the risk perception of population groups.

Laboratory Assessment Tool for laboratories implementing COVID-19 testing

This tool has been designed to assess the capacity of laboratories that have implemented or intend to implement testing for SARS-CoV-2, the virus that causes novel coronavirus disease 2019 (COVID-19). The tool is a shortened version of the 2012 Laboratory assessment tool that is widely used to assess national laboratory systems and the capacity of laboratories.

Laboratory biosafety guidance related to coronavirus disease (COVID-19)

The purpose of this document is to provide interim guidance on laboratory biosafety related to the testing of clinical specimens of patients that meet the case definition of the novel pathogen identified in Wuhan, China, that is, coronavirus disease 2019 COVID-19 in all duly accredited laboratories -


Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19)

This document summarizes WHO’s recommendations for the rational use of personal protective equipment (PPE) in health care and community settings, as well as during the handling of cargo; in this context, PPE includes gloves, medical masks, goggles or a face shield, and gowns, as well as for specific procedures, respirators (i.e. N95 or FFP2 standard or equivalent) and aprons.
The document includes guidance on PPE in various settings including points of entry in all healthcare facilities, quarantine and isolation rooms and laboratories.

**Global manual on surveillance of adverse events following immunization**

This Manual was developed by WHO in 2014 to provide guidance for the managers of immunization programmes and others responsible parties for vaccine safety and quality on the (a) strategies and systems for ensuring quality and safety of vaccines, (b) objectives of vaccine and immunization safety surveillance, (c) AEFI surveillance system: reporting, investigation, causality assessment and the new classification of cause-specific AEFI, (d) understanding vaccine reactions for better decision-making, (e) best use of surveillance data, and (f) response processes, including a communication strategy on immunization safety for the public and the media.

3.3.3 **Stockholm Convention**

The *Stockholm Convention on Persistent Organic Pollutants* is a global treaty to protect human health and the environment from chemicals that remain intact in the environment for long periods, become widely distributed geographically, accumulate in the fatty tissue of humans and wildlife, and have harmful impacts on human health or on the environment. Exposure to Persistent Organic Pollutants (POPs) can lead to serious health effects including certain cancers, birth defects, dysfunctional immune and reproductive systems, greater susceptibility to disease and damages to the central and peripheral nervous systems.

The Philippine government ratified the Convention in 2004 and is therefore required (under Article 5) to take measures to reduce or eliminate releases from unintentional POPs production. The Convention requires the promotion of best available techniques and best environmental practices to reduce these releases. Medical waste incineration is a significant source of POPs in the form of dioxins and furans which can be released in the form of emissions from the burning process and in ash remaining after combustion.

3.3.4 **Kigali Amendment to the Montreal Protocol on Substances that Deplete the Ozone Layer**

The Kigali Amendment to the Montreal Protocol on Substances that Deplete the Ozone Layer, which was adopted in the 28th Meeting of the Parties of the Protocol in 15 October 2016. The Kigali Amendment aims to phase down the consumption and production of hydrofluorocarbons (HCFs) as stated in Decision XXVIII/1. This was ratified by 65 countries and led by the UN Environment Programme (UNEP) with the aim of preventing global warming by up to 0.4°C this century by reducing the production and consumption of hydrofluorocarbons (HFCs) and potent greenhouse gases (GHGs).
3.3.5 Doha Declaration on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and Public Health

The Doha Declaration in 2001 which was adopted by the member states of the World Trade Organization (WTO) addresses the issue on the access of affordable medicines for developing countries in the context of disease control and public health protection, such as for HIV, tuberculosis, and malaria. It balances the interests of the suppliers with intellectual property rights protection and the consumers with interest on price affordability.

The Doha Declaration ratifies that the TRIPS agreement should not restrict access of countries from affordable drugs and details the ‘right to grant compulsory licenses and the freedom to determine the grounds upon which licenses are granted, the right to determine what constitutes a national emergency and circumstances of extreme urgency, and the freedom to establish the regime of exhaustion of intellectual property rights.’

In relation, the World Trade Organization delays decision on the waiver on COVID-19 drugs and intellectual property rights for COVID-19 vaccines\(^\text{16,17}\).

4 Environmental and Social Baseline

The Philippines moved aggressively to mitigate the COVID-19 pandemic at an early stage when confirmed cases were still at a very low level. The President declared the whole Philippines under a State of Calamity for a period of six months from March 16 and imposed an Enhanced Community Quarantine (ECQ) throughout the island of Luzon (which includes Metro Manila) from March 17 to May, with location-specific community quarantine guidelines per time period.

On March 24, 2020, the Congress passed the Bayanihan To Heal As One Act (Republic Act no. 11469) which declares a national emergency due to COVID-19, and grants the President expanded powers to adopt measure to prevent and suppress the spread of COVID-19 for three months. The Act also authorizes the Executive branch to reallocate and realign savings from the national budget as well as from government corporations. The Bayanihan to Recover As One Act or the Republic Act no. 11494 dated July 27, 2020 provides guidelines on the COVID-19 response and recovery interventions and acceleration of recovery including the economy.

The number of confirmed COVID-19 cases has continued to increase rapidly. After ramping up testing capabilities, current testing capacity is approximately 1,000 per day. Based on the official tally reported by DOH, as of December 14, 2020, there have been 450,733 confirmed cases and 8,757 deaths. Confirmed cases stretch across the age distribution, with a larger share among those age group of 20-30 with mostly male. The epicenter of COVID-19 is Metro Manila, which accounts for 72.6% of confirmed cases. In the COVID-19 Situation Report for the Philippines, the WHO notes that hospitals have faced shortages of active-duty healthcare workers, Personal Protective Equipment, and ventilators.


4.1 Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines

The Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines was drafted for the purpose of providing operational guidance in the implementation of the COVID-19 vaccine deployment and vaccination program. It is a living plan to be updated as more information becomes available or as recommendations are provided by international and national organizations. Its development has involved the participation of various government agencies to ensure alignment of policies and plans among agencies and integration of the said plans into national governance mechanisms. The development process for this Plan was participatory and involved various stakeholders led by the COVID-19 Vaccine Cluster and its Task Group (TG) and Sub-Task Group (STG) members. These TGs and STGs were composed of various Departments and Agencies as outlined in the section of Governance. The TGs and STGs under the COVID-19 Vaccine Cluster developed briefs to guide the implementation of the vaccine. Key Informant Interviews were also conducted to understand various perspectives in addition to various rapid assessments. A short-term technical assistance staff was hired to collate the briefs/guides developed by each of the TGs and STGs. A series of meetings were held to review and enrich the plan. The final draft of the NDVP was presented to the DOH Executive Committee, COVID-19 Vaccine Cluster of the National Task Force for endorsement.

The target audience includes policy makers, planners, program and project implementers, development partners, health service providers, partners in public and private sector, civil society organizations, health consumers, and the general public. The NDVP was approved and ratified by the IATF Resolution no. 95 and further reinforced by the NTF Against COVID-19 Memorandum Circular no. 5 series of 2021.

4.1.1 Shipment and Storage

1. Supply Chain System

To ensure uninterrupted availability of quality vaccines from manufacturer to service-delivery points, effective vaccine storage, handling, and stock management should be observed through proper temperature control in the cold chain and maintenance of adequate logistics management information systems. In response to the foreseen complex supply chain management of the COVID-19 vaccines, a rapid assessment has been conducted by the DOH to identify strengths and gaps in the existing end-to-end supply chain system to prepare and build capacity which include but are not limited to the following parameters: storage systems, distribution, real time temperature monitoring and tracking, real-time tracing, and reporting of vaccine stocks. Based on the results of the assessment, the implementation will be guided by the NDVP, with the following measures:

- Coordinated deployment plans and standard operating procedures (SOPs) are developed and communicated to all levels of the supply chain;
- Adequately trained, and sufficient quantity of supply chain and health staff;
- Sufficient cold chain capacity, including surge capacity, and capacity for ongoing maintenance, necessitating the contracting of private providers;
- Efficient supply chain system and infrastructure, preferably leveraging on existing systems;
- Real time robust data recording and reporting mechanism for vaccines and cold chain equipment;
- Robust oversight and data-driven management, including systems for monitoring adherence to cold chain practices; and
- Adequate secured resources from both internal and external sources.

The supply chain process will involve the receipt of vaccines in the Philippines from several manufacturers, the storage of these vaccines in a temperature controlled central storage facility, preparation of vaccines for distribution to vaccination locations and the delivery logistics to vaccination locations (Figure 4.1). Additional supply chain and logistics expertise across the wider public sector and the private sector will be leveraged where necessary.

**Figure 4.1. Five components of the supply chain management**

**Supply from manufacturers.** The arrangements for supply of potentially approved vaccines from pharmaceutical companies as well as from the GAVI COVAX facility and the timing of delivery to the Philippines are currently under discussion. It is expected that the volume of vaccines delivered will ramp-up through 2021 as production capacity increases. Shipping methods from manufacturing sites will mainly be by air and agreed upon with manufacturers. Supply Chain risks associated with natural disasters and emergencies will be included in contingency planning.

**Proposed distribution process flow for COVID-19 vaccines and ancillary immunization.** The proposed process flow of the vaccines and other immunization supplies at the national level from the notification of the delivery up to the reverse logistics for the final disposal of the immunization wastes gathered from all the vaccination sites is summarized in Figure 4.2. The CHDs and the LGUs as well as those that will be identified as recipients of these immunization commodities shall likewise develop their distribution plan appropriate to their situation. This shall be consolidated by the Task Force to develop a comprehensive national cold chain and logistics plan for COVID-19 vaccination. A detailed process in each category shall be presented. Existing relevant forms required for each process shall be reviewed, revised and adopted specific for this purpose.

**Figure 4.2. Distribution process flow for COVID-19 vaccines and ancillary immunization supplies**
2. Cold Chain Management

The storage of the COVID-19 vaccines will be centralized and managed preferably by a single logistics provider with substantial relevant experience considering the Philippines’ geographic size and population. It should be noted that the COVID-19 vaccines require refrigeration with temperature ranges of +2°C to +8°C, -15°C to -24°C and to as low as -70°C to -80°C. As the different types of vaccine require varying temperature storage requirements, (1) ultra-cold (-70°C to -80°C), (2) frozen (-15°C to -25°C), and (3) refrigerated (2°C to 8°C), the identified logistics partner/s should have substantial capacity for each temperature range.

Cold chain management, whereby adequate refrigeration levels are maintained from manufacturing, storage, and distribution of vaccines, ensuring integrity of vaccine compounds via specialized packaging as well as refrigeration and freezer devices are needed. However, ensuring effective cold chain management for COVID-19 vaccines shall entail particular requirements and constraints on temperature maintenance for transport and storage and administration of the vaccines. With this, supply chain readiness at all the management levels shall be in place to efficiently deploy COVID-19 vaccines to the target population.

To ensure the correct volume of vaccines are received by each Vaccination Administration Location (VAL) at the right time, a robust, accurate, real-time inventory management system will be in place to guarantee availability and maintenance of adequate supplies, minimize potential wastage, and accurately forecast demand which can be met. The varying storage temperatures and shelf-lives out of storage of each vaccine type will mean certain vaccine types may be more suited to certain vaccination location types, depending on the volume of vaccinations carried out at the setting and the storage facilities on site. The distribution plan has accounted for this assigning the different vaccines for different locations. Ensuring adequate availability of the vaccine for the second dose will also be considered when managing stock levels.
In view of the three (3) main temperature categories, namely: (1) +2°C to +8°C, (2) -20°C and (3) -70°C to -80°C, a scenario based planning has been developed. The first two temperature ranges can be handled in the current health structures because vaccines in the National Immunization Program (NIP) has the same temperature requirement. However, the vaccines requiring -70°C to -80°C are new and shall need a special storage package and a complicated distribution mechanism. Thus, the following scenarios has been considered in the vaccine distribution:

Table 4.1. Vaccination scenario per temperature requirement and cold chain management strategy

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Temperature (Deg C)</th>
<th>Proposed Cold Chain Management Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>+2 to +8</td>
<td>Distribution shall follow the pathway for the routine vaccines from the national cold storage facilities up the service delivery points, the health centers and hospitals allow the cold chain storage and distribution in NIP pathway of the current vaccines in the National Immunization Program of the DOH. These vaccines require +2°C to +8°C cold storage facilities. Such facilities are in place such as the Research Institute for Tropical Medicine (RITM) as the centralized vaccine hub, regional warehouses and the RHUs and hospitals.</td>
</tr>
<tr>
<td>2</td>
<td>-20 to -70 to -80</td>
<td>Currently, none of the government hospitals are capable of such, thus the government will have to procure or outsource/hire a private facility.</td>
</tr>
</tbody>
</table>

These scenarios may also vary based on the services that will be provided by the vaccine manufacturer such as but not limited to direct distribution to the service delivery sites and presence of distributors. In the country, the existing infrastructure and established vaccination distribution channels will mean vaccines can be delivered efficiently using air and road distribution channels directly from the central storage facility to the designated cluster hub warehouses. The logistics partner/s will also manage the delivery fleet and outbound logistics/delivery to the principal vaccination locations. All deliveries will be by chilled (+2°C to +8°C) distribution using the selected logistics partner’s fleet. The fleet will operate to a very high specification with full GPS monitoring, remote temperature monitoring and redundancy on the cooling systems on the vehicle. The vaccine handling characteristics for other vaccines will be more clearly defined by manufacturers as the regulatory approvals process emerges.

Assessment of Cold Chain Facilities and Dry Storage Capacities. The plan to introduce the vaccine includes the calculation of additional space requirements and cold chain equipment at the national, and local levels, and even in the vaccination rooms. The data on additional storage requirements are based on the dosage form and characteristics of the new vaccine and those currently in use. and transport capacity for the vaccine at each level of the cold chain, determining the need for additional equipment. This evaluation offers an ideal opportunity to update the national cold chain inventory by type of equipment and operating condition. Both public and privately managed cold storage facilities and logistics providers shall be assessed and visited in partnership with the FDA. As of today, the number and locations of the cold chain and dry storages are not yet finalized.
Distribution of the Ancillary Immunization Supplies. Ancillary immunization supplies provided by the program shall include auto-disabled (AD) needles and syringes, mixing syringes, safety collector boxes (SCB), PPEs (masks and face shields). The same process as above shall be followed. It is planned that all these items shall be delivered earlier than the vaccines.

4.1.2 Distribution and Deployment

The identification of eligible populations for vaccination was based on the WHO Strategic Advisory Group of Experts on Immunization (SAGE) Values Framework for the Allocation and Prioritization of COVID-19 Vaccination and the recommendations of the National Immunization Technical Advisory Group (NITAG) of COVID-19 Vaccines shall guide the identification and finalization of the eligible population, taking into consideration the national context, the epidemiologic settings and the COVID-19 vaccine characteristics and supply. The Decision Matrix and the priority eligible populations for COVID-19 vaccination are in Chapter 7.

1. Vaccine Deployment Strategies

The deployment of vaccines will be in a phased approach depending on the delivery (timing, available doses, logistical requirements) of vaccines to the country. It will be executed based on sectoral approach - that is, all frontline healthcare workers will be vaccinated first before proceeding to the next priority group. The number of individuals to be vaccinated in a round will depend on the total number of vaccines delivered, in which computation of the 2nd dose is already considered. Since the delivery of vaccines to the country is in tranches, the deployment of vaccines in specific geographical areas shall be based on the burden of COVID-19 cases. In the identification of geographical areas, the NITAG set the indicators in determining the areas with high burden of COVID-19 cases. The indicators are as follows:

1. Number of Active Cases in recent four weeks
2. Attack rate per 100,000 in recent four weeks

Active cases refer to the total confirmed cases less those recovered and fatalities. These active cases as such are assumed to be still infectious and currently isolated. For the purpose of this ranking, the attack rate was computed using the total newly reported cases in the recent 4 weeks divided by the region's projected population and a multiplier of 100,000 population. The determination of priority geographical areas will be per region. Likewise, the NITAG will review the burden of COVID-19 cases in the country every month and will recalibrate the priority areas accordingly.

Table 4.2. Priority regions based on burden of COVID-19 cases as of January 2021
As the National Government will roll-out policies and plans, several activities in coordination with the Local Government Units will be conducted, such as simulation activities, such as table activities and drills, to test local plans and implementation of policies in the local level (Figure 4.3).

Figure 4.3. Vaccine deployment and service delivery activities

### PRE-IMPLEMENTATION ACTIVITIES

- **Identification vaccine & eligible population**
  - Evaluation and Selection of Vaccine
    - FDA Approval (EUA) thru EO of the President
    - Other considerations
      - Subjects of Phase III clinical trials
      - Mass vaccination
    - Vaccine Expert Panel Health Technology Assessment
    - Council/National Immunization Technical Advisory Group recommendations
  - Simulation
    - Geographic
    - Priority eligible population
    - Sample size
    - Vaccination sessions
    - Strategies
    - Vaccination processes
  - Profiling & Screening
    - History and PIs
    - Possibly, diagnostics
  - Registration
    - With document requirements
    - Health declaration forms
    - Informed consent & schedule
    - Use of digital platform

- **Identification of Simulation Areas**

- **Masterlisting, Screening and Registration**

- **Vaccine Allocation & Distribution**

- **IMPLEMENTATION ACTIVITIES**

- **Vaccine Administration**

- **Post Authorization Surveillance**

- **AEFI monitoring and response**
  - Use of application for AEFI monitoring
  - AEFI monitoring for 24 and 12 months
  - Active and passive surveillance

### 2. Vaccine Distribution Strategies

As the manner of the distribution of vaccines will depend on the storage requirements specific to each vaccine, the DOH will provide a Department Memorandum detailing the operational
guidelines, including the vaccine storage and cold chain requirements, delivery and deployment mechanisms for each specific vaccine.

For vaccines requiring +2°C to +8°C storage, the vaccines will be delivered from the supplier to the RITM, which will serve as the government Centralized Vaccine Hub. From RITM, the vaccines will be passed on to the regional warehouses/hubs. The Centers for Health Development, in coordination with logistics partners and other government agencies, shall deliver the vaccines to Local Government Units. The LGUs will then allocate vaccines to implementing units such as medical centers, hospitals, infirmaries, RHUs and CHOs, and private clinics, where the vaccine will be administered to the eligible recipient. The distribution process for vaccines requiring -20°C storage will utilize the same process used for vaccines requiring +2°C to +8°C storage.

In addition, for vaccines requiring -70°C to -80°C storage, the vaccines will be delivered from the supplier to a private centralized vaccine hub. And through a private distributor, the vaccines will be delivered to hospitals and medical centers with cold chain capacity to store the vaccines. Or the vaccines can temporarily be stored in rented private warehouses before they are delivered to hospitals and medical centers. Plans and arrangements will be carefully made for the vaccines to be distributed to implementing units and the administration of the vaccine to the eligible recipient.

Figure 4.4. Distribution of vaccines according to storage facility requirements

Currently, the number and location of health care facilities as COVID-19 vaccination sites, the mode of transport and vehicles for vaccine delivery, the cold chain and dry storage facilities number and location, and number of health care workers in vaccination teams have not yet been determined.

Below are the results of the initial assessment on the cold chain and dry storage or warehousing capacity which was conducted by the DOH Supply Chain Management Service (SCMS):
Table 4.3. Net cold chain storage capacity of the regions as of 10 January 2021

<table>
<thead>
<tr>
<th>CHDs</th>
<th>SITE</th>
<th>Total Net Storage Capacity (liters)</th>
<th>Currently Occupied Volume (liters)</th>
<th>Available Net Volume (liters)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-2°C to 4°C</td>
<td>-15°C to -25°C</td>
<td>+2°C to +8°C</td>
<td>-15°C to -25°C</td>
</tr>
<tr>
<td>BIM-SDH</td>
<td>173,367</td>
<td>10,631</td>
<td>161,250</td>
<td>6,367</td>
</tr>
<tr>
<td>NCR</td>
<td>9,710</td>
<td>389</td>
<td>4,150</td>
<td>-</td>
</tr>
<tr>
<td>CAR</td>
<td>7,522</td>
<td>288</td>
<td>1,688</td>
<td>-</td>
</tr>
<tr>
<td>Region 1</td>
<td>18,824</td>
<td>432</td>
<td>3,641</td>
<td>177</td>
</tr>
<tr>
<td>Region 2</td>
<td>18,951</td>
<td>144</td>
<td>2,118</td>
<td>133</td>
</tr>
<tr>
<td>Region 3</td>
<td>8,571</td>
<td>720</td>
<td>7,140</td>
<td>410</td>
</tr>
<tr>
<td>Region 4-A</td>
<td>9,710</td>
<td>741</td>
<td>3,586</td>
<td>526</td>
</tr>
<tr>
<td>Region 4-B</td>
<td>4,988</td>
<td>247</td>
<td>149</td>
<td>-</td>
</tr>
<tr>
<td>Region 5</td>
<td>16,094</td>
<td>5,264</td>
<td>9,523</td>
<td>240</td>
</tr>
<tr>
<td>Region 6</td>
<td>14,286</td>
<td>194</td>
<td>2,425</td>
<td>30</td>
</tr>
<tr>
<td>Region 7</td>
<td>10,402</td>
<td>389</td>
<td>6,089</td>
<td>389</td>
</tr>
<tr>
<td>Region 8</td>
<td>14,539</td>
<td>338</td>
<td>5,917</td>
<td>338</td>
</tr>
<tr>
<td>Region 9</td>
<td>8,824</td>
<td>391</td>
<td>4,189</td>
<td>101</td>
</tr>
<tr>
<td>Region 10</td>
<td>10,693</td>
<td>683</td>
<td>1,587</td>
<td>91</td>
</tr>
<tr>
<td>Region 11</td>
<td>20,236</td>
<td>770</td>
<td>2,212</td>
<td>45</td>
</tr>
<tr>
<td>Region 12</td>
<td>15,045</td>
<td>292</td>
<td>2,256</td>
<td>48</td>
</tr>
<tr>
<td>CARAGA</td>
<td>8,824</td>
<td>432</td>
<td>1,650</td>
<td>113</td>
</tr>
</tbody>
</table>

| TOTAL BIM-SDH | 173,367 | 10,631 | 161,250 | 6,367 | 12,117 | 4,264 |
| TOTAL CHDs    | 197,161 | 11,714 | 58,439 | 2,731 | 138,722 | 8,983 |

Table 4.4. Inventory of warehouses per DOH regional office as of 22 January 2021 (in line with GSP)

<table>
<thead>
<tr>
<th>CHDs</th>
<th>WAREHOUSES</th>
<th>STATUS</th>
<th>AREA (in sqm)</th>
<th>IDEAL STORAGE CAPACITY (in cbm)</th>
<th>AVAILABLE STORAGE CAPACITY (in cbm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Owned</td>
<td>Rented</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metro Manila</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pasig WH</td>
<td>/</td>
<td></td>
<td>792</td>
<td>130</td>
<td>26</td>
</tr>
<tr>
<td>Tala WH</td>
<td>/</td>
<td></td>
<td>25</td>
<td>20</td>
<td>22.5</td>
</tr>
<tr>
<td>Mandaluyong WH</td>
<td>/</td>
<td></td>
<td>85</td>
<td>26</td>
<td>Full</td>
</tr>
<tr>
<td>CAR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOH-CHD CAR WH (609.74 cbm ambient; 30.50 temp. controlled)</td>
<td>/</td>
<td>400</td>
<td>640.24</td>
<td>0 ambient ; 0 temp controlled</td>
<td></td>
</tr>
<tr>
<td>Pucay WH (ambient)</td>
<td>/</td>
<td>350</td>
<td>586.89</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Marcos WH (ambient)</td>
<td>/</td>
<td>250</td>
<td>426.82</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warehouse 1</td>
<td>/</td>
<td></td>
<td>272.02</td>
<td>3087</td>
<td>6</td>
</tr>
<tr>
<td>Warehouse 2</td>
<td>/</td>
<td></td>
<td>1,200.00</td>
<td>22627</td>
<td>0</td>
</tr>
<tr>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD WH (Controlled temperature)</td>
<td>/</td>
<td>450</td>
<td>583.2</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>Covered court (ambient)</td>
<td>/</td>
<td>551</td>
<td>800</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Main (Controlled Temperature)</td>
<td>/</td>
<td>29</td>
<td>75.4</td>
<td>Full (nip routine vaccines)</td>
<td></td>
</tr>
<tr>
<td>Sindalan WH</td>
<td>/</td>
<td></td>
<td>1,500.00</td>
<td>3900</td>
<td>200 cbm (dry store)</td>
</tr>
<tr>
<td>IV-A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD CALABARZON WH</td>
<td>/</td>
<td>625</td>
<td>525 cbm ambient</td>
<td>100 cbm controlled</td>
<td>9 cu.m. controlled ambient full</td>
</tr>
<tr>
<td>IV-B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD MIMAROPA WH</td>
<td>/</td>
<td>515</td>
<td>650.74</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Main WH (temperature controlled)</td>
<td>/</td>
<td>216</td>
<td>648</td>
<td>not utilized due to ongoing renovation</td>
<td></td>
</tr>
<tr>
<td>Extension WH (temperature controlled)</td>
<td>/</td>
<td>156.93  831.74</td>
<td>400 cbm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>---</td>
<td>-------------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RMC WH (ambient)</td>
<td>/</td>
<td>844</td>
<td>6750</td>
<td>54.81 cbm</td>
<td></td>
</tr>
<tr>
<td>CHD Western Visayas WH (TCF)</td>
<td>/</td>
<td>131.86  322.88</td>
<td>Full (stocks delivered from CO)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD Western Visayas WH (ambient)</td>
<td>/</td>
<td>455.31  339.81</td>
<td>Full (local purchase stocks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaro WH (ambient)</td>
<td>/</td>
<td>230.00</td>
<td>250</td>
<td>Full (stocks delivered from CO)</td>
<td></td>
</tr>
<tr>
<td>Philpost (ambient)</td>
<td>/</td>
<td>24.13</td>
<td>67.625</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>CHD Central Visayas WH</td>
<td>/</td>
<td>538</td>
<td>596.88</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>Warehouse 1</td>
<td>/</td>
<td>136</td>
<td>129</td>
<td>10 cbm</td>
<td></td>
</tr>
<tr>
<td>Warehouse 2</td>
<td>/</td>
<td>132</td>
<td>171</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>Warehouse 3 (TB Room)</td>
<td>/</td>
<td>36</td>
<td>34</td>
<td>15 cbm</td>
<td></td>
</tr>
<tr>
<td>Warehouse 4</td>
<td>/</td>
<td>109</td>
<td>38</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>Warehouse 5 (New Warehouse)</td>
<td>/</td>
<td>300</td>
<td>313</td>
<td>21 cbm</td>
<td></td>
</tr>
<tr>
<td>Warehouse 6 (C2)</td>
<td>/</td>
<td>132</td>
<td>225</td>
<td>100 cbm</td>
<td></td>
</tr>
<tr>
<td>Warehouse 1</td>
<td>/</td>
<td>228</td>
<td>658.08</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>Warehouse 1</td>
<td>/</td>
<td>200</td>
<td>600</td>
<td>200 cbm</td>
<td></td>
</tr>
<tr>
<td>Warehouse 2 (XIMEX warehouse)</td>
<td>/</td>
<td>1,000.00</td>
<td>3000</td>
<td>500 cbm</td>
<td></td>
</tr>
<tr>
<td>Arrowgo Logistics (controlled and ambient)</td>
<td>/</td>
<td>1000 sqm (including air space)</td>
<td>800 cbm</td>
<td>200 cbm</td>
<td></td>
</tr>
<tr>
<td>DOH Regional Warehouse (ambient)</td>
<td>/</td>
<td>308 sqm</td>
<td>620 cbm</td>
<td>300 cbm</td>
<td></td>
</tr>
<tr>
<td>Regional Warehouse, Main (Controlled Temp)</td>
<td>/</td>
<td>418.4</td>
<td>1296</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>Regional Warehouse, Extension (Ambient)</td>
<td>/</td>
<td>336</td>
<td>2016</td>
<td>Full</td>
<td></td>
</tr>
<tr>
<td>DOH WH (Controlled Temp.)</td>
<td>/</td>
<td>TFA - 455</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>-1st floor</td>
<td>/</td>
<td>340</td>
<td>1655</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-2nd floor</td>
<td>/</td>
<td>115</td>
<td>330</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>Annex WH (Ambient)</td>
<td>/</td>
<td>1,000.00</td>
<td>7000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOH - Cotabato City WH</td>
<td>/</td>
<td>330</td>
<td>720</td>
<td>FULL</td>
<td></td>
</tr>
<tr>
<td>MOH - Zamboanga City WH (Transit point)</td>
<td>/</td>
<td>800</td>
<td>-</td>
<td>FULL</td>
<td></td>
</tr>
<tr>
<td>MOH Office WH</td>
<td>/</td>
<td>240</td>
<td>720</td>
<td>FULL</td>
<td></td>
</tr>
</tbody>
</table>
4.1.3 Implementation of Nationwide Vaccination

The implementation of a nationwide COVID-19 vaccination program shall be in a phased approach taking into consideration the quantity of vaccines delivered to the country, the cold chain requirements, and burden of COVID-19 cases in geographical areas. Therefore, there shall be several rounds of COVID-19 vaccination campaign conducted within the year.

The Local Government Units, as mandated in Republic Act 7160, otherwise known as the “Local Government Code of 1991”, shall take the lead in the implementation of the COVID-19 vaccination program in accordance with the policies and guidelines set by the COVID-19 Vaccine Cluster and DOH. Thus, participating agencies and the private sector are enjoined to closely coordinate with the LGUs in which their health facilities are located.

On the other hand, the National Government and its regional counterparts, shall provide strategic direction, and technical and logistical assistance; cascade policies and guidelines; and capacitate implementers, among others.

Specifically, for each deployment of a specific type and quantity of COVID-19 vaccine, the DOH shall provide a Department Memorandum detailing the specific operational guidelines applicable for the specific vaccine. Further, all vaccination activities, whether the COVID-19 vaccines to be administered have been procured by the National Government, the private sector or the LGU, shall be closely coordinated with DOH and shall follow DOH policies and guidelines. No vaccination activity shall be conducted without the guidance and the knowledge of DOH.

The implementation of a nationwide COVID-19 vaccination program is divided into three phases, namely: 1) the pre-implementation phase, where preparations for the actual vaccination activity are carried out, 2) the implementation phase or the actual vaccine administration schedule, 3) the post-implementation phase, where all activities and reports to conclude a certain round are completed.

1. Pre-Implementation Phase

In the pre-implementation phase, the following activities enumerated are to be undertaken by LGUs, specifically municipalities and cities:

   1. Establishment of a Vaccination Operations Center (VOC)
   2. Masterlisting of Eligible Populations, Vaccination Workforce, Implementing Units and Vaccination Sites/Posts
   3. Microplanning
   4. Mapping of Vaccination Sites and Vaccination Workforce
   5. Vaccines, Logistics and Cold Chain Inventory and Management
   6. Capacity Building and Training
   7. Advocacy, Community Engagement and Social Preparation
   8. Preparation of Vaccination Sites/Posts
   9. Monitoring and Supervision

Masterlisting, Microplanning, and Mapping (3Ms)

The 3Ms, namely, masterlisting of eligible population, vaccination workforce and implementing units and vaccination posts/sites; microplanning; and mapping of vaccination workforce and
vaccination posts/sites are critical in the implementation of the COVID-19 vaccination program. In the succeeding section, each of the Ms will be discussed in detail.

a. Masterlisting of eligible population, vaccination workforce and implementing units and vaccination posts/sites

To prepare the country for the COVID-19 vaccination program, creation and maintenance of a masterlist of priority sectors is necessary to: (a) provide basis for identification of target eligible groups for vaccination and identification of priority areas for registration of eligible individuals; (b) ensure uniqueness of individuals in the vaccine administration plan; and (c) provide input to operational planning especially for costing and allocation of resources.

Masterlisting is the linelisting and registration of the population prior to vaccination. This could be done through an online or offline platform developed by the DICT, and DOH’s KMITS and EB. From the masterlist, eligible population for specific vaccines will be culled out and accessed by appropriate regions or LGU for registration, scheduling, mapping-out on appropriate vaccination sites and advisory.

Phased Submission of LGU Masterlists. Masterlisting shall use the phased approach, as follows:

Table 4.5. Phases of masterlisting

<table>
<thead>
<tr>
<th>Group</th>
<th>Phase 1: Workers in Frontline Health Services</th>
<th>Phase 2: All Senior Citizens (Indicate if indigent)</th>
<th>Phase 3: Indigent Population</th>
<th>Phase 4: Uniformed Personnels (UPs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>Phase 5: Other Frontline Workers and Special Populations</td>
<td>Phase 6: Remaining Population</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Interim Minimum Data Standards for the COVID-19 Electronic Immunization Registry (CEIR). The COVID-19 Electronic Immunization Registry (CEIR) shall be the official platform for masterlisting and registration for COVID-19 vaccination. External systems may be used to submit the necessary information following the Interim Minimum Required Data Fields as indicated below.

Table 4.6. Interim minimum required data fields for masterlisting

<table>
<thead>
<tr>
<th>Data Set</th>
<th>Definition</th>
<th>Type</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Category</td>
<td>Category of the Target Eligible Population</td>
<td>String</td>
<td>Dropdown</td>
</tr>
<tr>
<td></td>
<td>01 – Health Care Worker</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>02 – Senior Citizen</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>03 – Indigent</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>04 – Uniformed Personnel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>05 – Essential Worker</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>06 – Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. CategoryID</td>
<td>ID number depending on the category type</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td></td>
<td>For 01 – PRC number</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>02 – OSCA number</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>03 – Facility ID number</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>04 – PWD ID</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>05 – Other ID</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Field Description</td>
<td>Type</td>
<td>Notes</td>
</tr>
<tr>
<td>---</td>
<td>-------------------</td>
<td>--------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>3.</td>
<td>PhilHealth ID</td>
<td>Integer</td>
<td>Freetext, 12 digits only</td>
</tr>
<tr>
<td>4.</td>
<td>Last name</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td></td>
<td>Surname/Last Name</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>First name</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td></td>
<td>First Name/Given name</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Middle Name</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td></td>
<td>Middle Name</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Suffix</td>
<td>String</td>
<td>Dropdown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Contact_no</td>
<td>Integer</td>
<td>Freetext, 12 digits only</td>
</tr>
<tr>
<td></td>
<td>Contact Number</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Mobile Number</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>or Landline)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>Full_address</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td></td>
<td>Unit/ Building/</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>House Number,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Street Name,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Purok, Zone</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Province</td>
<td>String</td>
<td>PSGC, Dropdown</td>
</tr>
<tr>
<td></td>
<td>Name of province</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MunCity</td>
<td>String</td>
<td>PSGC, Dropdown</td>
</tr>
<tr>
<td></td>
<td>Name of city or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>municipality</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Barangay</td>
<td>String</td>
<td>PSGC, Dropdown</td>
</tr>
<tr>
<td></td>
<td>Name of barangay</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Sex</td>
<td>String</td>
<td>Dropdown</td>
</tr>
<tr>
<td></td>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>01 – Female</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>02 – Male</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>03 – Not to</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>disclose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Birth date</td>
<td>String</td>
<td>Date picker</td>
</tr>
<tr>
<td></td>
<td>Date of birth</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(mm/dd/yyyy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>Civil status</td>
<td>String</td>
<td>Dropdown</td>
</tr>
<tr>
<td></td>
<td>Civil Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>01 – Single</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>02 – Married</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>03 – Widow/Widower</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>04 – Separated/</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Annulled</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>05 – Living with</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Partner</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td>Employed</td>
<td>String</td>
<td>Dropdown</td>
</tr>
<tr>
<td></td>
<td>Employment Status</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>01 – Government</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Employed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>02 – Private</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Employed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>03 – Self-employed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>04 - Private</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>practitioner</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>05 – Others</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>Profession</td>
<td>String</td>
<td></td>
</tr>
<tr>
<td></td>
<td>01 – Dental</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hygienist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>02 – Dental</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Technologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>03 – Dentist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>04 – Medical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Technologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>05 – Midwife</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>06 – Nurse</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>07 – Nutritionist-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dietician</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>08 – Occupational</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>09 – Optometrist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 – Pharmacist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11 – Physical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12 – Physician</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13 – Radiologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Technologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14 – Respiratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15 – X-ray</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Technologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16 – Barangay</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Health Worker</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>17 – Maintenance</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Staff</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18 – Administrative</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Staff</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct_covid</td>
<td>Providing direct COVID care?</td>
<td>Boolean</td>
<td>Dropdown</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>01 – Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 – None</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Employer_name</th>
<th>Name of employer</th>
<th>String</th>
<th>NHFR or freetext</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Employer_LGU</th>
<th>Province/ HUC/ ICC of employer</th>
<th>String</th>
<th>PSGC, Dropdown</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Employer_address</th>
<th>Full address of employer</th>
<th>String</th>
<th>Freetext</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Employer_contact_no.</th>
<th>Contact number of employer</th>
<th>Integer</th>
<th>Freetext, 12 digits only</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Preg_status</th>
<th>If female, pregnancy status</th>
<th>Boolean</th>
<th>Dropdown, conditional (if female only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 - Pregnant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 - Not Pregnant</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>W_allergy</th>
<th>With Allergy</th>
<th>Boolean</th>
<th>Dropdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 – Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 – None</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Allergy</th>
<th>Name of Allergy</th>
<th>String</th>
<th>Freetext, conditional (if with allergy only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 – Drug</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 – Food</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>03 – Insect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>04 – Latex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>05 – Mold</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>06 – Pet</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07 – Pollen</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>W_comorbidities</th>
<th>With Comorbidities</th>
<th>Boolean</th>
<th>Dropdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 – Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 – None</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-morbidity</th>
<th>Name of Comorbidity</th>
<th>String</th>
<th>Dropdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 – Hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 – Heart disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>03 – Kidney disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>04 – Diabetes mellitus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>05 – Bronchial Asthma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>06 – Immunodeficiency state</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07 – Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08 – Others</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>covid_history</th>
<th>Patient diagnosed with COVID-19</th>
<th>Boolean</th>
<th>Dropdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 – Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 – No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>covid_date</th>
<th>Date of first positive result / specimen collection (mm/yyyy)</th>
<th>Date</th>
<th>Date picker</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>covid_classification</th>
<th>Classification of infection</th>
<th>String</th>
<th>Dropdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 – Asymptomatic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 – Mild</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>03 – Moderate</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Prescribed Processes for Masterlisting Intended Vaccinees

1. Local Government Units shall lead masterlisting efforts within their catchment area and consolidate by municipality/CC/HUC/ICC.
2. All institutions (ex: health facilities) shall submit the masterslists to the municipality/CC/HUC/ICC, through any of the following methods:
   a. COVID-19 Electronic Immunization Registry (CEIR);
   b. Information system of the LGU linked to the CEIR through an application program interface (API);
   c. Dataset consistent with prescribed formats for bulk uploading through the CEIR;
   d. Dataset consistent with prescribed formats for bulk uploading through the assistance of DOH CHDs.

The CEIR platform may be accessed through http://ceir.doh.gov.ph. Training videos and submission templates may be retrieved from http://bit.ly/CEIRdocuments. Regional templates with PSGC codes are also available in said link. For help desk and support please contact covid19ceir@doh.gov.ph.

3. Masterlist data may be submitted and consolidated in phases, to include the following fields:
   a. Patient List - 1, 4, 7, 8, 10, 12
   b. Full Patient Demographics - 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12
   c. Full Patient Health Profile - 3, 13, 14, 15, 16, 17, 18

4. LGUs shall ensure that there will be no duplication in masterlists across facilities within their catchment. The DOH shall likewise conduct deduplication checks on the final endorsed masterlists.
   a. Masterlisting for Phase 1: Workers in Frontline Health Facilities shall be done based on the location of their health facility of assignment.
   b. For the eligible population with multiple affiliations (e.g.: health care worker in multiple hospitals), they shall choose only one health facility as their intended site for vaccination.

5. Masterlisting of UPs and essential personnel shall be based on their command.
   Masterlisting of the general population shall be based on the LGU where the vaccinee is residing in.

6. The province/HUC/ICC health office shall provide a status report and updated consolidation masterlist to their respective CHD every Friday.

7. After completion of masterlisting in a health facility, the Chief of Hospital or Head of Facility shall submit physically signed endorsement of all workers in the facility for phase 1 vaccination to the respective local government unit copy-furnish the CHD. The endorsement should indicate those who have and consented and who have not.
8. CHDs shall compile and store all signed and attested masterlists of all LGUs and health facilities, and scan copies saved according to the following format: Region-Health facility name, i.e., NCR-SAN LAZARO HOSPITAL. The document shall be saved in Portable Document Format (PDF) and be uploaded to the bit.ly link provided for their respective region.

9. Consistent with actions necessary for Universal Health Care, LGUs are instructed to initiate profiling the health status of their population now and generate a masterlist of population with comorbidities and other important information that will be necessary to implement the National Deployment and Vaccination Plan. Health profiling through Electronic Medical Records consistent with DOH standards is recommended.

10. Complete masterlist including patient list, full demographics, and full health profile is required prior to actual vaccine administration. Phased submissions shall guide local and national planning of the vaccine deployment plan.

---

**Masterlisting the Vaccination Workforce.** LGUs shall develop masterlists of the vaccination workforce by Municipality/CC/HUC/ICC using the following minimum data fields:

<table>
<thead>
<tr>
<th>Data Set</th>
<th>Definition</th>
<th>Type</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>healthfacility_name</td>
<td>Name of health facility</td>
<td>String</td>
<td>NHFR or freetext</td>
</tr>
<tr>
<td>healthfacility_LGU</td>
<td>Province/ HUC/ ICC of employer</td>
<td>String</td>
<td>PSGC, Dropdown</td>
</tr>
<tr>
<td>Last name</td>
<td>Surname/Last Name</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td>First name</td>
<td>First Name/Given name</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td>Middle name</td>
<td>Middle Name</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td>Suffix</td>
<td>Suffix</td>
<td>String</td>
<td>Dropdown</td>
</tr>
<tr>
<td>Position</td>
<td>Position or designation of the</td>
<td>String</td>
<td>Freetext</td>
</tr>
<tr>
<td>Team</td>
<td>Team category</td>
<td>String</td>
<td>Dropdown</td>
</tr>
<tr>
<td>Role</td>
<td>Role in the vaccination team</td>
<td>String</td>
<td>Dropdown</td>
</tr>
</tbody>
</table>

**Microplanning**

Microplanning is a “bottom-up” planning process carried out to determine local needs and gaps and to ensure smooth and satisfactory vaccine implementation. This is one of the key
activities to ensure the planning of the vaccination campaign lays out all operational aspects of the activity at the municipal/city and barangay levels. It is the translation of the national and regional macroplan to the local situation. Microplanning is one of the tools that health workers use and endorsed by the NIP to ensure that immunization services reach every community.

The microplanning activity has been tailored fit for COVID-19 vaccines taking into consideration diverse vaccine portfolios and the complexities of COVID-19 vaccine development. The following are the objectives of microplanning:

- To ensure that campaign objectives are reached and immunization strategies are well implemented at the service delivery points (health facilities and LGUs).
- To ensure that adequate resources are mobilized and in place with expected results to be accomplished on time.
- To anticipate the challenges and maximize use of limited resources in an efficient manner in the context of the COVID-19 pandemic.

The microplanning shall be done by the LGUs, specifically by municipalities and cities, and shall commence at once after masterlist and/or training has been obtained by the LGU. It is paramount that microplans get validated at each level as data are collected. This calls for effective supervision of the development of each microplan. Therefore, microplans are submitted in the following order: for municipalities and component cities, to the Provincial Health Offices (PHO) copy furnished Provincial DOH Offices (PDOHO), then the PHO to the CHDs; and for HUCs and ICCs, directly to the CHDs.

Once microplans from C/MHO level reach the province, they get aggregated and the provincial coordinators add province-specific costs (supervision, meetings, transport) are incorporated, before forwarding the plan up to the regional and national level. The microplan must be updated as frequently as possible.

A readiness assessment tool shall be used to assess and monitor the implementation of the plan. This can also be https://tinyurl.com/covidvaccineRA. Also, a microplanning template in excel form is accessible in this link: https://tinyurl.com/microplanningc19. The critical steps in microplanning are as follows:

**Critical Step 1:** Determine the number of eligible population for COVID-19 vaccination in your area.

**Criteria Step 2:** Identify the implementing units in your area, and the number of vaccination sites/posts, and plot in your operational spot map.

**Critical Step 3:** Identify the number of supervisors, vaccination teams, AEFI/AESI composite teams and other personnel needed and available for the vaccination activity.

**Critical Step 4:** Assign vaccinees and teams to an implementing unit / vaccination post/site.

**Critical Step 5:** Estimate the vaccine requirement and ancillary supplies needed

**Critical Step 6:** Identify gaps in cold chain capacity

**Critical Step 7:** Ensure timely delivery of vaccines and ancillary logistics

**Critical Step 8:** Prepare a Daily Vaccination Session Plan (daily itinerary)

**Critical Step 9:** Develop a communication plan for community advocacy, social mobilization, partnership and engagement

**Critical Step 10:** Prepare a supervision and monitoring plan and schedule
Critical Step 1: Prepare an AEFI/AESI management, surveillance and response plan
Critical Step 11: Develop a waste management plan

Mapping of Vaccination Workforce, Implementing Units and Vaccination Sites/Posts

Vaccination Workforce. For the COVID-19 vaccination campaign, a diverse set of professionals and personnel, both from the public and private sector, shall be utilized as part of the vaccination workforce. As more doses of vaccines become available during 2021-2022, there will be a need to expand the pool of skilled workforce to administer vaccines and to deliver the program.
Table 4.8. Recommended composition of the vaccination and AEFI composite teams, and other personnel needed in the implementing units

<table>
<thead>
<tr>
<th>Team/Other Personnel Needed</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccination Team (6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(2) for screening and assessment: Physician/Nurse/Midwife (1) as health educator: Allied Professionals/Volunteers from partner agencies (e.g. teachers, social workers, medical students, etc) (1) as vaccinator: Physician/Nurse/Midwife of RHU/Pharmacist (certified by PRC) (2) as documentor/recorder and vital signs-taker: Midwife/BHW/Health Staff/Volunteers from partner agencies (e.g. teachers, social workers, medical students, etc)</td>
</tr>
<tr>
<td>AEFI Composite Team (2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) to monitor and provide response: Paramedic/Nurse/Midwife (1) to conduct surveillance: Surveillance Officer/Nurse/Midwife/Pharmacist</td>
</tr>
<tr>
<td>Supervisors/Monitors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) Vaccination Team Supervisor: preferably a physician, for at least three (3) vaccination teams (1) Implementing Unit Level Supervisor: for the entire implementing unit (1) LGU Level Supervisor: for the entire LGU Internal Monitors and Independent Monitors</td>
</tr>
<tr>
<td>Other personnel needed in the implementing units</td>
<td>Cold Chain and Logistics Officer/s Local Officials (barangay captains) Security Personnel (PNP) Drivers Safety Officers (Barangay Tanods, among others)</td>
</tr>
<tr>
<td>Other personnel needed in community/health facilities</td>
<td>Social mobilizers: BHWs and hospital staff (HR) Navigators/Transport: BHWs and Local Officials, Health Facility Management</td>
</tr>
<tr>
<td>Teams and Personnel</td>
<td>Roles and Responsibilities</td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td><strong>1. Vaccination Team</strong></td>
<td></td>
</tr>
</tbody>
</table>
| a. Personnel assigned as documenter and recorder | ● Man the registration area  
● Ensure that documents and identification presented by the vaccinee are valid  
● Ensure that all information and data are encoded in the data management system  
● Assist other team members, especially on vital signs taking  
● Submit daily coverage, refusals and deferrals to the C/MHO |
| b. Personnel assigned as health educator | ● Man the health education area  
● Ensure that equipments and IEC materials are available during the vaccination post/area  
● Provide information to vaccinees, particularly on the benefits of vaccination, the possible adverse reactions, and how to seek help if with adverse reaction, either by answering their queries, or providing them with IEC materials  
● Facilitate the signing of the informed consent  
● Coordinate with social mobilizers and navigators for those who were deferred and those who refuse on-site. |
| c. Personnel assigned for screening and assessment | ● Man the screening and assessment area  
● Conduct physical examination and take the history of present illness (if applicable) and record in the CEIR  
● Provide clearance for the vaccinee to be vaccinated. Those deferred for vaccination shall be coordinated with the social mobilization team for follow-up and shall be provided with a possible vaccination schedule |
| d. Personnel assigned as a vaccinator | ● Man the vaccine administration area  
● Follow the step-by-step procedure of vaccine administration as recommended by the manufacturer and as guided by the immunization protocols  
● Completely fill-up the vaccination card and encode the needed information to the data management system  
● Dispose syringe and vials accordingly |
| **2. AEFI/AESI Composite Team** |  |
| a. Personnel assigned to monitor and | ● Monitor and observe the vaccinee for any adverse reaction in the 1st hour after vaccination |
| **provide response** | - If the vaccinee has any adverse reactions, provide immediate intervention/treatment  
- Refer vaccinee/s with adverse reaction/s to appropriate AEFI/AESI referral health facilities in a timely manner  
- Provide the vaccinee with information on what signs and symptoms he/she should watch for at home and where he/she should proceed to for treatment |
| b. Personnel assign for surveillance | - Monitor and observe the vaccine for any adverse reaction in the 1st hour after vaccination  
- If the vaccinee has any adverse reactions, conduct surveillance investigation  
- Follow-up the vaccinee/s for any adverse reaction/s at home |
| **Supervisors and Monitors** | **Supervisors**  
- Supervise and oversee the vaccination activity  
- Address concerns and coordinate accordingly  
- Ensure timely submission of reports  
**Monitors**  
- Monitor and evaluate the quality of vaccination implementation  
- Provide feedback to VOCs |
| a. Vaccination Team Supervisor | - Visit Vaccination Teams at least once a day for supportive supervision using the Supervision Checklist  
- Compile vaccination team reports, analyze them and report to higher level  
- Review team performance and undertake corrective actions if needed |
| b. Implementing Unit Level Supervisor | - Visit Vaccination Teams with Team Supervisors, at least once a day for supportive supervision using the Supervision Checklist  
- Compile and review vaccination team reports, analyze them and report to higher level  
- Review team performance and undertake corrective actions if needed  
- Communicate daily with Coordination team in the VOC |
| c. LGU Level Supervisor | - Visit implementing units 1-2 weeks prior to the campaign to monitor progress in preparedness.  
- Support training and microplanning activities  
- Review submitted reports, compile and analyze health center level data |
| d. Monitors and Independent Monitors | - Visit vaccination sites and complete monitoring forms  
- Monitor the vaccination implementation and ensure that it is based on the guidelines set by DOH  
- Participate in meetings of the coordination team  
- Assist in troubleshooting, as needed |
Implementing Units and Vaccination Sites/Posts. A permanent fixed-post vaccination strategy shall be used in the conduct of the COVID-19 vaccination campaign. As defined in the National Immunization Program, permanent fixed-posts are posts located at health facilities where there is sufficient capacity and equipment to immediately respond and refer AEFI/AESI cases, and where sufficient health human resources are available. The following shall be utilized as implementing units:

a. Medical centers, hospitals and infirmaries (private and public)
b. Rural Health Units
c. Health facilities of other government agencies (e.g. AFP hospitals and facilities, BJMP/BuCor health facilities, and DepEd clinics)
d. Private clinics

The LGUs shall ensure that all implementing units, including private health facilities, adhere to the protocols required for an implementing unit / vaccination posts/sites. No implementing unit shall be allowed to conduct vaccination activity without compliance to the protocols required of a vaccination post.

Human Resource Management and Training. The national training plan shall target (a) national and departmental coordinators of areas directly or indirectly related to vaccine introduction [e.g., information system, communication, cold chain, surveillance, etc.], who will facilitate the vaccination processes at the district/municipality and local levels, and (b) vaccination workforce who will directly or indirectly conduct the vaccination.

Table 4.10. Roles and responsibilities of the COVID-19 training teams

<table>
<thead>
<tr>
<th>Level of Training Team</th>
<th>Roles and Responsibilities</th>
</tr>
</thead>
</table>
| WHO, UNICEF and DOH vaccination experts and trainers | ● Develop/ Co-Develop the training materials  
● Conduct the initial ToT for the Core Trainers  
● Provide post training support to the Core trainers |
| DOH Cluster trainers                        | ● Identify regional training teams  
● Conduct TOT for the regional training teams  
● Work with the regional training teams to develop regional training plans  
● Provide oversight for the cascading of the trainings within each region  
● Monitor the standards of and the implementation of training for the local implementing units.  
● Conduct monitoring and evaluation of the training activities |
| Regional training teams                     | ● Conduct training needs assessment  
● Develop regional training plan  
● Conduct trainings for the local implementing units  
● Conduct post training supportive supervision, observation and mentoring for the local implementing units  
● Implement quality improvement as needed based on gaps identified during the post training support activities |

COVID-19 Vaccine and Cold Chain Capacity Inventory and Logistics Management

In the pre-implementation phase, in order to maintain a reliable vaccine cold chain and logistics management at the LGU level, the following key procedures shall be observed:
a. Receive vaccines logistics requirement for the vaccination campaign.
b. Count all vaccines and logistics (syringes, SCBs, re-sealable plastic, among others) received to ensure NO short shipment.
c. Check the vaccine label and ensure that it is intact.
d. Store vaccines and diluents within the required temperature ranges at all sites/levels.
   Keep vaccines in appropriate vaccine refrigeration equipment. Keep all COVID-19 vaccine vials together in the same cold chain equipment at all times.
e. Label storage equipment containing COVID-19 vaccines properly.

f. Use a temperature monitoring device to ensure temperatures remain according to the recommended temperature.
g. Pack and transport vaccines to and from implementing units according to recommended procedure. Transport vaccines to immunization sessions in a vaccine carrier, correctly packed using coolant packs that have been properly prepared.
h. Keep vaccines and diluents within recommended cold chain conditions during vaccination sessions. During the vaccination sessions, fit a foam pad (if available) at the top of the vaccine carrier.

The LGU and in implementing units, one person shall be in-charge of logistics and cold chain management. An alternate shall also be identified to take over if the in-charge is absent. Their responsibilities shall include:
   a. Checking and recording vaccine temperatures twice daily; in the morning and at the end of the session or day.
   b. Properly storing vaccines, diluents and ice packs.
   c. Handling preventative maintenance of the cold chain equipment.

Preparation of Vaccination Sites/Posts. The vaccination post/site shall have the following areas (as shown in Figure 4.4):

1. Waiting Area. The waiting area shall be prepared for vaccinees waiting for their vaccination turn.

2. Vaccination Area: The vaccination area shall have at least three (3) vaccination teams and three (3) AEFI/AESI composite teams. Each area shall have several sanitation areas for each vaccination team. The following areas, arranged in sequential order, shall be set in placed:
   a. Registration Area: An area where the vaccinee’s information and documents are checked and submitted. Each vaccination team shall have their respective areas in the registration area. Equipment needed to scan the QR code should be available in this area.
   b. Health Education Area. There shall be one health education area for the whole vaccination site/post. In this area, IEC materials, such as pamphlets, leaflets and brochures shall be made available. Also, a projector or a TV shall be set up in this area, or the least, a flipchart, for health education purposes.
   c. Screening Area. Since the screening procedure may take longer compared with other areas, it is advised that at least two screening stations per team shall be set up. Equipment needed to scan the QR code should be available in this area.
   d. Vaccination Area. Each vaccinator shall have his/her own area. The vaccination area should have an accessible cold chain equipment to store the vaccines in the vaccination post/site.
3. Post-vaccination Monitoring Area. Since the observation of vaccinees post-vaccination will take 30 minutes to one hour, it is expected that there might be pooling or crowding of vaccinees in this area. Thus, this area must be spacious enough to accommodate all vaccinees and to allow observance of physical distancing measures. In addition, equipment needed for AEFI response must be available and accessible.

![Figure 4.4. Vaccination site/post lay-out](image1)

![Figure 4.5. Equipment are needed in the vaccination site/post](image2)

2. Implementation Phase

*Mobilizing the eligible recipients.* During the vaccination activity, eligible recipients who have successfully registered for vaccination shall proceed to the assigned vaccination posts/sites based on the schedule provided or they may be fetched from assigned pick-up points through previously arranged transport mechanisms. BHWs, local officials and other personnel may
also do house-to-house visits to mobilize eligible recipients who have successfully registered for the vaccination, so that they can proceed to the assigned vaccination site (see Figure 4.6).

Figure 4.6. Illustration of the mobilization of eligible recipients for the actual COVID-19 vaccination

The following steps shall be undertaken every vaccination day:

1. Before every vaccination activity, prepare the vaccine carriers and the ice packs.
2. In each vaccine carrier, arrange the frozen ice packs exactly as recommended on the manufacturer’s instruction on the inside of the lid. Do not cover the frozen ice packs in paper.
3. Prepare re-sealable plastic bags and an extra one for opened/used vials (after the vaccination day).
4. Place 20 vaccine vials in one re-sealable plastic bag. The number of vaccines to be used per vaccination team shall be determined prior to the activity.
5. Put the resealable plastic with the vaccines in the middle of the vaccine carrier to protect them from damage due to condensation.
6. Daily issuances of vaccines should be recorded in the distribution and collection form acknowledged by the vaccination team leader / supervisor.
7. At the end of each vaccination day, all vials (unopened, fully or partially used) shall be placed in resealable plastic bags and returned to the same health facility where they received the vaccines in the morning. The facility supervisor shall record the vials received at the end of each vaccination day.
8. Health facilities / vaccination distribution points must then keep the unopened usable vials in the cold chain. The vaccines can be used for the next day.
9. All opened or unusable vials contained in resealable plastic by twenties (20s) must be kept in a sack and be picked up by the CHD at the end of the vaccination round for disposal.
Table 4.11. Vaccine distribution and collection form

<table>
<thead>
<tr>
<th>Region</th>
<th>Province</th>
<th>Vaccine Distribution and Collection Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Vaccinating City/Municipality</td>
<td>Vaccine Issued</td>
<td>Additional Vaccine Issued</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Vaccine Administration

Prior to the vaccination, the vaccinee will be provided with a vaccination date and time schedule, and an immunization card with a QR code, which he/she will bring to the vaccination post, to ensure smooth implementation of the vaccination activity and avoid congestion in the vaccination site/post. No walk-in vaccination shall be accommodated since vaccines allocated for the day are sufficiently allocated for the projected number of vaccinations to be conducted in a day. However, a walk-in eligible recipient shall be scheduled and provided with an immunization card with a QR code immediately, and advised accordingly.

Upon arrival at the vaccination site/post, the vaccinee shall wait for his/her turn in the waiting area. Upon entry in the waiting area, the vaccinee’s temperature will be checked. The Safety Officer shall ensure that physical distancing measures shall be implemented at all times at the waiting area.

Each vaccinee shall be assigned to a specific vaccination team. When his/her turn arrives, he/she will proceed to the vaccination area, and in a stepwise approach, he/she will proceed from the registration area, health education area, screening area and lastly, to the vaccination area.

At the registration area, the vaccinee shall present his/her immunization card with QR code and shall be scanned. The profile of the vaccinee shall be retrieved in the computer system and the vaccinee’s identity shall be verified by presenting his/her government ID (e.g. driver’s license, PRC license, PhilHealth ID, UMID, Passport, etc.). Other relevant documents shall be presented at the registration.

The vaccinee shall then be directed to the Health Education Area where health educators shall present IEC materials and answer any question the vaccinee may have regarding the COVID-19 vaccine. Once all questions are answered, the vaccinee shall be asked to sign the Final Consent form.

At the Screening Area, the personnel assigned shall scan the patient’s QR code and conduct history-taking and physical examination to ensure the eligibility of the vaccinee. Using both the CEIR and screening form hard copy, the health worker shall update the vaccinee’s profile and determine whether or not he/she is qualified to receive the vaccination.
The vaccinee shall then be directed to the Vaccination Area where the vaccine shall be administered. Once vaccinated, the QR code shall be scanned and the vaccination details (e.g., date of vaccination, vaccine manufacturer, batch number, lot number, name of vaccinator and signature) shall be recorded in the CEIR and immunization card.

For the data management on the COVID-19 vaccine deployment and administration, the DOH has developed the COVID-19 Electronic Immunization Registry (CEIR). It was agreed per IATF Resolutions 95 and 96 that the Philippine COVID-19 Vaccine Information Management System (VIMS) developed by the Department of Information and Communications Technology (DICT) will be adopted as the national data management system for the COVID-19 vaccination. This was further institutionalized through the NTF Memorandum dated 8 February 2021 with the subject ‘DICT as the Lead Agency for All COVID-19 Vaccine-Related Data Collection, Storage, Processing, and Analysis’. The overview on the objectives, components, and mechanism of the VIMS as well as details on information security and data privacy are in the PCERP Project Operations Manual (POM). Moreover, data collection in the actual vaccination process was described in the Omnibus Guidelines in Section I. Vaccination Process, Item 6- Vaccine Administration.

After vaccination, the vaccinee shall be observed for adverse reactions for 30 minutes to one hour at the post-vaccination monitoring area. The post-vaccination monitoring area must be closely linked with an identified referral health facility. After an hour, once cleared, the vaccinee shall be provided with instructions about the possible adverse reaction that the vaccinee might experience and the location of facilities where he/she can proceed should he/she experience adverse reactions.

**Figure 4.8. Vaccine administration flow**

<table>
<thead>
<tr>
<th>Registration (2)</th>
<th>Pre-vaccination Counselling and Final Consent (2)</th>
<th>Screening (2)</th>
<th>Vaccination (1)</th>
<th>Post-vaccination Monitoring, Surveillance and Recording (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Scan QR code generated from Pre registration</td>
<td>✓ Utilize script and checklist</td>
<td>✓ Conduct History taking and Physical Examination</td>
<td>✓ Utilize checklist before administering vaccination</td>
<td>✓ Observe the patient for 1 hour and watch out for any signs of breath (SOB), syncope, anaphylactic reaction.</td>
</tr>
<tr>
<td>✓ Check list of information</td>
<td>✓ Counsel patients by batches</td>
<td>✓ Utilize script and checklist</td>
<td>✓ Ensure proper vaccination technique</td>
<td>✓ Monitor Vital Signs every 15 minutes.</td>
</tr>
<tr>
<td>✓ Document requirements</td>
<td>✓ Answer questions about vaccine and possible side effects</td>
<td>✓ Utilize Check list and Form</td>
<td>✓ Encode the details in the immunization card and give to the vaccinee</td>
<td>✓ Utilize checklist</td>
</tr>
<tr>
<td>✓ Health declaration form</td>
<td>✓ Play Video on COVID-19 Vaccine</td>
<td>✓ Informed consent form</td>
<td>✓ Respond and give first aid to patients with AEFI.</td>
<td>✓ Refer to hospital if further management needed.</td>
</tr>
</tbody>
</table>

Infection Prevention and Control (IPC), Injection Safety, Management of Health Care Waste and Reverse Logistics
All throughout the implementation phase, infection prevention and control measures must be practiced. Table 4.9 shows minimum standards for IPC that must be practiced during the vaccination.

Table 4.12. Minimum infection prevention and control measures during COVID-19 vaccine administration

<table>
<thead>
<tr>
<th>Aspect of vaccine administration</th>
<th>Minimum IPC measures</th>
</tr>
</thead>
</table>
| Vaccination post                | ● Open or well-ventilated areas  
 ● Frequently disinfected areas  
 ● Spacious enough to implement physical distancing, crowd control measures  
 ● Limit number of vaccinees within the vaccination area to <24 individuals at a given time. |
| Vaccination Team and Composite Team, and other personnel in the vaccination site | ● Wear face mask and face shield  
 ● Practice hand hygiene before and after procedure/vaccine  
 ● Limit contact between vaccinator and vaccinee to less than 15 minutes  
 ● Daily self-monitoring for COVID-19 symptoms  
 ● Log-in upon entering and exiting a vaccination area on a daily basis |
| Vaccinees                       | ● Wear face mask and face shield  
 ● Frequently practice hand hygiene  
 ● Abide to physical distancing guidelines |

3. Post- Implementation Phase

**Reverse Logistics**

The following are reverse logistics guidelines:

a. Empty and unopened vials should be returned daily by the Vaccination Team to the implementing unit or RHU/CHO for consolidation.

b. At the end of each vaccination period, accounted empty/opened vials should be kept in a safe and secured place in the health facility.

c. Unopened usable vials should remain stored at required temperature.

d. Properly accomplish Form A to await pick up by the CHD for destruction.

**Computation and Terms**

a. Calculate vaccine wastage rate: (number of vaccine doses used - number of eligible population) / number of vaccine doses used x 100 = vaccine wastage rate (%)

b. “Vaccine doses used” includes doses used for immunization and all doses discarded or lost for any reason (including expiry, indication of heat exposure, missing inventory, cold chain failure, freezing or discarding of open vials of vaccine at the end of a session or campaign activity).

c. The wastage rate is the percentage of vaccine doses that are wasted - in other words, doses that are not used for immunization and are discarded or lost for any reason.
**Retrieval of vials from the field**

a. The vaccination team should return vials in re-sealable plastic bags (a maximum of 20 vials per resealable plastic bag).
b. Supervisors should count collected empty vials at the end of vaccination day.
c. Empty vial retrieved should be well accounted and documented.

**Vials accountability.** Unaccounted vials should be:

a. Reported to the supervisor.
b. Reason/s for the unaccountability should be stated.
c. Investigated with the support of the LGUs.
d. Incident report should be prepared and endorsed by the following: NIP, RHU, LGUs and submitted to overseeing VOC.

**4.1.4 Assessment, Monitoring, and Evaluation**

**Vaccine Safety Monitoring, and Management of Adverse Events Following Immunization**

The role of vaccine safety monitoring during COVID-19 vaccine introduction is to facilitate the early detection, reporting, notification, investigation and analysis, and feedback of Adverse Events Following Immunization (AEFIs) and Adverse Events of Special Interest (AESI), to ensure appropriate and timely case management and response. These activities shall assist vaccinees and ensure them of prompt and timely response should an AEFI occur. The AEFI surveillance entails:

- Timely detection of serious AEFIs/AESIs to provide up-to-date and accurate data that can be shared with relevant stakeholders for appropriate response;
- Generation of data to characterize the safety of the COVID-19 vaccines in use;
- Identification, investigation, assessment and validation of safety signals and recommendation of appropriate public health interventions or other interventions; and
- High quality safety surveillance and maintenance of public and stakeholder confidence in vaccines and immunization

The WHO defines *Adverse Event Following Immunization* (AEFI) as any untoward medical occurrence which follows immunization, and which does not necessarily have a causal relationship with the usage of the vaccine. If not rapidly and effectively dealt with, AEFIs can undermine confidence in a vaccine and ultimately have dramatic consequences for immunization coverage and disease incidence. Based on consultations with experts and the latest data from published clinical trials as of 16 January 2021, the following are the identified AEFI from various brands of COVID-19 vaccination and must be reported.

- Table 4.13. List of Adverse Events Following COVID-19 Vaccination of Selected Candidate COVID-19 Vaccine

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>University of Oxford and Astrazeneca</th>
<th>BioNTech and Pfizer</th>
<th>NIAID and Moderna</th>
<th>Novavax</th>
</tr>
</thead>
</table>

Page 79 of 278
<table>
<thead>
<tr>
<th>Adverse Events*</th>
<th>18-55</th>
<th>56-69</th>
<th>&gt;70+</th>
<th>&gt;18</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain at injection site</td>
<td>75%</td>
<td>64%</td>
<td>63%</td>
<td>54%</td>
<td>34%</td>
<td>22%</td>
<td>84.1%</td>
</tr>
<tr>
<td>Redness</td>
<td>7%</td>
<td>11%</td>
<td>12%</td>
<td>12%</td>
<td>11%</td>
<td>11%</td>
<td>9.5%</td>
</tr>
<tr>
<td>Swelling</td>
<td>7%</td>
<td>7%</td>
<td>12%</td>
<td>12%</td>
<td>14%</td>
<td>14%</td>
<td>10.5%</td>
</tr>
<tr>
<td>Tenderness</td>
<td>87%</td>
<td>75%</td>
<td>83%</td>
<td>76%</td>
<td>64%</td>
<td>62%</td>
<td>19.8%</td>
</tr>
<tr>
<td>Warmth</td>
<td>27%</td>
<td>25%</td>
<td>22%</td>
<td>32%</td>
<td>27%</td>
<td>14%</td>
<td></td>
</tr>
<tr>
<td>Itch</td>
<td>14%</td>
<td>25%</td>
<td>22%</td>
<td>18%</td>
<td>14%</td>
<td>11%</td>
<td></td>
</tr>
<tr>
<td>Induration</td>
<td>7%</td>
<td>7%</td>
<td>12%</td>
<td>12%</td>
<td>11%</td>
<td>11%</td>
<td></td>
</tr>
<tr>
<td>Feverish</td>
<td>58%</td>
<td>22%</td>
<td>27%</td>
<td>32%</td>
<td>22%</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>39%</td>
<td>7%</td>
<td>12%</td>
<td>12%</td>
<td>7%</td>
<td>7%</td>
<td>14.2%</td>
</tr>
<tr>
<td>Chills</td>
<td>50%</td>
<td>27%</td>
<td>27%</td>
<td>27%</td>
<td>14%</td>
<td>7%</td>
<td>31.9%</td>
</tr>
<tr>
<td>Joint Pain</td>
<td>48%</td>
<td>17%</td>
<td>35%</td>
<td>36%</td>
<td>27%</td>
<td>20%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Muscle Ache</td>
<td>67%</td>
<td>52%</td>
<td>56%</td>
<td>44%</td>
<td>32%</td>
<td>32%</td>
<td>38.3%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>87%</td>
<td>69%</td>
<td>69%</td>
<td>61%</td>
<td>56%</td>
<td>48%</td>
<td>62.9%</td>
</tr>
<tr>
<td>Headache</td>
<td>78%</td>
<td>45%</td>
<td>69%</td>
<td>54%</td>
<td>56%</td>
<td>34%</td>
<td>55.1%</td>
</tr>
<tr>
<td>Nausea/ Vomiting</td>
<td>41%</td>
<td>20%</td>
<td>31%</td>
<td>40%</td>
<td>20%</td>
<td>17%</td>
<td>1.1%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11.1%</td>
</tr>
<tr>
<td>Need for antipyretics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>27.8%</td>
</tr>
<tr>
<td>Malaise</td>
<td>56%</td>
<td>43%</td>
<td>46%</td>
<td>27%</td>
<td>39%</td>
<td>25%</td>
<td>0.5%</td>
</tr>
<tr>
<td>Serious Adverse Events* Event-based</td>
<td>0.7% (84/12021)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.4% (n=10841) 18-55</td>
<td>0.8% (n=7960) &gt;55</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Elderly: safety data limited in &gt;65, no dosing adjustments</td>
<td>Pediatric: no data available</td>
<td>Pregnancy: very limited</td>
<td>Immunocompromised: on stable ART for 6 months, Pediatric: limited participants</td>
<td>for use in individuals 18 years of age and older. Elderly &gt;65 no notable differences in the safety profiles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------------------------------------------------------</td>
<td>----------------------------</td>
<td>-------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Related to vaccine</td>
<td>Related to vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>Lymphadenopathy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shoulder injury due to incorrect administration</td>
<td>Should have infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appendicitis</td>
<td>Appendixis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facial paralysis (Bell’s palsy)</td>
<td>Facial paralysis (Bell’s palsy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventricular arrhythmia</td>
<td>Ventricular arrhythmia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T78.2 Anaphylaxis 7600</td>
<td>T78.2 Anaphylaxis 7600</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo group</td>
<td>Placebo group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaphylactoid reaction</td>
<td>Anaphylactoid reaction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>related to bee sting</td>
<td>related to bee sting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug hypersensitivity</td>
<td>Drug hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(doxycycline)</td>
<td>(doxycycline)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>Deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 deaths (2 active 4 placebo)</td>
<td>7 deaths (2 active 4 placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Due to pre-existing diseases</td>
<td>Due to pre-existing diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>including aortic rupture</td>
<td>including aortic rupture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuropathological disorders</td>
<td>Neuropathological disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nevralgia</td>
<td>nevralgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transverse myelitis</td>
<td>Transverse myelitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>idiopathic</td>
<td>idiopathic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever higher than 40°C</td>
<td>Fever higher than 40°C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>Deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Road traffic accident</td>
<td>Road traffic accident</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blunt force trauma</td>
<td>Blunt force trauma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homicide</td>
<td>Homicide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fungal pneumonia</td>
<td>fungal pneumonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coincidental</td>
<td>Coincidental</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active group</td>
<td>Active group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaphylactoid reaction</td>
<td>Anaphylactoid reaction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>related to bee sting</td>
<td>related to bee sting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug hypersensitivity</td>
<td>Drug hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(doxycycline)</td>
<td>(doxycycline)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>Deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T78.2 Anaphylaxis 7600</td>
<td>T78.2 Anaphylaxis 7600</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo group</td>
<td>Placebo group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaphylactoid reaction</td>
<td>Anaphylactoid reaction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>related to ant bite</td>
<td>related to ant bite</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16-17 years old</td>
<td>16-17 years old</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 facial bone fracture</td>
<td>1 facial bone fracture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>Deaths</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 deaths (2 active 4 placebo)</td>
<td>7 deaths (2 active 4 placebo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Due to pre-existing diseases</td>
<td>Due to pre-existing diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>including aortic rupture</td>
<td>including aortic rupture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In the context of the COVID-19 vaccination program, any health event that has occurred after vaccination must be reported and considered as AEFI, pending proper professional consultation/case classification. AEFI surveillance shall be performed by the Surveillance Officer (stimulated passive surveillance) every two (2) weeks for the first two (2) months, then monthly for one year. This is to ensure that no health event relevant to COVID-19 shall be experienced by the recipient per incubation period of the disease.

Figure 4.9. Process flowchart for AEFI surveillance and response in the context of COVID-19 vaccine administration
Figure 4.10. Process flowchart for responding to serious AEFIs of COVID-19 vaccine
Table 4.14. WHO-recommended safety surveillance activities for all countries introducing COVID-19 vaccine regardless of AEFI surveillance capacity

<table>
<thead>
<tr>
<th>Objective</th>
<th>Recommended AEFI surveillance activities</th>
</tr>
</thead>
</table>
| Strengthen routine passive AEFI surveillance reporting systems for the management of increased frequency or severity of AEFI reports (mild, moderate and severe) | • Conduct training on identification and reporting of AEFI for health care professionals.  
• Update, print and distribute AEFI surveillance tools.  
• Use both vaccine tracking information and passive AEFI reporting information to perform vaccine-specific safety analyses.  
• Review and adapt processes for timely reporting, review and data sharing nationally, regionally and globally (e.g. uploading data to global databases such as the WHO VigiBase)  
• Develop clear standard operating procedures (SOPs) for the coordination process between the NRA, NIP/EIP, and other institutions with responsibilities for AEFI surveillance.  
• Consider coordination of activities with Public Health Emergency Units.  
• Consider setting up AEFI committees at subnational as well as national level, particularly in large countries |
| Investigate potential AEFIs causing concern, such as clusters, serious events, programmatic errors, community concerns | • Prepare investigation teams and train them for AEFI investigation activities that are relevant in the population being vaccinated.  
• Update, print and distribute AEFI investigation tools to obtain information on specific outcomes.  
• Ensure the collection and storage of all relevant data to help make a causality assessment (AEFI reporting and investigation forms, clinical case record, laboratory reports, autopsy reports, etc.) |
| Perform systematic causality assessment of AEFIs causing concern | • Constitute an National AEFI committee to review and respond to AEFI safety signals and public concerns or contact the WHO Country or Regional Office or send email to gysi@who.int for assistance.  
• Provide training on causality assessment processes using WHO causality assessment guidelines for members of the National AEFI committee.  
• Ensure regular updates to the Committee members on COVID-19 vaccine development and safety data, including safety reports from ongoing phase III clinical trials or any events reported in clinical trials.  
• Foster and use the committee’s expertise to identify AEFI cases in need of further investigation, such as AESIs. 5. Anticipate an increased number of AEFI reports that will need to be reviewed and consider including AEFI committees at subnational as well as national level, particularly in large countries. |
| --- | --- |
| Use AEFI and disease surveillance data to detect potential safety signals or clustering of events | • Regularly review and report AEFI surveillance data, particularly those relevant to AESIs or other conditions identified during pre-licensure COVID-19 vaccine clinical trials.  
• Explore the use of disease surveillance data to complement AEFI surveillance systems for the detecting of AESIs, if indicated.  
• Consider use of early signal detection methods, especially for certain AESIs. |
| Prepare comprehensive plans to respond rapidly to any COVID-19 vaccine-related event | • Outline roles and responsibilities of key stakeholders (including the private sector) for the implementation of safety surveillance activities and responding to vaccine-related events.  
• Keep stakeholders up to date with COVID-19 vaccine safety information.  
• Communicate with WHO regions and globally and share data on outcomes of AEFIs and AESIs in a rapid, timely and regular manner. |
| Address concerns of healthcare professionals and maintain community confidence. (Link to communication module to be added) | • Create and share a COVID-19 vaccine safety communication plan with relevant stakeholders.  
• Train and support personnel at all levels to address concerns that may arise before, during and after COVID-19 vaccine introduction.  
• Develop, print, and distribute messages concerning the safety COVID-19 vaccines. |

The DOH has also been developing the ‘Standard Operating Procedure (SOP) in Handling Serious AEFI Cases in the Region’ with the aim of providing a standardized guideline to all epidemiology and surveillance units towards a robust implementation of safety surveillance and in order to maintain the public confidence in the national immunization program of the Department of Health. This SOP covers the general parameters in pursuance of AEFI surveillance and response across the private and government health facilities, with reference to the following guidelines:

- DOH Administrative Order no. 2016-0006: Revised Guidelines on Surveillance and Response to Adverse Events Following Immunization

Further details on the AEFI are in Section 7.4 of the ESMF.

4.2 Health Care Waste Management of Infectious Wastes Related to COVID-19

DENR Memorandum Circular 2020-16 provides the guidelines with which waste transporters and treatment, storage, and disposal (TSD) facilities need to comply with during the extended community quarantine. In order to avoid the piling of infectious health care wastes and prevent environmental and community contamination, the continuous operations of the waste transporters and TSD facilities are ensured through the simplified permit provisions such as through the issuance of a special permit to transport (SPTT) online and the extension of the validity of the TSD Registration Certificates and Transporter Registration Certificates for 60 days.
and immediate renewal within 5 days after lifting of the ECQ. Similarly, DENR Memorandum Circular 2020-20 provides for the simplified procedures for permit issuance of transporters and TSDs, as well as safety and health protocols through the submission of manifest or the report of compliance and completion of transport and the certificate of treatment (COT) by the transporter and TSD, respectively. The manifest of the registered transported shall be attested by the duly designated representative or PCO of the health care facility or hazardous waste generator and the TSD, within 24 hours for M501 wastes and 7 days for other hazardous wastes after delivery to the TSD facility. The TSD facility shall also submit a report of compliance and completion of treatment or the COT to be attested by their PCO within 7 days after M501 wastes and 21 days for other types of hazardous wastes, after completion of treatment.

The DENR Administrative Order 2013-22 entitled Revised Procedures and Standards for the Management of Hazardous Wastes provides the procedures for generation and compliance to the legal and technical requirements of hazardous waste management, including guidelines for waste generators, transporters, and treatment, storage, and disposal facilities. With this policy, pathological, infectious wastes, and sharps are categorized as M501 wastes or pathological or infectious wastes while the vials used in the vaccination activities will be classified as M503 or pharmaceuticals and drugs. Hence, the syringes, cottons, and other materials used in the vaccination which had contact to the patient are considered as infectious wastes (M501). The M501 and M503 health care wastes generated from the vaccination activities will be collected and transported by DENR-registered waste transporters and will be treated and disposed of by DENR-registered TSD facilities.

It is important to conduct a capacity mapping of the health care facilities on their health care waste management. This will be conducted through the HCWM self-audit tools developed under the Parent Project, including the determination if the health facility has existing in-house treatment and contract with DENR-accredited waste service providers. These will be done with consultation and requested assistance from the DOH Health Facilities Development Bureau.

In view of the upcoming COVID-19 vaccination, the DOH has released the Department Memorandum (DM) 2021-0031 entitled ‘Interim Guidelines on the Management of Health Care Wastes Generated from COVID-19 Vaccination.’ In this guideline, all materials used in the vaccination will be considered as infectious wastes, which include but are not limited to empty vaccine vials, syringes/sharps, PPEs, cottons, tissues, and other materials which had contact with the patient. It provides guidelines on the management of wastes generated from the COVID-19 vaccination activities, from segregation, onsite collection and transport, onsite storage, offsite transport, up to the offsite treatment and disposal of these hazardous/infectious wastes. It covers all cover all health care facilities, CHDs, and LGUs involved in the COVID-19 vaccination. This Interim Guideline includes reverse logistics to account and monitor the inventory of vaccines, through the collection of empty vaccine vials in groups of 20 pieces in resealable bags prior to storage in yellow plastic liners and waste audit, i.e., volume recording.

Since not all health care facilities which will be vaccination sites do not have contract with waste service providers, the CHD or Provincial Health Office (PHO) were designated as temporary storage areas, from which the waste service contractor to be procured by the DOH will be collecting (Table 4.15). The DOH has also submitted a request to DENR for a (1) Special Permit to Transport (SPTT) for the collection, transport, treatment, and disposal of the health care wastes generated from the COVID-19 vaccination activities through the DOH-procured transporters and TSD facilities and for the (2) DOH CHDs and PHOs to be allowed as temporary waste storage facilities to cater to those health care facilities without existing access to the TSD providers.
A series of orientation and consultation meetings had been conducted by the DOH DPCB with the Environmental Health Coordinators in the CHDs to discuss this DM. The CHD and PHO will determine suitable temporary waste storage areas in their facilities.

Table 4.15. COVID-19 Immunization Program Waste Collection Point for Health Care Facilities without Waste Service Providers

<table>
<thead>
<tr>
<th>Region</th>
<th>Waste Collection Point</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCR</td>
<td>CHD</td>
<td>6 Barangay Road, Welfareville Compound, Barangay Addition Hills, Mandaluyong City 1550</td>
</tr>
<tr>
<td>CAR</td>
<td>CHD</td>
<td>BGHMC Compound, Baguio City, Benguet 2600</td>
</tr>
<tr>
<td>I- Ilocos</td>
<td>CHD</td>
<td>8 MacArthur Highway, Parian, San Fernando City, La Union 2500</td>
</tr>
<tr>
<td>II- Cagayan Valley</td>
<td>CHD</td>
<td>Carig Regional Center, Tuguegarao, Cagayan</td>
</tr>
<tr>
<td>III- Central Luzon</td>
<td>CHD</td>
<td>Regional Government Center Park, Diosdado Macapagal Regional Center, Main Road San Fernando, Pampanga 2000</td>
</tr>
</tbody>
</table>
| IV-A- CALABARZON | PHOs          | **Provincial Health Office- Cavite**  
Cavite Collaboration Center for Public Health, Gen. Emilio Aguinaldo Memorial Hospital Compound, Brgy. Luciano  
Trece Martires City, 4109  

**Provincial Health Office- Laguna**  
J. De Leon St, Santa Cruz, Laguna 4009  

**Provincial Health Office- Batangas**  
Roxas Rd, Kumintang Ibaba, Batangas, 4200

**Provincial Health Office- Rizal**  
M. Santos Street, Antipolo City, Rizal

**Provincial Health Office- Quezon**  
Quezon Avenue, Lucena, Quezon Province 4301

| IV-B- MIMAROPA | PHOs          | **Provincial Health Office- Occidental Mindoro**  
Old Provincial Hospital Compound, Ilaya, Calapan 5200  

**Provincial Health Office- Oriental Mindoro**  
Mamburao, Occidental Mindoro, 5106

**Provincial Health Office- Marinduque**  
Santol Street, Boac, Marinduque

**Provincial Health Office- Romblon**  
Bldg. 1, RPH compound, Brgy. Liwanag, Odiongan, Romblon

**Provincial Health Office- Palawan**
### Table 1: PHOs and TSDs for Health Care Wastes

<table>
<thead>
<tr>
<th>Region</th>
<th>Type</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>V- Bicol</td>
<td>CHD</td>
<td>Bagtang Road, Legazpi, Albay 4500</td>
</tr>
<tr>
<td>VI- Western Visayas</td>
<td>CHD</td>
<td>Q. Abeto, Mandurriao, Iloilo City 5000</td>
</tr>
<tr>
<td>VII- Central Visayas</td>
<td>CHD</td>
<td>Osemen Boulevard, Cebu City</td>
</tr>
<tr>
<td>VIII- Eastern Visayas</td>
<td>CHD</td>
<td>Candahug, Palo Leyte 6501</td>
</tr>
<tr>
<td>IX- Zamboanga Peninsula</td>
<td>CHD</td>
<td>Labuan - Limpapa National Road, Zamboanga, Zamboanga del Sur</td>
</tr>
<tr>
<td>X- Northern Mindanao</td>
<td>CHD</td>
<td>J. Seriña St, Cagayan de Oro, 9000 Misamis Oriental</td>
</tr>
<tr>
<td>XI- Davao</td>
<td>CHD</td>
<td>JP Laurel Ave, Buhangin, Davao City, Davao del Sur</td>
</tr>
<tr>
<td>XII- Soccsksargen</td>
<td>CHD</td>
<td>ORG Compound, Gov. Gutierrez Ave., RH VII, Cotabato City 9600</td>
</tr>
<tr>
<td>XIII- Caraga</td>
<td>CHD</td>
<td>Pizarro-Narra Streets, Butuan, 8600 Agusan Del Norte</td>
</tr>
<tr>
<td>BARMM</td>
<td>PHOs</td>
<td><strong>Provincial Health Office- Lanao del Sur</strong>&lt;br&gt;Marawi City, Lanao del Sur</td>
</tr>
<tr>
<td>BARMM</td>
<td>PHOs</td>
<td><strong>Provincial Health Office- Lanao del Norte</strong>&lt;br&gt;Pigcarangan, Tubod, Lanao del Norte&lt;br&gt;Tubod, Philippines, 9209</td>
</tr>
<tr>
<td>BARMM</td>
<td>PHOs</td>
<td><strong>Provincial Health Office- Maguindanao</strong>&lt;br&gt;Old Provincial Capitol, Don Teodoro V. Juliano Avenue, Cotabato City</td>
</tr>
<tr>
<td>BARMM</td>
<td>PHOs</td>
<td><strong>Provincial Health Office- Basilan</strong>&lt;br&gt;Capitol Building, Isabela City Basilan 7300</td>
</tr>
<tr>
<td>BARMM</td>
<td>PHOs</td>
<td><strong>Provincial Health Office- Sulu</strong>&lt;br&gt;Asturias St., Jolo, Sulu 7400</td>
</tr>
<tr>
<td>BARMM</td>
<td>PHOs</td>
<td><strong>Provincial Health Office- Tawi-tawi</strong>&lt;br&gt;Tubig-Boh Bongao, Tawi-Tawi, Bongao, Tawi-Tawi</td>
</tr>
</tbody>
</table>

### 4.3 Health Care Waste Transporters and Treatment, Storage, and Disposal Facilities (TSDs)

As of the May 2020 data of the Department of Environment and Natural Resources-Environmental Management Bureau, not all regions in the Philippines have DENR-accredited waste treaters and treatment, storage, and disposal facilities (TSDs) for health care wastes, specifically for M501 and M503 wastes.

Tables 2 and 3 show the summary of DENR-accredited M501 and M503 waste treaters and TSDs, respectively. The full list of the treaters and TSDs for M501 and M503 wastes are in Annexes J and K, respectively. It should be noted that the MIMAROPA, Central Visayas, Zamboanga Peninsula,
Northern Mindanao, Davao, Soccsksargen, Caraga, and BARMM regions have no registered M501 and M503 waste transporters located in their region. Meanwhile, the Cagayan Valley, Bicol, Zamboanga Peninsula, Soccsksargen, and BARMM regions have no accredited M501 and M503 waste TSDs located in their regions.

The unavailability of appropriate DENR- accredited waste transporters and TSD facilities poses health and environment risks, such as exposure of the public to infectious wastes, considering the high volume of health care wastes expected to be generated from the COVID-19 immunization activities.

Table 4.16. DENR- accredited M501 and M503 waste treaters

<table>
<thead>
<tr>
<th>Region</th>
<th>Transporter</th>
<th>M501 only</th>
<th>M503 only</th>
<th>M501 and M503</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCR</td>
<td>1</td>
<td>9</td>
<td>5</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>CAR</td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>I- Ilocos</td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>II- Cagayan Valley</td>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>III- Central Luzon</td>
<td></td>
<td>7</td>
<td>11</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>IV-A- CALABARZON</td>
<td>1</td>
<td>12</td>
<td>16</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>IV-B- MIMAROPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V- Bicol</td>
<td>1</td>
<td></td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>VI- Western Visayas</td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>VII- Central Visayas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VIII- Eastern Visayas</td>
<td></td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>IX- Zamboanga Pen.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X- N. Mindanao</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XI- Davao</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XII- Soccsksargen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XIII- Caraga</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARMM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Grand Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>73</strong></td>
</tr>
</tbody>
</table>

Table 4.17. DENR- accredited M501 and M503 waste TSD facilities

<table>
<thead>
<tr>
<th>Region</th>
<th>No. of DENR- accredited M501/3 TSDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCR</td>
<td>6</td>
</tr>
<tr>
<td>CAR</td>
<td>1</td>
</tr>
<tr>
<td>I- Ilocos</td>
<td>2</td>
</tr>
<tr>
<td>II- Cagayan Valley</td>
<td>19</td>
</tr>
<tr>
<td>III- Central Luzon</td>
<td>7</td>
</tr>
</tbody>
</table>
### Training for Implementers on the COVID-19 Vaccination Activities

The DOH has developed a set of training modules in support to the upcoming vaccination activities against COVID-19. It aims to provide guidance to health workers and partner implementing agencies on the efficient nationwide implementation of the COVID-19 Immunization Program. Content experts on COVID-19, vaccination, human resource training, data management, logistics, health communication, and counselling, surveillance, and waste management were consulted for development of this training course. The training course encompasses the whole spectrum of the delivery of services from pre- to post-implementation.

This training course shall update the skills and knowledge of our program coordinators and implementers, surveillance teams, community health educators and workers and partner agencies on vaccination in consideration to dealing with a communicable / infectious disease and managing and administration of a new vaccine. This training course is composed of the following modules:

- Module 1 – Microplanning
- Module 2 - Profiling and Data Management
- Module 3 - Supply Chain and Cold Management
- Module 4 - Risk Communication and Community Engagement
- Module 5 - Mental Health and Psychosocial Support (MHPSS) and Counselling
- Module 6 – Immunization
- Module 7 - Managing Adverse Events Following Immunization (AEFI) following COVID-19 Vaccination
- Module 8 - Immunization Waste Management

Each module focuses on specific activities and tasks. The training shall follow a blended learning strategy combining different teaching and learning methodologies. eLearning for didactic topics and face-to-face skills training shall be utilized. Online and offline modules will be made available. Two (2-3) days shall be allotted to complete this whole training course.

A DOH Core and Regional Training Team will be organized to plan, strategize, oversee, and implement the cascading of this training course. They shall act as training lead and resource person on the conduct of training. Mentoring sessions and post-training supervision shall be conducted by trainers to ensure standard delivery of training and services.

The training course shall be monitored and reviewed by the Department of Health.

<table>
<thead>
<tr>
<th>Region</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV-B- MIMAROPA</td>
<td>1</td>
</tr>
<tr>
<td>V- Bicol</td>
<td></td>
</tr>
<tr>
<td>VI- Western Visayas</td>
<td>1</td>
</tr>
<tr>
<td>VII- Central Visayas</td>
<td>1</td>
</tr>
<tr>
<td>VIII- Eastern Visayas</td>
<td>1</td>
</tr>
<tr>
<td>IX- Zamboanga Peninsula</td>
<td></td>
</tr>
<tr>
<td>X- N. Mindanao</td>
<td>2</td>
</tr>
<tr>
<td>XI- Davao</td>
<td>1</td>
</tr>
<tr>
<td>XII- Soccsksargen</td>
<td></td>
</tr>
<tr>
<td>XIII- Caraga</td>
<td>1</td>
</tr>
<tr>
<td>BARMM</td>
<td></td>
</tr>
<tr>
<td><strong>Grand Total</strong></td>
<td><strong>43</strong></td>
</tr>
</tbody>
</table>

4.4 Training for Implementers on the COVID-19 Vaccination Activities
4.5 Air Quality and Healthcare Waste Incineration

Air quality in the Philippines (and Manila in particular) has improved substantially in the 20 year-period since the enactment of the *Clean Air Act of 1999* (CAA). A Japan International Cooperation Agency (JICA, 1997) study cited waste incineration as a major source of air pollution in Manila leading to a ban on incineration in 1999 under the CAA. The incineration ban was subsequently appealed with the Supreme Court ruling that only incinerators that emit poisonous and toxic emissions were banned. Hence, thermal waste treatment is permitted provided that emissions meet standards specified in the CAA. A phase-out of medical waste incinerators under the CAA was also deemed impractical due to the lack of affordable best available technologies (BAT). Incinerator operators are required to self-regulate emissions and report to the Department of Environment and Natural Resources Environmental Management Bureau (DENR-EMB).

WHO (2019) describes the following HCW management hierarchy:

- The preferred approach is to avoid generating waste and thus minimise the quantity entering the waste stream.
- Where practicable and safe, those waste items that can be recovered for secondary use is the next most preferable method.
- Waste that cannot be recovered must then be dealt with by the least harmful options, such as treatment or land disposal to reduce their health and environmental impacts.

Under COVID-19 conditions the HCW quantities are expected to increase substantially potentially overwhelming thermal treatment capacity with associated OH&S and environmental pollution implications.

The Stockholm Convention recommends that priority consideration should be given to alternative processes, techniques or practices that have similar usefulness, but which avoid the formation and release of dioxins and furans. Non-incineration waste treatment technologies should always be implemented wherever possible. WHO has called on all stakeholders to uphold the Stockholm Convention and work towards incrementally improving safe health care waste management practices to protect health and reduce harm to the environment.

4.6 Indigenous Peoples

The project is likely to take place in areas with indigenous peoples, particularly for some regional health facilities and local health centers. No direct adverse impacts on indigenous peoples are expected from project activities, although as generally a marginalized group they may be more affected by the virus should it spread in their communities. Civil works are expected to be confined to existing premises of health facilities and would not require any land acquisition. Some health facilities in areas with indigenous peoples may be directly supported with vaccines, equipment, supplies, and critical medical services. Stakeholder engagement and information sharing at these sites would be key to ensure that indigenous communities and COVID-19 affected persons are able to avail themselves of health services supported by the Project.

The term “indigenous cultural communities/indigenous peoples” (ICC/IP) is used in the Indigenous Peoples Rights Act (IPRA) of 1997 (Republic Act No. 8371) and includes a wide variety of groups that share certain conditions which set them apart from mainstream society in the Philippines.
The IPRA defines ICCs/IPs as a group of people or homogenous societies identified by self-ascription and ascription by others, who have continuously lived as organized community on communally bounded and defined territory, and who have, under claims of ownership since time immemorial, occupied, possessed and utilized such territories, sharing common bonds of language, customs, traditions and other distinctive cultural traits, or who have, through resistance to political, social and cultural inroads of colonization, non-indigenous religions and cultures, became historically differentiated from the majority of Filipinos.

The IPRA definition has been found to be consistent with the identifying characteristics for social groups covered by the Bank’s previous Operational Policy (OP 4.10) on indigenous peoples and is also considered consistent with the new E&S Standard 7 (ESS7) on indigenous peoples. ESS7 identifies social groups covered by the standard as a distinct social and cultural group possessing the following characteristics in varying degrees: (a) Self-identification as members of a distinct indigenous social and cultural group and recognition of this identity by others; and (b) Collective attachment to geographically distinct habitats, ancestral territories, or areas of seasonal use or occupation, as well as to the natural resources in these areas; and (c) Customary cultural, economic, social, or political institutions that are distinct or separate from those of the mainstream society or culture; and (d) A distinct language or dialect, often different from the official language or languages of the country or region in which they reside.

Indigenous peoples live in most areas of the Philippines, but the majority resides in Mindanao (about 60 percent) and North-Central Luzon (about 30 percent). There are no accurate census data regarding the number of indigenous peoples, but it is estimated to be between 10-15 million people. The National Commission on Indigenous Peoples (NCIP) officially recognizes the existence of 110 ethno-linguistic groups in the country. In Luzon, most of the indigenous peoples are concentrated in the northern mountain ranges of the Cordilleras (e.g. the Kalinga, Ifugao, Ibaloy, and Ilongot) and in the Sierra Madre mountain ranges (e.g. the Agta, Dumagat, and Itawis). They are also found in Zambales, Pampanga, Tarlac, Quezon Province, Pollilo Island, and the Bicol Peninsula (e.g. the Pinatubo, Baluga and Agta).

The Western Islands Region and Central Philippine Islands Region are home to the Mangyan, Tagbanua, Batak, Tau't Bato, Keney, Sulod, Magahat, Ata and Ati, mainly in Mindoro, Palawan, Panay and Negros. In the island of Mindanao, there are about fifteen major indigenous groups and several subgroups living in the interior rainforest, hills, plateaus, narrow valleys and marginal plains, which include the Mandaya, Manobo, Bilaan, T’boli, Tiruray, Subanun, Higaonon, Tasaday, Bagobo, Manuvu, Matigsalug, Ata, and others; collectively they are called Lumads. The majority Muslim population in Mindanao, called Moro, is not considered to meet the identifying criteria as indigenous peoples and ESS7 is not applicable to them. The Bangsamoro Autonomous Region in Muslim Mindanao or BARMM is inhabited by indigenous peoples, including some marginalized Muslim groups such as the Badjao.

4.7 Disadvantaged and Vulnerable Groups

4.7.1 Persons with Disabilities

As COVID-19 continues to have wide-reaching impacts across the globe, it is important to note how persons with disabilities are uniquely impacted by the pandemic and may have constraints in accessing services. This section serves as a brief overview of emerging impacts and sets out some preliminary steps to mitigate the impact within the Bank’s unfolding operations on COVID-19.
Situation Overview in Key Areas

Health

- Many persons with disabilities have additional underlying health needs that make them particularly vulnerable to severe symptoms of COVID-19, if they contract it.
- Persons with disabilities may be at increased risk of contracting COVID-19 because information about the spread of the disease, the symptoms associated with it, and how to prevent getting it are not provided in accessible formats, such as print materials in Braille or large print, sign language interpretation, captions, audio provision, and graphics.
- Persons with disabilities may be at increased risk of contracting COVID-19 as they may not have the same access to handwashing facilities/alternatives or may have trouble social distancing because they require in-person assistance in various ways.
- Some persons with disabilities who require personal protective gear or other medical supplies, such as ventilators, for their regular health needs may have more difficulty accessing them due to an increased demand for those particular items.
- In addition, in economies where persons with disabilities have personal assistants for essential home-based care social distancing mandates may jeopardize support received, and the burden of care heightened.
- Existing physical and communication barriers that limit the accessibility of health systems still exist and might prevent persons with disabilities from seeking appropriate care for COVID-19 and other needs.
- Reduced access to personal aides and support is likely to have harmful effects on health. In particular, there may be long-term impacts on sexual and reproductive health because of lack of access to clean water, contraceptives, and menstrual hygiene products.

Education

- As schools close nation-wide in over 160 countries and many more at localized levels, over 87% of the world’s student population is out-of-school, interrupting educational progress and risking that children with disabilities have difficulty returning to school.
- Interruption of schooling can also interrupt access to basic services like meal programs; assistive technologies; access to resource personnel; recreation programs; extracurricular activities; and water, sanitation, and hygiene programs, all of which have benefits for children with disabilities.
- In settings where online learning is possible and provided to ensure instructional continuity, children with disabilities may have difficulty accessing the online platforms and content if accessibility features are not considered. They may miss out on important therapies, services, or accommodations they typically receive to support their learning if alternative options are not offered.

Economic and Employment Impacts

- Persons with disabilities already experience higher poverty rates and lower levels of employment. The current economic situation is expected to exacerbate economic and employment instability for persons with disabilities, especially those who are freelance workers or self-employed.
- Persons with disabilities represent a high proportion of informal sector employment, including the gig economy which is particularly adversely affected by the current economic environment and pandemic.
• Workplace accommodations, including physical accommodations or assistive technologies, may be workplace bound and employees with disabilities may face delays in receiving similar setups at home to continue their job tasks.

Transport and Travel

• As public transport systems reduce or stop services, persons with disabilities who rely on these methods for accessible transport may not be able to travel, even for basic necessities or critical medical appointments.
• With rapidly changing guidance and travel restrictions, persons with disabilities might not be able to return to their homes or to places that are more accessible to them.

Social Protection and Safety Nets

• There are concerns and reports that existing barriers, isolation, stigma, and discrimination are intensifying amid the outbreak.
• Social protection systems are weak in many countries and do not always cater to the needs of persons with disabilities.
• Safety nets may need to cover caregiving and other expenses particularly those emerging from ruptures in services for persons with disabilities.
• With increased stress, family confinement, and isolation, there is also an increased risk of gender-based violence. Since evidence shows that persons with disabilities, particularly women and girls, experience greater rates of violence and abuse, they are at a heightened risk during this period.

4.7.2 Disability-Inclusion in the World Bank’s COVID-19 Response

With the robust funding commitments to help clients fight COVID-19, there are opportunities to address persons with disabilities and limit the impacts delineated above. DOH has consulted with organizations representing persons with disabilities (PWD) and developed measures to address their particular circumstances and needs.

The DOH Health Facilities Development Bureau (HFDB) has reported that there are 10 provincial hospitals which currently have Filipino sign language interpreters (FSL) who are mostly social workers employed by the hospital. They are as follows:

Table 4.18. Health care facilities with FSL interpreters

<table>
<thead>
<tr>
<th>Region</th>
<th>Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCR</td>
<td>Jose Fabella Memorial Hospital, Lung Center of the Philippines</td>
</tr>
<tr>
<td>I</td>
<td>Mariano Marcos Memorial Medical Center, Ilocos Training and Regional Medical Center, Region I Medical Center</td>
</tr>
<tr>
<td>IV</td>
<td>Batangas Medical Center</td>
</tr>
<tr>
<td>VI</td>
<td>Corazon Locsin Montelibano Memorial Regional Hospital, Don Jose Monfort Memorial Medical Center Extension Hospital</td>
</tr>
<tr>
<td>VII</td>
<td>Vicente Sotto Memorial Medical Center</td>
</tr>
<tr>
<td>XII</td>
<td>Cotabato Regional Medical Center</td>
</tr>
</tbody>
</table>

According to the Degenerative Disease Office of the Disease Prevention and Control Bureau (DPCB-DDO), the new education curriculum of social workers has integrated basic FSL. It should
be noted that hospitals have at least 1 social worker. It would be ideal if the employed social worker has background on FSL. The Metro Manila and CALABARZON Centers for Health Development (CHDs) are conducting community-based trainings on FSL. It is planned to cascade the training to the other regions in 2021. The Congress is also discussing the provision of FSL interpreters in health facilities. However, the timeline for this is not yet known.

The Project will be conducting a baseline assessment on the capacity of the recipient hospitals to provide accessible health services to vulnerable groups, including provision of virtual FSL services based on parameters such as availability of devices and internet connection. The baseline assessment will also cover GBV, VAWC, and IPs. Based on the results of this assessment, the Project in consultation with and through technical assistance of the DOH Bureaus will determine the support to be provided by DOH to these facilities to improve health service delivery to the vulnerable groups.

The DOH Health Promotion Bureau (HPB) has no COVID-19 health promotion materials for the PWDs at present. Currently, they only have the 30-second video with FSL interpretation for polio. The HPB and the DPCB-DDO have included PWD-accessibility in their Communication Plan for 2021 which will include printer materials with Braille and videos with sign language. The DPCB-DDO in partnership with the Philippine Information Agency (PIA), have previously developed a Communication Plan for PWDs which was also presented to the PWD CSOs.

The concerns of PWDs, particularly accessibility, will be considered in the activities under Component 3, Project Management and Monitoring and Evaluation, of the project by integrating into the prevention and preparedness activities. Project management and monitoring should ensure that the improved capacity of the health care facilities results in improved access for PWDs.

The request for vaccination of children and other vulnerable groups as well as the guidelines for carers/personal assistants of PWDs and children will be relayed to the DOH DPCB, HFDB, and the DOH IATF Focal Team. The PWD CSOs will be requested to submit a formal request to the IATF (iatfsecretariat@gmail.com) and DOH regarding the grievances of the carers/personal assistants.

*Other potential responses may include: Immediate, as part of the COVID-19 Support Package:*

- Inclusion of vulnerable groups in the priority populations for vaccination in line with the WHO SAGE guidelines.
- Ensure existing health needs of persons with disabilities are met, and not superseded, by additional health system needs.
- Contract health facilities and temporary testing and treatment facilities that comply with universal access standards.
- Provide health information and government guidance in accessible formats. This includes explanations of what is happening during the time of care for deaf, blind and people with cognitive disabilities. Accessible formats may include print materials in Braille or large print, sign language interpretation, captions, audio provision, and graphics.
- Disaggregated monitoring and evaluating for prevention, preparedness, and community-based disease surveillance by disability status and type to understand how persons with disabilities are impacted in pandemic situations. This should include data on differentiated rates of infection, economic impacts, and regarding the burden of care, barriers of access to care for people with disabilities.
• Integrate accessibility and disability considerations into all technical assistance the World Bank provides on supporting the outbreak. Considerations may need to balance disability-related and social distancing needs, including exemptions for personal caregivers during lockdowns/shelter-in-place procedures and access to personal protective equipment (PPE).
• Employ universal design principles in expanding clinical care capacities, including refurbishing ICUs or inpatient hospital facilities.

Long-term actions to ensure the needs of persons with disabilities are met in the coming months and future outbreak situations:

• Train health workers, including community health workers or volunteers in rural communities; government officials; emergency planners; and other stakeholders on interacting with persons with disabilities and how to support their needs.
• Strengthen disability-disaggregated data collection to address and mitigate risks to persons with disabilities during outbreak situations.
• Contract health facilities and temporary testing and treatment facilities that comply with universal access standards.
• Engage persons with disabilities in future public health emergency preparedness planning.
• Strengthen social security networks, particularly for people in the informal sector.
• Ensure that children with disabilities are supported in returning to school.
• Implement universal design standards in the development and use of online and virtual platforms, tools, and applications used to support government services, educational, employment, public awareness, emergency communications, and recreational activities.

4.7.3 Gender and Gender-based Violence

The Project will benefit both men and women by reducing the risks of COVID-19 to their personal health. The Department of Health generates sex and age-disaggregated data and it is expected that slight variations in project benefits will accrue by gender depending on the subgroup of the population being analyzed. Based on trends of DOH information of COVID-19 patients, men constitute around 60 percent of those afflicted with the disease with women comprising the remaining 40 percent. Although health care has shifted much from being a predominantly female profession and there is no gender-disaggregated data on COVID-19 frontline workers yet, anecdotal evidence and inference shows that there will be likely more women nurses, medical technologists, etc. who are involved in taking care of COVID-19 patients.

In the time of COVID-19, gender-based violence can occur in three major areas: in health facilities, at home by spouses or other members of the family, and in the streets by enforcers of community quarantine including the military, police, security personnel, and barangay patrollers. In hospitals and health clinics/centers, women health workers are exposed to sexual harassment by colleagues, patients, or relatives and friends of patients. The added stress of dealing with the pandemic could also result in other forms of workplace harassment including verbal abuse. Women patients are also prone to sexual harassment especially when unaccompanied in quarantine facilities. The medical profession has a code of ethics and it is expected that health facilities will be able to ensure that these are followed including their respective codes of conduct for their employees.

With families under quarantine, the incidence of domestic violence within a household can be expected to increase. This means that households experiencing domestic violence are more likely to experience it more and that domestic violence is not likely to spread across the community.
Women are faced with the risk of abuse as they stay at home and the risk of getting infected with the disease when they go out to seek help. However, with service-providers not in operation or overwhelmed with other tasks, women survivors are not able to receive the full support they need. At the very least, hotlines and online psychosocial support needs to be available to survivors.

With enforcers of community quarantine seemingly having more power, violence against women may also increase. In many households particularly in rural areas, women are tasked to go to the market which is the only allowed form of social mobility during quarantine. As they perform this role, women are exposed to formal and informal security forces stationed in their communities. Provided that maximum tolerance will be enforced and there will be no abuse of power, women should be generally safe from gender-based violence when they go outside their homes.

Further, aside from gender-based violence, access to sexual and reproductive care services have become limited due to exhaustion of resources addressing COVID-19. There are alleged reported cases of women who died due to birth-related complications caused by untimely maternal care by certain hospitals. With this, there is a risk of increase in maternal and infant mortality rates.

4.8 National Immunization Context

The DOH Field Health Services Information System (FHSIS) Annual Report 2018 provided data on the Expanded Program on Immunization (EPI). The percentage of fully immunized children in the Philippines in 2018 is 66.18%, with the Caraga Region as the highest at 74.30% and the Region IV-A (CALABARZON) as the region with least vaccinated children (58.47%). Meanwhile, in 2017, the fully immunized children at the national level is at 67.47% and 69.84% in 2016 (FHSIS 2016 and FHSIS 2017). Region 10 has the highest number of fully vaccinated children in 2016 and 2017 at 84.77% and 80.91%, respectively. Region V or Bicol Region has the least fully vaccinated children in 2016 at 51.54% and the BARMM in 2017 at 50.27%. Based on the FHSIS data on full vaccination on children, it can be said that immunization rate has decreased from 2016 to 2018.

4.9 Social and Behavioral Issues on Immunization

In 2016, the Department of Health (DOH) launched a program to vaccinate children against dengue, where more than 800,000 children received at least one dose of the dengue vaccine. But in the following year, the manufacturer released information that there may be an added risk for children who have received the vaccine. This change in guidance sparked public outrage and political turmoil that resulted in heightened public anxiety, and a general distrust in vaccines and the process of vaccination.

Between the years 2015 and 2019, the Vaccine Confidence Project estimated a significant drop in vaccine confidence in the Philippines. The percentage of people strongly agreeing that vaccines are important dropped from 99% in 2015, down to only 81% in 2019. Also, the percentage of people strongly agreeing that vaccines are safe dropped from 83% in 2015, down to only 60%
2019. Also, the percentage of people strongly agreeing that vaccines are effective dropped from 81% in 2015, down to only 63% in 201818.

In a survey done during the peak of Dengvaxia, 25% of respondents said they do not trust vaccines provided by DOH. NCR figures however are double of national average at 47%. In the same PulseAsia survey, reports on Dengvaxia and reports in the media of child deaths allegedly due to vaccines were identified as the top reasons that influenced the respondents to distrust the vaccines provided by the DOH.

However, the dengue vaccine controversy may not be the only contributing factor for the drop of vaccine confidence. Post-campaign reports for the DOH’s supplemental immunization activities (SIA) also identified a range of supply-side (e.g., access, availability of vaccines, etc) and demand-side factors (eg. religious beliefs, fears, distrust, etc) that may well have contributed to the decline of vaccine confidence and coverage even prior to the introduction of the dengue vaccine. This is supported by the data that shows that even before the 2017 dengue vaccine crisis, the vaccination rates of the basic vaccines for children in the Philippines have already been dropping.

The Philippine National Demographic Health Survey (NDHS) in 2017, which collected information on children born within three years prior to the survey, found that only an estimated 70% of children aged 12-23 months received all basic vaccines. This percentage is less than the findings of the NDHS in 2008 that reported estimated 80% of children aged 12-23 months received all basic vaccines. In preparation for the eventual vaccine roll-out for COVID-19 vaccines, UNICEF Philippines in partnership with the Department Health conducted a survey in September 2020 to understand the public’s perception on the COVID-19 vaccines. The key findings can be seen summarized in the table below:

---

**Table 4.19. Key findings of the UNICEF assessment on vaccine acceptability**

---

18 DOH National Demand Generation and Communications Plan for COVID-19 Vaccines (January 2021)
4.10 Lessons Learned on the Immunization Roll-out of a Novel Vaccine

The vaccination roll-out of the Dengvaxia against dengue, globally and in the Philippines in 2018 has posed several lessons on immunization of populations using a novel vaccine, as reported by Thomas and Yoon (2019), which are as follows:

- A more in-depth understanding of the induction, kinetics, and contributions to safety and protection of long-term homotypic, transient heterotypic, and long-term heterotypic immune responses is required, which will, in turn, require better ways to measure them;
- Multivalent replicating vaccines are at theoretical risk of experiencing immunodominance and immune interference in the recipient, likely necessitating a more iterative development approach to evaluate individual infectivity and immunogenicity (example – exploring monovalent dengue vaccines in separate clinical studies prior to combination);
- Since clinically relevant immune responses can change over time after natural infection or vaccination, the timing of efficacy measurements will need to be taken into account when considering vaccine efficacy and risk;
- Surveillance systems applied to vaccine efficacy trials should be designed to capture clinical end-points of interest for the period of time required to make a maximally informed decision about the vaccine’s potential for clinical benefit (i.e., how many dengue seasons?);
- Exploring immunogenicity and efficacy as a function of vaccine viral strains and contemporary circulating DENV types and genotypes should be considered by Sponsors, especially those using vaccine strains collected many years prior;
- Understanding the impact of age, baseline dengue and non-dengue flavivirus serostatus, infecting serotype, and time from vaccination on immunogenicity, efficacy, and safety should be a focus of Sponsors;

---

• Expanding and standardizing methods to complete quantitative and qualitative measures of humoral immune responses are required to leverage an understanding of protective and deleterious responses and what constitutes each (i.e., target epitopes);
• Exploring, in a prospective manner, immune correlates or surrogates of protection and risk should be a Sponsor priority, and will likely require collecting baseline blood samples on all trial participants, lengthening the duration of active surveillance, and having secondary efficacy endpoints assessing various time points remote from the vaccination; and
• Use of experimental human infection models should be considered to assist with early development decisions (i.e., antigen selection, dose, and schedule), gaining an early understanding of a vaccine candidate’s potential for clinical benefit prior to large clinical endpoint studies, and potentially adding to a data package supporting pursuit of a specific indication (example – fillings gaps in knowledge from field efficacy studies).

5 Potential Environmental and Social Impacts and Mitigation Measures

The anticipated overall environmental and social risks as in the parent project remain substantial. The measures to address social and environmental risks in the parent project remain relevant, including infection prevention and control improvements in health facilities, such as assessment and mitigation measures for medical waste risk management that will be expanded as inoculation sites expand. While experience indicates that substantial risk ratings can be expected for the environment, more attention should be given to address the medical waste and occupational health and safety risks, especially because of gaps in healthcare waste management systems, the appropriateness and safety of refrigerants, and the potential huge demand for cold storage and transportation requirements needed to cover the entire country. The social risk is anticipated to be at least substantial; in the Philippines there is a broader social risk of inequity in access to vaccines and elite capture, such as due to political pressures to provide vaccines to groups that are not prioritized.

These risks will be mitigated through several measures to ensure vaccine delivery targets the most vulnerable populations, particularly health care workers, poor and elderly populations, and uniformed personnel, as specified in this AF. First, the Bank will support the Philippines to develop and adopt an explicit, contextually appropriate, and well-communicated targeting criteria and implementation plan (e.g., the national vaccination program and any subsidiary programs), including criteria for access to vaccines. As part of the SEP, the Borrower will ensure that this plan is subject to meaningful consultations per ESS 10.

5.1 Methodology for Assessing Risk and Impacts

The ESMF is prepared based on an assessment of direct and indirect risks and impacts of the specific project activities. A direct impact is defined under the ESF as “...an impact which is caused by the project, and occurs contemporaneously in the location of the project.” An indirect impact is one “...which is caused by the project and is later in time or farther removed in distance than a direct impact, but is still reasonably foreseeable, and will not include induced impacts”. Induced impacts are those that are unknown, speculative, uncertain, or remote. Induced impacts are not
considered further in this document as they cannot be reasonably assessed or mitigated at this time. Induced impacts emerging during project implementation will be managed responsively and the ESMF amended accordingly.

The project will apply the World Bank’s Environment and Social Framework (ESF), procedures for IPF operations designed to respond to COVID-19 and processed as an emergency operation under paragraph 12 of the IPF Policy. The Project will have positive social and environmental impacts as it should improve COVID-19 immunization, surveillance, monitoring, and containment. However, the project could also cause substantial environment and social risks.

5.2 Risk Summary

5.2.1 Environmental Risks

The main environmental risks are the occupational safety and health risks (OSH) to the health care workers brought about by the profiling and screening of patients prior to vaccination, administration of the vaccine, and the operation of medical facilities and laboratories involved in COVID-19 response might expose the health care workers to infection and cause unsafe environment. There are also OSH risks to the workers/laborers due to the possible exposure during the construction activities in the health facilities and laboratories. Occupational safety and health risks for cleaners and waste handlers in health facilities and the waste service providers are present due to the possible exposure to infectious health care wastes during the collection, storage, treatment, and disposal stages. There are risks from infectious healthcare wastes as they are generated from the testing and vaccination activities, including waste collection from the health care facility by the facility’s waste handlers and cleaners and by the contracted waste service providers, as well as community health and safety issues related to the handling, transport, treatment, and disposal of the healthcare wastes are present. The COVID-19 vaccines require specific temperatures during storage and distribution to maintain efficacy and safety. The availability of cold storage and refrigerated transportation suitable to the temperature needs of the vaccine and in the location of vaccine administration is a potential risk to the Project’s implementation. Relatedly, the cold storage to be procured or rented may contain refrigerants which do not conform to the requirements of the Montreal Protocol, Kigali Agreement, and the chemical control order on ozone-depleting substances (ODS) and contribute to the generation of greenhouse gases (GHG). Other refrigerants are also toxic and flammable and can pose risk to people’s health and safety. Cold storage systems also require huge amount of energy to operate that may have an impact on climate change. The compliance with biosafety protocols during the transport of the vaccines is also a risk, as breakage of the vials and spillage of the vaccine might occur. Similarly, natural disasters such as earthquake, landslide, flooding, storm surge and other climate change-related risks as well as unstable power supply in some areas in the country may affect the security of the delivery and distribution of the vaccines.

Hazardous, infectious, and toxic (HIT) wastes that may be generated from the vaccine administration include liquid contaminated waste (e.g. blood, other body fluids and contaminated fluid) and infected materials (water used; syringes, vials, and cottons) which require special capacity to manage and dispose. Without proper handling, these infectious wastes may pose risk to the healthcare workers and communities who are in contact or handle the waste and live near its disposal area. Since the healthcare facilities have instituted HCWM protocol in its operations even before the COVID-19 pandemic and the third party hazardous waste TSD facilities as well as the landfill sites are heavily regulated by government to enable proper management of the risks
and impacts involved, the environmental risks are considered moderate. Moreover, the unavailability of appropriate DENR-accredited waste transporters and TSD facilities in some regions may pose incapacity to properly handle the high volume of health care wastes expected to be generated from the COVID-19 immunization activities and lead to health and environment risks, such as exposure of the public to infectious wastes, considering the

5.2.2 Social Risks

The social risks are considered substantial, although the direct social impacts and risks associated with the activities proposed by this project are expected to be mostly temporary, predictable, and avoidable. Any construction works that requires land acquisition and resettlement will not be financed by the Project, and it is part of the negative list of activities.

The major areas of social risks are expected to concern the biosafety issues of the vaccine, inequity and exclusion, social acceptability and acceptance of the vaccine, regulatory measures, misinformation surrounding biosafety and deployment and stigma and discrimination. Due to the novelty and relative timeframe of the development and clinical trials of the COVID-19 vaccine, the communities may have fear and apprehension on its scientific integrity, efficacy, and safety. The contraindications and storage and transport condition requirements of the vaccine may pose risk. Transparency on the vaccine information and manufacturer credibility are important considerations for the public. Misinformation and disinformation on the adverse health effects of vaccine is also a risk which should be addressed.

The case management of population for vaccination includes risks of contraindications and adverse health effects as result of improper or incomplete profiling and screening of individuals prior to vaccination. There is a risk of not completing the vaccine dose/shots due to the individual’s apprehension and/or schedule mismanagement. The data management of cases, surveillance system, and schedule monitoring are also risks. With the use of more than one vaccine during the immunization period, close monitoring of adverse events in vaccinated individuals using information technology, i.e., digital tracking system should be conducted. As the possibility of adverse effects of the vaccine is a risk, tracking of health effects in vaccinated individuals and follow-up assessments should be conducted.

The global demand for the vaccine and the limited vaccine production makes access to the COVID-19 vaccines a risk. The conduct of strict regulatory measures should be ensured in view of the novelty of the vaccine. Regulation and access concerns should be equally taken into consideration. Moreover, the work of relevant bodies such as the Food and Drug Administration (FDA), the National Immunization Technical Advisory Group (NITAG), and the Health Technology Assessment Committee (HTAC) should be continually aligned and synchronized to ensure the expeditious national approval of the vaccines.

Community health and safety risks consider infectious health care wastes generated from the vaccination and other COVID-19-related responses pose risk to community health and safety if not handled, transported, treated, and disposed of according to the proper health care waste management practices. Hospital visitors and other non-COVID-19 patients may also be exposed to the virus as well as the workers when establishing or upgrading health facilities. There is also a risk of not completing the vaccine dose/shots due to the individual’s apprehension and/or schedule mismanagement. The vaccine administration may also lead to crowding and violation of
physical distancing measures, increasing the risk of exposure of the candidates and the residents within the vicinity of the site.

Risks on social inequity and exclusion include the accessibility of COVID-19 vaccines due to its price is a risk. Due to the novelty and urgent need of the vaccine, there is a risk in price regulation and compliance with fair trade guidelines. There is an indirect risk of social exclusion in particular, the most vulnerable and marginalized groups such as the indigenous peoples in remote areas from access to the COVID-19 information, treatment, and vaccines. The elderly, those with underlying medical conditions, and people living with disability, though included in the priority populations to be vaccinated as identified in the WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply, may have limited access to the vaccines due to reduced mobility. The vulnerable groups may also be excluded from coverage of the national program and local responses to COVID-19. The information materials on the COVID-19 vaccine to be developed could exclude the most vulnerable or be developed in a way that is not sensitive to the needs and access of these different groups. The vaccine distribution and deployment may also exclude populations based on geographical distribution, i.e. those in far-flung areas in GIDAS, and on socioeconomic status, such as less access for the marginalized.

Stigma and discrimination risks involve misinformation on the adverse health effects of vaccines and hearsays on the conspiracy theories and underlying political agenda on the vaccines are widespread. The vaccine acceptance may also be affected by the country’s previous experience with the Dengvaxia vaccination. The fear and apprehension of individuals and communities on the scientific integrity, efficacy, and safety of the COVID-19 vaccines may lead to people refusing vaccination. It may also cause individuals to hide symptoms, avoid getting tested, and reject hygiene measures, which could lead to further spread of the virus. The health workers involved in the vaccine administration activities may face discrimination and harassment when going back to their communities due to people’s fear in contracting the virus, frustrations over medical care, or misinformation.

There may also be some risks concerning sexual exploitation and abuse and violence against women and children related to healthcare workers and people in quarantine. Civil works envisaged in the project mainly refer to repair and rehabilitation of existing buildings. New facilities will be on existing premises and activities that would require land acquisition or involuntary resettlement are not eligible for project financing.

The potential risks and impacts will be addressed through the implementation of a Stakeholder Engagement Plan (SEP), including a Grievance Mechanism, and this Environmental and Social Management Framework (ESMF), including Labor Management Procedures (LMP), prepared based on an assessment of environmental and social risks and impacts in line with the applicable WB ESSs of the WB’s ESF, the WHO COVID-19 guidance on risk communication and community engagement, and national laws and regulations.

Women, the elderly, adolescents, youth, and children, persons with disabilities, indigenous populations and minorities generally experience the highest degree of socio-economic marginalization. Marginalized people often become more vulnerable in emergencies due to poor, or lack of, access to health services, information, and lack of effective monitoring and early-warning systems. The Project aims to provide health services to all COVID-19 affected persons, however, in some instances additional measures may be needed to ensure inclusion and outreach to vulnerable and marginalized people.
5.3 Construction Stage

5.3.1 Environmental Risks

Environmental risks at the construction stage are not expected to be significant. Construction works will mainly involve fit-out type activities in existing premises. Minor quantities of construction waste will be generated; however, none is expected to be hazardous and all will be disposed in accordance with local regulations.

Construction activities within health facilities will need to comply with relevant regulations for the specific circumstances to ensure that the integrity of the facility is not compromised. The environmental guidelines that will be complied with include air and water quality, vibration and noise standards, COVID-19 protocol and healthcare wastes management guidelines relevant to the small works construction, management of healthcare equipment and operational activities of the healthcare facilities financed by the project.

5.3.2 Occupational Health and Safety

Risks

Occupational health and safety hazards during construction activities include potential exposure to COVID-19 and regular hazards associated with construction activities. COVID-19 transmission hazards can be considered in terms of work location in accordance with the LMP, with works in health facilities carrying the potential for nosocomial transmission (infection contracted because of an infection or toxin that exists in a certain location, such as a hospital). Hence, there is a slightly elevated risk of COVID-19 transmission due to proximity to patients and health workers. Works to establish quarantine facilities and decontamination stations carry similar hazards to normal community activities under COVID-19 restrictions. Depending on location and scope there may be some impacts to local communities near the site, e.g., in terms of dust, noise, traffic, workers. There may also be fear, mistrust and resistance among the local community. Information disclosure and stakeholder engagement is therefore required in these circumstances following the provisions of the SEP.

Mitigation Measures

All workers involved with construction activities must follow basic hygiene procedures at all times to prevent the transmission of COVID-19:

1. performing hand hygiene frequently with an alcohol-based hand rub if your hands are not visibly dirty or with soap and water if hands are dirty;
2. avoiding touching your eyes, nose, and mouth;
3. practicing respiratory hygiene by coughing or sneezing into a bent elbow or tissue and then immediately disposing of the tissue;
4. workers exhibiting respiratory symptoms must not attend the workplace and should seek immediate medical advice;
5. maintaining social distance (a minimum of 1 meter) from other persons, particularly if they are showing respiratory symptoms.

The contractors shall observe the health protocols and guidelines outlined by the IATF and observe the Labor Management Procedures (LMP). Conduct of training and awareness raising
activities will be done to ensure these procedures are followed, as needed. Construction works required under the project are low hazard activities; hence standard construction OH&S principles should be followed as described in Department of Labor and Employment (DOLE) (2020) *Occupational Safety and Health Standards*.

As an overarching philosophy the OHS hierarchy of controls should be adopted to mitigate OHS risks as shown in Figure 5.1.

![Hierarchy of Controls](image)

Figure 5.1. OHS Hierarchy of Controls

The provisions of Department Order No. 198 (DO 198-18) (Implementing Rules of Republic Act No. 11058) must be complied with by all construction contractors. Specifically, the following provisions must be adhered to:

- All employers, also applicable to contractors, must develop an Occupational Health and Safety Program in accordance with Section 12;
- All workers must undertake the Mandatory 8-hour Safety and Health Seminar for Workers (Section 3); and
- Each construction workforce must have a qualified Safety Officer in accordance with DO 198 Section 14

The Environmental and Social Management Plan (ESMP), Environmental Codes of Practice (ECOP), and the Labor Management Procedures (LMP), Contractor’s Personnel Grievance Redress Mechanism will be developed by the Contractors based on the templates as part of the bidding document. The ESMP, ECOP, LMP and GRM will be implemented, updated, and monitored by the Contractors and project recipient facilities throughout the project duration. Monthly monitoring reports will be prepared accordingly using the templates. To further specify the liability of the contractors to the workers if they contract COVID-19, it will be explicitly stated in the contract that the DOH and the recipient hospitals will not be in-charge of the medical bills and wages of the workers and that it will be covered by the contractor.
5.4 Operational Stage

5.4.1 Occupational Health and Safety

Occupational health and safety (OHS) risks in the operational stage are predominantly associated with COVID-19 transmission risk. There is a risk that health care workers are exposed to COVID-19 during the initial screening and vaccine administration in the health facility or community setting if the proper infection and prevention control measures are not observed. The hazard will vary according to the location of the activities and the exposure to the main modes of COVID-19 transmission. WHO\(^\text{20}\) notes “COVID-19 virus is primarily transmitted between people through respiratory droplets and contact routes.” Contact routes involve viral particles emitted from the respiratory tract of an infected individual landing on a surface. Then another person touches that object then touches their nose, mouth or eyes and the virus enters the body via the mucous membranes, infecting the second person. These are the predominant modes of COVID-19 transmission.

A secondary transmission mode is airborne. Airborne transmission is different from droplet transmission as it refers to the presence of microbes within droplet nuclei, which are generally considered to be particles less than 5 microns (μm) in diameter which can remain in the air for long periods of time and be transmitted to others over distances greater than one metre. This transmission mode “...may be possible in specific circumstances and settings in which procedures or support treatments that generate aerosols are performed; i.e., endotracheal intubation, bronchoscopy, open suctioning...” etc.\(^\text{20}\)

Noting the above “WHO continues to recommend droplet and contact precautions for those people caring for COVID-19 patients. WHO continues to recommend airborne precautions for circumstances and settings in which aerosol generating procedures and support treatment are performed, according to risk assessment\(^\text{20}\).”

Rational use of Personal Protective Equipment (PPE)

WHO\(^\text{21}\) (March 19 2020) noted “The current global stockpile of PPE is insufficient, particularly for medical masks and respirators; the supply of gowns and goggles is soon expected to be insufficient also. Surging global demand – driven not only by the number of COVID-19 cases but also by misinformation, panic buying, and stockpiling – will result in further shortages of PPE globally”. The European Centre for Disease Prevention and Control (ECDC)\(^\text{22}\) (May 2020) noted:

“...countries worldwide affected by COVID-19 have been experiencing difficulties in accessing personal protective equipment (PPE) and hand hygiene materials. Coordinated supply chains for PPE should ensure distribution of such materials to healthcare systems in order to reduce the potential of healthcare-associated transmission to vulnerable groups and healthcare workers.”


In these circumstances it is important that PPE is allocated in a rational way to ensure that those at highest risk of disease transmission are protected from infection. Judgements on the rational use of PPE should be guided by WHO\textsuperscript{21} (Table 1) reproduced in part in Table 2.

**Infection Control**

To ensure that infection is controlled, DOH has instituted a containment strategy that includes extensive testing, quarantine, isolation, and treatment either in a medical facility or at home. Details of the infection control measures are discussed in Annex I.

**Cargo Handling**

To date, there is no epidemiological information to suggest that contact with goods or products shipped from countries affected by the COVID-19 outbreak have been the source of COVID-19 disease in humans\textsuperscript{21}.

**Training**

WHO has developed a free course - *Infection Prevention and Control (IPC) for Novel Coronavirus (COVID-19)* (https://openwho.org/courses/COVID-19-IPC-EN) – targeted at healthcare workers and public health professionals. The course includes information on what facilities should be doing to be prepared to respond to a case of an emerging respiratory virus such as COVID-19, how to identify a case once it occurs, and how to properly implement IPC measures to ensure there is no further transmission to HCW or to other patients and others in the healthcare facility.

Guidance on the proper use of PPE will be promoted to participating health facilities based on WHO interim guidance on the rational use of PPE reflected in Table 2.
<table>
<thead>
<tr>
<th>Setting</th>
<th>Target personnel or patients</th>
<th>Activity</th>
<th>Type of PPE or procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inpatient facilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient room</td>
<td>Health care workers</td>
<td>Providing direct care to COVID-19 patients</td>
<td>Medical mask; Gown; Gloves; Eye protection (goggles or face shield)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aerosol-generating procedures performed on COVID-19 patients</td>
<td>Respirator N95 or FFP2 standard, or equivalent; Gown; Gloves; Eye protection; Apron</td>
</tr>
<tr>
<td>Cleaners</td>
<td></td>
<td>Entering the room of COVID-19 patients</td>
<td>Medical mask; Gown; Heavy duty gloves; Eye protection (if risk of splash from organic material or chemicals); Boots or closed work shoes</td>
</tr>
<tr>
<td>Visitors</td>
<td></td>
<td>Entering the room of COVID-19 patients</td>
<td>Medical mask; Gown; Gloves</td>
</tr>
<tr>
<td>Other areas of patient transit (e.g. corridors)</td>
<td>All staff, including health care workers</td>
<td>Any activity that does not involve contact with COVID-19 patients</td>
<td>No PPE required</td>
</tr>
<tr>
<td>Triage</td>
<td>Health care workers</td>
<td>Preliminary screening not involving direct contact.</td>
<td>Maintain spatial distance of at least 1 metre. No PPE required</td>
</tr>
<tr>
<td></td>
<td>Patients with respiratory symptoms</td>
<td>Any</td>
<td>Maintain spatial distance of at least 1 metre. Provide medical mask if tolerated by patient</td>
</tr>
<tr>
<td></td>
<td>Patients without respiratory symptoms</td>
<td>Any</td>
<td>No PPE required</td>
</tr>
<tr>
<td>Laboratory</td>
<td>Lab technician</td>
<td>Manipulation of respiratory samples</td>
<td>Medical mask; Gown; Gloves; Eye protection (if risk of splash)</td>
</tr>
<tr>
<td>Administrative areas</td>
<td>All staff, including health care workers</td>
<td>Administrative tasks that do not involve contact with COVID-19 patients</td>
<td>No PPE required</td>
</tr>
<tr>
<td><strong>Outpatient facilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consultation room</td>
<td>Health care workers</td>
<td>Physical examination of patient with respiratory symptom</td>
<td>Medical mask; Gown; Gloves; Eye protection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Physical examination of patient without respiratory symptom</td>
<td>PPE according to standard precautions and risk assessment.</td>
</tr>
<tr>
<td></td>
<td>Patients with respiratory symptoms</td>
<td>Any</td>
<td>Provide medical mask if tolerated.</td>
</tr>
<tr>
<td></td>
<td>Patients without respiratory symptoms</td>
<td>Any</td>
<td>No PPE required</td>
</tr>
<tr>
<td>Cleaners</td>
<td></td>
<td>After and between consultations with patients with respiratory symptoms</td>
<td>Medical mask; Gown; Heavy duty gloves; Eye protection (if risk of splash from organic material or chemicals); Boots or closed work shoes</td>
</tr>
<tr>
<td>Setting</td>
<td>Target personnel or patients</td>
<td>Activity</td>
<td>Type of PPE or procedure</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Waiting room</td>
<td>Patients with respiratory symptoms</td>
<td>Any</td>
<td>Provide medical mask if tolerated. Immediately move the patient to an isolation room or separate area away from others; if this is not feasible, ensure spatial distance of at least 1 metre from other patients.</td>
</tr>
<tr>
<td></td>
<td>Patients without respiratory symptoms</td>
<td>Any</td>
<td>No PPE required</td>
</tr>
<tr>
<td>Triage</td>
<td>Health care workers</td>
<td>Preliminary screening not involving direct contact.</td>
<td>Maintain spatial distance of at least 1 metre. No PPE required</td>
</tr>
<tr>
<td></td>
<td>Patients with respiratory symptoms</td>
<td>Any</td>
<td>Maintain spatial distance of at least 1 metre. Provide medical mask if tolerated.</td>
</tr>
<tr>
<td></td>
<td>Patients without respiratory symptoms</td>
<td>Any</td>
<td>No PPE required</td>
</tr>
<tr>
<td>Points of entry</td>
<td>Administrative areas</td>
<td>All staff</td>
<td>No PPE required</td>
</tr>
<tr>
<td>Screening area</td>
<td>Staff</td>
<td>First screening (temperature measurement) not involving direct contact.</td>
<td>Maintain spatial distance of at least 1 metre. No PPE required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second screening (i.e. interviewing passengers with fever for clinical symptoms suggestive of COVID-19 disease and travel history)</td>
<td>Medical mask</td>
</tr>
<tr>
<td></td>
<td>Cleaners</td>
<td>Cleaning the area where passengers with fever are being screened</td>
<td>Medical mask; Gown; Heavy duty gloves; Eye protection (if risk of splash from organic material or chemicals); Boots or closed work shoes</td>
</tr>
<tr>
<td>Temporary isolation area</td>
<td>Staff</td>
<td>Entering the isolation area, but not providing direct assistance</td>
<td>Maintain spatial distance of at least 1 metre; medical mask; gloves</td>
</tr>
<tr>
<td></td>
<td>Staff, health care workers</td>
<td>Assisting passenger being transported to a health care facility</td>
<td>Medical mask; gown; gloves; eye protection</td>
</tr>
<tr>
<td></td>
<td>Cleaners</td>
<td>Cleaning isolation area</td>
<td>Medical mask; Gown; Heavy duty gloves; Eye protection (if risk of splash from organic material or chemicals); Boots or closed work shoes</td>
</tr>
</tbody>
</table>
5.4.2 Healthcare Waste Management at Healthcare Facilities


Natural disasters and conflicts, by their nature, are highly disruptive and dangerous events. Their consequences are unpredictable, and it is inevitable that many essential public services will be interrupted. HCFs, public health and municipal services, such as waste management, may totally or partially cease due to destroyed buildings, damaged equipment, dislocation of staff and blocked roads.

In such situations, all forms of wastes including hazardous healthcare wastes (HCW) remains uncollected and untreated. It is inevitable that wastes will accumulate, and serious environment and health hazards (e.g. hepatitis B and C) may affect communities. Therefore, measures need to be taken to remove wastes as soon as possible after an emergency. The purpose is to reduce the proximity of people to accumulated wastes and so reduce the potential for disease transmission.

The purpose of HCWM in an emergency is to avoid wastes from being scattered indiscriminately around medical buildings and their grounds and reduce the likelihood of secondary infections. As a basic starting point and to avoid sharps injuries, HCW generated by emergency medical care activities (in tents, field hospitals, mobile hospitals) should be segregated using a “two-bin solution” that is, sorting waste into used sharps and non-sharps wastes (including general wastes and infectious, pathological, and pharmaceutical residues). The two bins should be kept segregated until final disposal. Basic considerations in emergency response in HCWM. Safety boxes are to be used for sharps. The following management measures are to be observed:

- All non-sharps wastes, without exception, should be collected in medical areas in rigid containers, such as plastic buckets with a cover, to prevent waste items from being exposed to disease transmission by contact by hand, airborne particles and flying insects.
- Containers and covers should be washed and disinfected daily after being emptied.
- Reuse of rigid waste containers after disinfection with a chlorine (0.2%) solution may be the most practical option to introduce quickly in an emergency situation and is low cost at a time when resources for better forms of waste segregation and storage may be scarce.
- Sharps wastes should be stored safely in puncture-proof and leak-proof containers.

Burial of non-sharps and sharps wastes in pits or trenches may be considered as a pragmatic option in emergency situations.

Hazards and Risks
Actual cases of non-sharps waste being demonstrated to cause an infection in health care personnel and waste workers are rarely documented. HCW handlers are at greatest risk from infectious hazards which include chemical exposures such as chemotherapeutic drugs, disinfectants and sterilants; physical hazards such as ionizing radiation; and ergonomic hazards. The COVID-19 health care wastes may not be properly segregated with the general health care wastes, posing threat to the waste collectors and general public.

**Mitigation Measures**

The following preventive measures can also be implemented during an emergency response phase to reduce public and occupational health risks:

- Provide hepatitis B vaccination to all health care personnel and waste handlers.
- Encourage hand hygiene (washing, preferably followed by disinfection).
- Use gloves and masks for handling HCW.
- Raise the awareness of staff about simple post exposure prophylaxis in the event of an occupational injury (e.g., needle-stick injury).
- Contain and promptly clean up spillages of infectious materials and disinfect quickly to avoid pathogen transmission.
- Disinfect body fluids before their discharge.
- Conduct on-site awareness-raising activities (whenever possible) to remind health care personnel about occupational exposures and the safe practices for managing HCW.

**Table: HCWM practice in emergencies**

<table>
<thead>
<tr>
<th>Segregation and packaging</th>
<th>All containers and bags should be filled to three quarters of their capacities to avoid spillage and kept covered to prevent casual access by people or disease vectors.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Should colour coding of plastic bags and containers not be possible, signs or marks can be put on containers to differentiate between hazardous health-care waste and general waste.</td>
</tr>
<tr>
<td></td>
<td>Segregated waste should be regularly removed and safely stored to reduce the risk of transmission of pathogens and improve general standards of cleanliness and hygiene in medical areas.</td>
</tr>
<tr>
<td></td>
<td>If plastic bags are not available, containers for non-sharps wastes should be washed and disinfected after being emptied.</td>
</tr>
<tr>
<td>Collection</td>
<td>Exclusively allocated carts or trolleys with lids should be used to collect and transport health-care waste. Carts should be regularly cleaned and disinfected.</td>
</tr>
<tr>
<td></td>
<td>Highly infectious wastes (e.g. laboratory wastes and wastes from persons with contagious diseases) should be collected quickly and carried to a</td>
</tr>
</tbody>
</table>
single, secure central storage area; on no account should collected waste be left anywhere other than at a central storage point.

Storage

Segregated waste should preferably be stored in specific restricted areas. The storage area should be a locked room or guarded enclosure.

If this is not available, large containers with lids may be used for temporary storage of segregated waste and should be placed in restricted areas to minimize contact with people and animals.

Mark the storage area with the biohazard symbol, or put a sign or mark that is understood locally to differentiate between hazardous and non-risk wastes.

Treatment and Disposal

Should resources not be available, minimal treatment and disposal practices should continue to be used as follows:

- onsite burial in pits or trenches;
- disposal in special cells in municipal dumping sites;
- incineration in low-cost double-chamber incinerators;
- encapsulation of sharps waste or small quantities of pharmaceuticals followed by onsite burial or burial in special cells in municipal dumping sites;
- incineration in high-temperature industrial incinerators (provided that there is a safe means of transportation);
- disinfection of infectious and sharps wastes with a small autoclave (when resources are available); non-sharps disinfected wastes should join the general waste stream.
- Body parts should be safely stored and disposed of according to local culture and customs.


Reference to the DOH Health Care Waste Management Manual 4th edition should be made for in-depth discussion on the management protocol on COVID-19 and Emerging Infectious Diseases.

An ongoing assessment is being done by the Project to evaluate the existing health care waste management system in the facilities that will be covered by the project to ensure that it will be able to handle the anticipated increase in HCW load, fulfills international standards, and to propose mitigating measures if found otherwise in the project’s environmental and social risk management instruments. This is being done using health care waste management self-audit tools developed by the project. The HCWM self-audit tools will be provided to the hospitals to aid in their regular assessment, recording, reporting, and monitoring of their health care waste management practices. This will assist the facilities in improving their practices, especially the segregation of infectious and general health care wastes. Results of the self-assessment of the hospitals will inform the Project if there is a need for provision of supplies and training on health care waste. Moreover, it should be ensured that the waste contractors or treatment, storage, and
disposal facilities (TSDs) personnel observe proper practices of the health care waste management streams as inspected by the health facilities upon renewal of service contract.

5.4.3 Wastes from COVID-19 Vaccination

Risks

The vaccination activities will produce wastes such as sharps and infectious non-sharp wastes that can cause direct negative health impacts on the community and healthcare workers. There are also indirect health effects to the community and environment resulting from inadequate treatment and disposal of these wastes.

Mitigation Measures

The management of wastes from the vaccination program will be in accordance with the DOH Health Care Waste Management Manual, 4th edition. Measures to be implemented include the following:

- Waste segregation and packaging
  - Segregation of sharps from non-sharps
  - Discard entire syringe with needle into a safety box immediately after use
  - Placement of the safety boxes (when full) into plastic bags closed hermetically and with clear marking to avoid leakage during transportation
  - Placement of empty vials into waste containers with plastic lining to avoid leakage.

- Waste treatment and final disposal
  - Placement of sharp boxes and containers of empty vials into secure septic vaults for on-site burial.
  - If septic vaults are not available, employ the services of a DENR-licensed hazardous waste treatment facility for the off-site transportation and treatment of the vaccination wastes.

- Return Back to Supplier

The vaccine procurement program will apply the Extended Producer Responsibility (EPR) concept or return back condition as a green procurement approach in managing vaccine wastes. The return-back condition in the contract agreement with vaccine suppliers will be specifically applied in areas with limited capacities for safe onsite disposal or in areas with no available third-party hazardous waste treatment facilities or whose municipal landfills do not have dedicated cells for hazardous wastes.

5.4.4 Labor Rights and Gender

Risks

The following potential risks at health facility may occur:
• Workers, in particular health personnel (especially nurses) and cleaners, may be asked to work overtime to respond to the COVID-19 pandemic. It is important that these personnel are able to access overtime pay as needed and required by law;
• Women in particular, if they are single heads of household and have child-care duties may have difficulties responding to requests for overtime;
• Health care and other staff, including cleaners, or workers in upgrade/rehabilitation may need medical care if they contract COVID-19;
• Health workers, a big proportion who are female, may face mental issues or burnout as result of an outbreak; and
• Health workers, cleaners or workers involved in upgrades experiencing respiratory symptoms may fear not getting paid and continue to show up at work.
• There is a risk that health care workers are exposed to COVID-19 during the initial screening and vaccine administration in the health facility or community setting.
• There is also a risk that the cleaners and waste collectors of the health care facilities and waste service providers are exposed.

There is a minor risk of underage workers working as cleaners in medical facilities or transporting medical supplies or equipment. Labor law prohibits anyone under 18 years being involved in hazardous work.

Mitigation Measures

The following mitigation measures are applicable to labor rights and gender as per the Philippines labor law and consistent with ESS2:

• All workers must be paid for overtime in accordance with Government labor laws;
• All workers must be provided with security of medical care, in particular ensuring they can access free medical care if they contract COVID-19.
• Ensure that staff with lower qualification or less experienced working in the health sector (e.g., cleaners, part-time workers, etc.) - often female workers - also have access to the required Personnel Protection Equipment (PPE) – including gloves, gowns, masks and eye protection if exposed to patients with COVID-19, their waste, clothes or linen – and training to make sure they work in a safe environment;
• Vulnerable workers should be identified, such as female single heads of household, who may need additional support in order for them to do their job (for instance, female nurses who are single heads of household may need additional support if they have to work overtime). Additional support to consider may include cash grants, access to food support or provision of childcare services;
• Health care workers must be actively supported by their employers and commended for their work, as well as offered psychological, emotional or mental support if possible;
• All workers must be reassured that they will continue to get paid if they need to self-isolate if they are showing with COVID-19/respiratory symptoms. These provisions must be made including for contracted staff and are included in the Labor Management Plan (LMP);
• Child labor or indentured labor is absolutely prohibited in the project. All medical staff, cleaners, and all others handling equipment, tests, wastes, etc. or involved in the transportation of medical equipment and supplies related to the project must be over 18 years.

5.4.5 Community Health and Safety

Risks

Potential community health and safety risks associated with the project activities include:

• Transport of wastes, transport of lab tests, transport of people who have tested positive with COVID-19 and movement of health workers and other staff in contact with patients with COVID-19, has the potential to spread the virus in the community (note transport of medical supplies and equipment is not expected to result in virus transmission);
• Communities may have fear and apprehension on COVID-19 vaccine efficacy and safety due to the novelty and relative timeframe of development;
• The proper storage conditions and transport of the vaccines are also major risks as they are needed to ensure the efficacy and safety of the vaccine.
• Misinformation and disinformation on the adverse health effects of vaccines and hearsays on the conspiracy theories and underlying political agenda on the vaccines are widespread.
• There is a risk of adverse health effects if the profiling and screening of candidate individuals to be vaccinated and proper data management were not observed to consider vaccine contraindications.
• Crowding or influx of people in the vaccination sites as well as the violation of physical distancing are also risks.
• Use of Security and Military personnel in the delivery and distribution of the vaccines may also exist.
• Health workers may face discrimination and harassment when going back to their communities due to people’s fear in contracting the virus, frustrations over medical care or misinformation;
• Screening of people entering the country, in particular land borders with migrants coming back into Philippines, as well as checks and/or enforcement of any community movement restrictions or quarantine/lockdown or social restriction measures, could lead to abuse of power by law enforcement, fear from community members (especially the elderly), a potential for discrimination of marginalized groups, GBV, Sexual Exploitation and Abuse (SEA) and/or VAC;

Mitigation Measures

The SEP provides measures for stakeholder engagement at participating health facilities to inform local communities of project activities, seek their feedback on potential risks and mitigation
measures. The following community health and safety measures will be applied and for civil works included in the ESMP:

- Transport of all COVID-19 wastes and lab tests, blood samples, etc., should be collected safely in designated containers and bags, treated and then safely disposed;
- Collection of samples, transport of samples and testing of the clinical specimens from patients meeting the suspect case definition should be performed in accordance with biosafety measures and WHO guidelines on Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases;
- Transport of medical equipment/supplies is not expected to be a vector in transmitting the virus, however, workers transporting materials should be reminded to wash hands appropriately and to avoid touching their face;
- To ensure the safety of the vaccines to be procured, the vaccine regulatory approval of the Stringent Regulatory Authorities (SRAs)\(^\text{23}\) identified by the World Health Organization will be required;
- Appropriate messages will be developed under the risk communication plan to address the vaccine safety concerns of communities;
- A Communications Campaign Plan will also be developed by the DOH Health Promotion Bureau (HPB) for the COVID-19 immunization program. It will have a whole-of-government, whole-of-system, and whole-of-society approach which will encompass general information on (i) COVID-19 and the need for sanitation and hygiene practices, (ii) COVID-19 vaccine basic information, (iii) trials results and procurement, and (iv) vaccine program roll-out. The WHO Risk communication and community engagement readiness and response to coronavirus disease (COVID-19) released on 19 March 2020 will also be used as reference in the development of messages and planning of risk communication and community engagement (RCCE) activities.
- A series of counselling and obtaining of informed consent will be conducted prior to the administration of the COVID-19 vaccine;
- The profiling and screening of candidate individuals to be vaccinated should be performed so as to avoid the risk of vaccine contraindications;
- A comprehensive data management system is also needed to support the profiling, screening, and scheduling to address the risk of individuals not completing the required shots/doses of the vaccine;
- Coordination with the local government units as well as the uniformed personnel will be done to assist in crowd management;
- Training must be provided to medical and other staff (doctors, nurses, cleaners, lab technicians, etc.) in contact with patients with COVID-19 and/or their wastes, clothes, linen or tests, on disinfection procedures when going back to their homes/communities. In extreme cases, this may involve isolating medical and other personnel involved with COVID-19 patients;

• Any medical or other hospital staff (including cleaners) experiencing symptoms of COVID-19 or a respiratory illness (fever + cold or cough) must remain at home/isolated and report symptoms immediately to supervisors;
• Communication materials must reinforce the positive contribution of health care workers and other essential workers and their need to be supported by community members;
• Communication materials should make clear the steps health workers and other staff are taking to protect themselves against the virus and their use of PPE;
• Ensure widespread engagement with communities in order to disseminate information related to community health and safety, particularly around social distancing, hand washing, high-risk demographics, self-quarantine, and mandatory quarantine; Workers and law enforcement personnel must adhere to Code of Conduct (CoC), including fair treatment and non-discrimination when carrying out their duties. Key points in CoC must be publicly available as part of disclosure and law enforcement personnel must be made aware and trained in key items (especially non-discrimination, OHS and issues relating to GBV).
• In view of the concerns on the efficacy and safety of the COVID-19 vaccine after administration, monitoring and management of adverse events following immunization (AEFI) will be conducted, with the lead of the National Adverse Events Following Immunization Committee. The Committee will also review all reported serious and cluster of AEFI cases presented for expert opinion and provide a final causality assessment of the AEFI cases. The details on the protocols and guidelines on the AEFI are described in Section 4.1.4. Assessment, Monitoring, and Evaluation of the ESMF which includes the provisions of the National Deployment and Vaccination Plan (NDVP) on AEFI.
• PNP Vaccination Plan ‘Caduceus’ sets forth the security and public safety guidelines and procedures to be undertaken by the PNP in support to the Philippine National COVID-19 Deployment and Vaccination Plan, as a member of the following Task Group (TG): Vaccine Cold Chain and Logistics Management, Immunization Program, and Demand Generation and Communication. Under the Plan, Police Regional Offices are tasked to provide security assistance in the transport of vaccine shipments from storage hubs to vaccination centers. Police Regional Offices are also tasked to establish Police Assistance Desks in vaccination centers to preclude criminal elements and threat groups from taking advantage. On the other hand, police medical frontliners may be fielded to assist the Department of Health, Local Government Unit (LGU) health workers in administering COVID-19 vaccines in designated vaccination centers.
• Security and military personnel may be utilized for vaccine deployment. It will be ensured that the security personnel follow a strict code of conduct and avoid any escalation consistent with the ESF and IFC guidance on the use of security personnel (IFC Good Practice Handbook on the Use of Security Forces: Assessing and Managing Risks and Impacts). In these cases, DOH will assess risks posed by these security arrangements to project workers and the local community. Security personnel will provide security services in a manner consistent with the applicable laws and code of practices and will be consistent with the relevant requirement of the World Bank’s ESS4.
• DOH will ensure that the workers and local community are informed about the security arrangements and the project’s GRM. DOH will review any allegations of unlawful or
abusive acts of security personnel, take action (or urge appropriate parties to take action) to prevent recurrence and, where necessary, report unlawful abusive acts to the relevant authorities. Any incidents, concerns or grievances regarding the conduct of security personnel will be received, monitored, documented (taking into account the need to protect confidentiality), and resolved through the Project’s grievance mechanism following incident classification: Indicative, serious and severe. Any severe incidents with such personnel need to be reported to the Bank no later than 48 hours with basic information and a detailed incident report within 10 working days. Details about incident classification and incident reporting are included under the Labour Management Procedure (LMP).

Regular community consultations will be conducted continuously to identify the additional risks and mitigation measures in the health care facilities as well as their additional needs. The Grievance Redress Mechanism is already in place.

5.4.6 Social Exclusion

Risks

The following potential risks of social exclusion have been identified:

- Planning and design of measures to screen people for COVID-19 and information materials developed could exclude the most vulnerable, including the poor, elderly, indigenous peoples, people living with a disability and households headed by single women, who are also less likely to have access or be active on social media.
- Limited access to COVID-19 testing and other public health services, especially in rural areas.
- Restrictions on travel, general movement, etc. have the potential to enhance negative impacts to the vulnerable groups, who may have lower incomes, lack social support, lose jobs, have childcare duties, and may also be the most vulnerable to contracting COVID-19.
- The information materials on the COVID-19 vaccine to be developed could exclude the most vulnerable or be developed in a way that is not sensitive to the needs and access of these different groups.
- Communication materials may not reach the most vulnerable, in particularly the elderly, IPs and workers from the informal sector, a lot of whom are women, who tend to have lower levels of education, lower incomes and may have lower literacy.
- There is an indirect risk of social exclusion, in particular, the most vulnerable and marginalized groups such as the indigenous peoples in remote areas from access to the COVID-19 vaccines.
- The elderly, those with underlying medical conditions, and people living with disability, though included in the priority populations to be vaccinated as identified in the WHO
SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply\textsuperscript{24}, may have limited access to the vaccines due to reduced mobility.

*Mitigation Measures*

The following mitigation measures are considered for social exclusion impacts:

- Planning of quarantine measures and social distancing restrictions need to take into account the livelihood impact it will have for the population, in particular the most vulnerable (the poor, elderly, women single heads of household, IPs, those with disabilities);
- Communication materials must be clear and concise and in a format/language that is understandable to all people, in particular the most vulnerable. Messages should be clear and concise, focusing on hygiene measures (hand washing, coughing), what to do if suspect have COVID-19, as well as restrictions if applicable (for instance specific guidelines on social-distancing). This may require different media (social media, radio, tv) plus engaging existing formal and informal public health and community-based networks (schools, healthcare service providers at local level, etc), including information on the vaccine and its administration.
- Communication materials must also be clear about (i) how to avoid contracting COVID-19 (good hygiene measures); (ii) symptoms of COVID-19; (iii) what to do if suspect have COVID-19.
- Workplaces should be encouraged to post and provide communication materials, in particular workplaces which may face a higher risk of COVID-19 spread, such as construction sites and factories.
- Transport assistance for vulnerable groups for increased access to vaccination sites or identification of strategic locations for vaccine administration.
- Information on how to protect oneself from COVID-19, the symptoms of COVID-19, where and how to get tested should be made available to everyone and ensure they are accessible to IPs, marginalized groups, those with disabilities, other vulnerable groups and the elderly.
- Identify trusted community groups (local influencers such as community leaders, religious leaders, health workers, community volunteers, celebrities) and local networks (such as women’s groups, youth groups, business groups, and traditional healers) that can help to disseminate messages.
- Stakeholder Engagement Plan (SEP) includes consultations with NGOs and other stakeholders that can provide recommendations on how to communicate information.

5.4.7 Gender-Based Violence (GBV) and/or Violence Against Children (VAC)

Gender is a critical consideration when designing policies and interventions in emergency

situations and pandemics. Gender plays an important role in who gets access, and how fast, to critical health services. Gender also determines the social roles ascribed to people that can influence their risk of exposure to disease, as well as of spreading it. At the same time, the biological sex can influence how susceptible a person is to disease and how well they respond to treatment and/or vaccines. In a pandemic, this has multiple implications. On the one hand, pandemic response has to be cognizant of the gender-based differences in access to and use of services due to limited mobility and financial capacity; and on the other, support needs to be provided to at-risk groups such as caregivers (the majority of whom are women taking care of children and the elderly) to reduce their risk of getting ill and/or passing it on to others. Moreover, pandemics can create or exacerbate economic and social vulnerabilities that especially put women and girls at risk of sexual exploitation.

Health care workers involved in the deployment of vaccines are comprised mostly of women, which in turn enhances outreach to women. In 2015, women comprised 57% of physicians and 74% of nurses (Philippine Institute of Development Studies, 2019). Barangay health workers also tend to be females. Women generally bear heavier care responsibilities at home, such as child and elder care. These female health workers (as well as males with care responsibilities) may therefore need alternative care arrangements as they perform their duties in the deployment effort.

The frontline health workers are also among the top three priority population groups to be given the COVID-19 vaccination, along with indigent senior citizens, and the remaining senior citizens. The 2015 population census shows that 56% of senior citizens are female (Philippine Statistics Authority). These three priority population groups, comprising 10% of the population, are therefore predominantly female. If the vaccination will cause some down time to vaccine recipients, this will compound the need for alternative care arrangements for female vaccine recipients who have care responsibilities at home.

Risks

GBV and VAC risks may include the following:

- Quarantine measures, together with fears over COVID-19, livelihood impacts as a result of any restrictions in movement, social isolation and increased economic pressures and loss of jobs (informal or formal sector) may exacerbate household tensions and lead to an increase in GBV and VAC.
- School closures mean children are at home and this could increase risk of VAC and GBV, in particular if family members are stressed, drinking or violent. Young females may be in particular risk.
- Project staff (civil servants and outsourced staff/contractors) may be involved in misconduct behaviours impacting women and children at local level.

Mitigation Measures

The following measures should be considered in mitigating GBV and VAC risks:

- Communication materials should include advice to cope with psychological aspects of the COVID-19 pandemic, including loss of jobs and quarantine measures. For instance, there should be information on how to cope with stress and anxiety, recommendations on how
to talk to children, etc. Information materials should provide links to resources/organizations that can provide support.

- Ensure that GBV-resolution mechanisms and GBV and other mental health services continue to be well resourced as there may be increased demand for their services. NGOs or other organizations working on GBV or mental health may need to be supported to increase their services (or, for instance, enhancing support to a hotline to report cases or to women’s shelters).

- Apply the WHO Code of Ethics and Professional Conduct -Code of Conduct (CoC) for all workers in the quarantine facilities as well as the provision of gender-sensitive infrastructure, such as segregated toilets and enough light in quarantine and isolation centers.

- Codes of Conduct (CoC) included in the letter of PIU’s staff appointment and contracts (for contracted workers) in line with relevant national laws and legislations and the project’s Labor Management Procedures (LMP).

- Training on community interaction and GBV/VAC to be provided for all teams, staff (civil servants and outsources staff/contractors) to ensure the teams respect local communities and their culture and not engage in misconduct.

5.4.8 Social Stigma

Another potential risk is the social acceptability of the vaccine given the biosafety characteristics of the vaccine and possible negative side effects. These risks will be mitigated through the establishment of a robust risk communication strategy informing society and beneficiary communities of safety issues and treatment if negative side effects are shown. The AF will support the development and implementation of vaccine demand generation and communication through the deployment of the vaccine and an M&E system. The DOH will introduce revised protocols regarding consent to vaccinations, a process for agreeing to or refusing to be vaccinated. Two indicators will be introduced to monitor citizen engagement and additional care and treatment to people with negative side effects. The National Adverse Events Following Immunization Committee will ensure that standard protocols for AEFI surveillance and investigation are correctly followed. The said Committee will also review all reported serious and cluster of AEFI cases presented for expert opinion and provide a final causality assessment of the AEFI cases. Likewise, as part of the AF, the SEP has been reviewed with additional measures for consultation with key stakeholders. Besides, the grievance redress mechanism (GRM) has continued developing since the parent project was approved. It should be in place and equipped to address community, worker, and/or individual grievances related to COVID-19 vaccine administration and deployment.

Other risk that has been identified is data-related, and this is rated as substantial. Large volumes of personal data, personally identifiable information and sensitive data are likely to be collected and used in connection with the management of the COVID-19 vaccination and deployment efforts under circumstances where measures to ensure the legitimate, appropriate and proportionate use and processing of that data may not feature in national law or data governance regulations, or be routinely collected and managed in health information systems. To the extent feasible, the project will incorporate good international practice for dealing with such data in such circumstances. Such measures may include, by way of example, data minimization (collecting only data that is necessary for the purpose), data accuracy (correct or erase data that are not
necessary or are inaccurate), use limitations (data are only used for legitimate and related purposes), data retention (retain data only for as long as they are necessary), informing data subjects of use and processing of data, and allowing data subjects the opportunity to correct information about them, etc.

Risks

Indirect risks include social stigma that could be precipitated by COVID-19 both to and from sufferers as follows:

- **Risk of fear and/or stigma towards the virus**, which may make people hide symptoms, avoid getting tested and even reject hygiene measures or wearing PPE equipment (or masks if recommended).
- Health workers may suffer stigma, in particular when coming back to their communities, as they may be seen as potential “carriers”.
- **Misinformation on the adverse health effects of vaccines and hearsays on the conspiracy theories and underlying political agenda on the vaccines are widespread.**
- The fear and apprehension of individuals and communities on the scientific integrity, efficacy, and safety of the COVID-19 vaccines may lead to people refusing vaccination activities.
- The vaccine acceptance may also be affected by the country’s previous experience with the Dengvaxia vaccination.

Mitigation Measures

Mitigation of social stigma should include the following measures:

- When developing communication messages about COVID-19, it is important to have social stigma issues in mind and choose language that does not exacerbate stigma. It is best to not refer to people with the disease as “COVID-19 cases”, “victims” “COVID-19 families” or “the diseased”. It is better to refer as “people who have COVID-19”, “people who are being treated for COVID-19”, or “people who are recovering from COVID-19”.
- Ensure accurate information about the virus is widely disseminated, and that there is also a focus on people who have recovered.
- Engage social influencers, such as religious leaders, who can help communicate accurate messages and help to reduce social stigma as well as support those who may be stigmatized.
- Communication materials must reinforce the positive contribution of health care workers and other essential workers and their need to be supported by community members.
- Communication materials should make clear the steps health workers and others are taking to protect themselves against the virus and their use of PPE.
- Engage community leaders of indigenous peoples when it comes to vaccination activities.
5.4.9 Cold Chain Operation

**Risks**

Refrigeration\(^{25}\) in the cold chain system for vaccine storage and distribution is necessary to maintain efficacy of the vaccines. Through proper refrigeration, the potential to generate vaccine rejects is also avoided. However, the refrigeration facilities (cold storage and refrigerated road transport), require huge amount of energy to operate and use different kinds of cooling agents/refrigerants in their cooling systems. The use of refrigerants in the cold chain system can cause depletion of the ozone layer and can contribute to greenhouse gas emissions that cause global warming. The lack of proper maintenance and knowledge very often translates into an inadequate management of the life cycle of refrigerant gases. More refrigerant leakage results to less efficient equipment and higher emission of high global warming potential (GWP) gases into the atmosphere.

Refrigerants are toxic and some are flammable and could form explosive mixture with air if leakage occurs, posing risk to people’s health and safety. Some cold storage warehouses use ammonia as a refrigerant which has negligible GWP but is toxic and mildly flammable, with the potential to cause health hazards. It is therefore necessary that safe practices are applied.

Moreover, some cold storage may not be energy-efficient.

**Mitigation Measures**

- Use of alternative refrigerants with zero or low climate impact in the refrigeration system
- Use of more energy-efficient technology for the refrigeration system
- To include relevant technical specifications as part of procuring cold storage/chain equipment and transport and/or stipulating performance standards for the cold chain service providers
- Ensure that the refrigeration system including its maintenance and servicing, complies with the requirements of the CCO on ODS
- Improve energy efficiency of refrigeration systems through maintenance of the refrigeration systems, implementation of procedures and best practices that reduces energy consumptions of chillers and refrigeration systems, e.g. closing the doors of cold rooms during operation, switching-off mobile refrigeration units while opening doors of refrigerated trucks, parking refrigerated trucks in the shade, regular controls and monitoring of all equipment parameters, such as energy performance, pressure, and temperature.
- Observe proper handling of refrigerants and during servicing and ensure that workers involved in servicing are trained to avoid leakage of refrigerant in the atmosphere and use PEEs to avoid exposure to refrigerants.

\(^{25}\) In the 2017 UNEP Report of the Technology and Economic Assessment Panel (Montreal Protocol on Substances that deplete the ozone layer), industrial refrigeration accounts for approximately 2% of HFC consumption in terms of CO2-eq and is projected to grow by approximately 6.7% annually between 2015 and 2050.
For the logistics of the vaccines, the Terms of Reference of the external third party logistics partner (3PL) to be hired by DOH was updated to include environmental and social safeguards such as the environmental safety of refrigerants, energy efficiency of cold chain systems, contingency planning and disaster preparedness, and security of vaccines. The details on the roles and responsibilities of parties and safeguards for the vaccine delivery are also included.

5.4.10 Climate-Change Related Risks

The Philippines has been screened for climate and disaster risk and found to be extremely vulnerable to the effects of climate change. There are particular vulnerabilities to extreme temperature, extreme precipitation and flooding, drought, sea level rise, storm surges, strong winds, and landslides. The Global Climate Risk Index ranks the Philippines as the world’s second most affected country by climate change-related shocks. Projected increases in temperature by as much as 0.9°C to 1.9°C across the country increase the risk of extreme heat events as well as potential changes in suitable crops. Increasing temperatures bring uncertainty for the prediction of precipitation patterns. It is predicted that there may be more intense and unpredictable rainfall during the monsoon season; these changes are associated with a higher probability of catastrophic cyclones associated with increased risk of tidal inundation. This has been evident in the recent cyclones that hit the country during lockdown. Incidence of floods is also on the rise. Concurrently there is also a risk of drought at other times, particularly associated with El Nino years, as observed during the 1980s and 1990s. The sea level has risen by as much as 5.7-7.0 mm/year over the Philippine Sea, higher than global average rates. These rising levels are exacerbated by long-term land subsidence, as observed in Manila from 1955-2015, attributed to excessive groundwater withdrawal. Projected changes in sea level in the Philippines are slightly higher than global averages. The Philippines has a mountainous terrain prone to landslides, which climate change-related precipitation is predicted to make more frequent.

The climate-related threats highlighted above are expected to affect the most vulnerable project beneficiaries. Older people and those with pre-existing health condition are at particular risk from higher climate-induced temperatures, including extreme heat events as well as increasing average temperatures. This is particularly the case for those suffering from chronic respiratory or cardiovascular conditions and diabetes. Extreme weather events, in particular those leading to heavy precipitation, flooding, storm surges, and high winds, inflict a heavy toll on human life—with acute impacts including physical injuries and drowning, followed by increases in risks of vector and waterborne disease. In the longer term, more profound adverse health impacts are mediated through damage to health infrastructure, as well as the mental health effects of traumatic experiences and the economic hardships these events precipitate. Each of these climate-related health threats are expected to hit poorest households and communities hardest, with income and health shocks driving them deeper into poverty. Conversely, severe food shortages from drought lead to numerous adverse nutrition impacts, with women and children the most vulnerable. Reduced social interaction and population movements implemented by the GOP to reduce the spread of COVID-19 can exacerbate social isolation and increase vulnerability to certain climate-related exposures, in particular extreme heat. Climate-related disruption to health facilities, healthcare delivery, and access to services also impact the most vulnerable populations, such as older people, women, babies, and young children. Moreover, the natural disasters such as earthquake, landslide, flooding, storm surge and other climate change-related risks as well as
unstable power supply resulting to power outages exist in some areas in the country which may affect the security of the delivery and distribution of the vaccines. The possible hot weather in the country may also have an effect on the efficacy of low temperature- requiring vaccines.

Adaptation Activities

The AF will work to minimize the aforementioned vulnerabilities and enhance resilience and adaptation through the following activities. Through Component 1, Strengthening Emergency COVID-19 Health Care Response, under sub-component 1.2: Provision of medical supplies, including Personal Protective Equipment (PPE), COVID-19 vaccines, medicines, and ambulances (AF of US$374.7 million), activities will support the procurement of COVID-19 vaccines for a large proportion of the population. This will be focused in the 2nd to 4th priority on coverage of climate vulnerable groups, including indigent and senior citizens, thereby allowing these groups to return to normal life and reduce their climate vulnerability—in particular to extreme heat events and other climate-sensitive diseases. These groups cover over 20% of the total population. Given that other populations groups are also climate vulnerable and will also be vaccinated, a minimum of 20% of the AF allocated to this should be considered to be adapting to climate change, perhaps significantly more. Under sub-component 1.3: Enhancing isolation/quarantine facilities (AF of US$10.7 million) is supporting the establishment, construction, retrofitting/refurbishment of quarantine facilities in major points of entry as well as increases in numbers of regular isolation rooms in DOH and provincial hospitals—and will ensure these facilities withstand the impacts of extreme climate related events, such as flooding and heat events, thereby enhancing the climate resilience of the populations and adapting these healthcare facilities to climate-related risks. The impact of this is important such that at least 10% of the AF allocated to this should be considered to be adapting to climate change.

Component 2: Strengthening laboratory capacity at national and sub-national level to support Emerging Infectious Diseases (EIDs) Prevention, Preparedness, and Response (AF of US$8.3 million) will support the establishment of national reference laboratories as well as selected sub-national and public health laboratories, thereby by enhancing the capacity of the health system to detect, track, and respond to future climate-related disease impacts, in particular emerging infectious and communicable diseases. In addition, the works themselves will be designed to withstand the impacts of extreme climate related events, in particular heat events, thereby enhancing the climate resilience of the populations and adapting these healthcare facilities to predicted climate related risks. The impact of this is significant to the extent that 30% of the AF allocated to this should be considered to be adapting to climate change. Furthermore, the adaptation activities are consistent with and support the DOH Health Sector Strategy for Climate Change Adaptation (Department Circular No. 2010-0187) and National Policy on Climate Change Adaptation for the Health Sector (Administrative Order No. 2012-005) and its operational guidelines (Administrative Order No. 2012-0018), thereby contributing to enhancing the Department’s institutional adaptive capacity.

Mitigation activities

In addition, specific project activities financed by this AF will support climate change mitigation through the following activities. Under Sub-component 1.3: Enhancing isolation/quarantine facilities (AF of US$10.7 million) the support for the afore mentioned works to improve healthcare facilities will be undertaken with attention to enhancing the energy efficiency of these facilities.
through improved insulation, door closures, and where possible renewable energy sources to reduce greenhouse gas emissions from these facilities. The impact means that 10% of the AF allocated to this should be considered to be mitigating climate change. Under Component 2: Strengthening laboratory capacity at national and sub-national level to support Emerging Infectious Diseases (EIDs) Prevention, Preparedness, and Response (AF of US$8.3 million) is with the above sub-component these works will be undertaken with attention to enhancing the energy efficiency to reduce greenhouse gas emissions from these facilities. This impact means that 10% of the AF allocated to this should be considered to be mitigating climate change. The mitigation activities support the DOH initiative to establish emergency efficiency standards as part of the Green Health Care Facilities Standards (Department Memorandum No. 2018-0035) and facilitates the Department’s compliance with the Government Energy Management Program under the Energy Efficiency and Conservation Act of 2019 (IAECC Resolution No. 01, s. 2020).

**Risks**

The potential impact of climate and geophysical hazards on the project’s investments is rated based on exposure ratings for the location, and an understanding of the project’s historical and future sensitivity to these risks. It is important to assess the effect that these impacts may have on the investment, and the ability of the project to sustain and enhance these investments under a changing climate.

In terms of health infrastructure, extreme temperatures can reduce comfort in health clinics and increase the need for heating and cooling devices, while extreme precipitation and flooding, strong winds or sea level rise and storm surge can damage hospitals and health care equipment and cause power outages in clinics and cold chain storages of vaccines. Building climate smart health infrastructure should be highly considered when enhancing resilience in these contexts.

In terms of other project activities pertaining to different subsectors, extreme precipitation and flooding or sea level rise and storm surge can prevent community health workers from traveling to provide education, treatment, or health care services in the community, while extreme temperature may disrupt the delivery of nutrition supplies.

**Mitigation Measures**

Information collection and development of management systems including early warning systems, improve risk management systems, and strengthening health systems to take into account these impacts from climate and geophysical hazards should be considered to enhance resilience.

Climate and disaster risk management plans of hospitals and health care facilities will be reviewed and updated consistent with the DOH Administrative Order No. 2012-005 "National Policy on Climate Change Adaptation for the Health Sector."

Greening of health care facilities and related establishments is a long-term measure. To ensure operation of vaccine cold storage during power outages, generators should be available.
6 Procedures to Address Environmental and Social Issues

6.1 Screening Process

Annex D. Screening Form for Potential Environmental and Social Issues comprises a screening form that should be used by the BIHC and DPCB in DoH to screen for the potential environmental and social risks and impacts of specific activities. Screening will allow BIHC and DPCB to identify the relevant Environmental and Social Standards (ESS), establish an appropriate environmental and social risk rating, and specify the type of environmental and social risk management measures required, including specific instruments, if needed.

In addition to Annex D, results from the VIRAT/VRAF (see Annex L) can inform the procedures to address environmental and social issues that will guide the development of the Vaccine Delivery and Distribution Manual and National Deployment and Vaccination Plan (NDVP). The VIRAT/VRAF has key indicators related to environmental and social risk management for the deployment of the COVID-19 vaccine including planning and coordination; budgeting, regulatory planning, and coordination; budgeting; regulatory framework; prioritization, targeting and COVID-19 surveillance; service delivery; training and supervision; monitoring and evaluation; cold chain, logistics and infrastructure; safety surveillance; and demand generation and communication.

Based on the initial assessment, the planning and coordination for vaccine deployment will build on and enhance the existing structures in the DOH and the Inter-Agency Task Force for Management of Emerging Infectious Diseases (IATF) to provide oversight for COVID-19 vaccine introduction; the STWG on Vaccine Development will be reconstituted to support the IATF in its oversight function; and a Vaccine Cluster established under National Task Force (NTF) against COVID-19 to promote whole government approach with participation of all government agencies.

The government will be guided by the National COVID-19 Vaccine Roadmap and COVID-19 Vaccine Deployment and Immunization Plan in exploring complementary options for accessing vaccines including COVAX facility, advance market commitments and bilateral negotiations with countries manufacturing vaccines. In addition, the management of wastes from the vaccination program as outlined in the criteria on waste management protocols for COVID-19 vaccination, both hazardous and non-hazardous, including development and dissemination of practices and guidelines for disposal routes, appropriate waste management systems in all relevant sites, and adequately trained human resources, and identification and mobilization of properly-licensed waste management providers for hazardous waste storage, transportation and disposal.

Various activities in the VIRAT/VRAF are in progress, albeit mostly in early stages related to Vaccine service delivery, cold chain, logistics and infrastructure. The HCWM self-audit tools developed under the Parent Project will assist DOH and health care facilities identify gaps and areas for improvement in HCWM specifically for COVID-19 wastes (i.e., COVID-19 Waste Management Self-Assessment - Compliance Audit Checklist, Monthly Ward / Department Review, and Healthcare Facility Compliance Statement). A COVID-19 Waste Management Operations Manual has been developed under the Parent Project to provide supplemental guidance on the requirements of the Government to manage wastes/recyclables correctly in line with current
legislation and relevant health policies (e.g. Infection Control and OHS). The manual covers pharmaceutical waste which includes COVID-19 vaccines and residues. Philippine government policies and regulations identified in the preceding section will similarly inform the action required to get a completed (or more than 90%) status of the VIRAT/VRAF activities. The COVID-19 Waste Management Operations Manual will be reviewed and the next steps on the use of the Manual will be vetted upon by the relevant DOH Bureaus.

Additional findings based on the initial VIRAT/VRAF assessment also shows that public consultation will be conducted in January 2021 other partners, government agencies, NGOs, and private sector and activities will be included in the SEP. Likewise, the Government is in the process of establishing an Emergency Operations Center with the complete data management systems and tools, including the management of the GRM system, starting on January 2021. In terms of risk communication and stakeholder engagement, the government will strengthen human resources including communication organizers and developing a risk communication strategy including data collection systems, including 1) social media listening and rumour management, and 2) assessing behavioural and social data.

6.2 Environmental and Social Management Plans

For activities involving civil works or construction activities an Environmental and Social Management Plan (ESMP) template has been prepared by DoH. The ESMP or ECOP, together with the LMP, and Contractor’s Personnel GRM will be accomplished by the Contractors together with the bid documents. The DoH will evaluate the capacity of the Contractors to implement the ESMP together with the aforementioned requirements. This will be included in the indicators for the selection of the bidders. The ESMP shall be site-specific, and proportionate and relevant to the hazards and risks associated with the particular activity and will be implemented by the health facility and contractors. For example, activities such as establishment of isolation tents and first line decontamination facilities are simple construction activities and the ESMP aside from the Labor Management Plan (LMP), may comprise simple standard management and mitigation measures such as those defined in the ECOPs provided in Annex G. Establishment of quarantine facilities involving the expansion of a new wing within the compound of a health facility, the possible establishment of warehousing for the vaccines, or the rehabilitation of an existing building that may involve extensive construction, a more comprehensive ESMP will be prepared and implemented.

An ESMP will comprise a simple matrix in the format shown in Annex E. When designing mitigation measures the ESMP should address site-specific environmental and OHS issues and shall draw on the Environmental Codes of Practice (ECOP) included in Annex G and relevant, up-to-date guidance from WHO, DOH, DENR and other relevant government agencies on COVID-19 specific advice.

The site specific ESMP or ECOP will include as attachments, as needed, the LMP, GRM, and ICWMP. For each identified environmental and social risk, the format shows (1) proposed risk mitigation measures, including measures to be implemented by the construction contractor; (2) responsibility for each risk mitigation measure, (3) Timeline (e.g. pre-construction, during construction, etc.); and (4) Budget. For mitigation measures that are the responsibility of the construction contractor, the
supervising engineer will verify that measure have been properly implemented. Implementation of E&S risk mitigation measures will be reported and will be a condition for approval of payments.

6.3 Health-care Waste Management

The project is supported by a consultant to provide technical assistance and capacity building to DOH on health-care waste management until materials and tools to supplement the DOH Health Care Waste Management Manual 4th Edition on management of health care wastes related to COVID-19 and emerging infectious diseases have been developed, and capacity building of concerned health workers are completed. HCWM is well-regulated in the Philippines through the Fourth Edition of the Health Care Waste Management Manual (April 2020) of DOH. However, capacity gaps in the implementation of the Manual still occurs.

The technical assistance program will involve provision of real-time capacity building support to DOH on immediate priorities for safely managing COVID-19 HCW. A second pre-testing of the developed health care waste management self- audit tools is being undertaken for six health facilities to establish a compliance baseline and assess the contents and user-friendliness of the tools. Using this baseline, a video training package will be developed for distribution across all health-care facilities. Annex I contains an Infection Control and Waste Management Plan (ICWMP) template which can be used as a checklist during the capacity building exercise and cross-referenced with the DOH Manual to determine any gaps or opportunities for improvement.

I DOH will coordinate with the Department of Environment and Natural Resources- Environmental Management Bureau (DENR-EMB) to discuss the surge of M501 and M503 health care wastes due to the COVID-19 vaccination activities. It is important to guarantee the capacity of the waste transporters and TSD facilities to accommodate the influx of health care wastes and that a clear road map/strategy is developed by the DOH in coordination with the DENR to strengthen capacity of the country to manage health care wastes. It should be noted that not all regions have DENR- accredited M501 and M503 wastes transporters and treatment, storage, and disposal facilities (TSDs) based on their area, as discussed in Chapter 4.

The DOH will also be conducting trainings for the implementers of the vaccine deployment and administration on proper health care waste management of infectious and pharmaceutical wastes.

6.4 Indigenous Peoples

Despite the strong rights provided by the IPRA and the historic recognition of indigenous peoples in the Philippines, conflicts over their identities and access to land and natural resources continue. And despite being relatively well- organized, including the existence of numerous local and national indigenous peoples’ organizations, they still face social and political marginalization. They are among the poorest population groups in the Philippines, far worse in terms of health and education indicators and are affected by civil conflicts such as in Mindanao.

Given these vulnerabilities, the COVID-19 pandemic poses particular risks to indigenous peoples. The United Nations’ Department of Economic and Social Affairs has noted that indigenous peoples often
“experience poor access to healthcare, higher rates of communicable and non-communicable diseases, lack of access to essential services, sanitation, and other key preventive measures, such as clean water, soap, disinfectant, etc.” Likewise, most nearby local medical facilities, if and when there are any, are often under-equipped and under-staffed. Even when indigenous peoples are able to access healthcare services, they can face stigma and discrimination.

A key factor is to ensure these services and facilities are provided in indigenous languages as part of the BIHC’s support to the DOH Centers of Health Development, and as appropriate to the specific situation. It is also noted that indigenous peoples’ traditional lifestyles are a source of their resilience, but can also pose a threat to spreading of the virus, e.g. through traditional gatherings to mark special events and living in multi-generational housing. Many communities in relative isolation and remote areas may be less exposed to the virus, but if it does reach such communities the risks would be heightened due to their lack of access to adequate health and social services and effective monitoring and early-warning systems.

Health facilities close to the indigenous communities are available to provide health services to nearby IPs. The upgraded facilities are to be located within existing premises of health facilities or government premises. As such, construction does not pose risks to indigenous peoples, but they would need to be included in stakeholder engagement processes for civil works activities. This is also prescribed in the SEP.

It has been found that providing health care to indigenous peoples can be more effective when integrating Western medicine with traditional knowledge, systems, and practices of healing, which may include herbal medicines, acupressure, acupuncture, and hilot, an ancient Filipino art of healing derived from shamanic traditions that uses different techniques of manipulation and massage to achieve the treatment outcome. A study of health perceptions and practices of the Lumads of Mindanao finds that they recognize the benefits of Western medicine provided through the government’s health services. However, they continue to combine such health care with their indigenous health and treatment beliefs, practices and rituals provided by the bayian or traditional healer when confronted with health problems.

The active participation of IPs, their organizations and health practitioners, is critical in providing efficient and culturally appropriate health services in indigenous communities. Such an approach is recognized by DoH in the “Guidelines on the Delivery of Basic Health Services for Indigenous Peoples/Indigenous Cultural Communities” or Joint Memorandum Circular No. 2013-01 agreed to between DOH, NCIP, the Department of Interior and Local Government (DILG) on April 19, 2013, which will guide the project’s approach to supporting health services in areas with indigenous peoples.

The project will not develop a stand-alone indigenous peoples instrument (e.g. an Indigenous Peoples Plan). Instead, the requirements of ESS7 will be addressed through a targeted engagement strategy, included in the Project’s Stakeholder Engagement Plan and in ESMPs when these are required for civil works. This is appropriate given the project activities to support hospitals and local health facilities to combat COVID-19, through procuring equipment and PPEs for health workers and enhancing testing, quarantine, and treatment capabilities. It is consistent with ESS7’s emphasis on developing plans that are proportionate to the potential risks and impacts of the project (paragraphs 13 and 17). No civil works outside of existing health premises are expected to be financed by the
project and no activities that would require any land acquisition will be financed. Therefore, no circumstances requiring free, prior, and informed consent under ESS7 are present in project activities. It should also be noted as part of the vulnerable groups, the indigenous peoples should be considered in the priority eligible population for COVID-19 vaccination, as aligned with the WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination.

Stakeholder engagement and public consultations with representatives of indigenous peoples and their organizations are provided for in the SEP. These organizations and representatives will be consulted during project implementation. The NCIP at national, regional, and local levels will also be consulted, particular for any project activities taking place within the ancestral domain of indigenous communities, and indigenous peoples in areas of site-specific project activities will be engaged and consulted consistent with the IPRA, the Joint Memorandum Circular No. 2013-01 and ESS7.

For site-specific project support to regional and local health facilities in areas with indigenous communities, DoH and local partners (e.g., LGUs) will consult with indigenous peoples, their representatives and NCIP; local NGOs or CSOs may also be consulted.

Project activities in areas with indigenous communities will be informed by the Joint Memorandum Circular, which provides guidelines around five key principles for delivering health services to indigenous peoples:

1) **Making basic health services available and culture-sensitive.**

   ‘Culture-sensitive’ health care, means policymakers and health workers acknowledge and respect cultural diversity among the populace since this affects values, learning, behaviour, health practices and outcomes. Health care providers will recognize existing beliefs and practices to the extent that these are not a hindrance to effective measures against the COVID-19 pandemic, and ‘culture-sensitive’ orientation and training to health workers, managers and other stakeholders is provided as appropriate.

   Indigenous health care practitioners in communities should be informed about COVID-19 symptoms and local outbreaks, and should be involved in engagements with indigenous communities and patients, as appropriate (indigenous practitioners are likely to be the first point of contact for indigenous peoples seeking medical services).

2) **Providing equitable distribution of needed health resources.**

   At project-supported health facilities in areas with indigenous peoples, they and their support organizations will be informed of the services provided and efforts will be made to ensure the indigenous peoples affected by COVID-19 will receive the same treatment as non-indigenous patients.

   Indigenous health care providers/staff at DoH and LGU facilities, when available, are provided with the same resources, including PPEs and information about COVID-19. These may also be provided to indigenous health practitioners.

3) **Ensuring non-discrimination of ICCs/IPs in the delivery of health services.**
‘Culture-sensitive’ orientation and training to health workers, managers and other stakeholders is provided as appropriate.

Indigenous health care providers at DoH and LGU facilities, when available, and indigenous health practitioners are involved in providing health care services to indigenous communities and patients, as appropriate.

4) **Managing geographical, financial and socio-cultural barriers so that IPs can access basic health services.**

As the project is financing emergency responses to COVID19 this principle is not applicable. However, once the emergency subsides additional measures to enhance IPs’ access to health services may be considered.

5) **Strengthening recognition, promotion, and respect of safe and beneficial traditional health practices.**

Efforts to hire indigenous health care workers should be made to the extent possible. Existing indigenous health care workers at DoH and LGU facilities will be involved in providing services to indigenous communities. An IP health care worker or an IP-oriented health care worker at health facilities should be designated to care for, or oversee care for, indigenous patients. Indigenous health practitioners are involved in providing health care services to indigenous communities and patients, as appropriate.

Measures to enhance benefits and avoid adverse impacts will be developed in consultation with representatives of the indigenous peoples as appropriate in the local context and in a manner proportional to the project activities’ risks and potential impacts or benefits. Physical distancing and other COVID-19 restrictions will be respected.

7 **Stakeholder Engagement, Consultation and Disclosure**

The Stakeholder Engagement Plan (SEP) has been developed to ensure that stakeholders are informed about project risks and mitigation measures, information is disclosed properly, communities and local government units are engaged, and social preparation for areas that will host isolation and quarantine facilities will be conducted.

7.1 Stakeholder Consultations on the Parent Project

Consultations with affected and interested stakeholders on the ESF documents of the Parent Project were conducted on 18-19 August 2020. Due to the physical distancing restrictions, the engagement process was conducted virtually through a WebEx meeting.

The ESF documents, i.e., ESMF, ESCP, and SEP, updated for the Additional Financing will be disclosed in the DOH website on 10 January 2021. Public consultation will be conducted in January 2021 with other partners, government agencies, civil society organizations, and private sector based on the initial inputs in the VIRAT/VRAF.

The key feedback of the stakeholders in the said consultation are as follows:

1. Highlight of the VAWC and GBV in the ESMF and SEP and awareness was suggested to be part of the project activities;
2. Development of guidelines for watchers, carers, and personal assistants, especially for the PWDs and children, in health care facilities, testing facilities, and quarantine areas is recommended;
3. Revision of the ESMF to include RA 11106 and 7277 to emphasize institutional mandate for support to PWDs;
4. Recommended provision of health promotion materials and virtual sign language interpretation for PWDs in health care facilities, testing facilities, and quarantine areas;
5. Recommended inclusion of disaggregated COVID-19 data on indigenous peoples;
6. Recommended provision of vaccines, e.g., pneumococcal, flu, and hepatitis B, for health care workers and vulnerable groups such as persons with disabilities (PWDs), children and the elderly;
7. Declaration of contractor’s liability on workers for medical bills and wages once they contract COVID-19;
8. Stricter compliance of waste generators and waste service providers (treatment, storage, and disposal facilities/ TSDs) to the DENR Environmental Management Bureau guidelines on health care wastes as improper disposal is still observed; and
9. Proposed extension of the Project benefits to other health care facilities.
Below are the detailed feedback of stakeholders during the National Stakeholders Consultation on 18-19 August 2020 and the responses and updates from DOH:

Table 7.1. Key agreements on the National Stakeholders Consultation of the Parent Project, August 2020

<table>
<thead>
<tr>
<th>Topic</th>
<th>Stakeholder</th>
<th>Comment / Feedback</th>
<th>Response</th>
</tr>
</thead>
</table>
| Stakeholder Engagement        | Save the Children Philippines | Query on the difference in the engagement among groups or if the groupings were made to facilitate consultation  
In view of the prolonged pandemic and its wide impact, it may also be necessary to review who are affected. | The SEP is a guide for stakeholder engagement throughout the project implementation. It is a living document which will be revised as appropriate, considering the feedback of the stakeholders. The SEP distinguishes between affected and interested stakeholders and identifies vulnerable stakeholders that may require special attention. |
|                                | Philippine Coalition on the UNCRPD | VAWC is an important issue. We should raise awareness, provide information on how to access, and provide help desks. | VAWC and GBV are highlighted in the ESMF and SEP and awareness will be integrated in the project activities.                                                                                             |
|                                | Saint Anthony Mother and Child Hospital | Risk of transmission is high for patient watchers within hospitals. Guidelines for control and mitigation measures of transmission and accommodation for them for social distancing is recommended to be provided. | The patient watchers are covered by the guidelines on the rational use of personal protective equipment (PPE). There are no accommodations for them due to the high number of cases needed to be catered and the risk of infection. |
| Strengthening capacity in the regions | MIMAROPA Center for Health Development (CHD)  
CARAGA CHD | Health care manpower is the main challenge, especially in geographically isolated and disadvantaged areas (GIDAs). Health care facilities are existing but there are no applicants.  
The locally stranded individuals or LSIs are major sources of COVID-19 infection (56%) in the MIMAROPA region. Ways in which the project can help address this problem are sought. | The project activities include mostly provision of equipment to build COVID-19 response capacity and some repairs of health care facilities and laboratories, including the isolation rooms.  
There will also be a capacity building component for health care workers. |
Moreover, ways to strengthen capacity at the regional and facility levels are sought. Project consultations and trainings will be provided. These will mostly be online due to challenges in the implementation of the project due to the pandemic.

| Services for persons with disabilities (PWDs) and children | National Commission on Disability Affairs (NCDA) | The accessibility of services and infrastructure (e.g., ramps) and hospitalization support for PWDs who will contract COVID-19 should be provided. It was also pointed out that each type of disability has specific needs and support services which may need capacity building of health care personnel. There is a need for virtual sign language interpretation services in health care facilities, testing centers, and quarantine/isolation areas. There are networks who may be able to provide sign language interpreters but they are mainly based in Manila. TFSL interpretation in health facilities through video calls provided by service providers is recommended. It was also pointed out that the DOH and DILG should comply with RA 11106 or the Filipino Sign Language Law by providing such services in health facilities, workplaces, and the media. Guidelines on FSL interpreter qualifications, including skills and ethical considerations is needed. Access to information for PWDs is also a main concern as sign language interpretation is still very limited. Unlike national TV news, regional TV news do not have sign language interpretation. Grassroots organizations have turned to social media to disseminate information. They requested that the project stress the importance of access to information through DOH, even if the COVID IEC funds come from a different donor source. | The DOH Health Facilities Development Bureau (HFDB) has reported that there are 10 provincial hospitals which currently have Filipino sign language interpreters (FSL) who are mostly social workers employed by the hospital. They are as follows: |
|---|---|---|
| Region | Hospital |
| NCR | Jose Fabella Memorial Hospital, Lung Center of the Philippines |
| I | Mariano Marcos Memorial Medical Center, Ilocos Training and Regional Medical Center, Region I Medical Center |
| IV | Batangas Medical Center |
| VI | Corazon Locsin Montelirano Memorial Regional Hospital, Don Jose Monfort Memorial Medical Center Extension Hospital |
| VII | Vicente Sotto Memorial Medical Center |
| XII | Cotabato Regional Medical Center |

According to the Degenerative Disease Office of the Disease Prevention and Control Bureau (DPCB-DDO), the new education curriculum of social workers has integrated basic FSL. It should be noted that hospitals have at least 1 social worker. It would be ideal if the
| Philippine Coalition on the UNCRPD | Assistance to the deaf in finding hospitals which are deaf- accessible and providing counseling services should be given.  
There is a need to accommodate and entertain carers/personal assistants of PWDs and children in health care facilities, testing centers, and quarantine/isolation areas.  
Vaccination for children and other vulnerable sectors should be provided.  
The PWD groups have expressed their interest in being engaged and involved in the project implementation. The need to recognize vulnerable groups, e.g. PWDs and IPs, were pointed out. | employed social worker has background on FSL.  
The Metro Manila and CALABARZON Centers for Health Development (CHDs) are conducting community-based trainings on FSL. It is planned to cascade the training to the other regions in 2021.  
The Congress is also discussing the provision of FSL interpreters in health facilities. However, the timeline for this is not yet known.  
The Project will be conducting a baseline assessment on the capacity of the recipient hospitals to provide accessible health services to vulnerable groups, including provision of virtual FSL services based on parameters such as availability of devices and internet connection. The baseline assessment will also cover GBV, VAWC, and IPs. Based on the results of this assessment, the Project in coordination with HFDB and DPCB-DDO, will determine the feasibility of the virtual FSL services which would be in partnership with the FSL interpreters and PWD representatives to be financed by the Project.  
The DOH Health Promotion Bureau (HPB) has no COVID-19 health promotion materials for the PWDs. Currently, they only have the 30-second video with FSL interpretation for polio. The HPB and the DPCB-DDO have included |
PWD accessibility in their Communication Plan for 2021 which will include printer materials with Braille and videos with sign language. The DPCB-DDO in partnership with the Philippine Information Agency (PIA), have previously developed a Communication Plan for PWDs which was also presented to the PWD CSOs.

The concerns of PWDs, particularly accessibility, will be considered in the activities under Component 3, Project Management and Monitoring and Evaluation, of the project by integrating into the prevention and preparedness activities.

Project management and monitoring should ensure that the improved capacity of the health care facilities results in improved access for PWDs.

The PWDs and other vulnerable sectors will be highly considered in the project. The ESMF will also be revised to include Republic Acts 11106 and 7277 and Batas Pambansa 344 to further strengthen the framework.

The request for vaccination of children and other vulnerable groups as well as the guidelines for carers/personal assistants of PWDs and children will be relayed to the DOH DPCB, HFDB, and the DOH IATF Focal Team. The PWD CSOs will be requested to submit a formal request to the IATF.
<table>
<thead>
<tr>
<th>Philippines (PIDSP)</th>
<th>(<a href="mailto:iatfsecretariat@gmail.com">iatfsecretariat@gmail.com</a>) and DOH regarding the grievances of the carers/personal assistants. The HFDB, with assistance from the Project, will develop a policy issuance to consider the carers of PWDs and children in health facilities.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indigenous Peoples</td>
<td>It was recommended to include disaggregated data for Indigenous Peoples related to the COVID-19 response. The group also relayed that they have conducted an assessment on IPs and COVID-19 which they may share with the Project Team. The DOH Epidemiology Bureau (EB) which is in-charge of the data management on COVID-19 does not have disaggregated data for IPs. The request has been communicated to EB. The Tebtebba Foundation has submitted their request for data on Indigenous Peoples (identified as to their ethnicity) infected by COVID-19 and history of infection aside from the usual data provided to the EB. The Project will further assist Tebtebba Foundation on this request. To ensure that IPs will have access to the COVID-19 related health services, the DOH Bureau of Local Health Systems Development (BLHSD) has issued Department Circular 2020-0192 last April 2020 entitled ‘Ensuring that people in GIDAs, Indigenous Cultural Communities/Indigenous Peoples are well-informed on COVID-19 and have access to Temporary Treatment and Monitoring Facilities and Referral Hospitals.’</td>
</tr>
<tr>
<td>BARMM</td>
<td>Coordination with BARMM MOH and project coverage inclusion was asked. BARMM is covered by the project. The Amai Pakpak Medical Center is included in the tentative list of recipient facilities. Coordination with BARMM MOH will be done</td>
</tr>
<tr>
<td>Grievance Redress Mechanism</td>
<td>Save the Children Philippines</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>ESMF</td>
<td>Philippine Medical Association</td>
</tr>
</tbody>
</table>

Occupational safety and health risks during construction should be addressed. It was inquired whether specific guidelines will be issued due to the
<table>
<thead>
<tr>
<th>Recipient hospitals and equipment</th>
<th>Cebu South Medical Center</th>
<th>COVID-19 pandemic, aside from the usual OHS and DOH issuances. The coverage of medical bills and wages of workers who will contract COVID-19 was queried. Experience on symptomatic workers in which the hospitalization costs and compensation were covered by the hospital was relayed.</th>
<th>distancing measures for construction will be adhered to. The contractors will also be asked to prepare the Environmental and Social Management Plan (ESMP), Environmental Codes of Practice (ECOP), Labor Management Procedures (LMP), and Contractor’s Personnel Grievance Redress Mechanism to minimize occupational risks in the civil works components. The Republic Act 11058, Department Order 198, and the IATF issuances set liability on the contractor. To further highlight the contractor’s responsibility, the liability clause will be explicitly stated in the contract. The ESMF includes Labor Management Procedures.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pangasinan Provincial Health Office</td>
<td>The health facilities which will be covered by the project and the equipment to be given were asked. The hospitals invited in the National Stakeholders Consultation are included in the initial list of recipients recommended by the HFPEMO. The local government units through the provincial, city, and municipal health offices were invited for their information and guidance on the project. It is envisioned to expand the testing in the rural areas also. However, the project recipients are chosen based on the ongoing application for testing accreditation.</td>
<td>The hospitals to be included as recipients of the World Bank loan are the 70 retained DOH hospitals and the 30 hospitals part of the Universal Health Care implementation sites which were first approved by the NEDA. Other hospitals not part of the project may be covered by other projects such as that of ADB. The recipient facilities were selected based on capacity to test, i.e., ongoing application for accreditation. The local government units through the provincial, city, and municipal health offices were invited for their information and guidance on the project.</td>
<td></td>
</tr>
<tr>
<td>Luis Hora Memorial Regional Hospital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mariano Marcos Memorial Hospital and Medical Center</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


It was also clarified that the project is different from the existing project of HFEMO.

The HFEMO will finalize the list of hospitals and equipment to be distributed.

<table>
<thead>
<tr>
<th>Project Implementation</th>
<th>Mariano Marcos Memorial Hospital and Medical Center</th>
<th>The project requirements and expectations from recipients, e.g., proposal, timelines, funding approval, project termination, and monitoring and evaluation.</th>
<th>There will be no project proposal required as the health care facilities are chosen beneficiaries of the project. It will follow the usual protocol on accepting donations from the DOH Central Office, such as accomplishing the Deed of Donation, i.e., formal transfer of ownership and acceptance from DOH to the recipient hospital. The recipient is expected to maintain the equipment for its sustainability. Post-evaluation and monitoring may also be conducted by the Project Team.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Corazon Locsin Montelibano Memorial Regional Hospital</td>
<td>It was queried if the civil works component of the project will cover only the existing facilities.</td>
<td>The HFEMO clarified that there will be mostly retrofitting/upgrading of the existing hospitals and that currently, only the National Center for Mental Health and Dr. Jose Rodriguez Memorial Hospital will have new constructions. The list of construction works will be sent by the HFEMO.</td>
</tr>
<tr>
<td>Project Sustainability</td>
<td>Tebtebba Foundation</td>
<td>The COVID-19 recovery will take a “heal as one” approach, aside from the direct results of the project, entailing community mobilization.</td>
<td>For the safety of the workers, PPEs will be worn and the hierarchy of controls will also be observed. Engineering controls and substitution will also be observed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To extend the benefits of the project, the recipient hospitals will have to and are expected to take good care of the project donations, such as the equipment. Training of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>It was asked if there would be an exit strategy to guaranteed sustainability of project benefits. It was also inquired how the exit strategy ensure that indigenous health care, knowledge and management systems, as well as traditional health care providers would be acknowledged and recognized, given their significant roles in community health.</td>
<td>personnel will also be part of the sustainability initiatives. In areas with IP, the ESMF includes measures to coordinate with traditional health care providers, consistent with DoH's Guidelines on the Delivery of Basic Health Services for Indigenous Peoples/Indigenous Cultural Communities.</td>
<td></td>
</tr>
</tbody>
</table>
The SEP provides further details on the consultations on the draft documents and the plan for continued stakeholder engagement during project implementation. The SEP has been developed to ensure that stakeholders are informed about project risks and mitigation measures, information is disclosed properly, communities and local government units are engaged, and social preparation for areas that will host isolation and quarantine facilities will be conducted. The SEP will be implemented in a way that takes into consideration specific circumstances for indigenous peoples, other vulnerable groups, and the locality’s ways of information dissemination and conducting consultations while communities or households may be in quarantine or physical distancing restrictions. The SEP includes a grievance redress mechanism by which people can raise concerns, provide feedback, or make complaints about project related activities.

A series of consultations will be conducted with the implementers of the GRM.

7.2 Stakeholder Consultations on the Additional Financing

A series of consultations participated by the implementers and stakeholders of the COVID-19 vaccination activities, in consultation with and per directive of the COVID-19 Vaccine Cluster Organizational Structure, had been conducted. These consultations involve the Centers for Health Development, the Food and Drug Administration, local government units (LGUs), the recipient health facilities, priority eligible population for vaccination, and the private sectors involved in cold chain management. The DOH HPB is also conducting Town Hall Meetings (https://doh.gov.ph/press-release/DOH-AND-PHILIPPINE-NURSES-ASSOCIATION-HOLD-TOWN-HALL-TO-PROMOTE-VACCINE-CONFIDENCE). The proceedings of which will be requested.

The DOH DPCB has conducted the online Public Consultation on the National Strategic Policy Framework for COVID-19 Vaccine Deployment and Immunization last December 7, 2020 and January 8, 2021 which was participated by national government agencies, DOH CHDs, health care facilities, professional organizations, the academe, civil society organizations, private sector (health insurance corporation), and development partners. The key agreements are as follows:

Table 7.2. Key agreements in the Public Consultation on the National Strategic Policy Framework for COVID-19 Vaccine Deployment on December 7, 2020

<table>
<thead>
<tr>
<th>Topic</th>
<th>Stakeholder</th>
<th>Key Agreement/ Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Guidelines</td>
<td>UP College of Medicine (UPCM)</td>
<td>To include communication and health education in the specific objectives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To include and to prioritize the widespread communication and understanding of COVID burden and its prevention</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To include and prioritize the widespread communication and understanding of COVID burden and its prevention</td>
</tr>
<tr>
<td></td>
<td>DOH</td>
<td>Reconsider statement that COVID-19 vaccine is a ‘public good’ as this term is different in economics</td>
</tr>
<tr>
<td><strong>Financing and Funding Mechanisms</strong></td>
<td><strong>UP College of Public Health (UP CPH)</strong></td>
<td>To consider the reciprocity Principle under WHO SAGE framework</td>
</tr>
<tr>
<td><strong>Identification of Eligible Population</strong></td>
<td><strong>UNICEF</strong></td>
<td>To identify the minimum list of the priority population</td>
</tr>
<tr>
<td></td>
<td><strong>DOH Epidemiology Bureau (EB)</strong></td>
<td>Inclusion of the term 'herd immunity'</td>
</tr>
<tr>
<td></td>
<td><strong>Coalition for People’s Right to Health (CPRH)</strong></td>
<td>Exclusion criteria must also be mentioned apart from eligibility</td>
</tr>
<tr>
<td><strong>Supply Chain and Management of Health Care Waste and Injection Safety</strong></td>
<td><strong>UNICEF</strong></td>
<td>To have the supply chain management plan linked to the overall EPI cold chain management plan and to use the evidences from the VRAT/VRAF assessment and EVMA recommendations</td>
</tr>
<tr>
<td></td>
<td><strong>Office of the Presidential Adviser on the Peace Process (OPAPP)/National Incident Command-Emergency Operations Center (NIC-EOC)</strong></td>
<td>Inclusion of the statement ‘Facilitate procurement through various mechanisms allowed under existing laws, rules, and regulations through bilateral, multilateral and other financial modalities (e.g., COVAX Facility, etc.)’</td>
</tr>
<tr>
<td><strong>Human Resource Management and Training</strong></td>
<td><strong>Philippine Pharmacists Association (PPhA)</strong></td>
<td>To include a provision for the active involvement of the barangay health workers at the level of the community</td>
</tr>
<tr>
<td></td>
<td><strong>DOH EB</strong></td>
<td>To include 'health care waste' management plan</td>
</tr>
<tr>
<td></td>
<td><strong>DOH DPCB Occupational Diseases Division (ODD)</strong></td>
<td>Consider to include in the definition of terms who are the members of the committees such as NITAG, etc.</td>
</tr>
<tr>
<td><strong>Vaccine Acceptance and Uptake</strong></td>
<td><strong>UP CPH</strong></td>
<td>To identify and consult the end-users of the data management system with the other stakeholders in the process of developing the information system (IS) to come up with a user-friendly digital system</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To train end-users in the functionality of the IS to minimize use of parallel (often paper-based) technologies which arise with non-familiarity with the new system</td>
</tr>
<tr>
<td><strong>Vaccine Safety Monitoring</strong></td>
<td><strong>UPCM</strong></td>
<td>To have an active surveillance system rather than just a passive surveillance system</td>
</tr>
</tbody>
</table>
Management of AEFI and Immunization Safety

There is a need for media management when it comes to AEFI reporting.

Immunization Registration, Monitoring and Data Management Systems

CPRH
There should be communication of exclusion criteria to be specified apart from eligibility.

DOH EB
A phased-in profiling of eligible populations based on areas with high burden of disease and priority population groups shall be conducted.

Roles and Responsibilities

OPAPP/NIC-EOC
Task Group on Procurement and Finance be led by the Department of Finance with DBM and DOH as members
One of the Task Groups to develop a strategic map with necessary indicators and targets for easy monitoring
To include the number and general description of the NITAG’s composition

DOH EB
To include FDA in the agencies/offices to be provided with recommendations by the NAEFIC

PPhA
Task Group on Cold Chain and Logistics to consider mobilizing pharmacies to be center for pharmacy-based immunization

CPRH
To review the implications on the implementation if Phase III clinical trials and the implementation of the vaccines with EUA will overlap

Table 7.3. Key agreements in the Public Consultation on the National Strategic Policy Framework for COVID-19 Vaccine Deployment on January 8, 2021

<table>
<thead>
<tr>
<th>Topic</th>
<th>Stakeholder</th>
<th>Queries/Recommendations</th>
<th>DOH Responses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation of the National COVID-19</td>
<td>Dr. Quizon</td>
<td>Why are indigent populations among priority groups? Their risk is no greater than a rich</td>
<td>DPCB answered that it will be discussed during the next NITAG meeting to discuss the order of priority</td>
</tr>
<tr>
<td>Deployment and Vaccination Plan</td>
<td></td>
<td>person. Is there evidence that those who got infected so far, are indigents?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>League of Provinces of the Philippines</td>
<td></td>
<td>Will the National Government's purchase of vaccines be provided to the LGUs, as identified according to the IATF’s priority plan?</td>
<td>DPCB said yes and all vaccines will be coursed through the LGUs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mr. Jose, Jr.</td>
<td></td>
<td>Order of priority for non-medical government officials such as Mayors; local Gov’t officials and Government workers in Government offices? Also Congressmen and Senators?</td>
<td>Dir. Sudiacal of DPCB responded that Government workers aside from those mentioned in Priority A area under Priority B.</td>
</tr>
<tr>
<td><strong>Far Eastern University - Nicanor Reyes Medical Foundation School of Medicine</strong></td>
<td><strong>How will the vaccinees be notified of their vaccination schedule?</strong></td>
<td><strong>The LGU and the implementing unit such as the health facility will determine your schedule. On the other hand, a digital system will notify you of your vaccination schedule date.</strong></td>
<td><strong>What is the implication of the vaccine pre-registration already being done by various LGUs (i.e., online registration via Google Forms) with the proposed plan of vaccine deployment?</strong></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Ms. Ramos</strong></td>
<td><strong>In the vaccination program and asked if the HCWs will be prioritized. However, this will impact the resources needed for the vaccination program as well as continuous health services. In particular for the first round of 1.7M HCWs, they will need time off after vaccination due to the expected side effects. Will there be a number of people who will supplement the HCWs while they are recuperating? How long will they be given time off?</strong></td>
<td><strong>The DOH is requiring each implementing unit to do micro planning to ensure that contingency plans are available if a health worker is not able to report due to adverse reactions. And the vaccination activity is done through a determined schedule basis. Thus, the health facility should be able to allocate adequate human resources for the conduct of continuous health services.</strong></td>
<td><strong>Ms. Ramos asked if the HCWs will be prioritized. However, this will impact the resources needed for the vaccination program as well as continuous health services. In particular for the first round of 1.7M HCWs, they will need time off after vaccination due to the expected side effects. Will there be a number of people who will supplement the HCWs while they are recuperating? How long will they be given time off?</strong></td>
</tr>
<tr>
<td><strong>Ms. Kraft</strong></td>
<td><strong>If remaining indigent population has been indicated as a priority population group, will this group include those who are below 17 years old? I ask because some of the vaccines have not been tested on children.</strong></td>
<td><strong>The vaccines will be given to eligible population groups. As of now, data shows that COVID-19 vaccines can only be administered to &gt;16 yo and above.</strong></td>
<td><strong>Ms. Kraft asked if the HCWs will be prioritized. However, this will impact the resources needed for the vaccination program as well as continuous health services. In particular for the first round of 1.7M HCWs, they will need time off after vaccination due to the expected side effects. Will there be a number of people who will supplement the HCWs while they are recuperating? How long will they be given time off?</strong></td>
</tr>
<tr>
<td><strong>Ms. Rabe</strong></td>
<td><strong>Can the LDRRM Fund or Quick Release Fund be used for the purchase of vaccines?</strong></td>
<td><strong>Unfortunately, we do not have any jurisdiction on this. We will forward your concern to DBM.</strong></td>
<td><strong>Ms. Rabe asked if the HCWs will be prioritized. However, this will impact the resources needed for the vaccination program as well as continuous health services. In particular for the first round of 1.7M HCWs, they will need time off after vaccination due to the expected side effects. Will there be a number of people who will supplement the HCWs while they are recuperating? How long will they be given time off?</strong></td>
</tr>
</tbody>
</table>

As reiterated by Usec. Cabotaje, the vaccines will not be available commercially until late
<table>
<thead>
<tr>
<th>Name</th>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms. Nievera</td>
<td>Will there be instances where vaccines will be used interchangeably - meaning another vaccine is used for the 2nd dose? How do we monitor/manage/avoid such cases?</td>
<td>The vaccines will be given to eligible population groups. As of now, data shows that COVID-19 vaccines can only be administered to &gt;16 yo and above.</td>
</tr>
<tr>
<td>Mr. Songco</td>
<td>Who is allowed to vaccinate?</td>
<td>Doctors and nurses.</td>
</tr>
<tr>
<td>Ms. Luzande</td>
<td>What kind of distribution model will the government employ? Centralized, Hub and/or Decentralized?</td>
<td>It will be a centralized hub.</td>
</tr>
<tr>
<td>Mr. Ybiernas</td>
<td>What type and brand of vaccine to be given to the Filipino People? Do we have a list of brands to consider?</td>
<td>Dr. Guerrero mentioned that there is a need for EUA before we can use and administer the vaccine. The FDA has yet to issue EUA to any vaccine but they have received at least 2 applications as of the moment.</td>
</tr>
<tr>
<td>Ms. Villa</td>
<td>Regarding prioritization of vaccines to be given, will it be considered to prioritize giving to those LGUs who have not manifested procurement of their own vaccines?</td>
<td>Yes, we are adhering to the principles of equity and reciprocity. The national government will provide vaccines to all LGUs/areas, following the priority eligible population.</td>
</tr>
<tr>
<td>Cotabato Regional Medical Center</td>
<td>If the individual has already been infected, what priority level will they belong to?</td>
<td>Dir. Arevalo mentioned that DOH through the Health Promo Bureau has done social listening and surveys. Demand Generation is headed by the PCOO along with DOH, DICT and PIA.</td>
</tr>
<tr>
<td>Ms. Maderazo</td>
<td>If the EAU will be given to DOH only for purposes of intense side effect monitoring, does it mean that the LGUs with alleged budget allocation for their own vaccine procurement is not necessary?</td>
<td>Conduct of a series of townhall meetings have started to increase awareness about the vaccination.</td>
</tr>
<tr>
<td>Laban Consumer</td>
<td>The acceptability of vaccination among Filipinos is only 50% as a result of the surveys. Therefore, what is the plan of the government to increase acceptance of the vaccine?</td>
<td>US experience: Vaccination sites were not prepared so the DOH</td>
</tr>
</tbody>
</table>
Ms. Kapunan

<table>
<thead>
<tr>
<th>Ms. Kapunan</th>
<th>Will the LGUs be able to independently procure vaccines or will the EUA be granted only to DOH?</th>
<th>The LGU can procure vaccine</th>
</tr>
</thead>
</table>

Health Technology Assessment Council (HTAC)

<table>
<thead>
<tr>
<th>Health Technology Assessment Council (HTAC)</th>
<th>How will the government certify that a person has been vaccinated? Will this certificate be recognized abroad? Are there internationally accepted formats right now?</th>
<th>The DPCB will coordinate with HFSRB and LGUs.</th>
</tr>
</thead>
</table>

Philippine Hospital Association

<table>
<thead>
<tr>
<th>Philippine Hospital Association</th>
<th>What is the role of hospitals in this immunization program?</th>
<th>Dir. Arevalo answered that Hospitals will be vaccination sites. Further, capacity building through e-learning will be done starting next week. Hence, both the Public and private hospitals are included in the training. Contact details of hospitals and LGUs where they are located were requested for succeeding trainings.</th>
</tr>
</thead>
</table>

Ms. Tiamzon

<table>
<thead>
<tr>
<th>Ms. Tiamzon</th>
<th>In the news there are private companies who are saying that they will also be procuring COVID-19 vaccine. How is this in sync with the government's procurement of the vaccine?</th>
<th>The DPCB will still coordinate with the private sectors.</th>
</tr>
</thead>
</table>

League of Provinces of the Philippines

<table>
<thead>
<tr>
<th>League of Provinces of the Philippines</th>
<th>On the EUA/FDA Approval: Can LPP get the contact information of the FDA approved supplier?</th>
<th>FDA will provide information on the vaccines approved by January 15, only one applied is currently being assessed. Usec. Myrna Cabotaje added that all vaccine trials are on Phase III, they have not finished Phase III and Phase IV yet. The DOH cannot introduce vaccines unless they are in Phase IV of the clinical trial.</th>
</tr>
</thead>
</table>

has started the capacity building and other strategies including communication before the vaccination.
The EUA is an authorization not a marketing authorization so this will not make the vaccine commercially available for procurement of individuals, private entities and the government.

Acquisition and access are done through Sec. Galvez. Consignee designation through Sec. Duque. Hence, we always have tripartite agreements.

**Ms. Delos Reyes**  
Is the vaccination program on a voluntary basis? How do we handle persons in the Priority Group who will not allow themselves to be vaccinated?

Vaccination will be based on vaccine availability. If they miss their opportunity to be vaccinated the first time they will have to wait for the second round based on the available vaccine.

Dir. Arevalo said that it depends upon the LGUs, Hospitals and Priority group heads to encourage them to be vaccinated. If they refuse, it will be given to other priority groups.

Dir. Arevalo encouraged them to be the champion among their organization to increase the uptake of COVID-19 vaccination.

**Mr. Salacut**  
Under Eligible Population in the presentation, No. 5 is Uniformed Personnel. For its Definition of Term, recommend the following: All Officers and Enlisted Personnel

This has been duly noted.

**Dr. Dy**  
Which Priority Group would non-senior citizen patients with underlying medical conditions (such as DM, with Congestive Heart Failure) belong to?

If they are healthcare workers they will be prioritized but there will be intersectoral prioritization for those with co-morbidities will be prioritized.
The WHO SAGE recommendation does not include the co-morbidities.

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Question</th>
<th>回答</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms. Ciriaco</td>
<td>In this program, the vaccine will be given to the priority population for free, be it private or government?</td>
<td>The secretariat will contact them.</td>
</tr>
<tr>
<td>Philippine Coast Guard Medical Services</td>
<td>How to register personnel to attend the TOT?</td>
<td></td>
</tr>
<tr>
<td>Ms. Tinio</td>
<td>What about the private clinics or physicians in private practice?</td>
<td>It will be determined based on the eligible population</td>
</tr>
<tr>
<td>Mr. Faraon</td>
<td>Will there will be a geographic prioritization based on local context and epidemiologic setting? how will allocation be done? NCR will have more allocation compared to Batanes?</td>
<td>The vaccinee will be vaccinated in his workplace as a frontliner</td>
</tr>
<tr>
<td>Mr. Cruz</td>
<td>What if, for example, a frontliner works in Quezon City but resides in San Juan City, which LGU will vaccinate this frontliner?</td>
<td>Dir. Arevalo said that there are communication handles to have greater uptake on COVID19 immunization. Training for navigators, community mobilizers will also be conducted especially those affected by previous vaccination initiatives. Dir. Arevalo enjoined all attending the forum to help promote the vaccination program of the government. Videos are being disseminated to Health Promotion Officers to be popularized.</td>
</tr>
<tr>
<td>Mr. Yudelmo</td>
<td>What interventions are done to ensure that people will get vaccinated?</td>
<td></td>
</tr>
<tr>
<td>Dr. Anthony Faraon</td>
<td>Will NCR be prioritized?</td>
<td>Dir. Arevalo said that Eligible population is based on the</td>
</tr>
<tr>
<td>Family Foundation</td>
<td>Considering the portfolio of medicines (5 to 6) how will this be allocated? What if an LGU has preference over a certain vaccine other than what is allocated to them?</td>
<td>burden (sectoral) and geographical (based on prevalence). The NITAG will discuss the priority population based on certain criteria (attack rate, case fatality, readiness of the LGU) tomorrow and give the recommendation to DOH and the vaccine czar. In terms of vaccine portfolio, the vaccines that will come based on the prioritization based on the specific guidelines that will not be based on preference. It will be administered as prioritized and not on preference. If they waive their opportunity to be vaccinated, there will be a second round still based on availability.</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Health Care Professional Alliance on COVID-19</td>
<td>After the use of EUA, will they still undergo HTAC review? Timeline after EAU to HTAC recommendation? Is there guidance for LGUs who already set aside their budget for procurement of vaccines?</td>
<td>Dr. Guerrero said that LGUs can not procure without the clearance of HTAC. Even without the EAU, the HTAC are already reviewing the evidence for the vaccines for publication. It is easier to issue the recommendation. Per Bayanihan Law, only Phase IV was waived. The second question was already answered by Usec. Cabotaje earlier based on specific guidelines to be released thru Sec. Galvez and Sec. Duque.</td>
</tr>
<tr>
<td>Mr. Dimagiba</td>
<td>After all requirements have been complied, what is the procedure for the vaccination? Will this be a prescriptive vaccine or available in the market for consumers?</td>
<td>The vaccine will not be available yet in the market and will not be available on prescription basis. We are still waiting for the EUA to vaccinate the priority population.</td>
</tr>
</tbody>
</table>
The LGU preparation will follow the usual campaign of the National Immunization Program except that the vaccine is not yet available in the market but through EUA.

| Ms. Paredes | It was suggested that the DOH and HTAC can be invited in their meeting for the Governors which they will schedule soon, to discuss the COVID-19 vaccines.

Please communicate through sandy.paredes.lpp@gmail.com 09167528005 | Noted. |

| When will the vaccine be commercially available? | The vaccine after clinical phase IV, will be given CPR and only then can it be commercially available.

The Director General of FDA predicts that it might be commercially available by late 2022.

Depending on the supply of the vaccine, all will be vaccinated on a phased implementation. |

| Ms. Rabe | What will be the guidelines/process for securing the consent of patients for the administration of the vaccine? what is the timeline for the release of the national roadmap on vaccine availment? | The STG on registry and data management is in close coordination with the Legal service. |

| LPP | How does DOH/IATF intend to allocate the limited vaccines to 82 provinces? | Distribution will be primarily based on sectoral prioritization. Followed by geographical prioritization,(based on disease burden - attack rate, incidence rate/active cases and readiness of LGU.|
Recently, there has been news that Taiwan has found 73 side effects of China's Sinopharm, while Sinovac's vaccine appeared to have efficacy of less than 80% in other countries, notwithstanding the more expensive price of these vaccines compared to other Western-made. Considering that the Duterte administration prefers vaccines from China and that the DOH prioritizes efficacy, how would the DOH (particularly the COVID-19 Task Force) compromise?

DPCB answered that the vaccines are evaluated regularly based on a set of guidelines.

Ms. Belen

Makati LGU announced that they can include the vaccine purchase of businesses around Makati if these companies would like to buy the vaccine. Is this allowed? Also, Red Cross, as mentioned by Sen Gordon the other day, can procure vaccines for the country, and sell these to those who can pay. Is this allowed as well?

The IATF will still have to determine the process.

PHPSP

Will the vaccine procurement undergo HTAC review?

Will the review happen before or after issuance of EUA?

HTAC recommendations can only be issued after an EUA is issued by the FDA to ensure that basic safety and efficacy standards are met.

7.3 Priority Eligible Populations for the COVID-19 Vaccination

The DOH Administrative Order No. 2021-0005 entitled “National Strategic Policy Framework for COVID-19 Vaccine Deployment and Immunization” provides the Decision Matrix in determining priority eligible population groups based on the principles of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) Values Framework for the Allocation and Prioritization of COVID-19 Vaccination and the recommendations of the National Immunization Technical Advisory Group (NITAG), taking into consideration the national context, the epidemiologic settings and the COVID-19 vaccine characteristics and supply. Table 7.4 below outlines the priority groups based on the said principles.
Table 7.4. Decision Matrix in determining priority eligible population groups

<table>
<thead>
<tr>
<th>Principles</th>
<th>Objectives</th>
<th>Population Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human well-being</td>
<td>● Reduce deaths and disease burden</td>
<td>● Health workers</td>
</tr>
<tr>
<td></td>
<td>● Protect those in the health services and essential services</td>
<td>● Older adults (senior citizens with or without comorbidities)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Persons with comorbidities</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Personnel in government agencies providing essential services (DSWD, DeEd, DILG, BJMP &amp; Bureau of Correction, PNP, AFP, PCG, BFP, CAFGU)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Government workers, teachers and students, essential workforce (agriculture, tourism, transportation, food industry, tourism, manufacturing, construction, among others)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● All workforce</td>
</tr>
<tr>
<td>Reciprocity</td>
<td>● Protect those who bear significant additional risks and burdens of COVID-19 to safeguard the welfare of others</td>
<td>● Health workers (all)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Essential workers outside the health sector, those with high-risk of exposure, such as contact tracers, social workers providing social services, among others</td>
</tr>
<tr>
<td>Equal respect</td>
<td>● Treat the interest of all individuals and groups with equal consideration as allocation and priority setting</td>
<td>● All citizens based on the availability of vaccines</td>
</tr>
<tr>
<td>National equity</td>
<td>● Ensure that vaccine prioritization takes into account vulnerabilities, risks and needs groups because of underlying societal, geographic or biomedical factors</td>
<td>● People living in poverty (indigent population)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Disadvantaged groups (PWD, PDLs, among others)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Low-income workers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Hard-to-reach areas</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Overseas Filipino Workers</td>
</tr>
</tbody>
</table>
Using the Decision Matrix, the National Government has determined that below will be the priority eligible groups for COVID-19 vaccination:

Table 7.5. Priority eligible groups for COVID-19 vaccination

<table>
<thead>
<tr>
<th>Priorities</th>
<th>Population Group</th>
<th>Definition of Terms</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Priority Eligible Group A*</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Frontline Health Workers</td>
<td>All health workers from the PRIVATE and PUBLIC sector currently on ACTIVE practice/service, whether they are permanent, contractual, job-order and/or outsourced employees or staff:</td>
</tr>
</tbody>
</table>
| a)         | Public and private health facilities [hospitals, medical centers, laboratories, infirmaries, Treatment Rehabilitation Centers (TRCs) and Temporary Treatment and Monitoring Facilities (TTMFs)] | - All those are working in medical centers, hospitals, clinics, laboratories, Temporary Treatment and Monitoring Facilities (TTMFs), and Treatment Rehabilitation Centers (TRCs). If the vaccine supply is limited, priority shall be given to hospitals and medical centers directly catering to COVID-19 patients, including suspects, probable and confirmed COVID-19 cases.  
- Specifically, all those who are assigned in the triage areas, out-patient departments, emergency rooms, wards, intensive care units, operating rooms, delivery rooms, laboratory, radiologic and pathology areas, rehabilitation units, among others.  
- Medical and allied health students who are serving as clerks or interns in hospitals  
- Those who are assigned as part of the disinfection or decontamination teams, medical social workers, admin personnel, and security guards of the above-mentioned facilities. |
| b)         | Public health workers (all RHU/CHO personnel, PHO, PDOHO, CHD and CO) and LGU contact tracers | All workers in the public health sector:  
- All employees in the public primary care facilities (Rural Health Units, City Health Offices (whether LGU-hired or DOH-hired/deployed)  
- All health workers employed/deployed/ detailed in Provincial Health Offices, Center for Health Development and Department of Health Central Offices, including Food and Drug Administration and Bureau of Quarantine  
- All health workers employed/deployed/ detailed in DOH-attached agencies such as Philippine Health Insurance Corporation, Philippine National AIDS Council, Philippine Institute of Traditional
<table>
<thead>
<tr>
<th>2</th>
<th>Indigent Senior Citizens</th>
<th>All indigent senior citizens registered and as determined by DSWD</th>
</tr>
</thead>
</table>

- Alternative Health Care, Dangerous Drugs Board, and National Nutrition Council
  - LGU-deployed/designated/hired contact tracers (those with appropriate documents stating deployment/designation of government employees as contact tracers either through an Executive Order (EO), resolution and/or ordinance)
  - Note: If the vaccine supply is limited, among workers in public health, priority shall be given to those who are providing direct health services.

- **c) Barangay Health Workers including Barangay Health Emergency Response Teams (BHERTs)**
  - All Barangay Health Workers in active service
  - All active members of the BHERTs (based on appropriate documents stating designation either through an LGU EO, resolution and/or ordinance)

- **d) Other NGAs (DSWD, DepEd, DILG, BJMP and Bureau of Correction)**
  - DSWD, and its regional and local counterparts
    - All employees manning close-setting facilities and long-term care facilities, e.g. orphanage, home for the aged, women’s crisis centers.
    - Social workers providing social amelioration, and social services in the communities
  - DepEd
    - Health and nutrition personnel
  - DILG
    - Those hired by DILG as contact tracers (active service)
  - BJMP (under DILG)
    - All employees and health workers assigned in direct contact with Persons Deprived of Liberty (PDLs) such as jail officers, wardens, and/or guards
  - BuCor (under DOJ)
    - All employees and health workers assigned in direct contact with Persons Deprived of Liberty (PDLs) such as jail officers, wardens, and/or guards
<table>
<thead>
<tr>
<th></th>
<th>Priority Eligible Group B**</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Remaining Senior Citizens</td>
</tr>
<tr>
<td>4</td>
<td>Remaining Indigent Population</td>
</tr>
</tbody>
</table>
| 5 | Uniformed Personnel         | All enlisted uniformed personnel in active services under the:  
                            ● Armed Forces of the Philippines  
                            ● Philippine National Police  
                            ● Philippine Coast Guard  
                            ● Bureau of Fire Protection  
                            ● Citizen Armed Force Geographical Unit |
| 6 | Teachers and school workers | ALL teachers and school workers, whether permanent, job-order, contractual or out-sourced in all educational levels, from primary, secondary and tertiary, and vocational educational institutions, both private and public |
| 7 | All government workers (national and local government) | All government workers, whether permanent, job-order, contractual or out-sourced, in national government agencies, government-owned and controlled corporations (GOCCs), government financial institutions (GFIs), local government units, among others. |
| 8 | Essential workers           |  
                            ● All workers providing basic services during this time of pandemic and essential to the growth of the economy as determined by DTI and DOLE  
                            ● These workers may come from the following sectors: agriculture, forestry and fisheries; transportation; construction; food industries; manufacturing of essential goods; tourism; essential retail; water-refilling stations; laundry services; logistics service providers; delivery and courier services; water supply and sanitation services; telecommunication services; energy and power companies; gasoline stations, among others |
| 9 | Socio-demographic groups at significant higher risk other than senior citizens and indigent populations [e.g. Persons Deprived of Liberty] |  
                            ● All Persons Deprived of Liberty as determined by BJMP and BuCor  
                            ● All Persons with Disability as determined by DSWD, and National Council for Disability Affairs (NCDA) and LGUs |
<table>
<thead>
<tr>
<th>Priority Eligible Group C**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12</strong> Remaining Filipino Citizens</td>
</tr>
</tbody>
</table>

*Persons with co-morbidities are being taken into consideration as part of Priority Eligible Group A depending on the latest development and scientific evidence. This is being discussed by the NITAG.*

**The Priority Eligible Group B and C may change as these categories will still undergo review of the NITAG and final approval of the COVID-19 Vaccine Cluster and the IATF.**

It should be noted that the prioritization of population groups are based on the following goals:

**Primary Goals**
- Direct reduction of morbidity and mortality.
- Maintenance of most critical essential services.

**Secondary Goals**
- Substantially control transmission
- Minimize disruption of social, economic and security functions.

**Tertiary Goal**
- Resumption to near normal.
Table 7.6. Priority groups per population with size

<table>
<thead>
<tr>
<th>Ranking of vulnerable group, or inclusion in which phase</th>
<th>Population group</th>
<th>Number of people</th>
<th>% of population</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Stage 1</em> (2021)</td>
<td>1st Priority: Frontline Health Workers</td>
<td>1,762,994</td>
<td>1.6%</td>
</tr>
<tr>
<td></td>
<td>a) Public and private health facilities (Hospitals, Treatment and Rehabilitation Centers, and Temporary Treatment and Monitoring Facilities)</td>
<td>612,975</td>
<td>0.6%</td>
</tr>
<tr>
<td></td>
<td>b) Public health workers (all Rural Health Units/City Health Office personnel; Provincial Health Office, Provincial DOH Officer, CHD, and Central Office field workers) and LGU contact tracers</td>
<td>602,982</td>
<td>0.6%</td>
</tr>
<tr>
<td></td>
<td>c) Barangay Health Workers including Barangay Health Emergency Response Teams</td>
<td>414,640</td>
<td>0.4%</td>
</tr>
<tr>
<td></td>
<td>d) Other National Government Agencies (Department of Social Welfare Development, DepEd, DILG, BJMP &amp; Bureau of Correction)</td>
<td>132,397</td>
<td>0.1%</td>
</tr>
<tr>
<td></td>
<td><strong>Sub-total</strong></td>
<td><strong>24,668,128</strong></td>
<td><strong>23%</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Stage 2</strong> (2022)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a. Teachers and school workers (public and private)</td>
<td>44,628,902</td>
<td>40%</td>
</tr>
<tr>
<td></td>
<td>b. All government workers (National and Local Government)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. Essential workers in agriculture, food industry, transportation, and tourism</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>d. Sociodemographic groups at significantly higher risk other than the senior citizens and indigent population (PDLs, Persons with Disability, Filipinos living in high-density areas)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>e. Overseas Filipino Workers (OFWs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>f. Other remaining workforces</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>g. Students</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Stage 3</strong> (2023)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>All remaining Filipino citizens</td>
<td>41,770,329</td>
<td>37%</td>
</tr>
<tr>
<td>Ranking of vulnerable group, or inclusion in which phase</td>
<td>Population group</td>
<td>Number of people</td>
<td>% of population</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>------------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>111,067,422</td>
<td>100%</td>
</tr>
</tbody>
</table>

### 7.4 Monitoring of Adverse Events Following Immunization (AEFI)

The National Adverse Events Following Immunization Committee was created to monitor and assess the possible adverse effects of the COVID-19 vaccine on individuals. The roles and responsibilities of the Committee include the following:

- Review all reported serious and cluster of AEFI cases presented for expert opinion and provide a final causality assessment of the AEFI cases as well as the cases that were not classified by the Regional AEFI Committee.
- Ensure evidence-based causality assessment by recommending further investigation and data collection as needed.
- Make final decisions on causality assessment of inconclusive investigations.
- Ensure standard protocols for AEFI surveillance and investigation are correctly followed.
- Engage with other national and international experts when requirements arise in establishing causality and vaccine quality issues.
- Provide recommendations to the National Immunization Program, EB and National Cold Chain Manager on improving immunization service delivery, compliance with injection safety and effective vaccine management based on lessons from the AEFI cases.
- Serve as technical advisory group on vaccine and immunization safety-related issues of highest consideration such as immediate recall of vaccine from the market or temporary/permanent withdrawal of a vaccine from the immunization program.
- Serve as resource person in other AEFI related meetings, conferences or capacity building activities as requested.

The draft DOH training modules on the COVID-19 vaccine administration provides guidelines on the Adverse Events Following Immunization (AEFI). The working objectives of the module are as follows:

**Objectives:**

1. To know the overall safety surveillance framework
2. To identify, manage, report and communicate effectively all adverse effects following immunization (AEFI) concerns
3. To be oriented on the basics of Immunization Safety
4. To be able to discuss AEFIs to patients and vaccine-recipients

By the end of this module, the health care worker should be able to:

1. Understand the safety surveillance framework and activities
2. Rapidly identify AEFI signs and symptoms for COVID-19 vaccines
3. Administer initial management of AEFI
4. Report AEFI cases to the national database timely and accurately
5. Able to discuss AEFIs to patients and vaccine-recipients
6. Vaccinator should be able to discuss Immunization Safety
7. Vaccinator should be able to discuss Injection Safety

The content of the module will include:


II. Overview of COVID-19 vaccines clinical trial results

III. Basics of what to look out for vaccine-recipients suspected for AEFI

IV. AEFI case management protocols (experiences from previous campaigns)
V. Significance of AEFI reporting (minor, serious, minor clusters)
VI. Procedural reporting of AEFI cases
VII. Procedural follow-up of vaccination cohort (with and with AEFI case)
VIII. FAQs on AEFI
IX. Counselling techniques on AEFI risk communications
X. Importance of Immunization Safety
XI. Ultra-Cold Chain Management
XII. Personnel and Equipment
XIII. Procedures, Vaccine Schedule and Storage
XIV. What is injection safety?
XV. Injection equipment
XVI. Effects of unsafe injection practices
XVII. Expired vaccines
XVIII. Practices that can harm recipient, health worker, and the community (in the context of COVID-19 pandemic)

As part of the module, it is preliminarily envisioned in the working plan that the vaccinators/program implementers should be able to develop a final operational plan for the COVID Vaccine Program Implementation, including a system or plan for AEFI monitoring with the AEFI Monitoring Protocol/Plan as an output with the identified persons responsible for AEFI Monitoring.
7.5 National Demand Generation and Communications Plan for COVID-19 Vaccines

The DOH Health Promotion Bureau has developed the National Demand Generation and Communications Plan for COVID-19 Vaccines, with the following objectives for the citizens:

- Understand, feel confident in the government’s approach to roll-out COVID-19 vaccines, and believe that it is fair;
- Maintain trust in, and demand for, COVID-19 vaccine and routine immunization;
- Understand the importance of physical and mental resilience and continued practice of other preventive health behaviors (hand washing, mask wearing, and physical distancing); and
- Rely on government-initiated platforms as the authoritative source of information on COVID-19 vaccines deployment.

The specific objectives are as follows:

- Adults, caregivers, and parents understand the threat of COVID-19 and the need for herd immunity to protect their families;
- Eligible Filipinos are aware of the COVID-19 deployment plan (authorization for safety and efficacy, prioritization of recipients) and implementation plan (schedule, venue, and requirements for safe vaccination before the deployment start date);
- All Filipinos understand the key difference of the COVID-19 vaccine clinical trials and the government-led roll out of the COVID-19 vaccines;
- Health workers, community volunteers, and other frontline workers are able to communicate key messages of the campaign, respond to concerns regarding the campaign, and verify information appropriately; and
- Private sector, civil society organizations, Local Chief Executives, and other key stakeholders are engaged to champion the immunization activities through provision of accurate and timely information and of resources for community mobilization.

The approaches and strategies will include the following:

- Raising awareness and engagement through unified messaging across multiple but streamlined communication platforms or spokespersons.
- Ensuring feedback loops from monitoring of platforms to inform calibration of messages.
- Strengthening capacities of health workers and other frontline workers on communication and engagement
- Advocacy and engagement of partners and influencers, including Local Chief Executives (LCEs)
- Media engagement and management

Table 7.7. Overview of the key messages per phase
Social listening allows the COVID-19 vaccine communication team to prioritize and evaluate feedback from the different sources of information in order to create messages with relevant content for target audiences. Through this, communication can be adjusted based on trends and continuously shift strategies to fit the current needs of the target audiences. Social listening activities will generate insights and recommendations that will guide the development of policies, demand generation plans, creation, and dissemination of frequently asked questions (FAQs) and other communication materials regarding COVID-19 vaccines, and the overall COVID-19 vaccine deployment plan and strategies.

Figure 7.1. Social listening framework for the COVID-19 vaccination

The social listening activities per geographic areas will be based in Table 7.8.
Table 7.8. Social listening strategy per geographic area level

<table>
<thead>
<tr>
<th>Tool</th>
<th>Level</th>
<th>Task</th>
<th>Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community Events</td>
<td>Regional</td>
<td>Communicate with local counterparts through established communication channels/social media groups; identify and consolidate relevant concerns</td>
<td>Weekly reporting to national Social Listening Sub-task Group (starting Feb) (every Friday)</td>
</tr>
<tr>
<td></td>
<td>Local</td>
<td>Organize Community Assemblies, Town Hall Meetings, or Community Engagement Activities; gather relevant concerns and respond to queries and concerns</td>
<td>Weekly feedback to the CHD/Regional Vaccine Operation Center (starting Feb)</td>
</tr>
<tr>
<td>COVID-19 Vaccine Online Survey (Healthcare Workers)</td>
<td>Regional</td>
<td>Disseminate the online survey to more than 345 healthcare workers in the region</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local</td>
<td>Help the Regional in disseminating the online survey to health care workers in their localities</td>
<td></td>
</tr>
<tr>
<td>COVID-19 Vaccine Provincial Face-to-Face Survey (General Adult Population)</td>
<td>Regional</td>
<td>Oversee and coordinate survey dissemination and data gathering activities; Communicate regularly with local counterparts to update on survey status through established communication channels/social media groups; Feedback regular updates on survey status to national Social Listening team</td>
<td>Monitoring of data encoded and submitted online by local counterparts</td>
</tr>
<tr>
<td></td>
<td>Local</td>
<td>Conduct face-to-face data gathering for more than 500 adult respondents per province and independent city; Feedback regular updates on survey status to CHD/Regional Vaccine Operation Center</td>
<td>Encode and submit data online on March (Round 1) and September (Round 2)</td>
</tr>
</tbody>
</table>

The following table shows critical topics that are recommended to be covered per target group of stakeholders (Table 7.9).

Table 7.9. Topics for targeted stakeholders for demand generation of the COVID-19 vaccines
The DOH Health Promotion Bureau (HPB) regularly convenes with the Office of the Vaccine Czar, with the following schedule:

- Mondays at 8:00 AM, with the Boston Consulting Group, Vaccine Czar, and leads of the Task Group (TG) Demand Generation and Communications
- Tuesdays at 6:00 PM, the Vaccine Cluster Meeting with other Task Groups (TGs) and Sub-task Groups (STGs)

Together with the Office of the Vaccine Czar, the DOH HPB holds the ‘Laging Handa: COVID-19 Vaccines Explained’ as information and demand generation campaign for the COVID-19 vaccines. The other platforms of interface include chat group with NTF, PIA, and DOH for issues management. The health promotion campaign of the HPB for the COVID-19 response (Figure 7.2) and the vaccination (Figure 7.3) may be summarized in the following figure:

<table>
<thead>
<tr>
<th>Non-HCW community frontliners</th>
<th>Overview of the Vaccine Deployment Plan: 10 THINGS YOU NEED TO KNOW</th>
<th>Demand Generation: Framework for Action</th>
<th>Demand Generation: Playbook</th>
<th>Feedback Mechanisms and Social Listening</th>
<th>Vaccine Reportage and Communications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Target Groups at the National Level</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD &amp; HEPGs, Provincial/Municipal Information Officers, LGU HEPGs, Provincial/City Health Officer, PDRRMOs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCE/LGUs (through ULAP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key HIGs (e.g. DILG, DepEd, DSWD, AFP, PNP, NDRRMC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Societies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Media | | | | |
| Faith-based groups | | | | |

| Provincial/Regional/Local focal points (capacity-building or cascading by Priority National Target Groups) | | | | |
| Barangay LGU Officials | | | | |
| BHWs / BHERT | | | | |
| Public and Private elementary and high school teachers | | | | |
| Medical societies and networks | | | | |
| Faith-based groups | | | | |
| Community Leaders | | | | |
| Youth-based groups | | | | |
Figure 7.2. Health promotion campaign strategy of DOH for the COVID-19 response

Figure 7.3. Health promotion campaign strategy of DOH for the COVID-19 vaccination
The PulseAsia has conducted a survey last December 2018 on who can get an individual vaccinated and it is shown that health care providers, relatives, and local government units play a crucial role, considering the devolved nature of health care in the country (Figure 7.4). It is important to note that this survey is not in the context of COVID-19.

The HPB also has been conducting a series of Town Halls wherein various stakeholder groups are invited to consult on the COVID-19 vaccination. Consultations with the Philippine Medical Association (PMA) last 14 January 2021, Philippine Nurses Association (PNA) last 16 January 2021, with pharmacists last 23 January 2021, and with midwives last 30 January 2021 show the vaccine acceptance of these groups, upon the poll on the question “How likely are you to get the COVID Vaccine if available, with safety and effectiveness comparable to other common vaccines, and with FDA approval for public use?”. Moreover, a town hall consultation with the Indigenous Peoples and their representatives, the National Commission Indigenous Peoples (NCIP), and other relevant CSOs will be conducted by the DOH HPB.

Table 7.10. Vaccination acceptance results during the Town Halls led by the HPB (2021)
Various health trainings on COVID-19 and vaccination are also made available at the DOH Academy E-Learning Platform (https://learn.doh.gov.ph/). The module on health promotion for COVID-19 vaccines includes the following topics:

Table 11. Health promotion module for COVID-19 vaccines in the DOH Academy E-Learning Platform

<table>
<thead>
<tr>
<th>Topic</th>
<th>Target Audience</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: Overview of the Vaccine Deployment Plan: 10 Things You Need to Know</td>
<td>Communicators, General Public</td>
</tr>
<tr>
<td>2: Demand Generation: Framework for Action</td>
<td>Communicators</td>
</tr>
<tr>
<td>3: Demand Generation: Playbook</td>
<td>Communicators</td>
</tr>
<tr>
<td>4: Feedback Mechanisms and Social Listening</td>
<td>Communicators</td>
</tr>
<tr>
<td>5: Vaccine Reportage and Communications</td>
<td>Communicators</td>
</tr>
</tbody>
</table>

7.6 DOH COVID-19 Hotline

In support of the other stakeholder engagement initiatives of DOH, the national COVID-19 hotline has been established last 17 March 2020. The toll free numbers accessible to the public are 1555 or (02) 894COVID (26843). The operating hours are daily with whole day duration (24/7) and no holidays. The hotline is operated by 20 agents with a 4-day rotating shift. The services provided by the hotline for COVID-19 include: providing information and advice to all types of COVID-19 inquiries, serving as a national referral network to all COVID-19 and other health-related concerns (e.g. referral to LGUs, DSWD, OWWA), providing free teleconsultation through volunteer medical experts, and providing end-to-end service for callers requiring COVID-19 assistance (LGU coordination, contact tracing advice in corporate setting).

From March 17 to December 31, 2020, the hotline has handled 102,225 calls with 1,498 teleconsultations of which 49% are COVID-19-related. There has also been 448 e-prescriptions issued. The hotline has also been an avenue for receiving grievances or complaints. The Complaints Handling Unit (CHU) is the central receiving body of complaints. The complaints received by KMITS in the DOH hotline are also forwarded to the CHU. Currently, the CHU has no official classification on
the nature of complaints. According to them, before the pandemic, complaints were usually about hospital violations such as negligence, anti-deposit issues, and illegal detention, and administrative concerns. When the pandemic has set in, complaints included those on quarantine facilities, Special Risk Allowances, and other rewards for frontliners. Complaints on COVID-19- specific care and corruption issues on medical equipment and PPEs are not prominent. The CHU is in the process of classifying the complaints by nature but the timeline to complete the process and officially issue the data has not yet been determined. The call algorithm for the DOH hotline is below.

Figure 7.5. Call algorithm of the DOH COVID-19 hotline

In view of the upcoming COVID-19 vaccination, there is a proposed hotline in support of the Vaccine Cluster. The objectives are as follows:

- Risk Communication - Provide a consistent, accurate information on COVID-19 vaccine to all COVID-19 Hotline callers
- Serve as a first level of technical support for vaccination teams for technical concerns concerning the registry
- Serve as a help desk to vaccination teams for any concerns regarding the deployment (supply request, program-specific questions, etc.)
- Serve as a source of real-time surveillance data to Epidemiology Bureau for COVID-19 Hotline callers with AEFI

The DOH COVID-19 Hotline agents may be trained for basic protocols or provided with information guide or FAQs or basic troubleshooting steps to augment available support to vaccination teams. This will filter calls which require more advanced support and may eventually be forwarded to the appropriate team for immediate assistance. The hotline may provide the following support:
Table 12. Possible support area of the COVID-19 vaccine hotline

<table>
<thead>
<tr>
<th>Area</th>
<th>Activities Supported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Information Technology</td>
<td>QR Code generation</td>
</tr>
<tr>
<td></td>
<td>Record inaccessibility</td>
</tr>
<tr>
<td></td>
<td>Registration concern</td>
</tr>
<tr>
<td>Implementation</td>
<td>Vaccine handling guide</td>
</tr>
<tr>
<td></td>
<td>Basic counseling</td>
</tr>
<tr>
<td>Coordination</td>
<td>LGU to LGU</td>
</tr>
<tr>
<td></td>
<td>LGU to national government and other agencies</td>
</tr>
</tbody>
</table>

The DOH COVID-19 Hotline may provide real-time information via email (or any provided platform) of collected epidemiologic information as it receives it from callers with AEFI ensuring immediate monitoring and follow-through of case as it is being investigated. The DOH COVID-19 Hotline will not replace, but simply augment existing communication channels. Below is the proposed process flow of the COVID-19 vaccine hotline.

Figure 7.6. Proposed process flow of the DOH COVID-19 vaccine hotline

8 Project Implementation Arrangements, Responsibilities, and Capacity Building

8.1 Implementation Arrangements

The Department of Health (DOH) will be the implementing agency for the Project. The DOH has appointed a Project Director (Undersecretary level), and a Project Manager (Director level), with two
Project Co-Directors for the implementation of the Project and the Additional Financing. The Project Director and Project Manager will be acting through DOH’s technical departments and national programs, as well as the regional health units, LGUs, referral hospitals, and health centers. Within the DOH, the Project will be implemented through the Bureau of International Health Cooperation (BIHC), Health Facility Enhancement Program Management Office (HFEPMO), Disease Prevention and Control Bureau (DPCB), Health Emergency Management Bureau (HEMB), Procurement Service (PS), Finance Management Service (FMS), and relevant units, with BIHC as the main project focal point. A Task Force will be created through a Department Personnel Order consisting of the focal persons of the DOH Bureaus to facilitate more effective coordination with the technical units involved.

The project implementation will use mainstream DOH processes and will not involve a parallel project implementation unit or secretariat. However, the DOH has assigned officials who will be in charge of project implementation. The project will have a provision to strengthen DOH units’ capacity and skills through additional consultants or advisors. Additional consultants or advisors will be recruited with an aim to strengthen the overall fiduciary, ESF functions as well as to support implementation of project activities. DOH will also ensure effective implementation at the sub-national levels and close coordination with relevant LGUs.

The Project Operations Manual, includes guidance on standard project fiduciary, environmental and social risk management (a summary of the ESMF and SEP provisions and arrangements, including for GRM), implementation, and M&E requirements, as well as relevant official documents to be developed. However, the SEP and ESMF, along with the ESCP, are the documents that describe the ESF provisions and implementation arrangements. In addition, Annual Work Plan and Budget (AWPB) will be submitted for no-objection to the World Bank no later than October 30 of each year, detailing the project work program and budget for each government fiscal year and specifying the allocation and sources of funding for all project components.

While the DOH had limited experiences working on Bank operations in recent years, lessons learned from previous projects could guide DOH to avoid past challenges in future projects. The last two health projects in the Philippines were National Sector Support for Health Reform (2006-2012) and Women’s Health and Safe Motherhood Project (2005-2013). The support from the first project led to an increase in the coverage of PhilHealth, from 13.6 million poor receiving subsidized coverage in 2007 to 31.4 million in 2013. This, in turn, contributed to the increased use of health services by the poor. The second project led to a large increase in the number of facility-based deliveries. However, there were key implementation challenges faced by both projects, including slow implementation by DOH, delays in delivery of key reports, limited support to LGUs. The implementation of the second project was so slow that only 18 percent of funds were disbursed in the first five years of the project. At project closing, 35 percent of project funds were not used and had to be cancelled.

DOH does not have recent experience or dedicated capacity implementing World Bank financed projects and is not familiar with the Bank’s safeguards or Environmental and Social Framework (ESF) requirements. It is, however, familiar with the Philippines’ relatively well-developed regulatory framework for environmental and social management as it pertains to the health sector.

DoH has a designated team of DOH’s civil service officials, led by a project director and project manager, and with one Environmental and one Social Risk Management Focal Points to coordinate ESF implementation, including the environment and social risk screening of the activities and the
compliance reviews of the ESMPs and other ESF measures. DoH designated the Focal Points already during project preparation. While the project management is at the central level, the roles, duties, and responsibilities of the personnel in the health care facilities and workers in the project sites will be re-defined based on their contracts.

The implementation of ESF instruments will be supported and monitored by World Bank staff throughout project implementation to assist the implementing agencies to undertake the planned environmental and social risk management measures, including stakeholder engagement and preparation of required management plans to be applied under the Project and provide training to the assigned staff.

The COVID-19 Vaccine Cluster Organizational Structure. The COVID-19 Vaccine Cluster shall serve as a unified command, control, coordination, communication, and cooperation mechanism that ensures the procurement, deployment of COVID-19 vaccine and the vaccination of identified eligible populations.

Figure 8.1. COVID-19 Vaccine Cluster organizational structure

The organizational structure and line of command for COVID-19 vaccines is as follows:

1. The **Inter-Agency Task Force on Emerging Infectious Diseases (IATF-EID)**, or merely the IATF is a task force created through Executive Order No. 168 s. 2014 by the Philippine President to respond to affairs concerning emerging infectious diseases in the country. For COVID-19 vaccines, the IATF-EID shall serve as the National Coordinating Committee.

2. For the COVID-19 pandemic response, President Rodrigo Roa Duterte established the **National Task Force (NTF) Against COVID-19** to oversee the operations of the national response. Detailing the strategic framework of the pandemic response, the National Task Force drafted the National Action
Plan Against COVID-19 (NAP) to guide the operations of the pandemic response anchoring on the principle that the response should be national-government-enabled, local government unit (LGU)-led, and people-centered.

3. Under the NTF Against COVID-19, there are three clusters namely, the Response Cluster, the Recovery Cluster and the COVID-19 Vaccine Cluster. As mentioned above, seeing the need for an organizational structure to support the strategic directions of the national government, the COVID-19 Vaccine Cluster was added based on the guidance stipulated in the NAP Phase III. In line with the directions of the VIRAT, the COVID-19 Vaccine Cluster shall serve as the National Technical Working Group. The COVID-19 Vaccine Cluster is led by Secretary Carlito G. Galvez, Jr., who was designated by President Rodrigo Roa Duterte as the COVID-19 Vaccine Czar. The President of the Philippines appointed a Vaccine Czar for the purchase of vaccines and negotiate with manufacturers. To support the Vaccine Czar, the Inter-agency Task Force on Emerging Infectious Diseases (IATF-EID) created a structure that would manage and distribute COVID-19 vaccines once they become available to the Philippines. The vaccine task group is led by the Department of Health.

4. Under the COVID-19 Cluster are six Task Groups, and based on the direction of the VIRAT, shall serve as the Sub-Technical Working Groups. Each TGs is represented by the designated lead in the COVID-19 Vaccine Cluster Executive Committee. The Committee, in turn, advises and updates the COVID-19 Vaccine Cluster Chair. The six Task Groups are (see Figure 2): a. Scientific Evaluation and Selection
   b. Diplomatic Engagement and Negotiation
   c. Procurement and Finance
   d. Cold Chain and Logistics Management
   e. Immunization Program
   f. Demand Generation and Communications.

The COVID-19 vaccination activities will be implemented in accordance with the directives of the COVID-19 Vaccine Cluster Organizational Structure. The Inter-Agency Task Force on the Management of Emerging Diseases is Chaired by Secretary Francisco Duque III of the Department of Health while the National Task Force Against COVID-19 is Chaired by Secretary Delfin Lorenzana of the Department of Defense. Secretary Carlito Galvez, Jr., Presidential Adviser on the Peace Process, is the Chairperson of the National Incident Command and COVID-19 Vaccine Cluster (Philippine National Vaccine Roadmap or PNVR). Undersecretary Leopoldo Vega of the Department of Health is the Chairperson of the Response Cluster while the National Economic and Development Authority (NEDA) is the Chair of the Recovery Cluster.

The following are the COVID-19 Vaccine Clusters and the Sub - Task Groups under the TG COVID-19 Immunization Program:

<table>
<thead>
<tr>
<th>COVID-19 Vaccine Cluster Task Group (TG)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TG Vaccine Evaluation and Selection</strong></td>
</tr>
<tr>
<td>Lead: DOST</td>
</tr>
<tr>
<td>Members: DOH, FDA, RITM, Vaccine Experts</td>
</tr>
<tr>
<td><strong>TG Cold Chain and Logistics Management</strong></td>
</tr>
<tr>
<td>Lead: TGRML</td>
</tr>
<tr>
<td>Members: DOH, DBM, DILG (PNP), DND (AFP, OCD)</td>
</tr>
</tbody>
</table>
The following are the roles and responsibilities of the COVID-19 Vaccine Cluster Organizational Structure:

<table>
<thead>
<tr>
<th>Team</th>
<th>Roles and Responsibilities</th>
</tr>
</thead>
</table>
| TG Vaccine Evaluation and Selection       | • Review results of clinical trials  
                                        | • Coordinate and Collaborate with the TGs and STGs, NITAG and HTAC                         |
| TG Diplomatic Engagement and Negotiation  | • Meet with international parties and entities.  
                                        | • Provide feedback and updates to the other respective TGs pertaining to vaccine development in the global market.  
                                        | • Coordinate and collaborate with TG Procurement and Finance in identifying viable global market vaccine manufacturers and entities. |
| TG Procurement and Finance                | • Facilitate advanced market commitment and/or framework contracting and/or procurement through international facilities (COVAX)  
                                        | • Activate price negotiation board subject to HTA’s cost-effective price  
                                        | • Coordinate with DBM and legislators, as may be necessary on budget and co-payment ceilings  
                                        | • Explore local vaccine production and supply |
| TG Cold Chain and Logistics Management    | • Map the potential port(s) of entry, points of storage (stores), and fallback facilities in the country with their respective cold chain |

The following are the roles and responsibilities of the COVID-19 Vaccine Cluster Organizational Structure:
and transportation/capacity distribution for vaccines, and ancillary products and assess dry storage and cold chain capacity at all levels
  - Facilitate acceptance and inventory of vaccines and logistics
  - Facilitate and ensure storage, distribution and delivery of vaccines and logistics to target areas
  - Monitor cold chain practices and ensure that vaccines are handled and disposed correctly and properly

| TG Immunization Program | • Plan and craft policies, guidelines and standard operating procedures related to the COVID-19 vaccine deployment and program implementation.
  • Estimate potential numbers of target populations that will be prioritized for access to vaccines stratified by target group and geographic location
  • Identify potential COVID-19 vaccine delivery strategies
  • Create a data information system for all vaccine recipients
  • Provide capacity building and trainings to implementers
  • Develop or adapt existing and implement AEFI/Post-marketing surveillance and monitoring framework
  • Ensure or craft guidelines, procedures and tools for planning and conducting vaccine pharmacovigilance activities |

| TG Demand Generation and Communications | • Design a demand and risk communication plan
  • Implement social mobilization and community engagement activities
  • Ensure social preparation of target population groups and geographical areas prior to vaccination |

| National Immunization Technical Advisory Group (NITAG) | • Review the latest position papers, studies, international guidelines and recommendations from internationally acknowledged resources [i.e., World Health Organization (WHO), Strategic Advisory Group of Experts for Immunization (SAGE)] for possible adoption in the country policies and plans for the National Immunization Programme.
  • Conduct existing policy analysis, review of the program data and evidence in order to provide evidence-based technical advice and recommendations for the development of appropriate and sustainable immunization policies, guidelines, strategies and approaches related to immunization program.
  • Advise the DOH in the formulation of policies, plans and strategies for research and development of existing and new vaccines and the vaccine delivery technology. |

| National Adverse Events Following Immunization Committee | • Review all reported serious and cluster of AEFI cases presented for expert opinion and provide a final causality assessment of the AEFI cases as well as the cases that were not classified by the Regional AEFI Committee.
  • Ensure evidence-based causality assessment by recommending further investigation and data collection as needed. |
- Make final decisions on causality assessment of inconclusive investigations.
- Ensure standard protocols for AEFI surveillance and investigation are correctly followed.
- Engage with other national and international experts when requirements arise in establishing causality and vaccine quality issues.
- Provide recommendations to the National Immunization Program, EB and National Cold Chain Manager on improving immunization service delivery, compliance with injection safety and effective vaccine management based on lessons from the AEFI cases.
- Serve as technical advisory group on vaccine and immunization safety-related issues of highest consideration such as immediate recall of vaccine from the market or temporary/permanent withdrawal of a vaccine from the immunization program.
- Serve as resource person in other AEFI related meetings, conferences or capacity building activities as requested.

<table>
<thead>
<tr>
<th>Health Technology Assessment Council</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Oversee and coordinate the health technology assessment process of candidate COVID-19 vaccine.</td>
</tr>
<tr>
<td>• Review and assess existing evidences of COVID-19 vaccines undergoing/undergone clinical trials.</td>
</tr>
<tr>
<td>• Coordinate and provide recommendations to the TG Vaccine Evaluation and Selection.</td>
</tr>
</tbody>
</table>

8.2 Security/ Uniformed Personnel Engagement in COVID-19 Vaccine Delivery and Deployment

The Philippine Government Security Plan or "Caduceus" has been developed to provide guidance on the engagement of security or uniformed personnel in the delivery and deployment of COVID-19 vaccines. The military and police shall be mobilized during the vaccination campaign as laterally and vertically coordinated with the Local Government Units. There is no need for an agreement between the DOH and uniformed units since the Department of National Defense and the Philippine National Police are integrated in the organizational structure managing the deployment of COVID-19 vaccines and the vaccination program, the COVID-19 Vaccine Cluster under the National Task Force Against COVID-19. In addition, a Presidential Decree (PD) no. 2020-157 was also given by the President instructing the DND and DILG to provide support to the COVID-19 vaccination efforts. Furthermore, since the country is still under a Public Health Emergency and a State of Calamity, the DND and DILG are mandated to perform their duties under Republic Act no. 10121 or the Philippine Disaster Risk Reduction and Management Act of 2010.

The PNP Vaccination Plan ‘Caduceus’ sets forth the security and public safety guidelines and procedures to be undertaken by the PNP in support to the Philippine National COVID-19 Deployment and Vaccination Plan, as a member of the following Task Group (TG): Vaccine Cold Chain and Logistics Management, Immunization Program, and Demand Generation and Communication. Under the
Plan, Police Regional Offices are tasked to provide security assistance in the transport of vaccine shipments from storage hubs to vaccination centers. Police Regional Offices are also tasked to establish Police Assistance Desks in vaccination centers to preclude criminal elements and threat groups from taking advantage. On the other hand, police medical frontliners may be fielded to assist the Department of Health, Local Government Unit (LGU) health workers in administering COVID-19 vaccines in designated vaccination centers.

The Security Sector will mobilize personnel to all vaccination sites and will put dedicated control points to ensure the unhindered and unimpeded movements of vaccines in support to the vaccination efforts. The Philippine government cannot currently divulge the number of military and police personnel to be deployed for security reasons.

Security personnel including the uniformed units who will be involved in the Project will abide by the Code of Conduct (CoC). The DOH will ensure that they are informed about the CoC and will receive appropriate training, as needed.

### Training on the Code of Conduct (CoC) for Uniformed Personnel

Schedule: March to April 2021
Platform: Online, through Webex

<table>
<thead>
<tr>
<th>Batch/Schedule</th>
<th>Participants</th>
<th>Training Contents</th>
<th>Training Design</th>
</tr>
</thead>
</table>
| Batch 1 4th Week of March 2021 | PNP Personnel in the following Regions:
NCR
CAR
I- Ilocos
II- Cagayan Valley
III- Central Luzon
IV-A- CALABARZON
IV-B- MIMAROPA
V- Bicol | A. Code of Ethics for PNP Personnel
- PNP Core Values
- Standard of Police Professionalism
- Police Professional Conduct
- Ethical Standards
- Police Customs on Courtesy
- Police Customs on Ceremonies
- Police Customs on Social Decorum
- Tradition | Lecture
Open Forum |
| Batch 2 1st Week of April 2021 | PNP Personnel in the following Regions:
VI- Western Visayas
VII- Central Visayas
VIII- Eastern Visayas
IX- Zamboanga Peninsula
X- Northern Mindanao
XI- Davao
XII- Soccsksargen
XIII- Caraga | B. Environmental and Social Safeguards
- Rights of Persons with Disabilities
- Rights of Indigenous Peoples
- Rights of Women and Children
- Prevention of Sexual Exploitation and Abuse (SEA)/ Sexual Harassment (SH) and Violence against Women and Their Children (VAWC) | |
| Batch 3 1st Week of April 2021 | PNP Personnel in BARMM | C. Prevention of Communicable Diseases
- COVID-19
- Sexually-Transmitted Diseases | |
|          |              | D. COVID-19 Vaccine Delivery and Deployment
- DOH Arrangements with CHDs and Vaccination Implementation Units
- Special Requirements in the Logistics of COVID-19 vaccines (temperature requirement)
- Safety and Security of vaccines (potential crimes associated with vaccine demand) | |
### Batch 4
2nd Week of April 2021

<table>
<thead>
<tr>
<th>AFP Personnel in the following Regions:</th>
<th>Contingency Planning (power outages and national disasters) Crowd management in vaccination sites</th>
<th>AFP Personnel in the following Regions:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCR</td>
<td>A. Code on Conduct for Military Personnel</td>
<td></td>
</tr>
<tr>
<td>CAR</td>
<td>• AFP Core Values</td>
<td></td>
</tr>
<tr>
<td>I- Ilocos</td>
<td>• Concepts and Issues Affecting the AFP</td>
<td></td>
</tr>
<tr>
<td>II- Cagayan Valley</td>
<td>• AFP Core Traditions</td>
<td></td>
</tr>
<tr>
<td>III- Central Luzon</td>
<td>• AFP Military Customs</td>
<td></td>
</tr>
<tr>
<td>IV-A- CALABARZON</td>
<td>B. Environmental and Social Safeguards</td>
<td></td>
</tr>
<tr>
<td>IV-B- MIMAROPA</td>
<td>• Rights of Persons with Disabilities</td>
<td></td>
</tr>
<tr>
<td>V- Bicol</td>
<td>• Rights of Indigenous Peoples</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Rights of Women and Children</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Prevention of Sexual Exploitation and Abuse (SEA)/ Sexual Harassment (SH) and Violence against Women and Their Children (VAWC)</td>
<td></td>
</tr>
</tbody>
</table>

### Batch 5
2nd Week of April 2021

<table>
<thead>
<tr>
<th>AFP Personnel in the following Regions:</th>
<th>Code on Conduct for Military Personnel</th>
</tr>
</thead>
<tbody>
<tr>
<td>VI- Western Visayas</td>
<td>A. Code on Conduct for Military Personnel</td>
</tr>
<tr>
<td>VII- Central Visayas</td>
<td>• AFP Core Values</td>
</tr>
<tr>
<td>VIII- Eastern Visayas</td>
<td>• Concepts and Issues Affecting the AFP</td>
</tr>
<tr>
<td>IX- Zamboanga Peninsula</td>
<td>• AFP Core Traditions</td>
</tr>
<tr>
<td>X- Northern Mindanao</td>
<td>• AFP Military Customs</td>
</tr>
<tr>
<td>XI- Davao</td>
<td>B. Environmental and Social Safeguards</td>
</tr>
<tr>
<td>XII- Soccsksargen</td>
<td>• Rights of Persons with Disabilities</td>
</tr>
<tr>
<td>XIII- Caraga</td>
<td>• Rights of Indigenous Peoples</td>
</tr>
<tr>
<td></td>
<td>• Rights of Women and Children</td>
</tr>
<tr>
<td></td>
<td>• Prevention of Sexual Exploitation and Abuse (SEA)/ Sexual Harassment (SH) and Violence against Women and Their Children (VAWC)</td>
</tr>
</tbody>
</table>

### Batch 6
2nd Week of April 2021

<table>
<thead>
<tr>
<th>AFP Personnel in BARMM</th>
<th>Code on Conduct for Military Personnel</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Code on Conduct for Military Personnel</td>
</tr>
<tr>
<td></td>
<td>• AFP Core Values</td>
</tr>
<tr>
<td></td>
<td>• Concepts and Issues Affecting the AFP</td>
</tr>
<tr>
<td></td>
<td>• AFP Core Traditions</td>
</tr>
<tr>
<td></td>
<td>• AFP Military Customs</td>
</tr>
</tbody>
</table>

### 8.3 Capacity Building

The Philippines, together with almost all countries, has capacity issues in responding to the unprecedented COVID-19 pandemic including infection control, testing and laboratory analysis, establishment and operation of quarantine and isolation facilities and waste management. Additionally, the citizen and stakeholder engagement process is continually evolving in response to the unpredictable disease outbreak.

The Project will provide funding, training, and capacity building to support these critical initiatives, building on international expertise to achieve international best practices in line with WHO guidelines as follows:

- supporting DOH in preparing a guidance note on standard design for hospital isolation and treatment centers to manage Severe Acute Respiratory Infections (SARI) patients;
- training on use of medical and laboratory equipment, devices, and testing kits for health providers and technicians; and supporting the necessary logistics arrangements to deploy goods and equipment to health facilities without delay;
• training on the appropriate use of PPE, guided by the WHO (2020) interim guidance *Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19)*, 19 March 2020;
• capacity building for laboratory staff and technicians on COVID-19 testing; and
• health care waste management and infection prevention and control in health care facilities;
• training of relevant DOH personnel and designated logistics team for the management and maintenance of cold chain and effective management for maximizing efficiencies

The DOH will be conducting trainings for the implementers of the vaccine distribution and administration prior to vaccine roll-out with the lead of the Public Health Services Team.

8.4 Estimated Budget

The costs of implementing the ESMF relate to activities and costs beyond the costs of the dedicated E&S personnel involved in various measures and actions of the ESMF. The main costs of implementing this ESMF relate to (i) training and workshops, (ii) development of E&S due diligence as well as measures and other tools, (iii) information and communication, and (iv) supervision, monitoring, and reporting. A budget estimate for these costs is provided in Table; it may be readjusted during project implementation to ensure adequate management of environmental and social risks.

**Table 8.3. ESMF Implementation Costs**

<table>
<thead>
<tr>
<th>ESMF Activities</th>
<th>Description of Activities</th>
<th>Estimated Cost (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training and capacity building</td>
<td>Development of annual work plans. Training on good practice environmental and social management, including healthcare waste management at national, provincial and local government level.</td>
<td>150,000</td>
</tr>
<tr>
<td>Development of E&amp;S Due Diligence,</td>
<td>Recruitment of consultants for preparation/adaption of ECOPs, ESMPs, etc.</td>
<td>120,000</td>
</tr>
<tr>
<td>Information and Communication</td>
<td>Development of communication strategy and stakeholder engagement. Production and dissemination of communication materials targeting vulnerable groups and indigenous peoples</td>
<td>50,000</td>
</tr>
<tr>
<td>Supervision, monitoring, and reporting</td>
<td>Travel to provinces for training and conducting monitoring and reporting</td>
<td>60,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td><strong>$380,000</strong></td>
</tr>
</tbody>
</table>
A  Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19</td>
<td>Coronavirus Disease 2019</td>
</tr>
<tr>
<td>CERC</td>
<td>Contingent Emergency Response Component</td>
</tr>
<tr>
<td>CoC</td>
<td>Code of Conduct</td>
</tr>
<tr>
<td>DBF</td>
<td>Department of Budget and Finance</td>
</tr>
<tr>
<td>DA</td>
<td>Designated Account</td>
</tr>
<tr>
<td>ECQ</td>
<td>Enhanced Community Quarantine</td>
</tr>
<tr>
<td>EOC</td>
<td>Emergency Operation Center</td>
</tr>
<tr>
<td>ESMF</td>
<td>Environmental and Social Management Framework</td>
</tr>
<tr>
<td>FMM</td>
<td>Financial Management Manual</td>
</tr>
<tr>
<td>FM</td>
<td>Financial Management</td>
</tr>
<tr>
<td>GCQ</td>
<td>General Community Quarantine</td>
</tr>
<tr>
<td>GRS</td>
<td>Grievance Redress Service</td>
</tr>
<tr>
<td>IDA</td>
<td>International Development Association</td>
</tr>
<tr>
<td>IBRD</td>
<td>International Bank for Reconstruction and Development</td>
</tr>
<tr>
<td>IHR</td>
<td>International Health Regulations</td>
</tr>
<tr>
<td>IPF</td>
<td>Investment Project Financing</td>
</tr>
<tr>
<td>IMF</td>
<td>International Monetary Fund</td>
</tr>
<tr>
<td>M&amp;E</td>
<td>Monitoring and Evaluation</td>
</tr>
<tr>
<td>DOH</td>
<td>Department of Health</td>
</tr>
<tr>
<td>PDO</td>
<td>Project Development Objective</td>
</tr>
<tr>
<td>SEP</td>
<td>Stakeholder Engagement Plan</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operational Procedures</td>
</tr>
<tr>
<td>SPRP</td>
<td>Strategic Preparedness and Response Program</td>
</tr>
<tr>
<td>STEP</td>
<td>Systematic tracking of Exchanges in Procurement</td>
</tr>
<tr>
<td>UNICEF</td>
<td>United Nations Child’en's Fund</td>
</tr>
<tr>
<td>WBG</td>
<td>World Bank Group</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
B Labor Management Procedures (LMP)

Under ESS2 on Labor and Working Conditions, Borrowers are required to develop labor management procedures (LMP). The purpose of the LMP is to facilitate planning and implementation of the project. The LMP identifies the main labor requirements and risks associated with the project, and helps the Borrower to determine the resources necessary to address project labor issues. The LMP is a living document, which is initiated early in project preparation, and is reviewed and updated throughout development and implementation of the project.

Projects supporting COVID-19 response activities – strengthening of health care systems and deployment of vaccines - will include many different categories of workers, some of whom will be engaged in activities that raise COVID-19 exposure concerns. It is important to identify (i) the type of activities the project will support, which may include capacity building, construction or rehabilitation of medical facilities or quarantine centers, development of treatment facilities, transportation, and storage of vaccines, disposal of hazardous and non-hazardous waste and the carrying out of vaccination programs; and (ii) the type of workers that will be engaged in such activities.

B.1 Characteristics of Project Workers

The minimum legal working age in the Philippines is 18 years old. All workers must meet this requirement. Contracted workers, mainly for civil works, will most likely be male. Health workers will most likely be female. Health workers will consist of medical professionals directly employed by the health facilities as organic staff or contracted on a temporary basis.

Specific attention should be paid to the types of workers listed below, as these groups of workers are specifically at risk in the COVID-19 context. They should be identified and, as far as possible, this section should include estimated numbers, type and duration of employment, relevant terms and conditions and a clear description of the activities they will carry out.

1. Direct Workers – these are employed or engaged directly by the Borrower to work specifically in relation to the project, such as the PCERP Secretariat managing the day-to-day operations of the Project, providing technical and administrative support to the implementation

2. Civil servants – are regular or plantilla public or government employees with security of tenure. They are bound by the laws and guidelines covering public workers such as the Civil Service Commission (CSC) Resolution no. 1701077 – 2017 Rules on Administrative Cases in the Civil Service (2017 RACCS), the DOH Administrative Order no. 2015-0048 – Revised Procedures on Handling Administrative Disciplinary Complaints in the Department of Health for DOH employees, and the Code of Conduct and Ethical Standards for Public Officials and Employees in accordance with Republic Act no. 6713. The civil servants also include regular workers of local government units, the Philippine National Police, military personnel, and government health care facilities.

Health workers are expected to already be working in the hospitals and laboratories. Provision of laboratory equipment may entail the need to hire additional technicians. Health workers will be at the forefront in the fight against COVID-19. As such, they are at the most risk of infection but with the provision of PPEs, reagents, and technology against the virus, they are also the main
beneficiaries. Health care workers may carry out a range of activities, for example, assessing, triaging and treating COVID-19 patients and workers; registering and recording details of people receiving vaccinations; vaccinating the public; establishing public health reporting procedures of suspected and confirmed cases; providing or reinforcing accurate infection prevention and control, vaccination and public health information, including for concerned workers. Given the significance of the vaccination effort for COVID-19, it is possible that other people, in addition to regular medical workers, will be involved in conducting or supporting vaccinations programs. Workers in this context may include ethnic or indigenous healthcare providers and other members of the community, particularly for populations who have limited access to the formal national healthcare system. Attention should be given to the terms on which they are engaged in the project, and the arrangements put in place to protect them.

3. **Contracted Workers** – These are employed or engaged through third parties to perform work related to the core functions of the PCERP, such as the following:

- Health care workers engaged by health facilities under Contract of Service
- Waste management workers, including sanitation workers, who are highly at risk and will benefit from the PPEs and other safety measures to be provided by the Project
- Security personnel of health care facilities engaged/contracted through third party firms. They will abide by the Code of Conduct (CoC) and DoH will ensure that they are informed about the CoC and receive appropriate training, as needed.
- Construction workers, which will be engaged for small scale civil works of the Project. Construction workers will be hired in time for the refurbishment or construction of the isolation facilities, laboratories, and health care facilities.

4. **Community Workers** – these are workers which are not regular in the civil service or engaged through Contract of Service. They are not compensated and only receives honoraria or allowance for their services. These include the Barangay Health Workers (BHWs) and Barangay Health Emergency Response Teams (BHERTS).

**B.2 Assessment of Potential Labor Risks**

Health workers, waste management and security personnel will be more at risk of infection without the provision of PPE and the use of disinfectants that will be provided by the project. With physical mobility being restricted and given the nature of construction activities, labor influx is not expected. However, the movement of laborers from the worksite to the community may increase the risk of infection in both areas.

COVID-19 specific risks relate to the activities being carried out by the workers, in the context in which the project is being conducted. Potential risks could include workers mobilized from adjoining provinces or regions, or local workers returning from abroad, become vectors for transmission of COVID-19 to other workers in construction project sites and nearby communities.
These risks may be minimized and addressed through:

- conducting pre-employment health checks
- controlling entry and exit from site/workplace
- reviewing accommodation arrangements, to see if they are adequate and designed to reduce contact with the community
- reviewing contract durations, to reduce the frequency of workers entering/exiting the site
- rearranging work tasks or reducing numbers on the worksite to allow social/physical distancing, or rotating workers through a 24-hour schedule
- providing appropriate forms of personal protective equipment (PPE)
- putting in place alternatives to direct contact, like telemedicine appointments and livestream of instructions.

Another example of potential risk is where the project activity is the treatment by health care workers of COVID-19 patients. In this case the risks could include pathogen exposure, infection and associated illness, death, illegal and untenable overtime, psychological distress, fatigue, occupational burnout, stigma and passing on infections to family and community.

### B.3 Labor Regulatory Framework

Presidential Decree No. 44, as amended by RA 6715, known as the “Labor Code of the Philippines”, governs all employment practices and relations in the country. Provisions of the code are aligned with international good practice on decent work and shall be strictly implemented. These provisions include:

#### Wage and Welfare

1. Employees shall receive their wages by means of legal tender, at least once every two weeks or twice a month at intervals not exceeding sixteen (16) days.
2. In a contracted work, employees of the contractor and of the latter’s subcontractor, shall also be paid in accordance with the labor code.
3. The wage paid by the employers to the workers shall not be lower than the prescribed minimum wage set by the Regional Tripartite Wages and Productivity Boards.

#### Working time, Rest Days and Holidays

1. The normal work hours for every employee shall not exceed eight (8) hours a day. If all or any part of the employee’s working hours falls on 10:00 PM to 6:00 AM, he/she shall be entitled to a night shift pay in addition to the regular wage. If the worked performed exceeds the normal working hours, he/she shall be given overtime pay.
2. It is the right of every employee for a rest period not less than twenty-four (24) consecutive hours after every six (6) consecutive normal workdays.
3. Compensation shall be given for work performed during holidays and Sundays.

#### Equal Rights
1. Workers shall have the right to self-organization and to form, join, or assist labor organizations of their own choosing for purposes of collective bargaining.

2. Minimum employable age is 18 years old.

3. Gender discrimination in employment and labor relations shall be prohibited. Male and female employees are entitled to equal compensation for work of equal value and access to promotion and training opportunities.

The Department of Labor and Employment (DOLE) Department Order no. 13 series of 1998 – Guidelines Governing Occupational Safety and Health in the Construction Industry ensures protection and welfare of workers employed in the construction industry, ensure the protection and welfare of the general public within and around the immediate vicinity of any construction worksite as well as the promotion of harmonious employer-employee relationships, and consider the relevant industry practices and applicable government requirements.

**Occupational Health and Safety**

According to Chapter III of Republic Act No. 11058 (the OSH Law), the following are the duties of every employer, contractor or subcontractor, and any person who manages, controls or supervises the work:

1. Equip a place of employment for workers free from hazardous conditions that are causing or are likely to cause death, illness or physical harm to the workers where physical distancing can be observed. Sanitation and hygiene facilities should also be present and well-disinfected regularly for the safety of workers.

2. Provide complete job safety instructions and proper orientation to all workers including, but not limited to, those entering the job for the first time and to those relating to familiarization with their work environment.

3. Inform the workers of the hazards associated with their work, health risks involved or to which they are exposed to, preventive measures to eliminate or minimize the risks, and steps to be taken in case of emergency.

4. Use only approved specific industry set of standards of devices and equipment for the workplace as applicable.

5. Comply with OSH standards including training, medical examination, and when necessary, provisions on protective and safety devices such as PPE and machine guards. Training for workers shall include health promotion, hazards associated with their work, health risks involved or to which they are exposed to, preventive measures to eliminate or minimize risks, steps to be taken in case of emergency, and safety instructions for the jobs, activities and tasks to be handled by workers.

6. Make arrangements for workers and their representatives to have the time and resource to participate actively in the processes of organizing, planning and implementation, monitoring, evaluation and action for improvement of the OSH management system.

7. Provide, when necessary, for measures identifying trainings and drills, evacuation plans, etc., to deal with emergencies, fires and accidents including first-aid arrangements.

To comply with the OSH standards, every employee/worker shall:
1. Participate in the capacity building activities on safety and health and other OSH related topics and programs
2. Proper use of all safeguards and safety devices furnished for workers’ protection and that of others
3. Comply with instructions to prevent accidents or imminent danger situations in the workplace
4. Observe prescribed steps to be taken in cases of emergency including participation in the conduct of national or local disaster drills
5. Report to their immediate supervisor or any other responsible safety and health personnel any work hazard that may be discovered in the workplace

Employed citizens, employees shall have the following common rights:

1. To refuse to work without threat or reprisal from the employer if an imminent danger situation exists.
2. To report accidents, dangerous occurrences, and hazards to the employer, to DOLE, and to other concerned competent government agencies.
3. To receive personal protective equipment, to be provided by their employer, contractor or subcontractor, free of charge, for any part of the body that may be exposed to hazards, and other lifeline
4. To receive information on workplace conditions, risks that can impose danger to health, industrial dangerous and poisonous factors

The Occupational Safety and Health Standards, in compliance with Article 162 of the Labor Code of the Philippines, was formulated to protect every working man against the dangers of injury, sickness or death through safe and healthful working conditions. For this project, chapters discussing standards for personal protective equipment and devices, construction safety, and hazardous materials are necessary and should be complied.

DPWH Department Order 56 series of 2005: Guidelines for the Implementation of Department of Labor and Employment (DOLE) No.13 series of 1998, Guidelines in the Governing Occupational Safety and Health in the Construction Industry, it is expected that the contractors should follow the said guidelines to eliminate or reduce occupational safety and health hazards in all work places, and institute new, and update existing programs to ensure safe and healthful working conditions in all places of employment.

The following international conventions, and directives may also support measures for addressing health and safety issues relevant to COVID-19:

- ILO Occupational Safety and Health Convention, 1981 (No. 155)
- ILO Occupational Health Services Convention, 1985 (No. 161)
- ILO Safety and Health in Construction Convention, 1988 (No. 167)
- WHO International Health Regulations, 2005
- WHO Emergency Response Framework, 2017
In case of Labor Legislation, reference to Chapter 8 – Implementation Arrangement should be made. It should be noted that besides that the Department of Health is the Implementing Unit of the Project, the Philippine government have the Inter-Agency Task Force on Emerging Infectious Diseases (IATF) and the National Task Force (NTF) Against COVID-19. The IATF has been established the Philippine President to respond to affairs concerning emerging infectious diseases in the country and serve as the National Coordinating Committee for the COVID-19 vaccines. Meanwhile, the NTF oversees the operations of the national response. Under the NTF, the COVID-19 Vaccine Cluster has been created to serve as the National Technical Working Group in view of the VIRAT/VRAF guidelines, with the lead of Secretary Carlito G. Galvez, Jr., who was designated by President Duterte as the COVID-19 Vaccine Czar.

The terms and conditions for staff, consultants, and contracted workers in the DOH and other relevant institutions in relation to COVID-19 will be subject to the agreed stipulations in their respective contracts. In instances of labor legislation, Philippine laws as well as the IATF and NTF guidelines will be observed.

Other Labor Related Policies on the Rights of Workers

1. RA 10911(2016) - Anti-Age Discrimination in Employment Act

Aims to promote equal opportunities in employment for everyone specifically for employment of individuals on the basis of their abilities, knowledge, skills, and qualifications rather than their age; prohibit arbitrary age limitations in employment; and promote the right of all employees and workers, regardless of age, to be treated equally in terms of compensation, benefits, promotion, training and other employment opportunities.

2. RA 9481 (2007) - An Act Strengthening The Workers’ Constitutional Right To Self-Organization, Amending For The Purpose Presidential Decree No. 442, As Amended, Otherwise Known As The Labor Code Of The Philippines

Amends and adds additional provisions on the RA, to include rights and requirements for self-organization. Federation, national union or industry or trade union center or an independent union shall acquire legal personality and shall be entitled to the rights and privileges granted by law to legitimate labor organizations upon issuance of the certificate of registration based on set forth requirements.

3. RA 9231 (2003) - Special Protection of Children Against Child Abuse, Exploitation and Discrimination Act

Provide guidelines for special protection to children from all forms of abuse, neglect, cruelty, exploitation and discrimination, and other conditions prejudicial to their development including child labor and its worst forms; provide sanctions for their commission and carry out a program for prevention and deterrence of and crisis intervention in situations of child abuse, exploitation and discrimination.

4. RA 6727 (1988) - Wage Rationalization Act
The RA applies to all workers and employees in the private sector regardless of their position, designation or status except household or domestic helpers, family drivers, workers in retail/service establishments, workers in businesses outside NCR, and workers with basic wage more than PhP 100/day. It aims to rationalize fixing of minimum wages and to promote productivity-improvement and gain-sharing measures to ensure a decent standard of living for the workers and their families; to guarantee the rights of labor to its just share in the fruits of production; to enhance employment generation in the countryside through industry dispersal; and to allow business and industry reasonable returns on investment, expansion and growth.

5. RA 11313 (2018) - Safe Spaces Act

Aims to ensure the fundamental equality of women and men providing security and safety not only in private, but also on the streets, public spaces, online, workplaces and educational and training institutions.

6. RA 11210 (2018) - 105-Day Expanded Maternity Leave Law

The 105-Day Expanded Maternity Leave Law aims to protect and promote the rights and welfare of working women, taking into account them maternal functions, and to provide an enabling environment in which their full potential can be achieved.

7. RA 11199 (2018) - Social Security Act of 2018

Aims to promote social justice through savings, and ensure meaningful social security protection to members and their beneficiaries against the hazards of disability, sickness, maternity, old age, death, and other contingencies resulting in loss of income or financial burden, extending social security protection to Filipino workers, local or overseas, and their beneficiaries.


The RA aims to protect the people from any threat of violence and exploitation, eliminate trafficking in persons, and mitigate pressures for involuntary migration and servitude of persons, not only to support trafficked persons but more importantly, to ensure their recovery, rehabilitation and reintegration into the mainstream of society.

9. RA 9710 (2008) - The Magna Carta of Women

The Magna Carta of Women (MCW) is a comprehensive women’s human rights law that seeks to eliminate discrimination through the recognition, protection, fulfillment, and promotion of the rights of Filipino women, especially those belonging in the marginalized sectors of the society. It conveys a framework of rights for women based directly on international law.

10. RA 7277, as amended by RA 9442 (2006) - Magna Carta For Disabled Persons

The RA provides guidance on the rights and privileges for disabled persons, ensuring adoption of policies for rehabilitation, self-development and self-reliance of disabled persons to develop their skills and potentials to enable them to compete favorably for available opportunities.

The Solo Parents’ Welfare Act of 2000 aims to develop a comprehensive program of services for solo parents and their children to be carried out by the Department of Social Welfare and Development (DSWD), the Department of Health (DOH), the Department of Education, Culture and Sports (DECS), the Department of the Interior and Local Government (DILG), the Commission on Higher Education (CHED), the Technical Education and Skills Development Authority (TESDA), the National Housing Authority (NHA), the Department of Labor and Employment (DOLE) and other related government and nongovernment agencies.


The RA aims to promote all the rights of Indigenous Cultural Communities/Indigenous Peoples (ICCs/IPs) by protecting the rights of ICCs/IPs to their ancestral domains to ensure their economic, social and cultural well being, reserve and develop their cultures, traditions and institutions, and strong expression of the ICCs/IPs for cultural integrity by assuring maximum ICC/IP participation in the direction of education, health, as well as other services of ICCs/IPs.

Labor-Related Policies and Issuances for the COVID-19 Pandemic

1. Civil Service Commission- Department of Health- Department of Labor and Employment Joint Memorandum Circular (JMC) no. 1 series of 2020 – Occupational Safety and Health (OSH) Standards for the Public Sector

The JMC on OSH Standards shall apply to all officials and employees in the national government agencies (NGAs), state universities and colleges (SUCs), local government units (LGUs), and government-owned and -controlled corporations (GOCCs), whether permanent, temporary, and casual status. The JMC guidelines aims to (a) institutionalize occupational health and safety in the public sector and government workplaces, (b) identify and delineate roles and responsibilities of lead agencies, heads of agencies and safety and health committees, within the scope of the Joint Memorandum Circular, and (c) establish Safety and Health Committees within government agencies.


Provides guidelines on workplace safety and health during the COVID-19 pandemic describing measures on increasing physical and mental resilience, reducing virus transmission, management of symptomatic and asymptomatic employees in the workplace, COVID-19 testing, notification and reporting, OSH Committees, disinfection and closure of buildings/workplaces, and leave of absences and entitlements.

Provides guidelines on the allowed construction activities during the COVID-19 pandemic and the corresponding safety protocols for the workers in the said period. It covers all allowed government and private construction projects as stated in the Inter-Agency Task Force (IATF)-issued Revised Omnibus Guidelines dated 15 May 2020 for areas under enhanced community quarantine (ECQ), modified enhanced community quarantine (MECQ), general community quarantine (GCQ), and modified general community quarantine (MGCQ).


The DO provides guidelines for all commercial and industrial establishments, project sites, and all other places, where work is being undertaken indoors, except health care facilities. It provides guidance on ventilation for non-airconditioned spaces, airconditioned spaces, local exhaust ventilation, restrooms and water closets, public transport (air, land, sea, and rail), and corresponding assessment.

B.4 Use of Security Personnel

At present, there is no official document such a Memorandum of Understanding (MOU) between the Department of National Defense (DND), Armed Forces on the Philippines (AFP), Philippine National Police (PNP), and Office of Civil Defense (OCD) with regard to the security in the deployment and delivery of COVID-19 vaccines. There is no need for an agreement between the DOH and uniformed units since the abovementioned unites are integrated in the organizational structure managing the deployment of COVID-19 vaccines and the vaccination program, as part of the NTF and COVID-19 Vaccination Cluster. In the National Deployment and Vaccination Plan (NDVP), the composition of the vaccination and AEFI composite teams and other personnel needed in the implementing units (Table 4.8 of ESMF), include the abovementioned as security personnel together with the safety officers comprised of the local government unit authorities.

A Presidential Decree (PD) no. 2020-157 was also given by the President instructing the DND and DILG to provide support to the COVID-19 vaccination efforts. Furthermore, since the country is still under a Public Health Emergency and a State of Calamity, the DND and DILG are mandated to perform their duties under Republic Act no. 10121 or the Philippine Disaster Risk Reduction and Management Act of 2010. The uniformed personnel have also firmly stated their commitment to take part in securing the vaccines in the NTF meetings last February 1,3, 5, and 8, 2021. In a press release by the Department of the Interior and Local Government last 10 February 2021 (https://dilg.gov.ph/news/DILG-to-PNP-Secure-all-arriving-COVID-19-vaccines/NC-2021-1034), the PNP ‘is expected to be a constant presence in accordance with the national government’s vaccination plan, primarily to secure and protect the COVID-19 vaccines and the team that will be administering them’ as member of the Task Group Supply Chain and Logistics.

Furthermore, the uniformed personnel have also been developing the Philippine Government Security Plan or "Caduceus" to provide guidance on the engagement of security or uniformed personnel in the delivery and deployment of COVID-19 vaccines.
Health facilities supported by the project is expected to use some security personnel. Military and security personnel may also be involved in the deployment and administration of the COVID-19 vaccines. Normally a security agency is contracted on a long-term basis by health care facilities to ensure safety of employees and the facility, including the equipment and supplies. In relation to security of the equipment during delivery, DOH’s freight service provider ensures that all equipment is delivered intact and safe onsite. DOH reports that security has not been an issue in the delivery of equipment in different areas nationwide.

The Project is not expected to use government security personnel in construction of facilities financed by the Project. However, as COVID-19 may develop in unpredictable ways and due to potential concerns among the public, the use of additional government security personnel from the local or national police, or in some instances possibly the military, may be directed to implement measures to ensure peace and order in affected areas, including at quarantine, isolation, decontamination, and other health facilities.

The potential scope of such security measures, and potential risks surrounding them, will be assessed and monitored during implementation and this LMP may be revised accordingly to manage environmental and social risks concerning project activities. The World Bank’s ESS4 on Community Health and Safety encourages disclosure of government security arrangements and that clients ensure that government personnel act in a manner consistent with the provisions of the standard.

In case project activities are supported by private or government security personnel, it will be ensured that the security personnel follow a strict code of conduct and avoid any escalation consistent with the ESF and IFC guidance on the use of security personnel (IFC Good Practice Handbook on the Use of Security Forces: Assessing and Managing Risks and Impacts). In these cases, DOH (through BIHC) will assess risks posed by these security arrangements to project workers and the local community. Security personnel will provide security services in a manner consistent with the applicable laws and code of practices and will be consistent with the relevant requirement of the World Bank’s ESS4. DOH will ensure that the workers and local community are informed about the arrangements and the project’s GRM. DOH will review any allegations of unlawful or abusive acts of security personnel, take action (or urge appropriate parties to take action) to prevent recurrence and, where necessary, report unlawful abusive acts to the relevant authorities. Any incidents, concerns or grievances regarding the conduct of security personnel will be received, monitored, documented (taking into account the need to protect confidentiality), and resolved through the Project’s grievance mechanism following incident classification: Indicative, serious and severe. Any severe incidents with such personnel need to be reported to the Bank no later than 48 hours with basic information and a detailed incident report within 10 working days. It is common practice for Governments to utilize military or security personnel during public health emergencies, especially in view of the declaration of the State of Public Health Emergency in the Philippines. Security personnel will provide security services in a manner consistent with the applicable laws and code of practices and will be consistent with the relevant requirement of the World Bank’s ESS4. The military and police shall be mobilized during the vaccination campaign as laterally and vertically coordinated with the Local Government Units.
Security personnel including the uniformed units who will be involved in the Project will abide by the Code of Conduct (CoC). The DOH will ensure that they are informed about the CoC and will receive appropriate training, as needed. Below are the requirements to comply with ESS4, including the CoC:

Prior to deploying military or security personnel, the DOH shall take measures to ensure that such personnel are:

(i) screened to confirm that they have not engaged in past unlawful or abusive behavior, including sexual exploitation and abuse (SEA), sexual harassment (SH) or excessive use of force;

(ii) adequately instructed and trained, on a regular basis, on the use of force and appropriate behavior and conduct (including in relation to SEA and SH), as set out in the Project Operations Manual, ESMF, and Security Management Plan; and

(iii) deployed in a manner consistent with applicable national law.

2. The DOH shall promptly review all allegations of unlawful or abusive acts of any military/security personnel, take action (or request appropriate parties to take action) to prevent recurrence and, where necessary, report unlawful and abusive acts to the relevant authorities.

Frequency of reporting will depend on the context and the risks associated with the activities the military is carrying out, and may be required monthly, weekly or even daily. Requirements should include:

- Immediate reporting (within 24 hours) of any serious incident
- A written weekly or monthly report (depending on the risk) covering:
  - status of activities being conducted by the military
  - training conducted (specifying subject matter)
  - current status of review of serious incidents (if any) and any relevant reporting
  - a summary of any minor (but reportable) issues, suspected incidents or potential issues
  - details of any incidents involving use of force or weapons
  - details of upcoming activities which may pose a risk (e.g. distribution of supplies) and measures being put in place to reduce such risk
  - lessons learned, to inform conduct of future activities

Other reference documentation: The International Code of Conduct under the Montreux Document.

B.5 Additional Policies and Procedures for the COVID-19 Vaccination

As the project supports delivery and deployment of COVID-19 vaccines, the following additional policies and procedures should be observed:

- Obtaining adequate supplies of medical PPE, including gowns, aprons, curtains; medical masks and respirators (N95 or FFP2); gloves (medical, and heavy duty for cleaners); eye protection (goggles or face screens); hand washing soap and sanitizer; and effective cleaning equipment. Where relevant PPE cannot be obtained, the plan should consider viable
alternatives, such as cloth masks, alcohol-based cleansers, hot water for cleaning and extra handwashing facilities, until such time as the supplies are available. Proper PPE should be provided for all health workers including waste handlers and cleaners.

- Prioritizing different groups for allocation of vaccines, based on WHO guidance for the fair and equitable allocation of COVID-19 vaccination or national regulations (as appropriate) and corresponding training of medical staff on equity and vaccine allocation.
- Training medical staff on the latest WHO advice and recommendations on the specifics of COVID-19, IPC, and vaccine allocation.
- For vaccination sites, ensuring that the space is organized in a safe and socially distant manner, and necessary logistical controls, environmentally-safe cold chain systems, and waste management are planned for in advance.
- Implementing a communication strategy/plan to support regular communication, accessible updates and clear messaging, regarding the spread of COVID-19 in nearby locations, the latest facts and statistics, and applicable procedures, especially for vulnerable groups and GIDAS.

B.6 Contractor Management

The guidelines on civil works implementation for the PCERP is in the DOH Department Circular no. 2020-0398 issued on 3 November 2020.

Responsibilities of BIHC

1. The BIHC will request details in writing before a contract is signed from the Contractor of the measures being taken to address labor and working conditions risks. The construction contract should include health and safety requirements, and these can be used as the basis for identification of, and requirements to implement, COVID-19 specific measures. The measures may be presented as a contingency plan, as an extension of the existing project emergency and preparedness plan or as standalone procedures. The measures may be reflected in revisions to the project’s health and safety manual.

2. The BIHC should require the Contractor to convene regular meetings with the project health and safety specialists and medical staff (and where appropriate the local health authorities), and to take their advice in designing and implementing the agreed measures.

3. The contractor shall assign a senior staff as a focal point to deal with COVID-19 issues during construction. This can be a work supervisor or a health and safety specialist. This person can be responsible for coordinating preparation of the site and making sure that the measures taken are communicated to the workers, those entering the site and the local community. It is also advisable to designate at least one back-up person, in case the focal point becomes ill; that person should be aware of the arrangements that are in place.

4. The BIHC may provide support in identifying appropriate mitigation measures, particularly where these will involve interface with local services, in particular health and emergency services. In many cases, the BIHC can play a valuable role in connecting the Contractor with
local Government agencies, and helping coordinate a strategic response, which takes into account the availability of resources.

5. Workers should be encouraged to use the existing project grievance mechanism to report concerns relating to COVID-19, preparations being made by the project to address COVID-19 related issues, how procedures are being implemented, and concerns about the health of their co-workers and other staff.

6. The BIHC, in coordination with local LGU and health facility, shall issue construction quarantine pass to the individual qualified personnel of the contractors, subcontractors, and suppliers, clearly stating the identification, designation, nature of work, validity and destination. It is understood that the pass shall cover transit of personnel from (a) General Community Quarantine (GCQ) area to Enhanced Community Quarantine (ECQ) area, and vice versa and (b) an area not under community quarantine to a GCQ or ECQ area, and vice versa.

**Responsibilities of the Contractor**

**Prior to Deployment**

1. Only persons from eighteen (18) to fifty-nine (59) years of age, without pre-existing health conditions, such as, but not limited to, immunodeficiency, comorbidities, or other health risks, including any person who resides with the aforementioned; and who did not come into contact with someone with COVID-19 shall be allowed to be included in the workforce, in accordance with the Omnibus Guidelines on the Implementation of Community Quarantine in the Philippines (“OG”) dated 22 October 2020 and relevant DPWH guidelines.

2. Construction personnel shall be required to undergo any available COVID-19 test, as may be prescribed by DOH, and retested as the need arises. In this regard, consultation with medical doctors (duly accredited by DOH, if possible) prior to the conduct of COVID-19 test shall be made.

3. The contractors, subcontractors, and suppliers shall provide for their personnel/workers the necessary welfare facilities and amenities, such as employees’ quarters for board and lodging, ensuring compliance to social distancing, proper hygiene, etc. Contractors shall submit the design for the said welfare facilities and amenities, for monitoring, to BIHC.

4. Contractors shall ensure compliance with DOLE D.O. NO. 13 series of 1998. Contractors shall provide their personnel and workers continuous supply of vitamins, particularly vitamin C, other over-the-counter medicines, quarantine facilities, and oxygen tanks for emergency purposes.

5. Contractors shall provide disinfection facilities in their respective project sites in compliance with pertinent DOH and IATF Guidelines, to be placed at strategic locations to ensure the safety and welfare of all personnel.

6. Proper information dissemination regarding COVID-19 construction protocols on top of existing construction safety practices shall be conducted by Safety Officers to all personnel.
7. For Government construction projects, personal records of all personnel necessary for contact tracing shall be submitted by the contractors, subcontractors, and suppliers to the DPWH IO and shall be resubmitted and updated monthly, or as the need arises.

**During Deployment**

1. Conduct an inventory of works for the construction sequencing to be followed and undertaken to uphold the required social distancing. Break times shall be conducted in a staggered manner.

2. Employees shall be housed in their respective quarters for the entire duration of the project covered by the ECQ and GCQ. Otherwise, “Prior to Deployment” procedures shall be conducted at every instance of re-entry.

3. Errands to be conducted outside the construction site premises shall be kept to a minimum. Number of personnel running errands shall be limited and shall be properly disinfected and closely monitored for symptoms within fourteen (14) days upon re-entry.

4. Field offices, employees’ quarters, and other common areas shall be regularly maintained including the daily disinfection of such facilities.

5. Adequate food, safe/potable drinking water, disinfectants, and hand soaps shall be made available by the concessionaires, contractors, subcontractors, and suppliers to its in – house personnel.

6. Daily monitoring of the pre- and post- work health conditions of workers shall be undertaken by the contractors, subcontractors, and suppliers including, but not limited to, temperature, health, and exposure monitoring, as preventive measures. Personnel with manifestations or symptoms relative to COVID-19 shall be immediately isolated and quarantined for fourteen (14) days and if necessary, brought to the nearest DOH COVID-19 treatment facility under strict confidentiality and privacy. Proper protocols in accordance with the DTI and DOLE Interim Guidelines on Workplace Prevention and Control of COVID-19 shall likewise be strictly observed. For Government construction projects, a daily health monitoring report to be prepared by the Safety Officer shall be submitted to the DPWH IO. The Contractor will also cover the medical bills and wages of the workers should they be infected by the virus.

7. Work activities shall be under daily strict monitoring by the Safety Officer at site to ensure compliance to safety standards and quarantine protocols.

8. For government construction projects, the DPWH Engineers assigned at the site shall ensure strict compliance to DOLE D.O. 13, series of 1998, and implementation of wearing additional Personal Protective Equipment (PPE) required such as, but not limited to, face masks, safety glasses/goggles, face shields, and long sleeve T-shirts, to contain the spread of COVID-19 in the workplace. On the other hand, contractors for essential private construction projects under GCQ shall assign a full-time safety officer devoted to ensure compliance with D.O. 13, series of 1998 and implementation of social distancing measures provided herein.
9. For off-site employees’ quarters, transport service, duly disinfected before and after use, shall be provided, with social distancing observed.

10. Sharing of construction and office equipment is discouraged. However, if necessary, the shared equipment must be disinfected in between transfers amongst personnel.

11. All material and equipment delivery and disposal shall be conducted by a specific team of personnel on an isolated loading/unloading zone while limiting contact with the delivery/disposal personnel. All material and/or equipment entering the construction site shall be duly disinfected, as possible.

12. Non-essential personnel, visitors, and the general public shall be restricted to enter the construction site, employees’ quarters, and field offices. Otherwise, all personnel entering the construction site premises on a temporary basis (e.g. Delivery truck drivers, inspectors, etc.) shall be properly logged and checked for symptoms. Gatherings, Liquors, and/or merry – making are strictly prohibited within the construction site premises.

13. Proper waste disposal shall be provided for infectious waste such as PPEs and other waste products coming from outside the construction premises.

14. Requirements on general hygiene should be communicated and monitored, to include:

   • Training workers and staff on site on the signs and symptoms of COVID-19, how it is spread, how to protect themselves (including regular handwashing and social distancing) and what to do if they or other people have symptoms.
   • Placing posters and signs around the site, with images and text in local languages
   • Ensuring handwashing facilities supplied with soap, disposable paper towels and closed waste bins exist at key places throughout site, including at entrances/exits to work areas; where there is a toilet, canteen or food distribution, or provision of drinking water; in worker accommodation; at waste stations; at stores; and in common spaces. Where handwashing facilities do not exist or are not adequate, arrangements should be made to set them up. Alcohol based sanitizer (if available, 60-95% alcohol) can also be used.
   • Setting aside part of worker accommodation for precautionary self-quarantine as well as more formal isolation of staff who may be infected
   • Conducting regular and thorough cleaning of all site facilities, including offices, accommodation, canteens, common spaces. Review cleaning protocols for key construction equipment (particularly if it is being operated by different workers).
   • Providing cleaning staff with adequate cleaning equipment, materials and disinfectant.
   • Reviewing general cleaning systems, training cleaning staff on appropriate cleaning procedures and appropriate frequency in high use or high-risk areas.
   • Where it is anticipated that cleaners will be required to clean areas that have been or are suspected to have been contaminated with COVID-19, providing them with appropriate PPE: gowns or aprons, gloves, eye protection (masks, goggles or face screens) and boots or closed work shoes. If appropriate PPE is not available, cleaners should be provided with best available alternatives.
• Training cleaners in proper hygiene (including handwashing) prior to, during and after conducting cleaning activities; how to safely use PPE (where required); in waste control (including for used PPE and cleaning materials).

• Any medical waste produced during the care of ill workers should be collected safely in designated containers or bags and treated and disposed of following relevant requirements (e.g., national, WHO).

15. Consider whether existing project medical services are adequate, taking into account existing infrastructure (size of clinic/medical post, number of beds, isolation facilities), medical staff, equipment and supplies, procedures and training. Where these are not adequate, allocate in the project cost the upgrading of services, including:

• Training medical staff, which should include current WHO advice on COVID-19 and recommendations on the specifics of COVID-19. Where COVID-19 infection is suspected, medical providers on site should follow WHO interim guidance on infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected.

• Assessing the current stock of equipment, supplies and medicines on site, and obtaining additional stock, where required and possible. This could include medical PPE, such as gowns, aprons, medical masks, gloves, and eye protection. Refer to WHO guidance as to what is advised.

• If PPE items are unavailable due to world-wide shortages, medical staff on the project should agree on alternatives and try to procure them. Alternatives that may commonly be found on constructions sites include dust masks, construction gloves and eye goggles. While these items are not recommended, they should be used as a last resort if no medical PPE is available.

• Ventilators will not normally be available on work sites, and in any event, intubation should only be conducted by experienced medical staff. If a worker is extremely ill and unable to breathe properly on his or her own, they should be referred immediately to the local hospital.

• Review existing methods for dealing with medical waste, including systems for storage and disposal.

16. Given the limited scope of project medical services, the project may need to refer sick workers to local medical services. Preparation for this includes:

• Obtaining information as to the resources and capacity of local medical services (e.g. number of beds, availability of trained staff and essential supplies).

• Conducting preliminary discussions with specific medical facilities, to agree what should be done in the event of ill workers needing to be referred.

• Considering ways in which the project may be able to support local medical services in preparing for members of the community becoming ill, recognizing that the elderly or those with pre-existing medical conditions require additional support to access appropriate treatment if they become ill.

• Clarifying the way in which an ill worker will be transported to the medical facility, and checking availability of such transportation.

• Establishing an agreed protocol for communications with local emergency/medical services.
• Agreeing with the local medical services/specific medical facilities the scope of services to be provided, the procedure for in-take of patients and (where relevant) any costs or payments that may be involved.

B.7 Grievance Redress Mechanism


Other policies on the guidelines and complaints mechanisms, such as for sexual harassment cases in the 2017 CSC RACCS and RA 9262, are in Section B.3.

**DOH Workers**

Management of DOH personnel is governed by the Civil Service Commission which requires the establishment of a Grievance Redress Committee in charge of preventing and addressing grievances as stipulated in the following provisions:

• The Grievance Committee shall develop and implement pro-active measures or activities to prevent grievance such as employee assembly which shall be conducted at least once every quarter, “talakayan” counseling and other HRD interventions;
• Conduct continuing information drive on Grievance machinery among officials and employees in collaboration with the Personnel Administration Division;
• Conduct dialogue between and among the parties involved;
• Conduct investigation and hearing within ten (10) days from receipt of the grievance and render decision within five (5) working days after the investigation. Provided, however where the object of the grievance is the grievance committee, the aggrieved party may submit the grievance to top management;
• Direct the documentation of the grievance management process including the preparation and signing of written agreements reached by the parties involved;
• Issue Certification on the Final Action on the Grievance (CFAG) which shall contain, among other things, the information, history and final action taken by the agency on the grievance, and;
• Submit a quarterly report of its accomplishments and status of unresolved grievance to the Civil Service Commission Regional Office concerned.

**Contractors**

Contractors are expected to hire much of their laborers upon assuming the civil works contract. At the time of recruitment, workers will be informed of the grievance mechanism and the measures put in place to protect them against any reprisal for its use. The grievance mechanism shall be made easily accessible to all project workers. Regular meetings with the project workers to discuss any
work-related issues and concerns will be conducted. Every grievance raised by a worker will be
documented with the actions undertaken by the office to address such grievance. The aggrieved
worker may raise any issue anonymously through a letter which shall be submitted to his/her
immediate supervisor’s office. All non-anonymous grievances relative to adequate working
conditions, standard occupational safety and health and other concerns from the workers shall be
addressed following the procedures outlined below:

• The grievance shall be filed by the workers to the Contractor who shall follow the DOLE
procedures in handling the complaints. The Contractor shall act within 15 days upon receipt
thereof;
• If no understanding or amicable solution can be reached, or if the complainant does not
receive a response from the Contractor within 15 days of registry of the complaint, he/she
can appeal to the project grievance focal person within DOH, which should act on the
complaint/grievance within 15 days from the day of its filing. If the PIU does not see itself fit
to address the complaint it will immediately bring the matter to the concerned DOLE office.
• If the complainant is not satisfied with the resolution offered by the PIU, he/she can appeal
to the concerned DOLE office, which should act on the complaint/grievance within 15 days
from the day of its filing.

Incidents categorization

There are three levels of classification: Indicative, Serious and Severe Indicative –

Indicative: A relatively minor, small-scale, localized incident that negatively impacts a small
geographical area or a small number of people and does not result in significant or irreparable harm
to people or the environment, or failure to implement required E&S measures with limited
immediate impacts. Although relatively minor and limited in its immediate effects, this type of
incident may be indicative of wider-scale issues or underlying organizational weaknesses within a
project that could lead to serious or severe incidents if left uncorrected.

Serious: An incident that caused or may cause significant harm to the environment, workers,
communities, or natural or cultural resources, is complex or costly to reverse and may result in some
level of lasting damage or injury; or failure to implement E&S measures with significant impacts or
repeated non-compliance with E&S policies; or failure to remedy Indicative non-compliance that may
potentially cause significant impacts. Examples of serious incidents may include injuries to workers
that require off-site medical attention, exploitation or abuse of vulnerable groups, consistent lack of
Occupational Health and Safety (OHS) plans in a civil works project, and large-scale deforestation.

Severe- Incidents that caused or may cause great harm to individuals or the environment, or present
significant reputational risks that could hamper the Bank’s ability to operate in a country or region.
The Borrower’s inability or unwillingness to remedy situations that could result in serious or severe
harm would be a factor in classification. A severe incident is complex and expensive to remedy (if
possible) and is likely irreversible. A fatality is automatically classified as severe, as are incidents of
major environmental contamination, forced or child labor, abuses of community members by project
security forces or other project workers (including GBV) violent community protests a project,
kidnapping, and trafficking in endangered species.
Severe incidents need to be reported to the World Bank no later than 48 hours with basic information and a detailed incident report within 10 working days.

Incident Report:

The **Incident Report** should be 1 – 2 pages and include, at a minimum, the following information:

- Country, Name of Project,
- Preliminary classification of the incident,
- What was the incident? What happened? To what or to whom?
- Where and when did the incident occur?
- When and how did the Project find out about it?
- Are the basic facts of the incident clear and uncontested, or are there conflicting versions? What are those versions?
- What were the conditions or circumstances under which the incident occurred (if known at this stage)?
- Is the incident still ongoing or is it contained?
- Is loss of life or severe harm involved?
- What is their response to date?
- What measures have been or are being implemented by the Project/Contractor?
C. Labor Management Procedures (LMP) Monitoring Form Template

Additional inputs may be provided based on the LMP submitted by the Contractor and the project recipient facility.

<table>
<thead>
<tr>
<th>Item</th>
<th>Status (Complied/Not Complied)</th>
<th>Timeline</th>
<th>Gaps/ Barriers for Implementation of Item</th>
<th>Actions to be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B1. Labor and Working Conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Workers are above minimum legal age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Workers are provided and are wearing proper PPEs at all times</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Workers are aware and practice the Code of Conduct (CoC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Designated OHS Committee and Safety Personnel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>B2. Assessment of Potential Labor Risks</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-employment health checks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controlled entry and exit from site/workplace</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provision of accommodation arrangements to reduce contact with community which enables physical distancing with regular disinfection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provision of sanitation and hygiene facilities which are regularly disinfected</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewed contract durations, to reduce the frequency of workers entering/exiting the site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rearranged work tasks or reducing numbers on the worksite to allow social/physical distancing, or rotating workers through a 24-hour schedule</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provided appropriate forms of personal protective equipment (PPE) to all personnel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternatives to direct contact such as telemedicine appointments and livestream of instructions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>B3. Labor Legislation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wage and Welfare</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Employees shall receive their wages by means of legal tender, at least once every two weeks or twice a month at intervals not exceeding sixteen (16) days.  

In a contracted work, employees of the contractor and of the latter’s subcontractor, shall also be paid in accordance with the labor code.  

The wage paid by the employers to the workers shall not be lower than the prescribed minimum wage set by the Regional Tripartite Wages and Productivity Boards.  

**Working time, Rest Days and Holidays**  
The normal work hours for every employee shall not exceed eight (8) hours a day. If all or any part of the employee’s working hours falls on 10:00 PM to 6:00 AM, he/she shall be entitled to a night shift pay in addition to the regular wage. If the worked performed exceeds the normal working hours, he/she shall be given overtime pay.  

It is the right of every employee for a rest period not less than twenty-four (24) consecutive hours after every six (6) consecutive normal workdays.  

Compensation shall be given for work performed during holidays and Sundays.  

**Equal Rights**  
Workers shall have the right to self-organization and to form, join, or assist labor organizations of their own choosing for purposes of collective bargaining.  

Gender discrimination in employment and labor relations shall be prohibited. Male and female employees are entitled to equal compensation for work of equal value and access to
**Occupational Health and Safety**

Equip a place of employment for workers free from hazardous conditions that are causing or are likely to cause death, illness or physical harm to the workers where physical distancing can be observed. Sanitation and hygiene facilities should also be present and well-disinfected regularly for the safety of workers.

Provide complete job safety instructions and proper orientation to all workers including, but not limited to, those entering the job for the first time and to those relating to familiarization with their work environment.

Inform the workers of the hazards associated with their work, health risks involved or to which they are exposed to, preventive measures to eliminate or minimize the risks, and steps to be taken in case of emergency.

Use only approved specific industry set of standards of devices and equipment for the workplace as applicable.

Comply with OSH standards including training, medical examination, and when necessary, provisions on protective and safety devices such as PPE and machine guards.

Training for workers shall include health promotion, hazards associated with their work, health risks involved or to which they are exposed to, preventive measures to eliminate or minimize risks, steps to be taken in case of emergency, and safety instructions for the jobs, activities and tasks to be handled by workers.
| Make arrangements for workers and their representatives to have the time and resource to participate actively in the processes of organizing, planning and implementation, monitoring, evaluation and action for improvement of the OSH management system |
| Provide, when necessary, for measures identifying trainings and drills, evacuation plans, etc., to deal with emergencies, fires and accidents including first-aid arrangements |
| Report to their immediate supervisor or any other responsible safety and health personnel any work hazard that may be discovered in the workplace |
| Report accidents, dangerous occurrences, COVID-19 cases, and hazards to the employer, to DOLE, and to other concerned competent government agencies. |

### B4. Contractor’s Personnel Grievance Redress Mechanism (GRM)

| Development of a GRM for the project site |
| Implementation and monitoring of the GRM for civil works |

### B5. Contractor Management

#### Prior to Deployment

Only persons from 21 to 59 years of age, without pre-existing health conditions, such as, but not limited to, immunodeficiency, comorbidities, or other health risks, including any person who resides with the aforementioned; and who did not come into contact with someone with COVID-19 shall be allowed to be included in the workforce.

Construction personnel shall be required to undergo any available COVID-19 test, as may be prescribed by DOH, and retested as
the need arises. In this regard, consultation with medical doctors prior to the conduct of COVID-19 test shall be made.

<table>
<thead>
<tr>
<th>The contractors, subcontractors, and suppliers shall provide for their personnel/workers the necessary welfare facilities and amenities, such as employees’ quarters for board and lodging, ensuring compliance to social distancing, proper hygiene, etc. Contractors shall submit the design for the said welfare facilities and amenities, for monitoring to DPCB.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contractors shall provide their personnel and workers continuous supply of vitamins, particularly vitamin C, other over-the-counter medicines, quarantine facilities, and oxygen tanks for emergency purposes.</td>
</tr>
<tr>
<td>Contractors shall provide disinfection facilities in their respective project sites in compliance with pertinent DOH and IATF Guidelines, to be placed at strategic locations to ensure the safety and welfare of all personnel.</td>
</tr>
<tr>
<td>Information dissemination regarding COVID-19 construction protocols on top of existing construction safety practices shall be conducted by Safety Officers to all personnel.</td>
</tr>
<tr>
<td>For Government construction projects, personal records of all personnel necessary for contact tracing shall be submitted by the contractors, subcontractors, and suppliers to the DPWH IO and shall be resubmitted and updated monthly, or as the need arises.</td>
</tr>
<tr>
<td>During Deployment Conduct an inventory of works for the construction sequencing to be followed and undertaken to uphold</td>
</tr>
</tbody>
</table>
the required social distancing. Break times shall be conducted in a staggered manner. Employees shall be housed in their respective quarters for the entire duration of the project covered by the ECQ and GCQ. Otherwise, “Prior to Deployment” procedures shall be conducted at every instance of re-entry.

Errands to be conducted outside the construction site premises shall be kept to a minimum. Number of personnel running errands shall be limited and shall be properly disinfected and closely monitored for symptoms within fourteen (14) days upon re-entry.

Field offices, employees’ quarters, and other common areas shall be regularly maintained including the daily disinfection of such facilities.

Adequate food, safe potable drinking water, disinfectants, and hand soaps shall be made available by the concessionaires, contractors, subcontractors, and suppliers to its in-house personnel.

Daily monitoring of the pre- and post-work health conditions of workers shall be undertaken by the contractors, subcontractors, and suppliers including, but not limited to, temperature, health, and exposure monitoring, as preventive measures.

Personnel with manifestations or symptoms relative to COVID-19 shall be immediately isolated and quarantined for fourteen (14) days and if necessary, brought to the nearest DOH COVID-19 treatment facility under strict confidentiality and privacy.

Work activities shall be under daily strict monitoring by the Safety Officer at site to ensure compliance
to safety standards and quarantine protocols.

The Contractor will also cover the medical bills and wages of the workers should they be infected by the virus.

Implementation of wearing additional Personal Protective Equipment (PPE) required such as, but not limited to, face masks, safety glasses/goggles, face shields, and long sleeve T-shirts, to contain the spread of COVID-19 in the workplace.

For off-site employees’ quarters, transport service, duly disinfected before and after use, shall be provided, with social distancing observed.

Sharing of construction and office equipment is discouraged. However, if necessary, the shared equipment must be disinfected in between transfers amongst personnel.

All material and equipment delivery and disposal shall be conducted by a specific team of personnel on an isolated loading/unloading zone while limiting contact with the delivery/disposal personnel.

Non-essential personnel, visitors, and the general public shall be restricted to enter the construction site, employees’ quarters, and field offices.

Proper waste disposal shall be provided for infectious waste such as PPEs and other waste products coming from outside the construction premises.

Training workers and staff on site on the signs and symptoms of COVID-19, how it is spread, how to protect themselves, and what to do if they or other people have symptoms.
<table>
<thead>
<tr>
<th>Activity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placing posters and signs around the site, with images and text in local languages.</td>
<td></td>
</tr>
<tr>
<td>Ensuring handwashing facilities supplied with soap, disposable paper towels and closed waste bins exist at key places throughout site, including at entrances/exits to work areas; where there is a toilet, canteen or food distribution, or provision of drinking water; in worker accommodation; at waste stations; at stores; and in common spaces.</td>
<td></td>
</tr>
<tr>
<td>Setting aside part of worker accommodation for precautionary self-quarantine as well as more formal isolation of staff who may be infected.</td>
<td></td>
</tr>
<tr>
<td>Conducting regular and thorough cleaning of all site facilities, including offices, accommodation, canteens, common spaces.</td>
<td></td>
</tr>
<tr>
<td>Provision of cleaning staff with adequate cleaning equipment, materials, and disinfectant.</td>
<td></td>
</tr>
<tr>
<td>Review of general cleaning systems, training cleaning staff on appropriate cleaning procedures and appropriate frequency in high use or high-risk areas.</td>
<td></td>
</tr>
<tr>
<td>Where it is anticipated that cleaners will be required to clean areas that have been or are suspected to have been contaminated with COVID-19, providing them with appropriate PPE: gowns or aprons, gloves, eye protection (masks, goggles or face screens) and boots or closed work shoes.</td>
<td></td>
</tr>
<tr>
<td>Training cleaners in proper hygiene (including handwashing) prior to, during and after conducting cleaning activities; how to safely use PPE (where required); in waste control (including for used PPE and cleaning materials).</td>
<td></td>
</tr>
</tbody>
</table>
Any medical waste produced during the care of ill workers should be collected safely in designated containers or bags and treated and disposed of following relevant requirements (e.g., national, WHO).

Consider whether existing project medical services are adequate, taking into account existing infrastructure (size of clinic/medical post, number of beds, isolation facilities), medical staff, equipment and supplies, procedures and training.

**B6. Use of security personnel**

In case project activities are supported by private or government security personnel, it will be ensured that the security personnel follow a strict code of conduct and avoid any escalation consistent with the ESF and IFC guidance on the use of security personnel (IFC Good Practice Handbook on the Use of Security Forces: Assessing and Managing Risks and Impacts)

Is there any support needed from DOH?

__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
D. Code of Conduct and Ethical Standards for Public Officials and Employees

The Republic Act no. 6713 – Code of Conduct and Ethical Standards for Public Officials and Employees and its Implementing Rules and Regulations (IRR) provide guidelines on the conduct and ethics of all official and employees in public services, whether elective or appointive, permanent or temporary, whether in career or non-career service, including military and police personnel, whether or not they receive compensation, regardless of amount. Public officials and employees shall be accountable at all times to the people and shall discharge their duties with utmost responsibility, integrity, competence, and loyalty, act with patriotism and justice, lead modest lives, and uphold public interest over personal interest.

In addition to this COC and the COC for public health workers, military personnel and the PNP, the Civil Service Commission (CSC) Resolution no. 1701077 – 2017 Rules on Administrative Cases in the Civil Service (2017 RACCS) and the Republic Act 9262- Anti- Violence Against Women and Their Children Act provides guidelines and complaints mechanism for sexual harassment cases.

The following are the provisions of the Republic Act and its IRR:

A. Norms of Conduct of Public Officials and Employees

Every public official and employee shall observe the following as standards of personal conduct in the discharge and execution of official duties:

1. Commitment to public interest - Public officials and employees shall always uphold the public interest over and above personal interest. All government resources and powers of their respective offices must be employed and used efficiently, effectively, honestly and economically, particularly to avoid wastage in public funds and revenues.

2. Professionalism - Public officials and employees shall perform and discharge their duties with the highest degree of excellence, professionalism, intelligence and skill. They shall enter public service with utmost devotion and dedication to duty. They shall endeavor to discourage wrong perceptions of their roles as dispensers or peddlers of undue patronage.

3. Justness and sincerity - Public officials and employees shall remain true to the people at all times. They must act with justness and sincerity and shall not discriminate against anyone, especially the poor and the underprivileged. They shall at all times respect the rights of others, and shall refrain from doing acts contrary to law, good morals, good customs, public policy, public order, public safety and public interest. They shall not dispense or extend undue favors on account of their office to their relatives whether by consanguinity or affinity except with respect to appointments of such relatives to positions considered strictly confidential or as members of their personal staff whose terms are coterminous with theirs.

4. Political neutrality - Public officials and employees shall provide service to everyone without unfair discrimination and regardless of party affiliation or preference.

5. Responsiveness to the public - Public officials and employees shall extend prompt, courteous, and adequate service to the public. Unless otherwise provided by law or when required by the public interest, public officials and employees shall provide information of their policies and procedures in clear and understandable language, ensure openness of information, public consultations and hearings whenever appropriate, encourage suggestions, simplify and systematize policy, rules and procedures, avoid red tape and
develop an understanding and appreciation of the socio-economic conditions prevailing in
the country, especially in the depressed rural and urban areas.

6. Nationalism and patriotism - Public officials and employees shall at all times be loyal to the
Republic and to the Filipino people, promote the use of locally produced goods, resources
and technology and encourage appreciation and pride of country and people. They shall
endeavor to maintain and defend Philippine sovereignty against foreign intrusion.

7. Commitment to democracy - Public officials and employees shall commit themselves to the
democratic way of life and values, maintain the principle of public accountability, and
manifest by deeds the supremacy of civilian authority over the military. They shall at all
times uphold the Constitution and put loyalty to country above loyalty to persons or party.

8. Simple living- Public officials and employees and their families shall lead modest lives
appropriate to their positions and income. They shall not indulge in extravagant or
ostentatious display of wealth in any form.

B. Duties of Public Officials and Employees

In the performance of their duties, all public officials and employees are under obligation
to://awphi1.net

1. Act promptly on letters and requests - All public officials and employees shall, within fifteen
(15) working days from receipt thereof, respond to letters, telegrams or other means of
communications sent by the public. The reply must contain the action taken on the request.

2. Submit annual performance reports - All heads or other responsible officers of offices and
agencies of the government and of government-owned or controlled corporations shall,
within forty-five (45) working days from the end of the year, render a performance report of
the agency or office or corporation concerned. Such report shall be open and available to the
public within regular office hours.

3. Process documents and papers expeditiously - All official papers and documents must be
processed and completed within a reasonable time from the preparation thereof and must
contain, as far as practicable, not more than three (3) signatories therein. In the absence of
duly authorized signatories, the official next-in-rank or officer in charge shall sign for and in
their behalf.

4. Act immediately on the public's personal transactions - All public officials and employees
must attend to anyone who wants to avail himself of the services of their offices and must,
at all times, act promptly and expeditiously. The period of fifteen (15) working days herein
provided shall be counted from the date of receipt of the written or verbal communication
by the department, office or agency concerned.

   a. In departments, offices or agencies that are usually swamped with persons calling
      for a particular type of service, the head of the department, office or agency shall
device a mechanism so as to avoid long queues, such as by giving each person a
ticket number duly countersigned which shall specify the time and the date when
the person, whose name and address shall be indicated, can be served without
delay. Said person shall have the right to prompt service upon presentation of said
ticket number.

   b. In case of written requests, petitions or motions, sent by means of letters, telegrams,
or the like, the official or employee in charge shall act on the same within fifteen (15)
working days from receipt thereof, provided that:

      ▪ If the communication is within the jurisdiction of the office or agency, the
       official and employee must:
i. Write a note or letter of acknowledgement where the matter is merely routine or the action desired may be acted upon in the ordinary course of business of the department, office or agency, specifying the date when the matter will be disposed of and the name of the official or employee in charge thereof.

ii. Where the matter is non-routine or the issues involved are not simple or ordinary, write a note or letter of acknowledgement, informing the interested party, petitioner or correspondent of the action to be taken or when such requests, petitions or motions can be acted upon. Where there is a need to submit additional information, requirements, or documents, the note or letter of acknowledgement shall state, specifying a reasonable period of time within which they should be submitted, and the name of the particular official or employee in charge thereof. When all the documents or requirements have been submitted to the satisfaction of the department or office or agency concerned, the particular official or employee in charge shall inform the interested party, petitioner, or correspondent of the action to be taken and when such action or disposition can be expected, barring unforeseen circumstances.

- If communication is outside its jurisdiction, the official or employee must:
  i. Refer the letter, petition, telegram, or verbal request to the proper department, office or agency.
  ii. Acknowledge the communication by means of a note or letter, informing the interested party, petitioner, correspondent of the action taken and attaching a copy of the letter of referral to proper department, office or agency.

5. Make documents accessible to the public - All public documents must be made accessible to, and readily available for inspection by, the public within reasonable working hours.

C. Transparency of Transactions and Access to Information

1. Heads of departments, offices and agencies shall establish measures and standards that will ensure transparency of and openness in public transactions in their respective offices, such as biddings, purchases, other internal transactions, including contracts, status of projects, and all other matters involving public interest. They shall establish information systems that will inform the public of the following: (a) policies, rules, and procedures; (b) work programs, projects, and performance targets; (c) performance reports; and (d) all other documents as may hereafter be classified as public information. Such information shall be utilized solely for the purpose of informing the public of such policies, programs and accomplishment, and not to build the public image of any official or employee or to advance his own personal interest.

2. Every department, office or agency shall provide official information, records or documents to any requesting public, except if:
   a. information, record or document must be kept secret in the interest of national defense or security or the conduct of foreign affairs
   b. disclosure would put the life and safety of an individual in imminent danger
c. information, record or document sought falls within the concepts of established privilege or recognized exceptions as may be provided by law or settled policy or jurisprudence

d. information, record or document compromises drafts or decisions, orders, rulings, policy, decisions, memoranda, etc.

e. disclose information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy

f. disclose investigatory records compiled for law enforcement purposes, or information which if written would be contained in such records or information would (i) interfere with enforcement proceedings, (ii) deprive a person of a right to a fair trial or an impartial adjudication, (iii) disclose the identity of a confidential source and, in the case of a record compiled by a criminal law enforcement authority in the course of a criminal investigation, or by an agency conducting a lawful national security intelligence investigation, confidential information furnished only by the confidential source, or (iv) unjustifiably disclose investigative techniques and procedures; or

g. disclose information the premature disclosure of which would (i) in the case of a department, office or agency which agency regulates currencies, securities, commodities, of financial institutions, be likely to lead to significant financial speculation in currencies, securities, or commodities or significantly endanger the stability of any financial institution, or (ii) in the case of any department, office or agency be likely or significantly to frustrate implementation of a proposed official action, except that subparagraph (f) (ii) shall not apply in any instance where the department, office or agency has already disclosed to the public the content or nature of its proposed action, or where the department, office or agency is required by law to make such disclosure on its own initiative prior to taking final official action on such proposal.

3. Every head of department, office and agency shall establish information systems and networks that will effect the widest possible dissemination of information regarding the provisions of the Code, and the policies and programs relative thereto.

D. Reforms on Public Administrative Systems

The Civil Service Commission shall adopt positive measures to promote (1) observance of these standards including the dissemination of information programs and workshops authorizing merit increases beyond regular progression steps, to a limited number of employees recognized by their office colleagues to be outstanding in their observance of ethical standards; and (2) continuing research and experimentation on measures which provide positive motivation to public officials and employees in raising the general level of observance of these standards.

The following are some reforms on the public administrative systems:

1. Every department, office and agency shall conduct value development programs for its officials and employees in order to strengthen their commitment to public service and help promote the primacy of public interest over personal interest in the performance of their duties. Such programs and other parallel efforts on value development shall include, among other things, the following subjects:
   a. Ethical and moral values
b. Rights, duties and responsibilities of public servants  
c. Nationalism and patriotism  
d. Justice and human rights  
e. Democracy in a free and just society  
f. Philippine history, culture, and tradition  
g. Socio-economic conditions prevailing in the country, especially in the depressed areas, and the need for a code of Conduct and Ethical Standards

2. Professional, scientific, technical trainings and education programs shall enhance to the highest degree, professionalism, excellence, intelligence and skills in the performance and discharge of duties and responsibilities of officials and employees. These programs shall be conducted in all offices of the government and may include subjects that are enumerated in the preceding section.

3. It is the responsibility of every head of department, office and agency to ensure that officials and employees attend the value development program and participate in parallel value development efforts.

4. Every department, office and agency shall conduct continuing studies and analyses of their work systems and procedures to improve delivery of public services. Towards this end, such studies and analyses shall: (1) identify systems and procedures that lead or contribute to negative bureaucratic behavior; (2) simplify rules and procedures to avoid red tape; and (3) devise or adopt systems and procedures that promote official and employee morale and satisfaction.

5. Each department, office or agency shall develop a service guide or its functional equivalent which shall be regularly updated and made available to the transacting public. A workflow chart showing procedures or flow of documents shall likewise be posted in conspicuous places in the department, office or agency for the information and guidance of all concerned.

6. Every department, office and agency shall consult the public they serve for the purpose of gathering feedback and suggestions on the efficiency, effectiveness and economy of services. They shall establish mechanisms to ensure the conduct of public consultations and hearings.

7. Every department, office and agency shall continuously conduct research and experimentation on measures and adopt innovative programs which will provide motivation to officials and employees in raising the level of observance of public service ethical standards.

8. Every department, office and agency shall appoint or designate a resident Ombudsman, who shall act immediately on all request for public assistance referred to him by the Ombudsman and his Deputies. He shall be held accountable for the disposition of all requests for assistance.

9. Government officials shall make themselves available to their staff for consultations and dialogues.

E. System of Incentives and Rewards

A system of annual incentives and rewards is hereby established in order to motivate and inspire public servants to uphold the highest standards of ethics. For this purpose, a Committee on Awards to Outstanding Public Officials and Employees is hereby created composed of the following: the Ombudsman and Chairman of the Civil Service Commission as Co-Chairmen, and the Chairman of the Commission on Audit, and two government employees to be appointed by the President, as members.
The following criteria shall be considered in the conferment of awards:

- Years of service
- Quality and consistency of performance
- Obscurity of the position
- Level of salary
- Unique and exemplary quality of achievement
- Risk or temptation inherent in the work
- Any similar circumstances or considerations in favor of the particular awardee

Incentives and rewards to government officials and employees of the year may take the form of any of the following, as may be determined by the Committee on Awards established under the Code:

- Bonuses
- Citations
- Directorships in government-owned or controlled corporations
- Local and foreign scholarship grants
- Paid vacations
- Automatic promotion to the next higher position suitable to his qualifications and with commensurate salary; provided, that if there is no next higher position or it is not vacant, said position shall be included in the next budget of the office; except when the creation of a new position will result in distortion in the organizational structure of the department, office or agency. Where there is no next higher position immediately available, a salary increase equivalent to the next higher position shall be given and incorporated in the base pay. When a new position is created, that which is vacated shall be deemed abolished.

The grants of awards shall be governed by the merit and fitness principle.

F. Prohibited Acts and Transactions

In addition to acts and omissions of public officials and employees now prescribed in the Constitution and existing laws, the following shall constitute prohibited acts and transactions of any public official and employee and are hereby declared to be unlawful:

1. Financial and material interest - Public officials and employees shall not, directly or indirectly, have any financial or material interest in any transaction requiring the approval of their office.
2. Outside employment and other activities related thereto - Public officials and employees during their incumbency shall not:
   a. Own, control, manage or accept employment as officer, employee, consultant, counsel, broker, agent, trustee or nominee in any private enterprise regulated, supervised or licensed by their office unless expressly allowed by law
   b. Engage in the private practice of their profession unless authorized by the Constitution or law, provided, that such practice will not conflict or tend to conflict with their official functions
   c. Recommend any person to any position in a private enterprise which has a regular or pending official transaction with their office.
3. Disclosure and/or misuse of confidential information - Public officials and employees shall not use or divulge, confidential or classified information officially known to them by reason of their office and not made available to the public, either:
   - To further their private interests, or give undue advantage to anyone
   - To prejudice the public interest
4. Solicitation or acceptance of gifts - Public officials and employees shall not solicit or accept, directly or indirectly, any gift, gratuity, favor, entertainment, loan or anything of monetary value from any person in the course of their official duties or in connection with any operation being regulated by, or any transaction which may be affected by the functions of their office. As to gifts or grants from foreign governments, the Congress consents to:
   a. The acceptance and retention by a public official or employee of a gift of nominal value tendered and received as a souvenir or mark of courtesy.
   b. The acceptance by a public official or employee of a gift in the nature of a scholarship or fellowship grant or medical treatment.
   c. The acceptance by a public official or employee of travel grants or expenses for travel taking place entirely outside the Philippine (such as allowances, transportation, food, and lodging) of more than nominal value if such acceptance is appropriate or consistent with the interests of the Philippines, and permitted by the head of office, branch or agency to which he belongs.

G. Statements and Disclosure

Public officials and employees have an obligation to accomplish and submit declarations under oath of, and the public has the right to know, their assets, liabilities, net worth and financial and business interests including those of their spouses and of unmarried children under eighteen (18) years of age living in their households.

1. Statements of Assets and Liabilities and Financial Disclosure - All public officials and employees, except those who serve in an honorary capacity, laborers and casual or temporary workers, shall file under oath their Statement of Assets, Liabilities and Net Worth and a Disclosure of Business Interests and Financial Connections and those of their spouses and unmarried children under eighteen (18) years of age living in their households. The two documents shall contain information on the following:
   - real property, its improvements, acquisition costs, assessed value and current fair market value
   - personal property and acquisition cost
   - all other assets such as investments, cash on hand or in banks, stocks, bonds, and the like
   - liabilities
   - all business interests and financial connections

2. Identification and disclosure of relatives - It shall be the duty of every public official or employee to identify and disclose, to the best of his knowledge and information, his relatives in the Government in the form, manner and frequency prescribed by the Civil Service Commission.

H. Divestment
A public official or employee shall avoid conflicts of interest at all times. When a conflict of interest arises, he shall resign from his position in any private business enterprise within thirty (30) days from his assumption of office and/or divest himself of his shareholdings or interest within sixty (60) days from such assumption. The same rule shall apply where the public official or employee is a partner in a partnership. The requirement of divestment shall not apply to those who serve the Government in an honorary capacity nor to laborers and casual or temporary workers.

I. Penalties

1. Any public official or employee, regardless of whether or not he holds office or employment in a casual, temporary, holdover, permanent or regular capacity, committing any violation of this Act shall be punished with a fine not exceeding the equivalent of six (6) months' salary or suspension not exceeding one (1) year, or removal depending on the gravity of the offense after due notice and hearing by the appropriate body or agency. If the violation is punishable by a heavier penalty under another law, he shall be prosecuted under the latter statute. Violations of Sections 7, 8 or 9 of this Act shall be punishable with imprisonment not exceeding five (5) years, or a fine not exceeding five thousand pesos (P5,000), or both, and, in the discretion of the court of competent jurisdiction, disqualification to hold public office.

2. Any violation hereof proven in a proper administrative proceeding shall be sufficient cause for removal or dismissal of a public official or employee, even if no criminal prosecution is instituted against him.

3. Private individuals who participate in conspiracy as co-principals, accomplices or accessories, with public officials or employees, in violation of this Act, shall be subject to the same penal liabilities as the public officials or employees and shall be tried jointly with them.

4. The official or employee concerned may bring an action against any person who obtains or uses a report for any purpose prohibited by Section 8 (D) of this Act. The Court in which such action is brought may assess against such person a penalty in any amount not to exceed twenty-five thousand pesos (P25,000). If another sanction hereunder or under any other law is heavier, the latter shall apply.

E. Code of Conduct of Public Health Workers

The Republic Act no. 7305 or the Magna Carta of Public Health Workers provides guidelines on the code of conduct of all public health workers, defines as all persons who are engaged in health and health-related work, and all persons employed in all hospitals, sanitariums, health infirmaries, health centers, rural health units, barangay health stations, clinics and other health-related establishments owned and operated by the Government or its political subdivisions with original charters and shall include medical, allied health professional, administrative and support personnel employed regardless of their employment status.

A. General Principles

1. The primary essence of the practice of public health is service to mankind, irrespective of race, sex, creed or political affiliation. In practice, financial gain is of secondary consideration.

2. It is the obligation of the public health worker to uphold standards in the practice of health and medical profession. He/She takes pride in his/her calling and practices his profession according to ethical standards.
3. In relating to his clients, the public health worker applies appropriate technical knowledge to best serve his/her client(s).

4. In relating to the state and to the community, the public health worker performs his/her civic duties as a law-abiding citizen and cooperates with government authorized in the practice of his/her profession.

5. The public health work continually seeks to improve and develop himself by upgrading his/her knowledge and skills for a more effective delivery of his/her services.

6. The public health workers gives his/her full cooperation and operates as a member team in the total and integrated delivery of health services.

7. The public health worker safeguards the legitimate interests, reputation and dignity of his/her colleagues.

8. The public health worker looks upon the Department of Health as the lead government agency responsible for maintaining the health of the Filipino people by providing for effective and responsive strategies and policies governing the delivery of health and medical services.

B. Values to Be Adopted by Public Health Workers

The delivery of public health service seeks to improve the quality of life of the Filipino people to protect and preserve individual lives. Aware of this commitment, the public health worker adopts the following values:

1. The public health worker shall be humane.
   a. He/She shall accord his/her every client with respect befitting a human being who is unique and made in the image of his/her Divine Creator.
   b. He/She shall serve anybody to the best of his/her physical and intellectual capacity.
   c. He/She shall provide clients his/her services with compassion and responsive to his/her client’s needs, including those beyond health matters.
   d. He/She shall provide clients with the necessary information to enable them to decide on the manner and form of medical care and assistance.
   e. He/She shall at all times, uphold the sanctity of human life.
   f. He/She shall under no circumstances directly or indirectly participate in acts curtailing human life.

2. The public health worker shall uphold his/her personal integrity and that of his/her profession.
   a. He/She shall continually seek to improve on his/her professional skills, knowledge and expertise with other members of his/her profession and encourage their professional development.
   b. He/She shall practice his/her profession always to the best of his/her ability and strives to render quality services.
   c. He/She shall not claim authority or expertise over matters beyond his/her position or capability.
   d. He/She shall not use his/her position to obtain personal favors.
   e. He/She shall endeavor to be a role model for a respectable and healthful lifestyle.
   f. He/She shall take pride in being health servant and not allow anyone to degrade him/her or his/her profession. He/She shall promote a favorable public image of the public health worker.
   g. He/She shall faithfully abide by the Code of Conduct of his/her profession.

3. The public health worker shall be just.
   a. He/She shall treat persons equally without bias to race, social class, education, sex, age, physical or mental capabilities, political and religious affiliation.
b. He/She shall make professional, administrative or technical judgments in favor of the common good and the less privileged, taking into consideration overall cost to the government.

4. The public health worker shall be generous in spirit and deed.
   a. He/She shall actively seek opportunities to be of service to the state, the public and to his/her colleagues.
   b. He/She shall prepare to respond to the call of duty during emergencies and situations demanding additional manpower or hours of work.
   c. He/She shall volunteer to provide his/her services where and when they are most needed, even if he/she is not required to do by his/her superior.
   d. He/She shall coordinate and work with other office, government agencies, and private organizations or entities for the furtherance of the public health service.

5. The public health worker shall exercise courage to protect the interest of public health.
   a. He/She shall assert his rights and privileges as a public health worker at all times.
   b. He/She shall readily take risk necessary to perform his/her duties and functions in public health service.
   c. He/She shall practice and protect known and accepted ideals in public health delivery systems, and enforce rules, regulations, and standards as promulgated by the duly constituted authority without fear or favor.

C. Duties and Obligations

The public health worker is bound to the following duties and obligations, in addition to those embodied under Rule VI, Sections 1 to 8 of the Code of Conduct and Ethical Standards for Public Officials and Employees:

1. To the Clientele
   - The public health worker shall attend to his/her clients faithfully and conscientiously. He/She shall strive to provide them with all possible benefits from his/her knowledge and skills.
   - The public health worker shall serve at anytime all people in his/her area of jurisdiction without discrimination.
   - The public health worker shall exercise good faith and strict honesty in the discharge of his/her duties and responsibilities especially in disseminating information to clients and their families.
   - The public health worker shall guard as sacred trust anything confidential or private in nature that is discovered or relayed to him/her by the clients. He/She shall not divulge confidential information that may reflect on the clients, except, when required by law, in the interest of public health and safety, or upon the client’s consent.
   - The public health worker shall provide his/her clients with the best quality service at least cost.
   - The public health worker shall serve the needs of his/her clients throughout the duration of the client’s treatment or make the necessary referral until the treatment is complete. (This includes all required follow-up treatment).
   - The public health worker shall act and respond to any call for his/her services at any time.
   - The public health worker shall at all times maintain quality and prompt delivery of health services without discrimination.
   - The public health worker shall maintain a cordial professional relationship with his/her clients at all times.
2. To the Community
   - The public health worker shall fully cooperate with local authorities in the performance of his/her duties and responsibilities.
   - The public health worker shall assist in the administration of justice when called upon to provide expert opinion on health public safety and medico-legal cases.
   - The public health worker shall provide correct and accurate information on the risk and injury to health and to life existing in the community.
   - The public health worker shall take the initiative to organize the community to become self-reliant for their health and medical needs to maintain their health facilities and to mobilize resources for health.
   - The public health worker shall make himself/herself available to the community anytime his/her services are needed especially emergencies and calamities.

3. To Co-Workers
   - The public health worker shall maintain a harmonious relationship with his/her co-worker and shall avoid destructive competition with them.
   - The public health worker shall seek assistance through consultations with his/her colleagues whenever necessary, for the benefit of the client and the community.

4. To the Government
   - The public health worker shall ensure that services are delivered to the intended population.
   - The public health worker shall help improve and maintain a healthy population which contributes to socio-economic development of the country.
   - The public health worker shall pay all taxes due the government.
   - The public health worker shall wisely and efficiently use all equipment and facilities provided to him/her for an effective delivery of health services.
   - The public health worker shall strive as much as he/she can about the programs of the government especially those related to health, such that he/she is able to discuss them intelligently at any given time.
   - The public health worker shall strive for excellence in the performance of his/her duties and responsibilities as a public servant.

D. Penal Provision

Any person who shall willfully interfere with, restrain, or coerce any public health worker in the exercise of his rights or shall commit any act violating any of the provisions in the Revised Implementing Rules and Regulations of the Magna Carta of Public Health Workers, shall be punished, upon conviction, with a fine of not less than Twenty Thousand Pesos (P20,000.00) but not more than Forty Thousand Pesos (P40,000.00); or imprisonment of not more than one (1) year, or both at the discretion of the court.

If the offender is a public official, the court may impose the penalty of disqualification from office, in addition to the penalties provided in the preceding paragraph.
F. Code of Conduct and Ethical Standards for Military Personnel

The Code of Conduct and Ethical Standards for Military Personnel has been developed in line with the Republic Act no. 6713 – Code of Conduct and Ethical Standards for Public Officials and Employees and its Implementing Rules and Regulations (IRR).

The Armed Forces of the Philippines (APF) is composed of regular and citizen armed forces with three distinct armed major components which are the Philippine Army (PA), Philippine Air Force (PAF), and Philippine Navy (PN). According to the Article VII, Section 18 of the 1987 Philippine Constitution, the President shall be the Commander-in-Chief of all armed forces of the country and whenever it becomes necessary, may call out such armed forces to prevent or suppress lawless violence, invasion, or rebellion. The functions of the AFP include defense of State sovereignty, civil assistance, response to disasters and national emergencies, and national development. The following are the provisions of the Code of Conduct and Ethical Standards for Military Personnel.

A. AFP Core Values

1. Honor – A significant core value and military conduct which necessitates clear consciousness of personal dignity and self-worth
2. Service – This core value and military conduct demands unflinching loyalty to the Constitution which appeals obedience to the duly constituted political order and chain of command
3. Patriotism – A core value and military conduct which places loyalty to the Republic and the Filipino people at the fore, including but not limited to the appreciation and pride of country and the people

The following acts of disloyalty must be prevented:

- Treason
- Misprision of treason
- Espionage
- Mutiny or sedition
- Any form of cowardice, desertion, abandonment of post, duty, assignment without leave
- Contempt or disrespect by words or deeds towards the Commander-in-Chief and appropriate civilian authorities, superior, and non-superior officer, i.e., rudeness, by-passing chain of command, usurpation of authority

B. Concepts and Issues Affecting the AFP

1. Commitment to Democracy – Upholding democratic principles instilled in the Constitution and public accountability at all times
2. Commitment to Public Interest – Commitment to the interest of the public over one’s self-interest
3. Esprit de Corps – Consolidation and integration of the unit to develop camaraderie and commitment as a unified entity
4. Exercise of Religion and Family Life – Recognition of the free exercise of religion and spiritual beliefs among its members and acknowledgement of the role and obligations of AFP members to their families
5. Human Rights and Social Justice – Commitment to the protection of inalienable human rights and dignity that would promote social justice and not discriminate against anyone, irrespective of their ethnic group, gender, religion, etc.

6. Partisan Political Activity – Persistence as an apolitical organization and strict limitation of political activity to the exercise of the right to suffrage.

7. Responsiveness to the Public - Develop a positive working relationship with the media, public ‘netizens,’ aimed at broadening understanding on issues of national security and concerns and programs

8. Supremacy of Civilian Authority – Uphold the supremacy of civilian authority over the military.

9. Use of Armed Force – Exercise with utmost restraint and precaution the used of armed force to implement government policies and goals

10. War – As the constituent element in the defense of the state, the AFP shall always be ready to defend and suppress any external or internal threats to national security and sovereignty

C. AFP Core Traditions

The AFP maintains a strict adherence to a series of traditions and customs which serve as guide to the ethical and moral standards of the whole organization.

1. Tradition of Valor
2. Tradition of Duty
3. Tradition of Honor
4. Tradition of Solidarity
5. Tradition of Loyalty

D. AFP Military Customs

1. Courtesy Calls
2. Courtesy of the Post
3. Ceremony for Retiring Personnel
4. Flag Raising and Retreat Ceremonies
5. Happy Hour
6. Salute and Other Forms of Military Honor
7. Pipe, Trumpet, or Bugle Call
8. Rank Privilege or RHIP
9. Survivor Assistance to Bereaved Famility
10. Use of the Word ‘Sir’, ‘Madam’, or ‘Ma’am’
11. Visiting a Sick
12. Wearing of Decoration
13. Welcome/Farewell to Newly Assigned/Departing Officer
G. Philippine National Police (PNP) Ethical Doctrine

The Philippine National Police (PNP) Ethical Doctrine was developed in 1992 to provide guidelines on the moral and ethical standards to all PNP personnel and set the moral tone and norms of professional conduct in the police service. The PNP Director General issued a Memorandum on 11 February 2014 on the Propagation of the PNP ethical doctrine to all the PNP personnel.

A. PNP Core Values

The police service is a noble profession which demands from its members specialized knowledge and skills, as well as high standard of ethics and morality. Hence, the members of the Philippine National Police must adhere to and internalize the enduring core values of love of God, respect for authority, selfless love and service for people, sanctity of marriage and family life, responsible dominion and stewardship over material things, and truthfulness.

B. Standard of Police Professionalism

PNP members shall perform their duties with integrity, intelligence and competence in the application of specialized skill and technical knowledge with excellence and expertise.

C. Police Professional Conduct

1. Commitment to Democracy – Uniformed PNP members shall commit themselves to the democratic way of life and values and maintain the principle of public accountability. They shall, at all times, uphold the Constitution and be loyal to our country, people and organization above their loyalty to any person.
2. Commitment to Public Interest – PNP members shall always uphold public interest over and above personal interest. All government properties, resources and powers of their respective offices must be employed and used effectively, honestly and efficiently, particularly to avoid wastage of public funds and revenues. PNP members must avoid and prevent the “malversation” of human resources, government time, property, and funds.
3. Non-Partisanship – PNP Members shall provide services to everyone without discrimination regardless of party affiliation in accordance with existing laws and regulations.
4. Physical Fitness and Health – PNP members shall strive to be physically and mentally fit and in good health at all times. Toward this end, they shall undergo regular physical exercises and annual medical examination in any PNP hospital or medical facility, and actively participate in the Physical Fitness and Sports Development Program of the PNP.
5. Secrecy Discipline – PNP members shall guard the confidentiality of classified information against unauthorized disclosure, including confidential aspects of official business, special orders, communications and other documents, roster or any portion thereof of the PNP, contents of criminal records, identities of persons who may have given information to the police in confidence and other classified information on intelligence material.
6. Social Awareness – PNP members and their immediate family members shall be encouraged to actively get involved in religious, social and civic activities to enhance the image of the organization without affecting their official duties.
7. Non-Solicitation of Patronage – PNP members shall seek self-improvement through career development and shall not directly or indirectly solicit influence or recommendation form politicians, high-ranking government officials, prominent citizens, persons affiliated with civic or religious organizations with regard to their assignments, promotions, transfer or those of other members of the force, nor shall they initiate any petition to be prepared and presented by citizens in their behalf. Moreover, they shall advise their immediate relatives not to interfere in the activities of the police service particularly in the assignment and reassignment of personnel.
8. Proper Care and Use of Public Property – PNP members shall promote and maintain sense of responsibility in the protection, proper care and judicious disposition and use of public property issued for their official use or entrusted to their care and custody just like “a good father of the family”. When the Commander/Director is relieved from his post, all properties/equipment belonging to the government must be turned-over to the incoming. A committee for the purpose shall be proper. Hence, it is a taboo for
outgoing Commander/Director to detach, remove and bring home or to his new assignment properties which do not personally belong to him.

9. Respect for Human Rights – In the performance of duty, PNP members shall respect and protect human dignity and uphold the human rights of all persons. No member shall inflict, instigate or tolerate extra-judicial killings, arbitrary arrests, any act of torture or other cruel, inhuman or degrading treatment or punishment, and shall not invoke superior orders or exceptional circumstances such as a state-of-war, a threat to national security, internal political instability or any public emergency as a justification for committing such human rights violations.

10. Devotion to Duty – PNP members shall perform their duties with dedication, thoroughness, efficiency, enthusiasm, determination, and manifest concern for public welfare, and shall refrain from engaging in any activity which shall be in conflict with their duties as public servants.

11. Conservation of Natural Resources – PNP members shall help in the development and conservation of our natural resources for ecological balance and posterity as these are the inalienable heritage of our people.

12. Discipline – PNP members shall conduct themselves properly at all times keeping with the rules and regulations of the organization.

13. Loyalty – PNP members shall be loyal to the Constitution and the police service as manifested by their loyalty to their superiors, peers, and subordinates as well.

14. Obedience to Superiors – PNP members shall obey lawful orders and be courteous to superior officers and other appropriate authorities within the chain of command. They shall readily accept whenever they are assigned anywhere in the country. Therefore, it is taboo for any personnel to petition in court or in any public forum his assignment.

15. Command Responsibility – In accordance with the Doctrine on Command Responsibility, immediate Commanders/Directors shall be responsible for the effective supervision, control and direction of their personnel and shall see to it that all government resources shall be managed, expended or utilized in accordance with laws and regulations and safeguard against losses thru illegal or improper disposition.

D. Ethical Standards

Ethical standards shall refer to established and generally accepted moral values. Ethical acts to be observed are the following:

1. Morality – PNP members shall adhere to high standards of morality and decency and shall set good examples for others to follow. In no instance during their terms of office, among other things, shall they be involved as owners, operators, managers or investors in any house of ill-repute or illegal gambling den or other places devoted to vices, nor shall they patronize such places unless on official duty, and tolerate operations of such establishments in their respective areas of responsibilities. They shall be faithful to their lawfully wedded spouses.

2. Judicious Use of Authority – PNP members shall exercise proper and legitimate use of authority in the performance of duty.

3. Integrity – PNP members shall exercise proper and legitimate use of authority in the performance of duty.

4. Justice – PNP members shall strive constantly to respect the rights of others so that they can fulfill their duties and exercise their rights as human beings, parents, children, citizens, workers, leaders, or in other capacities and to see to it that others do likewise.

5. Humility – PNP members shall recognize the fact that they are public servants and not the masters of the people and towards this end, they shall perform their duties without arrogance. They shall also recognize their own inadequacies, inabilities and limitations as individuals and perform their duties without attracting attention or expecting the applause of others.

6. Orderliness – PNP members shall follow logical procedures in accomplishing tasks assigned to them to minimize waste in the use of time, money and effort.

7. Perseverance – Once a decision is made, PNP members shall take legitimate means to achieve the goal even in the face of internal or external difficulties, and despite anything which might weaken their resolve in the course of time.

E. Police Customs on Courtesy

1. Salute – Salute is the usual greeting rendered by uniformed members upon meeting and recognizing person entitled to a salute.
2. Salute to National Color and Standard – Members stand at attention and salute the national color and standard as it pass by them or when the national color is raised or lowered during ceremonies.

3. Address/Title – Junior in rank address senior members who are entitled to salute with the word “Sir” or “Ma’am”. All Police Commissioned Officers shall be addressed sir or ma’am by Police Non-Commissioned Officers and Non-Uniformed Personnel.

4. Courtesy Calls – The following are the customs on courtesy calls:
   a. Courtesy Call of Newly Assigned/Appointed Member – PNP members who are newly appointed or assigned in a unit or command call on the chief of the unit or command and other key personnel as a matter of courtesy, as well as for accounting, orientation and other purposes.
   b. Christmas Call – PNP members pay a Christmas Call on their local executives in their respective area of responsibility.
   c. New Year’s Call – PNP members pay a New Year’s call on their commanders and/or key officials in their respective area of responsibility.
   d. Promotion Call – Newly promoted PNP members call on their unit head. On this occasion, they are usually given due recognition and congratulations by their peers for such deserved accomplishment.
   e. Exit Call – PNP members pay an Exit Call on their superiors in the unit or command when relieved or reassigned out of the said unit or command.
   f. Courtesy of the Post – The host unit extends hospitality to visiting personnel who pay respect to the command or unit.
   g. Rank Has-Its-Own Privilege (RHIP) – PNP members recognize the practice that different ranks carry with them corresponding privileges.

F. Police Customs on Ceremonies

The following are police customs on ceremonies:

1. Flag Raising Ceremony – The PNP members honor the flag by hoisting it and singing the National Anthem before the start of the official days’ work.
2. Flag Lowering Ceremony – At the end of the official days’ work, the PNP members pause for a moment to salute the lowering of the flag.
3. Half-Mast – The flag is raised at half-mast in deference to deceased uniformed members of the command.
4. Funeral Service and Honors – Departed uniformed members, retirees, war veterans or former PC/INP members are given vigil, necrological services and graveside honors as a gesture of farewell.
5. Ceremony Tendered to Retirees – In recognition of their long, faithful and honorable service to the PNP, a testimonial activity shall be tendered in their honor.
6. Honor Ceremony – Arrival and departure honor ceremonies are rendered to visiting dignitaries, VIPs PNP Officers with the grade of Chief Superintendent and above and AFP officers of equivalent grade. Unless waived.
7. Turn Over Ceremony – The relinquishment and assumption of command or key position is publicly announced in a Turnover Ceremony by the outgoing and incoming officers in the presence of the immediate superior or his representative. Outgoing Commander/Director should not leave his post without proper turnover. Turnover includes turnover of properties/equipment, human and material resources.
8. Wedding Ceremony – During marriage of PNP members, a ceremony is conducted with participants in uniform and swords drawn.
9. Anniversary – The birth or institutional establishment of a command or unit is commemorated in an Anniversary Ceremony.

G. Police Customs on Social Decorum

1. Proper Attire – PNP members always wear appropriate and proper attire in conformity with the occasion.
2. Table Manners – PNP members observe table etiquette at all times.
3. Social Graces – PNP members conduct themselves properly in dealing with people during social functions.
4. Uniform/Appearance – The public looks upon a PNP member as distinctively a man among men. It is a welcome sight when PNP members wear their uniform properly wherever they may be. Bulging stomach is a taboo in the uniformed service. Since disciplined PNP members are best exemplified by those who are neat in appearance and wearing the prescribed uniform, they must therefore observe the following:
a. Wearing of prescribed uniform
   b. Adherence to haircut prescribed by rules and regulations.

5. Manner of Walking – Every PNP member is expected to walk with pride and dignity.

H. Tradition

1. Spiritual Belief – The PNP members are traditionally religious and God-loving person. They attend religious services together with the members of their family.
2. Valor – History attests that the Filipino law enforcers have exemplified the tradition of valor in defending the country from aggression and oppression. They sacrificed their limbs and lives for the sake of their countrymen whom they have pledges to serve.
3. Patriotism – The PNP members are traditionally patriotic by nature. They manifest their love of country with a pledge of allegiance to the flag and a vow to defend the Constitution.
4. Discipline – The discipline of PNP members is manifested by instinctive obedience to lawful orders and thorough and spontaneous actions towards attainment of organizational objectives guided by moral, ethical, and legal norms.
5. Gentlemanliness – PNP members are upright in character, gentle in manners, dignified in appearance, and sincere in their concern to fellowmen.
6. Word of Honor – The PNP members' word is their bond. They stand by and commit to uphold it.
7. Duty – PNP members have historically exemplified themselves as dedicated public servants who perform their tasks with a deep sense of responsibility and self-sacrifice. They shall readily accept assignment anywhere in the country.
8. Loyalty – PNP members are traditionally loyal to the organization, country and people as borne by history and practice.
9. Camaraderie – The binding spirit that enhances teamwork and cooperation in the police organization, extending to the people they serve is manifested by the PNP members' deep commitment and concern for one another.

H. Screening Form for Potential Environmental and Social Risk

This form is to be used by DOH to screen for the potential environmental and social risks and impacts of specific project activities. It will help the BIHC identify the relevant Environmental and Social Standards (ESS), establishing an appropriate E&S risk rating for these activities and specifying the type of environmental and social assessment required (if any), E&S risk management measures and specific instruments if required (e.g. ESMP/ECOP, SEP, LMP). Use of this form will allow DOH to form an initial view of the potential risks and impacts. It is not a substitute for specific E&S assessments or specific mitigation plans, if needed.

The screening form will be used both for participating health facilities benefiting from the project (e.g. receiving equipment and PPE) and for health facilities that will involve civil works. Participating health facilities that will not involve civil works will follow the guidance and requirements of the ESMF, for instance concerning health care waste management. If they are located in areas with indigenous peoples additional efforts will be made to engage with them and provide additional measures as described in the ESMF. The use of security personnel will also be assessed and addressed as needed.

Annex E provides a template for an ESMP that will be prepared for project activities that include civil works. It also provides standards Environmental and Social Codes of Practice for various project activities.
A note on *Considerations and Tools for E&S Screening and Risk Rating* is included in this Annex to assist the process.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Location</th>
<th>Health Care Facility</th>
<th>Estimated Investment</th>
<th>Start/Completion Date</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Questions</th>
<th>Answer</th>
<th>ESS relevance</th>
<th>Due diligence / Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the activity include any of those in the negative list?</td>
<td></td>
<td></td>
<td>If yes, activity is not eligible</td>
</tr>
<tr>
<td>Does the project activity involve civil works inside the compound of the healthcare facilities including new construction, expansion, upgrading or rehabilitation of healthcare facilities and/or waste management facilities?</td>
<td></td>
<td>ESS1</td>
<td>If yes, prepare ESMP or ECOP</td>
</tr>
<tr>
<td>Does the project activity involve land acquisition and/or restrictions on land use?</td>
<td></td>
<td>ESS5</td>
<td>If yes, activity is not eligible</td>
</tr>
<tr>
<td>Does the project activity involve acquisition of assets for quarantine, isolation or medical treatment purposes?</td>
<td></td>
<td>ESS5</td>
<td>If yes, activity is not eligible</td>
</tr>
<tr>
<td>Is the local health facility associated with any external waste management facilities such as a sanitary landfill, incinerator, or wastewater treatment plant for healthcare waste disposal?</td>
<td></td>
<td>ESS3</td>
<td>In both cases (Y/N), prepare ESMP or ECOP (scope and substance will depend on risks)</td>
</tr>
<tr>
<td>Is there a sound set of practices, protocols, procedures and institutional capacity in place for healthcare facility infection control and healthcare waste management?</td>
<td></td>
<td>ESS1</td>
<td>In both cases, prepare ESMP or ECOP (scope and substance will depend on risks)</td>
</tr>
<tr>
<td>Question</td>
<td>ESS Code(s)</td>
<td>Response</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Does the local health facility have an adequate system in place (capacity, processes and management) to address healthcare waste?</td>
<td>ESS3</td>
<td>In both cases, prepare ESMP or ECOP (scope and substance will depend on risks)</td>
<td></td>
</tr>
<tr>
<td>Does the project activity involve recruitment of workers including direct, contracted and/or community workers?</td>
<td>ESS2</td>
<td>If yes, prepare LMP and observe SEP</td>
<td></td>
</tr>
<tr>
<td>Does the local health facility have appropriate OHS procedures in place, and an adequate supply of PPE (where necessary)?</td>
<td>ESS2</td>
<td>In both cases, prepare LMP, ESMP</td>
<td></td>
</tr>
<tr>
<td>Does the project activity involve transboundary transportation (including Potentially infected specimens may be transported from healthcare facilities to testing laboratories, and transboundary) of specimen, samples, infectious and hazardous materials?</td>
<td>ESS3</td>
<td>If yes, prepare LMP, ESMP</td>
<td></td>
</tr>
<tr>
<td>Does the project activity involve use of security or military personnel during construction and/or operation of healthcare facilities and related activities including deployment of COVID-19 vaccines?</td>
<td>ESS2, ESS4</td>
<td>If yes, prepare Assessment of Risks, Code of Conduct, Training and report any incidents base on WB incident categorization: indicative, serious, severe. Severe incidents need to be reported to the WB within 48 hours.</td>
<td></td>
</tr>
<tr>
<td>Is the project activity located within or in the vicinity of any ecologically sensitive areas that will cause to generate significant impacts?</td>
<td>ESS6</td>
<td>If yes, activity is not eligible</td>
<td></td>
</tr>
</tbody>
</table>
Are there any indigenous groups (meeting specified ESS7 criteria) present in the subproject area and are they likely to be affected by the proposed project activity negatively or positively?

| 
| --- |
| **ESS7** |
| If yes, observe SEP provisions. Meaningful consultations with IP community and traditional health practitioners, coordination with traditional health practitioners |

Is the project activity located within or in the vicinity of any known cultural heritage sites that will cause the generation of significant impacts?

| 
| --- |
| **ESS8** |
| If yes, activity is not eligible |

Does the project area present considerable Gender-Based Violence (GBV) and Sexual Exploitation and Abuse (SEA) risk?

| 
| --- |
| **ESS1, ESS2, ESS4** |
| If yes, prepare Code of Conduct and Training |

---

**Potential Subproject Site Screening Checklist: Environmental Site Risk Assessment**

**Instruction:** As part of environmental screening, vulnerability of the proposed subproject site as well as the communities around it to specific environmental hazards will be assessed. A risk-screening template is shown below which may be used to evaluate the existing condition of the areas.

<table>
<thead>
<tr>
<th>Location/Area</th>
<th>Date Inspected</th>
<th>Contact Person</th>
<th>Inspected by</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Land Use and Classification of the Area:**

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Result of Screening Based on Hazard and Vulnerability Map (Refer to PSR)</th>
<th>Information Required for Hazard Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None</td>
<td>Low Risk</td>
</tr>
<tr>
<td>Earthquakes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquefaction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rain-Induced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Landslides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hazard Type</td>
<td>Map Details</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Ground Shaking</td>
<td>Ground Shaking Potential Map (PHIVOLCS)</td>
<td></td>
</tr>
<tr>
<td>Ground Rupture</td>
<td>Fault line maps (PHIVOLCS)</td>
<td></td>
</tr>
<tr>
<td>Tsunami</td>
<td>Tsunami Hazard Map (PHIVOLCS)</td>
<td></td>
</tr>
<tr>
<td>Storm Surges</td>
<td>Storm surges hazard maps (MGB)</td>
<td></td>
</tr>
<tr>
<td>Typhoons</td>
<td>Historical typhoon that hit the area (PAGASA)</td>
<td></td>
</tr>
<tr>
<td>Flooding</td>
<td>Flood susceptibility map (Mines and Geoscience Bureau)</td>
<td></td>
</tr>
</tbody>
</table>
Environmental and Social Due Diligence for an Existing Cold Chain Facility

**Instruction:** Below is the checklist of required documents that will be needed in conducting the environmental and social due diligence for an existing/active cold chain facility site which will be proposed for inclusion as a subproject. The applicable documents will be reviewed to check the existing environmental and social issues/risks at the site.

<table>
<thead>
<tr>
<th>Location/Area</th>
<th>Date Inspected</th>
<th>Contact Person</th>
<th>Inspected by</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Information/Document Requirement</th>
<th>Specifics</th>
<th>Observations/ Remarks (Tick ☐, when completed)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A. Information on Cold Chain Facility/System</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 1. **Description of the cold chain facility/system** | • Describe the cold chain system/management involved  
• Indicate process and technology used and the type of refrigerant used. | ☐ |
| 2. **Products stored** | • Determine all the type of products stored | ☐ |
| 3. **Refrigerants Used** | • Volume, frequency of delivery, consumption  
• Permits | |
| 4. **Location** | • Identify specific address | ☐ |
| **B.1 Environmental Aspects** | | |
| 1. **Existing management plans** | • Review the project’s environmental management plan (EMP) and environmental monitoring plan (EMoP) | ☐ |
| 2. **Pollution control system** | • Describe the pollution prevention and control features of the site (water pollution, air pollution, solid and hazardous wastes)  
• Indicate equipment installed with specifications (if, any) | ☐ |
| 3. **Environmental and socio-economic benefit of the project** | • Indicate and quantify anticipated benefits of the project to the environment and surrounding communities (i.e., ODS potentials) | ☐ |
| 4. **Personnel protection equipment** | • Indicate existing personnel protective equipment used by miners | ☐ |
| 5. **Training** | • List any formal/informal training of the workers | ☐ |
| 6. Proper Waste Management Plan | • Review if there is an existing method/procedure on waste handling, treatment and disposal | □ |

**B.2 Social Aspects**

| 1. Social safeguards documentation | • Indicate the status of ownership of the subproject area | □ |
| 2. Cultural property screening | • Are there or were there cultural, heritage, historical sites affected by the activities? | □ |
| 3. Indigenous people screening | • Are there IPs directly and indirectly affected by the project? • If there are IPs directly affected, review if there is an existing IP development plan consistent with the requirements of NCIP | □ |
| 4. Gender and Development | • Indicate number of women, PWD and children directly affected by the project | □ |

**B.3 Proper Management Plan of Hazardous Waste**

| 1. Storage Management Plan | • Review the plan for the storage for refrigerants | □ |
| 2. Contingency Plan | • Review if there is a contingency plan for accidental spills or spillage | □ |

**C. Screening of Permits**

| 1. Certificate of Accreditation from DA | • Indicate Validity | □ |
| 2. TSD Permit (if there is a formal TSD facility) | • Indicate TSD Permit No. and validity | □ |
| 3. Permit to Operate Air Pollution Control Devices | • This P/O will be required for generators exceeding the cut-off for exemptions. • Indicate Validity | □ |
| 4. Hazardous waste registration ID | • When the facility generates hazardous wastes (i.e., used oil), a HW registration ID must be secured from the EMB regional office • Provide ID No. and validity | □ |
| 5. FPIC if applicable | • This will be required if the proposed projects area is in ancestral domain. | □ |
| 6. Discharge Permit | • Indicate validity of the permit • Indicate location and classification of discharging body of water | □ |
INFECTION CONTROL: CONSIDERATIONS AND TOOLS TO ASSIST IN E&S SCREENING AND RISK RATING:

In the context of global COVID-19 outbreak, this project will adopt a containment strategy that includes extensive testing, quarantine, isolation and treatment either in a medical facility or at home.

This COVID-19 response project will include the activities below. Details are found in Annex I.

- construction of and/or operational support to medical laboratories, quarantine, and isolation centers at multiple locations and in different forms, and infection treatment centers in existing healthcare facilities
- procurement and delivery of medical supplies, equipment and materials, such as reagents, chemicals, and Personal Protective Equipment (PPEs)
- transportation of potentially infected specimens from healthcare facilities to testing laboratories
- construction, expansion or enhancing healthcare waste and wastewater facilities
- training of medical workers and volunteers
- community engagement and communication

1. Screening E&S Risks of Medical laboratories

This project will include capacity building and operational support to existing medical laboratories. It is important that such laboratories put in place procedures relevant to appropriate biosafety practices. WHO advises that non-propagative diagnostic work can be conducted in a Biosafety Level 2 (BSL-2) laboratory, while propagative work should be conducted at a BSL-3 laboratory. Patient specimens should be transported as Category B infectious substance (UN3373), while viral cultures or isolates should be transported as Category A “Infectious substance, affecting humans” (UN2814). The process for assessing the biosafety level of a medical laboratory (including management of the laboratory operations and the transportation of specimens) should consider both biosafety and general safety risks. OHS of workers in the laboratory and potential community exposure to the virus should be considered.
The following documents provide further guidance on screening of the E&S risks associated with a medical laboratory. They also provide information for assessing and managing the risks.

- WHO; Prioritized Laboratory Testing Strategy According to 4Cs Transmission Scenarios
- WHO COVID-19 Technical Guidance: Laboratory testing for 2019-nCoV in humans:
- WHO Laboratory Biosafety Manual, 3rd edition
- US CDC, EPA, DOT, et al; Managing Solid Waste Contaminated with a Category A Infectious Substance (August 2019)

2. Screening E&S Risks of Quarantine and Isolation Centers

According to WHO:

- **Quarantine** is the restriction of activities of or the separation of persons *who are not ill but who may have been exposed* to an infectious agent or disease, with the objective of monitoring their symptoms and ensuring the early detection of cases
- **Isolation** is the separation of *ill or infected persons* from others to prevent the spread of infection or contamination.

This project will include construction, renovation and equipping of quarantine and isolation centers at Point of Entry (POE), in urban and in remote areas. There may also be circumstances where tents are used for quarantine or isolation. Public or private facilities such as a stadium or hotel may also be acquired for this purpose.

In screening for E&S risks associated with quarantine and isolation, the following may be considered:

- contextual risks such as conflicts and presence or influx of refugees
- construction and decommissioning related risks
- land or asset acquisition
- use of security personnel or military forces
- availability of minimum requirements of food, fuel, water, hygiene
- whether infection prevention and control, and monitoring of quarantined persons can be carried out effectively
- whether adequate systems are in place for waste and wastewater management

The following documents provide further guidance regarding quarantine of persons.

- WHO; Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19)
• WHO; Key considerations for repatriation and quarantine of travelers in relation to the outbreak of novel coronavirus 2019-nCoV

• WHO; Preparedness, prevention and control of coronavirus disease (COVID-19) for refugees and migrants in non-camp settings

3. SCREENING E&S RISKS OF TREATMENT CENTERS

WHO has published a manual that provides recommendations, technical guidance, standards and minimum requirements for setting up and operating severe acute respiratory infection (SARI) treatment centers in low- and middle-income countries and limited-resource settings, including the standards needed to repurpose an existing building into a SARI treatment center, and specifically for acute respiratory infections that have the potential for rapid spread and may cause epidemics or pandemics.

• WHO Severe Acute Respiratory Infections Treatment Centre
• WHO Covid-19 Technical Guidance: Infection prevention and control / WASH
• WBG EHS Guidelines for Healthcare Facilities

4. SCREENING E&S RISKS RELATING TO LABOR AND WORKING CONDITIONS

A COVID-19 project may include different types of workers. In addition to regular medical workers and laboratory workers who would normally be classified as direct workers, the project may include contracted workers to carry out construction and community workers (such as community health volunteers) to provide clinical support, contact tracing, and data collection, etc. The size of the workforce engaged could be considerable. Risks for such a workforce will range from occupational health and safety to types of contracts and terms and conditions of employment. Further details relevant to labor and working conditions for COVID-19 projects are discussed in the LMP section.
I. Environmental and Social Management Plan Template

I. Subproject Information

<table>
<thead>
<tr>
<th>Subproject Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subproject Location</td>
<td></td>
</tr>
<tr>
<td>Subproject Proponent</td>
<td></td>
</tr>
<tr>
<td>Estimated Investment</td>
<td></td>
</tr>
<tr>
<td>Start/Completion Date</td>
<td></td>
</tr>
</tbody>
</table>

II. Site/Location Description

Concisely describes the proposed location and its geographic, ecological, social, and temporal context including any offsite investments that may be required (e.g., access roads, water supply, etc.). Normally includes a map showing the location and project areas of influence.

III. ESMP Matrix

<table>
<thead>
<tr>
<th>Potential E&amp;S Risks and Impacts</th>
<th>Proposed Risk Mitigation Measures</th>
<th>Responsibility</th>
<th>Timeline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community Health and Safety</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legal issues of the construction</td>
<td>All legally required permits have been acquired for construction and/or rehabilitation. The public has been notified of the works through appropriate notification in the media and/or at publicly accessible sites (including the site of the works).</td>
<td>Contractor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Below is a sample of accomplished ESMP Matrix
| **Dust due to construction activities** | Demolition debris shall be kept in controlled area and sprayed with water mist to reduce debris dust.  
During pneumatic drilling/wall destruction, dust shall be suppressed by ongoing water spraying and/or installing dust screen enclosures at site.  
The surrounding environment (sidewalks, roads) shall be kept free of debris to minimize dust.  
During interior demolition, debris-chutes shall be used above the first floor | Contractor |
| **Road blockage/ heavier traffic due to construction activities.** | There will be no excessive idling of construction vehicles at sites.  
Allocation of designated areas for construction vehicles. | Contractor |
| **Increased community solid waste.** | There will be no open burning of construction/waste material at the site.  
The site will establish appropriate erosion and sediment control measures such as e.g. hay bales and / or silt fences to prevent sediment from moving off site and causing excessive turbidity in nearby streams and rivers.  
Waste collection and disposal pathways and sites will be identified for all major waste types expected from demolition and construction activities.  
Proper waste collection, storage, and disposal of wastes generated from construction activities.  
Construction waste will be collected and disposed properly by licensed collectors.  
Mineral construction and demolition wastes will be separated from general refuse, organic, liquid, and chemical wastes by on-site sorting and stored in appropriate containers. | Contractor |
| **Increased wastewater discharge.** | The approach to handling sanitary wastes and wastewater from building sites (installation or reconstruction) must be approved by the local authorities. | Contractor |
Before being discharged into receiving waters, effluents from individual wastewater systems must be treated in order to meet the minimal quality criteria set out by national guidelines on effluent quality and wastewater treatment.

| Noise from construction activities | Construction noise will be limited to restricted times agreed in the permit.  
During operations, the engine covers of generators, air compressors and other powered mechanical equipment shall be closed, and equipment placed as far away from residential areas as possible.  
Monitoring of new wastewater systems (before/after) will be carried out.  
Construction vehicles and machinery will be washed only in designated areas where runoff will not pollute natural surface water bodies. | Contractor |

| Community exposures to physical hazards (dust, noise, traffic) | Compliance of contractors to DOLE Department Order No. 198 (DO 198-18) (Implementing Rules of Republic Act No. 11058) |  |

| Fear, mistrust and resistance among the local community | Conduct of community consultations and open feedback loop for communities. | Contractor |

| Potential discrimination of marginalized groups, GBV, Sexual Exploitation and Abuse (SEA) and/or VAC | Law enforcement personnel must adhere to Code of Conduct (CoC), including fair treatment and non-discrimination | Contractor |

| Civil servants and outsourced staff/contractors may be involved in misconduct impacting women and children at local level. | Training on community interaction and GBV/VAC | Contractor, DOH |

| Occupational Health and Safety | | |

| Transfer of potentially infected specimens and exposure to contaminated working/construction area | Observance of biosafety practices.  
Patient specimens should be transported as Category B infectious substance (UN3373), while viral cultures or isolates should be transported as Category A “Infectious substance, affecting humans” (UN2814).  
Disinfection of area prior to construction. | RITM |

<p>| Exposure of workers and visitors as the | Designation of respective areas and re-routing scheme | RITM |</p>
<table>
<thead>
<tr>
<th>Construction activity might coincide with COVID-19 vaccination</th>
<th>Compliance to construction regulations.</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occupational, Health, and Safety (OHS) risks for project workers associated with the upgrading activities</td>
<td>All employers must develop an Occupational Health and Safety Program in accordance with DO 198-18 Section 12. All workers must undertake the Mandatory 8-hour Safety and Health Seminar for Workers (Section 3). Each workforce must have a qualified Safety Officer in accordance with DO 198 Section 14</td>
<td>Contractor</td>
</tr>
<tr>
<td>OHS risks related to the spread of the virus</td>
<td>Rational use of PPE. All workers involved with construction activities must follow basic hygiene procedures at all times to prevent the transmission of COVID-19. Conduct on-site awareness-raising activities to remind personnel about occupational exposures and safe practices. Practice of minimum public health standards. Practice of occupational Safety and Health Standards.</td>
<td>Contractor</td>
</tr>
<tr>
<td>Workers may be asked to work overtime</td>
<td>Provide OT pay. Consult with workers.</td>
<td>Contractor</td>
</tr>
<tr>
<td>Occupational health risks: Exposure to infectious waste (chemical and physical hazards)</td>
<td>Encourage hand hygiene (washing, preferably followed by disinfection). Use gloves for handling waste. Raise the awareness of staff about simple post exposure prophylaxis in the event of an occupational injury (e.g., needle-stick injury).</td>
<td>Contractor</td>
</tr>
<tr>
<td>Workers experiencing respiratory symptoms may fear not getting paid and continue to show up at work</td>
<td>All workers must be reassured that they will continue to get paid if they need to self-isolate if they are showing with COVID-19/respiratory symptoms. These provisions must be made including for contracted staff and are included in the Labor Management Procedures (LMP).</td>
<td>Contractor</td>
</tr>
<tr>
<td>Possibility of underaged workers</td>
<td>Ensure that all staff must be over 18 years and below 60 years old.</td>
<td>Contractor</td>
</tr>
</tbody>
</table>
### Sample ESMP for the Vaccine Deployment and Delivery

<table>
<thead>
<tr>
<th>Environmental and Social Risks</th>
<th>Mitigating Measures</th>
<th>Location</th>
<th>Timeline</th>
<th>Responsibility</th>
<th>Cost of Mitigation</th>
</tr>
</thead>
</table>
| **Accidental lock-in of employees in the cold storage facility** | • Only authorized and trained personnel can access the storage facility  
• Emergency exit is provided and operational  
• Install alarm system  
• Use buddy system and avoid people working in isolation | Project Site | Operation phase | Facility Owner  |                    |
| **Health hazards from prolonged exposure to cold temperatures** | • Wear PPEs  
• Risk training for the workers  
• Only authorized and trained personnel can access the storage facility  
• Regular health check-up | Project Site | Operation phase | Facility Owner  |                    |
| **Exposure to refrigerants due to accidental release during operation, maintenance and/or repair.** | • Wear PPEs  
• Provide proper training to workers  
• Regularly check equipment for possible leakage  
• Develop and implement SOP  
• Emergency plan  
• Proper ventilation | Project Site | Operation phase | Facility Owner  |                    |
| **Possible explosion due to accidental release of refrigerants during operation, maintenance and/or repair.** | • Regularly check equipment for possible leakage  
• Provide proper training to workers  
• Develop and implement SOP  
• Emergency plan  
• Proper ventilation | Project Site | Operation phase | Facility Owner  |                    |
| **Explosion and other fire hazards from equipment/vessel failure** | • Develop and implement of emergency preparedness and response plan.  
• Provision of fire safety equipment, water sprinkler system, fire exits, and other requirements of the Fire Code of the Philippines. | Project Site | Operation phase | Facility Owner  |                    |
<p>| <strong>Occupational health and safety hazards</strong> | • Only authorized and trained personnel can operate heavy equipment | Project Site | Operation phase | Facility Owner  |                    |</p>
<table>
<thead>
<tr>
<th><strong>ENVIRONMENTAL AND SOCIAL RISKS</strong></th>
<th><strong>MITIGATING MEASURES</strong></th>
<th><strong>LOCATION</strong></th>
<th><strong>TIMELINE</strong></th>
<th><strong>RESPONSIBILITY</strong></th>
<th><strong>COST OF MITIGATION</strong></th>
</tr>
</thead>
</table>
| FROM OPERATION OF HEAVY EQUIPMENT | • REGULAR MAINTENANCE OF EQUIPMENT  
• DEVELOP AND IMPLEMENT OCCUPATIONAL HEALTH AND SAFETY PROCEDURES | PROJECT SITE | OPERATION PHASE | FACILITY OWNER | |
| OCCUPATIONAL HEALTH AND SAFETY HAZARDS FROM STACKING OF PRODUCTS | • PROPER TRAINING OF WORKERS  
• DEVELOP AND IMPLEMENT BEST PRACTICES  
• PROVIDE VISUAL WARNINGS  
• ENSURE STORAGE RACKING SHELVES ARE DESIGNED AND MAINTAINED TO WITHSTAND SEISMIC ACTIVITY | PROJECT SITE | OPERATION PHASE | FACILITY OWNER | |
| OCCUPATIONAL HEALTH AND SAFETY HAZARDS FROM MANUAL HANDLING OF HEAVY OBJECTS | • PROPER TRAINING OF WORKERS  
• MINIMIZE THE NEED FOR LIFTING  
• USE BUDDY SYSTEM AND AVOID PEOPLE WORKING IN ISOLATION | PROJECT SITE | OPERATION PHASE | FACILITY OWNER | |
| POSSIBLE INJURIES FROM FALLING FROM HEIGHT | • ONLY AUTHORIZED AND TRAINED PERSONNEL CAN CONDUCT THE ACTIVITY  
• PROPER USE OF LADDERS  
• USE BUDDY SYSTEM AND AVOID PEOPLE WORKING IN ISOLATION | PROJECT SITE | OPERATION PHASE | FACILITY OWNER | |
| POSSIBLE INJURIES FROM SLIPS AND TRIPS | • OBSERVE GOOD HOUSEKEEPING PRACTICES AT ALL TIMES  
• USING SLIP-RESISTANT FLOOR SURFACES TO REDUCE SLIP HAZARDS | PROJECT SITE | OPERATION PHASE | FACILITY OWNER | |
| GENERATION OF SOLID WASTES | • IMPLEMENTATION OF SOLID WASTE MANAGEMENT PLAN.  
• SOLID WASTE MANAGEMENT PLAN WILL DEFINE STORAGE, COLLECTION, SEGREGATION, RECYCLING, REUSE AND DISPOSAL PROCEDURES FOR ALL TYPES OF WASTES GENERATED IN THE AREA | PROJECT SITE | OPERATION PHASE | FACILITY OWNER | |
| GENERATION OF HAZARDOUS WASTES | • PROPER HANDLING AND DISPOSAL OF HAZARDOUS WASTES.  
• ONLY HIRE DENR-REGISTERED HAZARDOUS WASTES TREATERS. | PROJECT SITE | OPERATION PHASE | FACILITY OWNER | |
<table>
<thead>
<tr>
<th><strong>ENVIRONMENTAL AND SOCIAL RISKS</strong></th>
<th><strong>MITIGATING MEASURES</strong></th>
<th><strong>LOCATION</strong></th>
<th><strong>TIMELINE</strong></th>
<th><strong>RESPONSIBILITY</strong></th>
<th><strong>COST OF MITIGATION</strong></th>
</tr>
</thead>
</table>
| **GENERATION OF DOMESTIC/PROCESS WASTEWATER** | • PROVISION OF WASTEWATER TREATMENT FACILITY  
• WASTEWATER MUST MEET THE REQUIRED EFFLUENT QUALITY PRIOR TO DISCHARGE | PROJECT SITE | OPERATION PHASE | FACILITY OWNER | ~ |

**IV. Attachments**

ECOPs*, ICWMP*, Contractor’s Personnel GRM, and LMP

*= not mandatory

**V. Review & Approval**

| **Prepared By:** ……………………………(Signature) | **Position:** ………………………… Date ……………………… |
| **Reviewed By:** ……………………………(Signature) | **Approved By:** …………………………(Signature) |
| **Position:** …………………………… Date ……………………… | **Position:** …………………………… Date ……………………… |
J. Environmental and Social Management Plan Monitoring Report Template

I. Subproject Information

<table>
<thead>
<tr>
<th>Subproject Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subproject Location</td>
<td></td>
</tr>
<tr>
<td>Subproject Proponent</td>
<td></td>
</tr>
<tr>
<td>Estimated Investment</td>
<td></td>
</tr>
<tr>
<td>Start/Completion Date</td>
<td></td>
</tr>
</tbody>
</table>

II. Site/Location Description

Concisely describes the proposed location and its geographic, ecological, social and temporal context including any offsite investments that may be required (e.g. access roads, water supply, etc.). Normally includes a map showing the location and project areas of influence.

III. ESMP Matrix

<table>
<thead>
<tr>
<th>Potential E&amp;S Risks and Impacts</th>
<th>Proposed Risk Mitigation Measures</th>
<th>Responsibility</th>
<th>Target Timeline</th>
<th>Budget</th>
<th>Status (Complied or Not)</th>
<th>Actual Timeline (Date Complied/to be Done)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IV. Attachments

ESMP, ECOPs*, ICWMP*, Contractor’s Personnel GRM, and LMP

*= not mandatory

V. Review & Approval

<table>
<thead>
<tr>
<th>Prepared By: .........................(Signature)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position: .....................................</td>
</tr>
<tr>
<td>Date ........................................</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviewed By: ............................(Signature)</th>
<th>Approved By: ............................(Signature)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position: .....................................</td>
<td>Position: .....................................</td>
</tr>
<tr>
<td>Date ........................................</td>
<td>Date ........................................</td>
</tr>
</tbody>
</table>

Page 242 of 278
CHECKLIST 1 Environmental and Social Codes of Practice – COVID 19 EXPOSURE AT HEALTH CARE FACILITY

Target: Health Care Workers/Health Care Facility Visitors/Construction Workers

**General Infection Prevention and Control**
- ✓ Procedures for entry into health care facilities, such as minimizing visitors and visitor hours, taking temperature checks and having separate area (including entry area) for patients presenting with COVID-19 symptoms/respiratory illness, who should be taken to a different area and given a face mask. All persons visiting hospitals should wash hands before entering and before leaving.
- ✓ Minimize contact between patients and other persons in the facility: health care professionals should be the only persons having contact with patients suspected of having COVID-19 and this should be restricted to essential personnel only (except in cases of young children or other persons requiring assistance, then a family member may be present but they must also be wearing PPE – at least gloves and mask – and adhering to protocols).
- ✓ Provide alcohol-based hand sanitizer (60-95% alcohol), tissues and facemasks in waiting rooms and patient rooms.

**Isolation and Treatment**
- ✓ Isolate patients as much as possible, separate from people presenting with COVID-19. People with COVID-19 should be separate from each other by curtains or in different rooms if possible. Only place together in the same room patients who are have all contracted COVID-19. People with COVID-19 must be separated at all times from other hospital patients and health and other staff. This means there must be dedicated toilet facilities (or bedpans), hand washing facilities, and medical equipment (stethoscope, blood pressure machine, etc.) for patients with COVID-19 only.
- ✓ Use of Personnel Protection Equipment (PPE) at all times for medical staff and cleaners as needed (particularly facemask, gowns, gloves, eye protection and potentially face shield) when in contact with someone who may have COVID-19.

**Staff Occupational Health and Safety**
- ✓ Immediate and ongoing training on the procedures to all categories of workers (lab technicians, doctors, nurses, cleaning staff, etc.) on use of PPE, personal hygiene and thorough disinfecting of surfaces on a regular basis (multiple times per day using a high-alcohol based cleaner to wipe down all surfaces and when COVID-19 patients are discharged; wash instruments with soap and water and then wipe down with high-alcohol based cleaner; dispose of rubbish by burning etc.) Put signage in hospital as a reminder.
- ✓ Make particular efforts to ensure that all staff (such as cleaners and those doing the washing) are able to understand these procedures and have access to the necessary PPE.
- ✓ Laboratories undertaking testing for COVID-19 virus should adhere strictly to appropriate biosafety practices and WHO guidelines on Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases.
- ✓ Labor personnel needs to be trained and acquainted with key provisions in Labor Management Plan (LMP), in particular Occupational Health and Safety (OHS) aspects.

**Sanitation and Waste Management**
- ✓ Ensure that the designs for medical facilities consider the collection, segregation and treatment of medical waste
- ✓ The treatment of healthcare wastes produced during the care of COVID-19 patients should be collected safely in designated containers and bags, treated and then safely dispose
- ✓ General cleaning strategies: (i) proceed from cleaner to dirtier areas to avoid spreading dirt and microorganisms; (ii) proceed from top areas to bottom areas to prevent dirt and microorganisms from dripping or falling down and contaminating already cleaned areas (for example clean mattress first, then clean bed legs); (iii) proceed in a methodical, systematic manner to avoid missing areas (for example, proceed from left to right or clockwise).
- ✓ Provide training to cleaning staff on these procedures, as well as on the use of PPE equipment, and put signage of reminders throughout health centers.

Hospitals/health centers will also need to develop procedures and facilities for handling dirty linen and contaminated clothing, and preparing and handling food. For instance, social distancing measures (people 2m apart) should be implemented for those preparing and serving food in hospitals, ensuring
thorough handwashing as per above guidelines, with reminders in kitchen and eating areas, and cooks/servers should wear masks.

REFERENCES
➢ WHO interim guidance on Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected;
➢ WHO technical brief water, sanitation, hygiene and waste management for COVID-19;
➢ WHO guidance on infection prevention and control at health care facilities (with a focus on settings with limited resources);
➢ WHO interim practical manual for improving infection prevention and control at the health facility;
➢ CDC Guidelines for isolation precautions: preventing transmissions of infectious agents in healthcare settings;
➢ CDC guidelines for environmental infection control in healthcare facilities
CHECKLIST  2 Environmental and Social Codes of Practice – COVID 19 WASTE MANAGEMENT PROCEDURES

Target: Health Care Workers/Health Care Facilities/Laboratories

General Instructions
✓ All health care waste produced during the care of COVID-19 patients must be considered as infectious waste and should be collected safely in designated containers and bags, treated and then safely disposed (WHO).
✓ Train the staffs who are assigned in handling and disposal of waste management
✓ Train staffs on how to put and remove PPE.
✓ Ensure necessary PPE (Gown, gloves, face mask, goggles or face shield, gumboots) is provided to all staffs.
✓ Ensure staff wear PPE when handling and disposing waste according to HCW guideline.

General Waste - Food waste, paper, disposable cups, plates, spoons etc
✓ Collect in black bag
✓ Close and tie when 2/3rd full
✓ Transfer the waste to a temporary storage point for general waste along a specified route at a fixed time point and store the waste separately at a fixed location
✓ Transport to landfill away from facility

Infectious Waste - Gown, gloves, apron, shoe cover, disposable items, mask etc
✓ Collect in small biohazard red bags
✓ Close, seal the bag with cable ties and tie lose when 2/3 full
✓ Transfer the waste to a temporary storage point for medical waste along a specified route at a fixed time point and store the waste separately at a fixed location
✓ Securely transfer out for incinerating
✓ Transport outcome as general waste

Sharps Waste
✓ Put in puncture proof plastic container
✓ Close the lid and seal the container when 2/3 full
✓ Put in the red bag and tie lose
✓ Transfer the waste to a temporary storage point for medical waste along a specified route at a fixed time point and store the waste separately at a fixed location
✓ Securely transfer out for incinerating or appropriate disposal

REFERENCES
➢ WHO interim guidance on Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected;
➢ WHO technical brief water, sanitation, hygiene and waste management for COVID-19;
➢ WHO guidance on infection prevention and control at health care facilities (with a focus on settings with limited resources);
➢ WHO interim practical manual for improving infection prevention and control at the health facility;
➢ CDC Guidelines for isolation precautions: preventing transmissions of infectious agents in healthcare settings;
➢ CDC guidelines for environmental infection control in healthcare facilities
CHECKLIST  3 Environmental and Social Codes of Practice – COVID 19 COMMUNITY AND SOCIAL INCLUSION

Target: General Population/Vulnerable Groups/

General Communication
✓ When developing communication materials it is important to ensure that they are clear and concise, and that they are in a format/language that is understandable to all people, in particular the most vulnerable. Messages should be clear and concise, focusing on hygiene measures (hand washing, coughing), what to do if suspect have COVID-19, as well as restrictions if applicable (for instance specific guidelines on social-distancing).
✓ Utilize appropriate media needs to be used (social media, radio, tv) plus engaging existing formal and informal public health and community-based networks (schools, healthcare service providers at local level, etc).
✓ Communication materials must also be clear about (i) how to avoid contracting COVID-19 (good hygiene measures); (ii) symptoms of COVID-19; (iii) what to do if suspect have COVID-19.
✓ Place signages in the project site/vicinity visible to the public informing on the construction activities and associated risks, e.g. falling debris.
✓ Identify trusted community groups (local influencers such as community leaders, religious leaders, health workers, community volunteers, celebrities) and local networks (such as women’s groups, youth groups, business groups, and traditional healers) that can help to disseminate messages. Define clear and easy mechanisms to disseminate messages and materials based on community questions and concerns
✓ A focus of information materials should be on women, as they tend to be the best venue of communication for children and the elderly in the household.
✓ RGC/MOH should consider having a dedicated hotline for people to call for questions and recommendations on what to do if they suspect they may have COVID-19.

Infection Prevention
✓ Information on how to protect oneself from COVID-19, the symptoms of COVID-19, where and how to get tested should be made available to everyone and ensure they are accessible to IPs, marginalized groups, those with disabilities, other vulnerable groups and the elderly, and in a manner that is culturally appropriate to the respective groups and specific needs.
✓ Promote large scale social and behaviour change. Introduce preventive community and individual health and hygiene practices with a focus on handwashing. Could include gifting of soap bars, distributed by commune authorities or District health officials.
✓ Workplaces should be encouraged to post and provide communication materials, in particular workplaces which may face a higher risk of COVID-19 spread, such as construction sites and factories. This may include social isolation measures in workplaces, separating people from each other (2m), opening spaces to allow for natural ventilation, providing hand sanitation facilities (soap/water or hand sanitizer), etc.

Stakeholder Engagement
✓ Stakeholder Engagement Plan (SEP) must use different communication methods.
✓ Stakeholder Engagement Plan (SEP) should ensure consultations with NGOs and other stakeholders that can provide recommendations on how to communicate information and develop Risk Communication and Community Engagement Plan (RCCE).

REFERENCES
| **Community Health and Safety** | ✓ The local construction and environment inspectorates and communities have been notified of upcoming activities  
| | ✓ The public has been notified of the works through appropriate notification in the media and/or at publicly accessible sites (including the site of the works) |
| **Worker Safety** | ✓ Designate Safety Officer/s.  
| | ✓ Access to sanitation facilities in the project site.  
| | ✓ Access to clean and safe transient quarters for workers allowing social distancing and with regular disinfection.  
| | ✓ Access to clean and safe drinking-water.  
| | ✓ Workers’ PPE will comply with international good practice (always hardhats, as needed masks and safety glasses, harnesses and safety boots) |
| **General Rehabilitation and/or Construction** | ✓ The Contractor formally agrees that all work will be carried out in a safe and disciplined manner designed to minimize impacts on neighboring residents and environment.  
| | ✓ All legally required permits have been acquired for construction and/or rehabilitation  
| | ✓ During interior demolition debris-chutes shall be used above the first floor  
| | ✓ Demolition debris shall be kept in controlled area and sprayed with water mist to reduce debris dust  
| | ✓ During pneumatic drilling/wall destruction dust shall be suppressed by ongoing water spraying and/or installing dust screen enclosures at site  
| | ✓ The surrounding environment (sidewalks, roads) shall be kept free of debris to minimize dust  
| | ✓ There will be no open burning of construction / waste material at the site  
| | ✓ There will be no excessive idling of construction vehicles at sites  
| | ✓ Construction noise will be limited to restricted times agreed to in the permit  
| | ✓ During operations the engine covers of generators, air compressors and other powered mechanical equipment shall be closed, and equipment placed as far away from residential areas as possible  
| | ✓ The site will establish appropriate erosion and sediment control measures such as e.g. hay bales and / or silt fences to prevent sediment from moving off site and causing excessive turbidity in nearby streams and rivers. |
| **Waste Management** | ✓ Waste collection and disposal pathways and sites will be identified for all major waste types expected from demolition and construction activities.  
| | ✓ Mineral construction and demolition wastes will be separated from general refuse, organic, liquid and chemical wastes by on-site sorting and stored in appropriate containers.  
| | ✓ Proper waste collection, storage, and disposal of wastes generated from construction activities.  
| | ✓ Construction waste will be collected and disposed properly by licensed collectors |
| **Wastewater Treatment** | ✓ The approach to handling sanitary wastes and wastewater from building sites (installation or reconstruction) must be approved by the local authorities  
| | ✓ Before being discharged into receiving waters, effluents from individual wastewater systems must be treated in order to meet the minimal quality criteria set out by national guidelines on effluent quality and wastewater treatment  
| | ✓ Monitoring of new wastewater systems (before/after) will be carried out  
<p>| | ✓ Construction vehicles and machinery will be washed only in designated areas where runoff will not pollute natural surface water bodies. |</p>
<table>
<thead>
<tr>
<th>REFERENCES</th>
</tr>
</thead>
<tbody>
<tr>
<td>➢ WHO technical brief <em>water, sanitation, hygiene and waste management for COVID-19</em>;</td>
</tr>
<tr>
<td>➢ WHO guidance on <em>infection prevention and control at health care facilities (with a focus on settings with limited resources)</em>;</td>
</tr>
</tbody>
</table>
L. Environmental Codes of Practice (ECOP) Monitoring Form Template

I. Subproject Information

<table>
<thead>
<tr>
<th>Subproject Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Subproject Location</td>
<td></td>
</tr>
<tr>
<td>Subproject Proponent</td>
<td></td>
</tr>
<tr>
<td>Estimated Investment</td>
<td></td>
</tr>
<tr>
<td>Start/Completion Date</td>
<td></td>
</tr>
</tbody>
</table>

II. Checklist Monitoring and Evaluation

Date of Accomplishing the Checklist:
_____________________________________________________

<table>
<thead>
<tr>
<th>Checklist</th>
<th>Items not Practiced/Complied</th>
<th>Gaps/ Barriers for Implementation of Item</th>
<th>Actions to be Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: COVID-19 Exposure at Health Care Facility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2: COVID-19 Waste Management Procedures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3: COVID-19 Community and Social Inclusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4: COVID-19 Small Scale Construction, Upgrades, Rehab, Expansion</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Are there any support needed from the DOH Project Team?
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________________________________________________________

III. Review & Approval

Prepared By: ..................................(Signature)
Position: ............................ Date .......................
M. Infection Control and Waste Management Plan (ICWMP)

1. Introduction

1.1 Describe the project context and components

1.2 Describe the targeted healthcare facility (HCF):

- Type: e.g. general hospital, clinics, inpatient/outpatient facility, medical laboratory, quarantine or isolation centers;

- **Special type of HCF in response to COVID-19:** E.g. existing assets may be acquired to hold yet-to-confirm cases for medical observation or isolation;

- Functions and requirement for the level infection control, e.g. biosafety levels;

- Location and associated facilities, including access, water supply, power supply;

- Capacity: beds

1.3 Describe the design requirements of the HCF, which may include specifications for general design and safety, separation of wards, heating, ventilation and air conditioning (HVAC), autoclave, and waste management facilities.

2. Infection Control and Waste Management

2.1 Overview of infection control and waste management in the HCF

- Type, source and volume of healthcare waste (HCW) generated in the HCF, including solid, liquid and air emissions (if significant)

- Classify and quantify the HCW (infectious waste, pathological waste, sharps, liquid and non-hazardous) following WBG EHS Guidelines for Healthcare Facilities and pertaining GIIP.

- **Given the infectious nature of the novel coronavirus, some wastes that are traditionally classified as non-hazardous may be considered hazardous. It's likely the volume of waste will increase considerably given the number of admitted patients during COVID-19 outbreak. Special attention should be given to the identification, classification and quantification of the healthcare wastes.**

- Describe the healthcare waste management system in the HCF, including material delivery, waste generation, handling, disinfection and sterilization, collection, storage, transport, and disposal and treatment works

- Provide a flow chart of waste streams in the HCF if available

- Describe applicable performance levels and/or standards
- Describe institutional arrangement, roles and responsibilities in the HCF for infection control and waste management

2.2 Management Measures

- Waste minimization, reuse and recycling: HCF should consider practices and procedures to minimize waste generation, without sacrificing patient hygiene and safety considerations.

- Delivery and storage of specimen, samples, reagents, pharmaceuticals and medical supplies: HCF should adopt practice and procedures to minimize risks associated with delivering, receiving and storage of hazardous medical goods.

- Waste segregation, packaging, color coding and labeling: HCF should strictly conduct waste segregation at the point of generation. Internationally adopted method for packaging, color coding and labeling the wastes should be followed.

- Onsite collection and transport: HCF should adopt practices and procedures to timely remove properly packaged and labelled wastes using designated trolleys/carts and routes. Disinfection of pertaining tools and spaces should be routinely conducted. Hygiene and safety of involved supporting medical workers such as cleaners should be ensured.

- Waste storage: A HCF should have multiple waste storage areas designed for different types of wastes. Their functions and sizes are determined at design stage. Proper maintenance and disinfection of the storage areas should be carried out. Existing reports suggest that during the COVID-19 outbreak, infectious wastes should be removed from HCF’s storage area for disposal within 24 hours.

- Onsite waste treatment and disposal (e.g. an incinerator): HCFs with their own waste incineration facilities installed onsite should practice due diligence to examine its technical adequacy, process capacity, performance record, and operator’s capacity. In case any gaps are discovered, corrective measures should be recommended. For new HCF financed by the project, waste disposal facilities should be integrated into the overall design and ESIA developed. Good design, operational practices and internationally adopted emission standards for healthcare waste incinerators can be found in pertaining EHS Guidelines and GIIP.

- Transportation and disposal at offsite waste management facilities: Not all HCF has adequate or well-performed incinerator onsite. Not all healthcare wastes are suitable for incineration. An onsite incinerator produces residuals after incineration. Hence offsite waste disposal facilities provided by local government or the private sector are probably needed. These offsite waste management facilities may include incinerators, hazardous wastes landfill. In the same vein, due diligence of such external waste management facilities should be conducted to examine its technical adequacy, process capacity, performance record, and operator’s capacity. In case any gaps are discovered, corrective measures should be recommended and agreed with the government or the private sector operators.

- Wastewater treatment: HCF wastewater is related to hazardous waste management practices. Proper waste segregation and handling as discussed above should be conducted to minimize entry of solid waste into the wastewater stream. In case wastewater is discharged into municipal
sewer sewerage system, the HCF should ensure that wastewater effluent comply with all applicable permits and standards, and the municipal wastewater treatment plant (WWTP) is capable of handling the type of effluent discharged. In cases where municipal sewage system is not in place, HCF should build and properly operate onsite primary and secondary wastewater treatment works, including disinfection. Residuals of the onsite wastewater treatment works, such as sludge, should be properly disposed of as well. There’re also cases where HCF wastewater is transported by trucks to a municipal wastewater treatment plant for treatment. Requirements on safe transportation, due diligence of WWTP in terms of its capacity and performance should be conducted.

3. Emergency Preparedness and Response

Emergency incidents occurring in a HCF may include spillage, occupational exposure to infectious materials or radiation, accidental releases of infectious or hazardous substances to the environment, medical equipment failure, failure of solid waste and wastewater treatment facilities, and fire. These emergency events are likely to seriously affect medical workers, communities, the HCF’s operation and the environment.

Thus, an Emergency Response Plan (ERP) that is commensurate with the risk levels is recommended to be developed. The key elements of an ERP are defined in ESS 4 Community Health and Safety (para. 21).

4. Institutional Arrangement and Capacity Building

A clearly defined institutional arrangement, roles and responsibilities should be included. A training plan with recurring training programs should be developed. The following aspects are recommended:

- Define roles and responsibilities along each link of the chain along the cradle-to-cradle infection control and waste management process;
- Ensure adequate and qualified staff are in place, including those in charge of infection control and biosafety and waste management facility operation.
- Stress the chief of a HCF takes overall responsibility for infection control and waste management;
- Involve all relevant departments in a HCF, and build an intra-departmental team to manage, coordinate and regularly review issues and performance;
- Establish an information management system to track and record the waste streams in HCF; and
- Capacity building and training should involve medical workers, waste management workers and cleaners. Third-party waste management service providers should be provided with relevant training as well.

5. Monitoring and Reporting

Many HCFs in developing countries face the challenge of inadequate monitoring and records of healthcare waste streams. HCF should establish an information management system to track and
record the waste streams from the point of generation, segregation, packaging, temporary storage, transport carts/vehicles, to treatment facilities. The HCF is encouraged to develop an IT based information management system should their technical and financial capacity allow.

As discussed above, the HCF chief takes overall responsibility, leads an intra-departmental team and regularly reviews issues and performance of the infection control and waste management practices in the HCF. Internal reporting and filing systems should be in place.

Externally, reporting should be conducted per government and World Bank requirements.
<table>
<thead>
<tr>
<th>Activities</th>
<th>Potential E&amp;S Issues and Risks</th>
<th>Proposed Mitigation Measures</th>
<th>Responsibilities</th>
<th>Timeline</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>General HCF operation – Environment</td>
<td>General wastes, wastewater and air emissions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General HCF operation – OHS issues</td>
<td>- Physical hazards;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Electrical and explosive hazards;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Fire;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Chemical use;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Ergonomic hazard;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Radioactive hazard.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCF operation - Infection control and waste management plan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waste minimization, reuse and recycling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delivery and storage of specimen, samples, reagents, pharmaceuticals and medical supplies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Storage and handling of specimen, samples, reagents, and infectious materials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waste segregation, packaging, color coding and labeling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onsite collection and transport</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waste storage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onsite waste treatment and disposal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waste transportation to and disposal in offsite treatment and disposal facilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCF operation – transboundary movement of specimen, samples, reagents, medical equipment, and infectious materials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Emergency events | Spillage;  
- Occupational exposure to infectious;  
- Exposure to radiation;  
- Accidental releases of infectious or hazardous substances to the environment;  
- Medical equipment failure;  
- Failure of solid waste and wastewater treatment facilities;  
- Fire;  
- Other emergent events | Emergency response plan |
| Operation of acquired assets for holding potential COVID-19 patients |  |
| To be expanded |  |
### N DENR- Accredited M501 and M503 Waste Transporters

<table>
<thead>
<tr>
<th>Region</th>
<th>Name of Transporter</th>
<th>Address</th>
<th>Contact No.</th>
<th>Email Address</th>
<th>Date of Expiration</th>
<th>Waste Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR</td>
<td>Cybertechnologies Co.</td>
<td>Km. 12, ACOP, Tublay, Benguet</td>
<td>0928-6898770; 0919-0017547</td>
<td><a href="mailto:yollycybertech@yahoo.com">yollycybertech@yahoo.com</a></td>
<td>16-Jan-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Edgardo Rivera Trading</td>
<td>2848 Int. 4 Lorenzo Dela Paz St., Barangay 839, Pandacan, Manila</td>
<td>(02) 748-4263</td>
<td><a href="mailto:riveraegay@gmail.com">riveraegay@gmail.com</a></td>
<td>02-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>EK2 Marketing</td>
<td>1151 Oliveros Cpd. F. Bautista St. Ugong, Valenzuela City</td>
<td>02-4428663</td>
<td><a href="mailto:ek2.eddieong@gmail.com">ek2.eddieong@gmail.com</a></td>
<td>17-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>RiveRainier General Merchandise</td>
<td>1121 A-2 New Antipolo Street, Tondo, Manila</td>
<td>353-6675</td>
<td><a href="mailto:riverainier@yahoo.com">riverainier@yahoo.com</a></td>
<td>02-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Eco Safe Hazmat Treatment Inc.</td>
<td>Lot 7 West Los Angeles Street, California Village, San Bartolome Novaliches, Quezon City</td>
<td>417-8888</td>
<td><a href="mailto:ecosafe_hazmat@yahoo.com">ecosafe_hazmat@yahoo.com</a></td>
<td>30-Jan-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>OASIS RECYCLING &amp; RECOVERY MANAGEMENT CORP.</td>
<td>Unit 305 Emerald Place Bldg. 604 Shaw Blvd., Kapitolyo, Pasig City / Garage Address: 3406-A Lubiran St., Bacooc, Sta. Mesa, Manila</td>
<td>(02) 358-7557</td>
<td><a href="mailto:oasisrrmc@gmail.com">oasisrrmc@gmail.com</a></td>
<td>02-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Mr. Trustbin Environmental and Maintenance Services</td>
<td>14 Maria Teresa St., Commonwealth, Quezon City; Garage Address: 483 Manotok Compound, Tullahan Road, Sta.Quiteria, Brgy. 162, District 1, Caloocan City</td>
<td>0977-0492567</td>
<td><a href="mailto:mrtrustbin@gmail.com">mrtrustbin@gmail.com</a></td>
<td>06-May-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Blue Sea Energy Technology Corp.</td>
<td>439 C3 Road, Kaunlaran Village, Caloocan City</td>
<td>282-5344</td>
<td><a href="mailto:info@blueseacompensations.com">info@blueseacompensations.com</a></td>
<td>09-Jan-21</td>
<td>M501</td>
</tr>
<tr>
<td>NCR</td>
<td>Marpila Trading</td>
<td>22-I Maysan Rd., Malinta, Valenzuela City</td>
<td>298-3582</td>
<td><a href="mailto:marpilatrdng02@gmail.com">marpilatrdng02@gmail.com</a></td>
<td>02-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>JM ECOTECH SOLUTIONS CO.</td>
<td>168 Gen. Luis St., Brgy. Kaybiga, Caloocan City</td>
<td>(02) 936-4632</td>
<td><a href="mailto:docs@jmcotech.com">docs@jmcotech.com</a>; <a href="mailto:sales@jmcotech.com">sales@jmcotech.com</a></td>
<td>30-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Name</td>
<td>Address</td>
<td>Phone</td>
<td>Email</td>
<td>Date</td>
<td>M503</td>
</tr>
<tr>
<td>-----</td>
<td>------</td>
<td>---------</td>
<td>-------</td>
<td>-------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>NCR</td>
<td>Adcan Petroleum Products, Inc.</td>
<td>144 F. Dulalia St., Lingunan, Valenzuela City</td>
<td>294-6764, 282-2358</td>
<td><a href="mailto:adcanpetroleumproducts@yahoo.com">adcanpetroleumproducts@yahoo.com</a></td>
<td>09-Jan-21</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Trame Oil &amp; Environmental Specialist, Inc.</td>
<td>L2 B2 Pearl Island Industrial Compound, Brgy. Punturin, Valenzuela City</td>
<td>02-9689575</td>
<td><a href="mailto:trameoil.environmental@gmail.com">trameoil.environmental@gmail.com</a></td>
<td>04-Mar-21</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Udenna Environmental Services, Inc.</td>
<td>4 Sta. Maria Drive, Sta. Maria Industrial Estate, Bagumbayan, Taguig City</td>
<td>(02) 551-7235</td>
<td><a href="mailto:adrian.borebor@udenna.ph">adrian.borebor@udenna.ph</a></td>
<td>13-Jun-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>NCR</td>
<td>HAZARD WASTE MANAGEMENT SERVICES</td>
<td>165 Isagani st. Rizal Village Alabang Muntinlupa City</td>
<td>7889339, 8420612</td>
<td><a href="mailto:hazardwaste2002@yahoo.com.ph">hazardwaste2002@yahoo.com.ph</a></td>
<td>16-Jan-21</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>A. Sevidal Trading</td>
<td>Block 1 Lot 12 Saint Urcising St., Saint Joseph Subd., Pulanglup Dos, Las Piñas City</td>
<td>874-0169, 872-5330, 874-0250</td>
<td><a href="mailto:asevidaltrading@gmail.com">asevidaltrading@gmail.com</a>; <a href="mailto:anastasia.sevidal@yahoo.com">anastasia.sevidal@yahoo.com</a></td>
<td>28-Nov-20</td>
<td>M503</td>
</tr>
<tr>
<td>NCR</td>
<td>Myra A. Osbuna Transport Services</td>
<td>No5 Puerto Azul St, Camella Homes 4, Poblacion, Muntinlupa City</td>
<td>850-3302</td>
<td><a href="mailto:obsuna.mao@yahoo.com.ph">obsuna.mao@yahoo.com.ph</a></td>
<td>12-Dec-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>I</td>
<td>Servo-Treat Philippines, Incorporated</td>
<td>Brgy. Pinmaludpod, Urdaneta City, Pangasinan</td>
<td>0917-8058448</td>
<td><a href="mailto:servotreat_phils@yahoo.com">servotreat_phils@yahoo.com</a></td>
<td>02-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>II</td>
<td>R2 Safewaste Management Services</td>
<td>Ipil St., District 1, Cauayan City, Isabela</td>
<td>0917-8469774</td>
<td><a href="mailto:r2sms@yahoo.com">r2sms@yahoo.com</a></td>
<td>30-Jan-21</td>
<td>M501</td>
</tr>
<tr>
<td>III</td>
<td>ADL Waste Management</td>
<td>Sitio Binasak, Brgy. Mabiga, Hermosa, Bataan 2111</td>
<td>(047) 250-0385</td>
<td><a href="mailto:adlwastemanagement@yahoo.com.ph">adlwastemanagement@yahoo.com.ph</a></td>
<td>17-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Envirocare Mgt. Precision, Inc.</td>
<td>53 C Mercado St., Poblacion, Guiguinto, Bulacan</td>
<td>(02) 242-9810 loc. 106</td>
<td><a href="mailto:info@envirocare.ph">info@envirocare.ph</a></td>
<td>17-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Aide Environmental Management</td>
<td>B8 L20 Ph 1 Pecsonville Subdivision, Brgy. T. Mangga, District 1, San Jose del Monte, Bulacan</td>
<td>(02) 504-5859</td>
<td><a href="mailto:aemanagement19@yahoo.com">aemanagement19@yahoo.com</a></td>
<td>02-Jul-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Fuelcycle Int’l. Co. Ltd.</td>
<td>Tibagan, Sta. Rosa II, Marilao, Bulacan</td>
<td>0926-0569203</td>
<td><a href="mailto:admin@fuelcycleph.com">admin@fuelcycleph.com</a></td>
<td>14-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Wacuman Incorporated</td>
<td>Sitio Tiakad, Brgy. San Mateo, Norzagaray, Bulacan</td>
<td>(02) 573-7710</td>
<td><a href="mailto:info_wacuman@yahoo.com">info_wacuman@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>JCZS TRADING</td>
<td>Warehouse 316, Brgy. Sulucan, Bocaue, Bulacan</td>
<td>(02) 261-4205</td>
<td><a href="mailto:litazafra@yahoo.com">litazafra@yahoo.com</a>; <a href="mailto:litazafra14@gmail.com">litazafra14@gmail.com</a></td>
<td>27-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Company Name</td>
<td>Address</td>
<td>Contact</td>
<td>Email</td>
<td>Date of Purchase/Issue</td>
<td>M501, M503</td>
</tr>
<tr>
<td>-----</td>
<td>--------------</td>
<td>---------</td>
<td>---------</td>
<td>-------</td>
<td>------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>III</td>
<td>ALL WASTE SERVICES, INC.</td>
<td>Km 32 McArthur Highway, Tuktukan, Guiguinto, Bulacan</td>
<td>(044) 794 2669, 794 2668</td>
<td><a href="mailto:pco@aws.ph">pco@aws.ph</a></td>
<td>12-Dec-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Far East Fuel Corporation</td>
<td>888 Purok 5, Irabagon St., Brgy. Anyatam, San Ildefonso, Bulacan</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>16-Jan-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Asia United Oil Industry Corp.</td>
<td>Muralla St., Iba, Meycauayan, Bulacan</td>
<td>(044) 764-9525/0926670-8114</td>
<td><a href="mailto:asiauoi@yahoo.com.ph">asiauoi@yahoo.com.ph</a></td>
<td>27-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Positive A Envirotech Specialist</td>
<td>#651 Tibagan Road, Brgy. Sta. Rosa II, Marilao, Bulacan</td>
<td>0915-8412353</td>
<td><a href="mailto:positivea.es@gmail.com">positivea.es@gmail.com</a></td>
<td>12-Feb-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>DCH Ecogreen Solutions</td>
<td>No. 29 R. Nicolas Sr. St., Poblacion, Sta. Maria, Bulacan</td>
<td>(044) 913-6193</td>
<td><a href="mailto:dch.ecogreensolutions@gmail.com">dch.ecogreensolutions@gmail.com</a></td>
<td>08-Nov-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Globaltec Waste Management, Inc.</td>
<td>9 Westmont Industrial Subdivision, Brgy. Loma De Gato, Marilao, Bulacan</td>
<td>0927-2781300; 0918-3337600</td>
<td><a href="mailto:gtwminc@gmail.com">gtwminc@gmail.com</a></td>
<td>27-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Safewaste Incorporated</td>
<td>Bldg. 9801 A-C DOST-Technology Resource Center, Mabalacat City, Pampanga</td>
<td>(045) 436-6008</td>
<td><a href="mailto:safewaste@ymail.com">safewaste@ymail.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Semirecycling Co., Inc.</td>
<td>Phase II Lot 1-A, CPIP, IES, M.A. Roxas Highway, Clark Freeport Zone, Pampanga</td>
<td>045-599-6953; 499-3150/1</td>
<td><a href="mailto:srci@semirecycling.com">srci@semirecycling.com</a></td>
<td>08-Nov-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>DoloMatrix Philippines, Inc.</td>
<td>Angeles Industrial Park, Inc. Calibutbut, Bacolor, Pampanga</td>
<td>(02) 671-4060, 671-5295</td>
<td><a href="mailto:pco@dolomatrix.com.ph">pco@dolomatrix.com.ph</a></td>
<td>08-Nov-20</td>
<td>M503</td>
</tr>
<tr>
<td>III</td>
<td>Unified Hazwaste Expert, Inc.</td>
<td>1-E-4 Brgy. Gandus Mexico, Pampanga</td>
<td>0917-8451140</td>
<td><a href="mailto:unifiedhazwaste@yahoo.com">unifiedhazwaste@yahoo.com</a></td>
<td>03-Mar-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Joechem Environmental Corporation</td>
<td>Brgy. Aranguren, Capas, Tarlac</td>
<td>(02) 281-3227; (045) 493-0474</td>
<td><a href="mailto:joechemenvironmental@gmail.com">joechemenvironmental@gmail.com</a>; <a href="mailto:pco.joechemenvironmental@gmail.com">pco.joechemenvironmental@gmail.com</a></td>
<td>02-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>III</td>
<td>Cleanway Environmental Management Solutions, Inc.</td>
<td>Barangay Cutcut II, Capas, Tarlac</td>
<td>9178677629</td>
<td><a href="mailto:dean.castaneda@cleanway.com.ph">dean.castaneda@cleanway.com.ph</a></td>
<td>01-Apr-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Company Name</td>
<td>Address Details</td>
<td>Phone Numbers</td>
<td>Email/Website</td>
<td>Date</td>
<td>Code</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>IV-A</td>
<td>Earthclean Environmental Management Corp.</td>
<td>T.M Kalaw St. Brgy. 3 Lipa City, Batangas; Garage Address: Purok Almasiga, Brgy. Inicbulan, Bauan, Batangas</td>
<td>(043) 302-1080; 706-6058</td>
<td><a href="mailto:earthclean.2014@yahoo.com">earthclean.2014@yahoo.com</a></td>
<td>06-May-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Sanikleen Laundry Corporation</td>
<td>Brgy. Pinagkawitan, Lipa City</td>
<td>(043) 756-5541</td>
<td><a href="mailto:sanikleen15@yahoo.com">sanikleen15@yahoo.com</a></td>
<td>03-Sep-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>258 Global Ventures, Inc.</td>
<td>Sitio Muzon, Brgy. Puting Kahoy, Silang, Cavite</td>
<td>(046) 404-3650</td>
<td><a href="mailto:258globalventures@gmail.com">258globalventures@gmail.com</a></td>
<td>22-Jan-21</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Dynamo Trucking &amp; Development Corporation</td>
<td>Brgy. Mambugan, Antipolo City, Rizal; Garage Address: Unit 307 J &amp; F Bldg. 2, V.V. Soliven Avenue 3, San Isidro, Cainta, Rizal</td>
<td>(02) 477-7613</td>
<td><a href="mailto:ddc_philippines@yahoo.com">ddc_philippines@yahoo.com</a></td>
<td>03-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Jen and Janette Junkshop</td>
<td>Brgy. Tinurik, Tanuan, Batangas</td>
<td>(043) 406-1598</td>
<td><a href="mailto:jhen.perilla_19@yahoo.com">jhen.perilla_19@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Solvtech Consultancy Resources</td>
<td>BIK 11 Lot 6A Phase 1 Sterling Technopark Maguyam,Silang Cavite</td>
<td>(02) 994-2241, 826-3285</td>
<td><a href="mailto:aav@navsolvtech.com">aav@navsolvtech.com</a>; <a href="mailto:navsolvtech@gmail.com">navsolvtech@gmail.com</a></td>
<td>13-Jun-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Green Eco Techwin, Inc. (Formerly Clean Echo Techwin, Inc.)</td>
<td>B2 L8 P2 Golden Gate Business Park Buenavista II General Trias Cavite</td>
<td>(046) 428-1846, 423-1846</td>
<td><a href="mailto:ad.cleanecho@gmail.com">ad.cleanecho@gmail.com</a>; <a href="mailto:orly.julian@yahoo.com">orly.julian@yahoo.com</a></td>
<td>24-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Waste and Resources Management, Inc.</td>
<td>Pineapple St., Sitio Pag-asa I, Brgy. Aguado, Trece Martires City, Cavite</td>
<td>(046) 419-1100</td>
<td><a href="mailto:lmcarino@warmphilippines.com">lmcarino@warmphilippines.com</a></td>
<td>20-Aug-20</td>
<td>M501</td>
</tr>
<tr>
<td>IV-A</td>
<td>Danvis Trading</td>
<td>Barangay Lambingan, Tanza, Cavite</td>
<td>(046) 450-2722</td>
<td><a href="mailto:danvistrading@yahoo.com">danvistrading@yahoo.com</a></td>
<td>18-Oct-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Red Stallion Trading</td>
<td>Alano Compound Brgy. Mabuhay, Carmona, Cavite</td>
<td>0977-853-3206</td>
<td><a href="mailto:redstalliontrading@yahoo.com">redstalliontrading@yahoo.com</a></td>
<td>02-Jul-20</td>
<td>M501, M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Jorm Trading Corporation</td>
<td>595 General Trias Drive, Tejero, General Trias, Cavite</td>
<td>(046) 437-8623; 509-4274</td>
<td><a href="mailto:jormtrading@yahoo.com">jormtrading@yahoo.com</a></td>
<td>07-Feb-21</td>
<td>M503</td>
</tr>
<tr>
<td>IV-A</td>
<td>Company Name</td>
<td>Address</td>
<td>Phone Number</td>
<td>Email Address</td>
<td>Date</td>
<td>M501, M503</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>----------------------------------------</td>
<td>---------</td>
<td>------------</td>
</tr>
<tr>
<td>VDGPEnterprises</td>
<td>10-A Tagaytay Sta. Rosa Road, Purok IV, Barangay Putting-Kahoy, Silang, Cavite City</td>
<td>(046) 404-6346</td>
<td><a href="mailto:vdgp@orangehub.com">vdgp@orangehub.com</a></td>
<td>17-Sep-20</td>
<td>M501, M503</td>
<td></td>
</tr>
<tr>
<td>Eco Care Trading and Waste Management Services (Formerly J.I.T TRADING, HAULING AND SORTING SERVICES)</td>
<td>#37, 38 Block 4, Sitio Manalo, Brgy. Sampaloc, Dasmariñas City, Cavite</td>
<td>046-5385113</td>
<td><a href="mailto:acpullon@yahoo.com">acpullon@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
<td></td>
</tr>
<tr>
<td>Blue Ocean General Merchandise</td>
<td>Block 4 Lot 6, Golden Gate Business Park I, Brgy. Buenavista II, General Trias, Cavite</td>
<td>(02) 243-3429</td>
<td><a href="mailto:blueocean.general@yahoo.com">blueocean.general@yahoo.com</a></td>
<td>01-Aug-20</td>
<td>M503</td>
<td></td>
</tr>
<tr>
<td>Ecoserv Environmental Technologies &amp; Services</td>
<td>Lot 2 Block 30, Zone 1, Bulihan, Silang, Cavite</td>
<td>(046) 424-0865</td>
<td><a href="mailto:francis.phillip.armena@gmail.com">francis.phillip.armena@gmail.com</a></td>
<td>18-Oct-20</td>
<td>M503</td>
<td></td>
</tr>
<tr>
<td>AUGUST-10 ENTERPRISE CO</td>
<td>192 Brgy. Sto. Tomas Binan Laguna</td>
<td>(049) 512-6421/542-9693</td>
<td><a href="mailto:august_10_enterprises@yahoo.com">august_10_enterprises@yahoo.com</a></td>
<td>07-May-21</td>
<td>M503</td>
<td></td>
</tr>
<tr>
<td>Maritran Recycler, Inc</td>
<td>Unit 3 D.M. Ragasa Warehouse, #763 National Highway, Parian Calamba City, Laguna</td>
<td>(049) 545-9055, 545-9056</td>
<td><a href="mailto:meselag@pltdsl.net">meselag@pltdsl.net</a>; <a href="mailto:norie_genove@maritranrecycler.com">norie_genove@maritranrecycler.com</a></td>
<td>03-Dec-20</td>
<td>M503</td>
<td></td>
</tr>
<tr>
<td>Riffa Antonio Gen. Merchandise &amp; Services</td>
<td>Blk. 5A2 Lt-16C, Juana 6 Subdivision, Gabriel St., San Francisco, Biñan, Laguna</td>
<td>(02) 664-4024/529-2157</td>
<td><a href="mailto:benjie.razalan@yahoo.com">benjie.razalan@yahoo.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
<td></td>
</tr>
<tr>
<td>Something Nice Environmental Corp.</td>
<td>No. 67 Purok 1, Brgy. Milagros, Calamba, Laguna</td>
<td>(049) 511-8245</td>
<td><a href="mailto:sales@sne-corp.com">sales@sne-corp.com</a></td>
<td>02-Dec-20</td>
<td>M501, M503</td>
<td></td>
</tr>
<tr>
<td>F.R.O.A. Enterprises</td>
<td>0190 Unit A, Purok III, Brgy. Timbao, Timbao, Biñan City, Laguna</td>
<td>0908-8155021; 0917-3044053</td>
<td><a href="mailto:fropaenterprises@gmail.com">fropaenterprises@gmail.com</a></td>
<td>07-Jul-20</td>
<td>M503</td>
<td></td>
</tr>
<tr>
<td>Tritek Reverse Logistics Corporation</td>
<td>7270 Magsaysay Rd., San Antonio, San Pedro, Laguna</td>
<td>(02) 869-8404</td>
<td><a href="mailto:hsbarawid@tritek.com.ph">hsbarawid@tritek.com.ph</a></td>
<td>02-Jul-20</td>
<td>M503</td>
<td></td>
</tr>
<tr>
<td>RV CABRERA TRADING</td>
<td>1490 Espiritu Compound, Pooc, Sta. Rosa City, Laguna</td>
<td>530-2581</td>
<td><a href="mailto:rvcabreratrading@yahoo.com">rvcabreratrading@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
<td></td>
</tr>
<tr>
<td>AR-BI ABERGOS ENTERPRISES</td>
<td>Block 9 Lot 1 Brgy. Don Jose, Sta. Rosa City, Laguna</td>
<td>0918-3037066; 0927-8851877</td>
<td><a href="mailto:arbiabergos@yahoo.com">arbiabergos@yahoo.com</a></td>
<td>02-Aug-20</td>
<td>M503</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Name</td>
<td>Address</td>
<td>Phone</td>
<td>Email</td>
<td>Date</td>
<td>M501,</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>--------------------------------------------</td>
<td>------------</td>
<td>-------</td>
</tr>
<tr>
<td>IV-A</td>
<td>Greensouth Waste Transport Services (Formerly Christian and Aileen's Trading)</td>
<td>329 Barangay Talangan Nagcarlan, Laguna</td>
<td>(049) 559-1615</td>
<td><a href="mailto:greensouth.wts@yahoo.com">greensouth.wts@yahoo.com</a></td>
<td>29-Jan-21</td>
<td></td>
</tr>
<tr>
<td>IV-A</td>
<td>CleanHAUL Environmental Services Inc.</td>
<td>Lot 31, 32 &amp; 33 Block 1 Pines Street. Pinesville, Brgy. Dolores, Taytay Rizal</td>
<td>02-727-9005, 727-9001</td>
<td><a href="mailto:admin@cleanhaul.ph">admin@cleanhaul.ph</a></td>
<td>28-Nov-20</td>
<td>M501,</td>
</tr>
<tr>
<td>IV-A</td>
<td>New Parbuilt Construction &amp; Services Corporation</td>
<td>67 Gen. Luna St., Ampid 2, San Mateo Rizal</td>
<td>570-2059, 997-7220, 571-9627</td>
<td><a href="mailto:newparbuiltcs@yahoo.com">newparbuiltcs@yahoo.com</a>; <a href="mailto:newparbuiltcorp@gmail.com">newparbuiltcorp@gmail.com</a></td>
<td>17-Sep-20</td>
<td>M501,</td>
</tr>
<tr>
<td>IV-A</td>
<td>Royal Earth Enterprises</td>
<td>Road 20 Extension, Nagtinig, Brgy. San Juan, Taytay, Rizal</td>
<td>(02)298-7385, 0938435008, 0956-5960195</td>
<td><a href="mailto:royalearthent@gmail.com">royalearthent@gmail.com</a></td>
<td>17-Sep-20</td>
<td>M503</td>
</tr>
<tr>
<td>V</td>
<td>Philippine Geothermal Production Company, Inc.</td>
<td>Brgy. Libjo, Tiwi, Albay</td>
<td>7976-6108</td>
<td><a href="mailto:apvs@pgpc.com.ph">apvs@pgpc.com.ph</a></td>
<td>12-Feb-21</td>
<td>M501,</td>
</tr>
<tr>
<td>V</td>
<td>Zigs Eco Sanitation Corporation</td>
<td>Sitio Banasian, Brgy. San Ramon, Daraga, Albay</td>
<td>9199990706</td>
<td><a href="mailto:zigseco@gmail.com">zigseco@gmail.com</a></td>
<td>22-Apr-21</td>
<td>M501</td>
</tr>
<tr>
<td>VI</td>
<td>Westy Transporter (Formerly Westy Used Cooking Oil Trading)</td>
<td>Sitio Airport, Caticlan, Malay, Aklan</td>
<td>(036) 288-9518</td>
<td><a href="mailto:hazwastewestytransporter@gmail.com">hazwastewestytransporter@gmail.com</a></td>
<td>01-Aug-20</td>
<td>M501,</td>
</tr>
<tr>
<td>VII</td>
<td>One Stop Logistics Solutions, Inc.</td>
<td>Warehouse 16, Benedict Ventures, Inc., P. Basubas St., Tipolo, Mandaue City, Cebu; Garage Addresses: c/o Tell Trans, Inc., Tayud, Consolacion, Cebu; c/o San Remegio Trucking Services, E.O. Perez St., North Reclamation Area, Subangdaku, Cebu City</td>
<td>(02) 527-5555</td>
<td><a href="mailto:oisi@msl.com.ph">oisi@msl.com.ph</a></td>
<td>07-Feb-21</td>
<td>M501,</td>
</tr>
<tr>
<td>VII</td>
<td>Pollution Abatement Systems Specialist Inc</td>
<td>Rm 10 A. Geson Bldg D. Jakosalem St. Cebu City; Garage Address: Sanitary Landfill, White Road Inayawan, Cebu City</td>
<td>(032) 2551535, 5203251</td>
<td><a href="mailto:mailfwd.passi@gmail.com">mailfwd.passi@gmail.com</a></td>
<td>13-Jun-20</td>
<td>M501</td>
</tr>
<tr>
<td>VII</td>
<td>Davao City Environmental Care, Inc.</td>
<td>Dumpsite Road, Plaridel St., Barangay Paknaan, Mandaue City</td>
<td>(032) 236-2011</td>
<td><a href="mailto:dceci_ph2012@yahoo.com.ph">dceci_ph2012@yahoo.com.ph</a></td>
<td>12-Feb-21</td>
<td>M501</td>
</tr>
</tbody>
</table>

Page 262 of 278
<table>
<thead>
<tr>
<th>Region</th>
<th>Name of Transporter</th>
<th>Address</th>
<th>Contact No.</th>
<th>Email Address</th>
<th>Date of Expiration</th>
<th>Waste Type</th>
<th>TSD Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR</td>
<td>Lepanto Consolidated Mining Company (LCMC)</td>
<td>Lepanto, Paco, Mankayan, Benguet</td>
<td>09154760056</td>
<td><a href="mailto:rolando.reyes@lepantomining.com">rolando.reyes@lepantomining.com</a></td>
<td>10-Jul-20</td>
<td>M501</td>
<td>A</td>
</tr>
<tr>
<td>NCR</td>
<td>Eco Safe Hazmat Treatment Inc.</td>
<td>Lot 7 West Los Angeles Street, California Village, San Bartolome, Novaliches, Quezon City</td>
<td>417-8888, 419-9267</td>
<td><a href="mailto:ecosafe_hazmat@yahoo.com">ecosafe_hazmat@yahoo.com</a></td>
<td>17-Sep-20</td>
<td>M501, M503</td>
<td>E</td>
</tr>
<tr>
<td>NCR</td>
<td>Integrated Waste Management, Inc.</td>
<td>Lung Center of the Philippines Compound, Quezon Ave. Quezon City</td>
<td>(02) 519-4583, 519-4583</td>
<td><a href="mailto:michai.marzan@gmail.com">michai.marzan@gmail.com</a>, <a href="mailto:policarpiobernie@yahoo.com">policarpiobernie@yahoo.com</a></td>
<td>18-Oct-20</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>NCR</td>
<td>Green Planet Management, Inc.</td>
<td>Lot 9 Block 4, Joy Street, Pearl Island Industrial Compound, Punturin, Valenzuela City</td>
<td>984-8647, 984-8648</td>
<td><a href="mailto:gpmi_planeta@yahoo.com.ph">gpmi_planeta@yahoo.com.ph</a></td>
<td>29-Aug-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>NCR</td>
<td>Trame Oil &amp; Environmental Specialist, Inc.</td>
<td>L2 B2 Pearl Island Compound, Punturin, Valenzuela</td>
<td>27968957</td>
<td><a href="mailto:trameoil.environmental@gmail.com">trameoil.environmental@gmail.com</a></td>
<td>22-Jan-21</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>NCR</td>
<td>JM Ecotech Solutions Co.</td>
<td>168 Gen. Luis St., Kaybiga, Caloocan City</td>
<td>(02) 936-4632</td>
<td><a href="mailto:mail@jmecotech.com">mail@jmecotech.com</a>; <a href="mailto:docs@jmecotech.com">docs@jmecotech.com</a></td>
<td>18-Oct-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>NCR</td>
<td>Maya Med Waste Corporation</td>
<td>WH#30, Toprite Industrial Compound, 1617 P. Jacinto St. Sitio Malinis, Bagbaguin, Valenzuela City</td>
<td>02 281-8513</td>
<td><a href="mailto:mayamedwastecorp@yahoo.com">mayamedwastecorp@yahoo.com</a>; <a href="mailto:info@mayawastesolutions.com">info@mayawastesolutions.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
</tbody>
</table>

O DENR-Accredited M501 and M503 Waste Treatment, Storage, and Disposal (TSD) Facilities
<table>
<thead>
<tr>
<th>I</th>
<th>La Union Medical Center</th>
<th>Nazareno, Agoo, La Union Engr. Rodney Abibuag</th>
<th>09178058448, 09176304103</th>
<th><a href="mailto:servotreat_phils@yahoo.com">servotreat_phils@yahoo.com</a> M</th>
<th>28-Apr-21</th>
<th>M501</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Servo-Treat Philippines, Incorporated</td>
<td>Zone 6, Brgy. Pinmaludpod, Urdaneta City, Pangasinan</td>
<td>(02) 551-7235</td>
<td><a href="mailto:christopher.ambito@udenna.ph">christopher.ambito@udenna.ph</a></td>
<td>06-Mar-21</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Udenna Environmental Services, Inc.</td>
<td>Brgy. Mambog, Hermosa, Bataan</td>
<td>(02) 732 2230, 7322564</td>
<td><a href="mailto:info_wacuman@yahoo.com">info_wacuman@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
<td>C</td>
</tr>
<tr>
<td>III</td>
<td>Wacuman Incorporated</td>
<td>Sitio Tiakad, Brgy. San Mateo, Norzagaray, Bulacan</td>
<td>(02) 732 2230, 7322564</td>
<td><a href="mailto:info_wacuman@yahoo.com">info_wacuman@yahoo.com</a></td>
<td>15-Aug-20</td>
<td>M501, M503</td>
<td>C</td>
</tr>
<tr>
<td>III</td>
<td>Holcim Philippines, Inc.</td>
<td>Norzagaray, Bulacan</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Asia United Oil Industry Corporation</td>
<td>Muralla Street, Iba, Meycauayan, Bulacan</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Far East Fuel Corporation</td>
<td>Purok 5, Irabagon St., Brgy. Anyatam, San Ildefonso, Bulacan</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>All Waste Services, Inc.</td>
<td>Km32 McArthur Highway, Tuktukan, Guiguinto, Bulacan</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Total Organic Environmental Solutions, Inc.</td>
<td>Brgy. Longos, Pulilan, Bulacan</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Recytechphil Inc.</td>
<td>138 Provincial Road, Brgy. Tambubong, Bocaue</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Globaltec Waste Management, Inc.</td>
<td>9 Westmont Industrial Subdivision, Brgy. Loma De Gato, Marilao, Bulacan</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Glochem Marketing &amp; Recycling Corp.</td>
<td>Purok 6, Brgy. San Roque, San Isidro, Nueva Ecija</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Dolomatrix Philippines, Inc.</td>
<td>Angeles Industrial Park, Inc. (AlPI), Brgy. Calibubut, Bacolor, Pampanga</td>
<td>(02) 366-9072</td>
<td><a href="mailto:fareastfuel@gmail.com">fareastfuel@gmail.com</a></td>
<td>09-Jul-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>SafeWaste Incorporated</td>
<td>9801 A-C Technology Resource Center, Paralayunan, Mabalacat City, Pampanga</td>
<td>045-4366008</td>
<td><a href="mailto:safewaste@ymail.com">safewaste@ymail.com</a></td>
<td>10-Feb-21</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>VAG General Merchandise</td>
<td>Brgy. Gutad, Floridablanca, Pampanga</td>
<td>09171680400; 09323623872</td>
<td><a href="mailto:vag_genmerchandise@yahoo.com">vag_genmerchandise@yahoo.com</a></td>
<td>12-Dec-20</td>
<td>M503</td>
<td>D, E</td>
</tr>
<tr>
<td>III</td>
<td>RMS Petroleum Technology and Waste Management Corporation</td>
<td>Brgy. San Nicolas, Mexico, Pampanga</td>
<td>(02) 710-5660</td>
<td><a href="mailto:rmspetroleumtechnology@gmail.com">rmspetroleumtechnology@gmail.com</a></td>
<td>20-Nov-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Metro Clark Waste Management Corporation</td>
<td>Clark Special Economic Zone, Sub-zone D, Sitio Kalangitan, Cutcut II, Capas, Tarlac</td>
<td>(045) 606-8830, 599-6317</td>
<td><a href="mailto:info@mcwm.net">info@mcwm.net</a>; <a href="mailto:joseantonioramos@yahoo.com">joseantonioramos@yahoo.com</a></td>
<td>04-Jul-20</td>
<td>M501, M503</td>
<td>C</td>
</tr>
<tr>
<td>III</td>
<td>Tarlac Provincial Hospital</td>
<td>San Vicente, Tarlac City, Tarlac</td>
<td>045-9821234</td>
<td><a href="mailto:enro_tarlac@yahoo.com">enro_tarlac@yahoo.com</a></td>
<td>07-Feb-21</td>
<td>M501</td>
<td>A</td>
</tr>
<tr>
<td>III</td>
<td>Clean Leaf International Corporation</td>
<td>Brgy. Anupul, Bamban, Tarlac</td>
<td>(02) 990-6607, 962-8313</td>
<td><a href="mailto:cleanleaf@gmail.com">cleanleaf@gmail.com</a></td>
<td>20-Nov-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>III</td>
<td>Cleanway Environmental Management Solutions, Inc</td>
<td>Brgy. Cutcut II, Capas, Tarlac</td>
<td>(02) 529-8329, 046) 865-2952</td>
<td><a href="mailto:marosel@cleanway.com.ph">marosel@cleanway.com.ph</a></td>
<td>31-Jul-20</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>IV-A</td>
<td>Republic Cement &amp; Building Materials, Inc.</td>
<td>Brgy. Mapulo, Taysan, Batangas</td>
<td>(02) 887-5116, 815-2678 to 79</td>
<td><a href="mailto:sharry.apud@republiccement.com">sharry.apud@republiccement.com</a></td>
<td>01-Aug-20</td>
<td>M503</td>
<td>A/D</td>
</tr>
<tr>
<td>IV-A</td>
<td>Green Eco Techwin Inc.</td>
<td>Block 2 Lot 8 Phase 2, Golden gate Business Park, Brgy. Buenavista II, Gen. Trias, Cavite</td>
<td>(046) 470-1846</td>
<td><a href="mailto:orly.julian@yahoo.com">orly.julian@yahoo.com</a></td>
<td>30-Aug-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>IV-A</td>
<td>Green Horizon Environmental Management, Inc.</td>
<td>223 Ilaya St., Brgy. Niog II, Bacoor City, Cavite</td>
<td>(046) 417-0317</td>
<td><a href="mailto:mugar.angie@gmail.com">mugar.angie@gmail.com</a></td>
<td>08-Nov-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>IV-A</td>
<td>HAZCHEM, INC.</td>
<td>0947 Purok V, Brgy. Makiling, Calamba City, Laguna</td>
<td>(049) 502-6989</td>
<td><a href="mailto:hazcheminc@yahoo.com.ph">hazcheminc@yahoo.com.ph</a></td>
<td>12-Dec-20</td>
<td>M501, M503</td>
<td>B, E</td>
</tr>
<tr>
<td>IV-A</td>
<td>AUGUST-10 ENTERPRISE CO.</td>
<td>192 Brgy.Sto.Tomas Binan Laguna</td>
<td>(049) 542-9693</td>
<td><a href="mailto:august_10_enterprises@yahoo.com.ph">august_10_enterprises@yahoo.com.ph</a></td>
<td>13-Aug-20</td>
<td>M503</td>
<td>B</td>
</tr>
<tr>
<td>IV-A</td>
<td>Green Resource &amp; Environmental Management Solutions, Inc</td>
<td>Warehouse 6, MMG 3 Industrial Compound, E. Gerodias St., San Antonio, San Pedro City, Laguna</td>
<td><a href="mailto:info@greenresourceincph.com">info@greenresourceincph.com</a>; <a href="mailto:jabacunawapco@greenresourceincph.com">jabacunawapco@greenresourceincph.com</a></td>
<td>02-Jul-20</td>
<td>M503</td>
<td>E</td>
<td></td>
</tr>
<tr>
<td>IV-B</td>
<td>Pollution Abatement Systems Specialists, Inc.</td>
<td>Sanitary Landfill, Brgy. Sta. Lourdes, Puerto Princesa City, Palawan</td>
<td><a href="mailto:mail.fwd@gmail.com">mail.fwd@gmail.com</a></td>
<td>28-Apr-21</td>
<td>M501</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td>VI</td>
<td>Pollution Abatement Systems Specialists, Inc.</td>
<td>Calajanunan Dumpsite, Mandurriao, Iloilo City, Iloilo</td>
<td>14-Feb-21</td>
<td>M501</td>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VII</td>
<td>Davao City Environmental Care, Inc.</td>
<td>Dumpsite Road, Plaridel St., Brgy. Paknaan, Mandaue City, Cebu</td>
<td>(032) 236-2011</td>
<td><a href="mailto:dceci_ph2012@yahoo.com.ph">dceci_ph2012@yahoo.com.ph</a></td>
<td>12-Feb-21</td>
<td>M501</td>
<td>B</td>
</tr>
<tr>
<td>VIII</td>
<td>Cleanway Philippines Inc.</td>
<td>LIDE, Brgy. Libertad, Isabel, Leyte</td>
<td>053-556 8705</td>
<td><a href="mailto:jqmoraleta@cleanway.com.ph">jqmoraleta@cleanway.com.ph</a>, <a href="mailto:cheryl.mahusay@cleanway.com.ph">cheryl.mahusay@cleanway.com.ph</a></td>
<td>20-Dec-20</td>
<td>M503</td>
<td>E</td>
</tr>
<tr>
<td>X</td>
<td>Republic Cement</td>
<td>Iligan, Inc. Kiwalan, Iligan City</td>
<td>(063) 222-0801 loc 3114; 0917-8245370</td>
<td><a href="mailto:nisa.sampaco@republiccement.com">nisa.sampaco@republiccement.com</a></td>
<td>09-Jan-21</td>
<td>M503</td>
<td>B/D</td>
</tr>
<tr>
<td>X</td>
<td>Philippine Sinter Corporation</td>
<td>PHIVIDEC Industrial Estate, Villanueva, Misamis Oriental</td>
<td>(088) 565-0005, 565-0026</td>
<td><a href="mailto:bernard.baobao@philsinter.com.ph">bernard.baobao@philsinter.com.ph</a></td>
<td>03-Mar-21</td>
<td>M501</td>
<td>A</td>
</tr>
<tr>
<td>XI</td>
<td>Maya Med Waste Corporation</td>
<td>Brgy. New Carmen, Tugbok District, Davao City</td>
<td>(082) 224-2505, 224-2538</td>
<td><a href="mailto:gel.radgreendavao@gmail.com">gel.radgreendavao@gmail.com</a></td>
<td>01-Aug-20</td>
<td>M501, M503</td>
<td>B</td>
</tr>
<tr>
<td>XIII</td>
<td>Taganito HPAL Nickel Corporation</td>
<td>Taganito Special Economic Zone, Brgy. Taganito, Claver, Surigao del Norte</td>
<td>(02) 548-7140; 548-7141; 856-7170</td>
<td><a href="mailto:Osamu.Nakai@smm.com.ph">Osamu.Nakai@smm.com.ph</a></td>
<td>08-Nov-20</td>
<td>M501, M503</td>
<td>A</td>
</tr>
</tbody>
</table>
### Vaccination readiness findings from the VIRAT/VRAF 2.0 assessment

<table>
<thead>
<tr>
<th>Core Activity Areas</th>
<th>Assessment Area</th>
<th>Readiness and Key Gaps</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Planning and Management</td>
<td>A1. Vaccination objectives and targets</td>
<td><strong>Readiness:</strong> Consultations held among key stakeholders at national and sub-national levels and vaccine objectives and targets agreed. A Department of Health Administrative Order on National Strategic Policy Framework for COVID-19 Vaccine Deployment and Immunization has been issued on January 12, 2021, providing strategic policy guidance and direction on the selection, access, deployment of the COVID-19 vaccine and the COVID-19 immunization program. The Interim NDVP have been ratified by IATF on January 21, 2021 and disseminated through the National Task Force Memorandum Circular No. 5 series of 2021. DOH has conducted online public consultations on the National Strategic Policy Framework for COVID-19 Vaccine Deployment and Immunization in December 2020 and January 2021 with a range of stakeholders, including national government agencies, regions, health care facilities, professional organizations, the academe, civil society organizations, private sector (health insurance corporation), and development partners. <strong>Key gaps:</strong> Wider public consultations on the newly developed NDVP and table-top exercises with key stakeholders including NGOs, the private sector, development partners, and government agencies are still to be scheduled, followed by orientation of local chief executives and local leaders.</td>
</tr>
<tr>
<td>A2. Regulation and Standards</td>
<td>Readiness: Guidelines for Emergency Use Authorization exist (FO 121 &amp; FDA Circular No. 2020-036). <strong>Key gaps:</strong> Details on time taken for import approvals and lot releases are required.</td>
<td></td>
</tr>
<tr>
<td>A3. Performance management and M&amp;E</td>
<td><strong>Readiness:</strong> Monitoring tools for the National Immunization Program are being adapted for COVID-19 vaccine deployment. Both paper based and electronic monitoring tools are under development. <strong>Key gaps:</strong> Piloting of electronic monitoring tools under NITAG oversight still to be completed; public consultations and finalization.</td>
<td></td>
</tr>
<tr>
<td>A4. Budgeting</td>
<td><strong>Readiness:</strong> Budget available for the implementation of the National COVID-19 Vaccine Deployment and Vaccination Plan from the 2021 General Appropriations Act (GAA) (P2.5 billion) and continuing appropriations from 2020 for Bayanihan II (P10 billion). Financing sought from the ADB, World Bank, and AIIB to complement grant from GAVI COVAX. <strong>Key gaps:</strong> Estimation and budgeting of operational costs required for each vaccine platform as negotiations with developers are still ongoing (quantity and vaccine preparations i.e. prefilled syringe, 5-dose vial, 10-dose vial).</td>
<td></td>
</tr>
<tr>
<td>B. Supply and Distribution</td>
<td>B1. Vaccines, PPEs and other</td>
<td><strong>Readiness:</strong> The NDVP has been completed and has been ratified by the IATF. Draft guidelines for COVID-19 vaccine and ancillary immunization supplies prepared.</td>
</tr>
</tbody>
</table>
B2. Logistics and cold chain  
**Readiness:** National logistics working group in place. Data gathering on cold chain, transportation and warehousing capacity at sub-national level covering both government and private sector in progress.  
**Key gaps:** Final assessment of gaps in cold chain, warehousing, and transportation is still to be completed.

B3. Waste management  
**Readiness:** Guidelines for reverse logistics of immunization wastes prepared for different levels of facilities and draft contract for providers to offer Treatment, Storage, and Disposal (TSD) of medical wastes for hospitals ready.  
**Key gaps:** Adaptation of guidelines by regional and local governments is still to be completed. Additional Center for Health Development (CHD) and LGU training in immunization and waste management of novel vaccine are still to be completed.

C. Program Delivery  
C1. Community engagement and advocacy  
**Readiness:** Comprehensive plan for social mobilization developed. Key stakeholders, Philippines Information Agency and private sector partners have concurred to the plan; orientation of regional staff and partners has been conducted.  
**Key gaps:** Pretesting and production of communication materials are still to be completed. Dedicated Call Center for clarifying any doubts and concerns is still to be operationalized.

C2. Points of delivery  
**Readiness:** COVID-19 vaccine delivery including outreach strategies and consent being incorporated in the NDVP guidelines.  
**Key gaps:** Adaption of operational manual and guidelines by regional and local levels and training is still to be completed.

C3. Vaccine safety surveillance  
**Readiness:** Existing guidelines on AEFI being updated. Provisions for manufacturers to report safety data to NRA in place.  
**Key gaps:** Updating AEFI guidelines incorporating COVID-19 vaccination.

D. Supporting Systems and Infrastructure  
D1. Data quality  
**Readiness:** Data standards finalized and IT systems under development.  
**Key gaps:** Establishment of Emergency Operations Center with complete data management systems by early 2021.

D2. Infrastructure  
**Readiness:** Needs being identified at regional and local government levels.  
**Key gaps:** Hiring of encoders and procurement of tablets and other IT inputs such as computer hardware, software, and infrastructure for establishment of Emergency Operations Center is still to be completed.

---

**Indicative Action Plan to address key readiness gaps for COVID-19 Vaccine Deployment**

<table>
<thead>
<tr>
<th>Core Activity Areas</th>
<th>Assessment area</th>
<th>Actions to be completed</th>
<th>Indicative timeline</th>
</tr>
</thead>
</table>
| A. Planning and Management | A1. Vaccination objectives and targets | ● Piloting and finalization of electronic monitoring tool.  
● Criteria for prioritization spread over 3 stages | ● Complete wide consultation on NDVP by March 2021  
● Electronic monitoring tool piloted and finalized by February 2021 |
<table>
<thead>
<tr>
<th>A2. Regulation and Standards</th>
<th>Philippines Statistical Authority (PSA) will launch the registration process spread over two phases. National ID will not be mandatory for registration.</th>
<th>PSA to register 14.9 million eligible population covering frontline health workers, indigent, elderly, and uniformed forces during January-March 2021. Remaining registration to be completed during April-December 2021.</th>
</tr>
</thead>
</table>
| A2. Regulation and Standards | ● Mechanisms for indemnification against product liability claims and payment of no-fault compensation defined by the government (*)  
● Regulatory pathways finalized for: (i) data privacy and governance of vaccination data; (ii) process of obtaining consent to vaccinations including measures to protect those refuse to be vaccinated (*) | ● Mechanisms for indemnification and remaining regulatory arrangements to be finalized by early 2021 |

**A4. Budgeting**

**B.Supply and Distribution**

**B1. Vaccines, PPEs, and other medical and non-medical supplies**

**B2. Logistics and cold chain**

● Vaccination delivery including outreach strategies being incorporated in the NDVP guidelines including sites identification, cold chain, logistics, and enhanced Infection Prevention and Control (IPC) procedures (*)  
● Procurement plan is being updated for ancillary supplies and PPEs

● Strategies for addressing gaps in cold chain, warehousing and transportation; and finalization and dissemination of SOP for storage, distribution, and delivery in NDVP to be agreed by early 2021.

● Updating of procurement plans will be continuous process due to dynamic nature of the program

● Strategy for addressing gaps in cold chain, transportation and warehousing through additional support from WHO and UNICEF or contracting private sector to be finalized and approved by early 2021.

**B3. Waste management**

● Award of contract to Treatment, Storage and Disposal (TSD) providers.

● Contracts for TSD to be awarded by March 2021.
| C. Program Delivery | C1. Community engagement and advocacy | • Comprehensive plan for social mobilization developed to provide information on vaccine safety and efficacy, eligibility, registration process, vaccination sites, timing, and reporting any adverse events  
• Call center to support COVID-19 vaccine related grievances and address public queries.  
• Technical assistance on Infodemic management and social listening; and contracting agency for third party surveys. | Hiring community organizers, pretesting and production of communication material and operationalization of dedicated call center by February 2021  
• Call center to be operationalized by March 2021  
• DOH finalizes plan for TA for infodemic management, social listening and third-party surveys with support for development partners by February 2021. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C2. Points of delivery</td>
<td>• Vaccination teams trained and equipped with necessary knowledge and skills ongoing</td>
<td></td>
</tr>
</tbody>
</table>
• Adaptation of NDVP operational manual and guidelines by regional and local governments followed by training to be completed by March 2021.  
• Trainings for initial arrival of vaccines will be finalized by negotiations, with ongoing trainings during project implementation. |
| | C3. Vaccine safety and surveillance | • Data standards finalized and IT system under development under the oversight of Department of Information and Communication Technology (DICT)  
• Existing guidelines on AEFI being updated. Legal provisions for manufacturers to report safety data to NRA in place |  
• Agency for development of IT system contracted by negotiations.  
• Dedicated Emergency operation center made operational by March 2021  
• National AEFI guidelines updated incorporating COVID-19 vaccination to be completed by Appraisal followed by positioning of planned additional staff. |
| D. Supporting Systems and Infrastructure | D1. Data quality | • A dedicated Emergency Operations Center with complete data management systems to be established at DOH to monitor including adverse events and grievance reporting to be setup |  
• Dedicated Emergency Operations Center made operational by March 2021 |
| | D2. Infrastructure | • Additional infrastructure needs to be identified by regional and local governments |  
• Additional infrastructure needs including tablets and IT support to be finalized by March 2021. |

Note: Actions marked with (*) need to be completed before vaccine roll-out. Others can be completed within the first 6 months after deployment.
Q  Resource List: COVID-19 Guidance

World Bank Environmental and Social Management Framework for COVID-19 Response, April 20, 2020

Given the COVID-19 situation is rapidly evolving, a version of this resource list will be regularly updated and made available on the World Bank COVID-19 operations intranet page (http://covidoperations/).

WHO Guidance

Advice for the Public

- WHO advice for the public, including on social distancing, respiratory hygiene, self-quarantine, and seeking medical advice, can be consulted on this WHO website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public

Technical guidance

- Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected, issued on March 19, 2020
- Recommendations to Member States to Improve Hygiene Practices, issued on April 1, 2020
- Severe Acute Respiratory Infections Treatment Center, issued on March 28, 2020
- Infection prevention and control at health care facilities (with a focus on settings with limited resources), issued in 2018
- Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19), issued on March 18, 2020
- Laboratory Biosafety Manual, 3rd edition, issued in 2014
- Laboratory testing for COVID-19, including specimen collection and shipment, issued on March 19, 2020
- Prioritized Laboratory Testing Strategy According to 4Cs Transmission Scenarios, issued on March 21, 2020
- Infection Prevention and Control for the safe management of a dead body in the context of COVID-19, issued on March 24, 2020
- Key considerations for repatriation and quarantine of travelers in relation to the outbreak COVID-19, issued on February 11, 2020
- Preparedness, prevention and control of COVID-19 for refugees and migrants in non-camp settings, issued on April 17, 2020
- Coronavirus disease (COVID-19) outbreak: rights, roles and responsibilities of health workers, including key considerations for occupational safety and health, issued on March 18, 2020
- Oxygen sources and distribution for COVID-19 treatment centers, issued on April 4, 2020

• Considerations for quarantine of individuals in the context of containment for coronavirus disease (COVID-19), issued on March 19, 2020

• Operational considerations for case management of COVID-19 in health facility and community, issued on March 19, 2020

• Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19), issued on February 27, 2020

• Getting your workplace ready for COVID-19, issued on March 19, 2020

• Water, sanitation, hygiene and waste management for COVID-19, issued on March 19, 2020

• Safe management of wastes from health-care activities, issued in 2014

• Advice on the use of masks in the community, during home care and in healthcare settings in the context of the novel coronavirus (COVID-19) outbreak, issued on March 19, 2020

• Disability Considerations during the COVID-19 outbreak, issued on March 26, 2020

WORLD BANK GROUP GUIDANCE

• Technical Note: Public Consultations and Stakeholder Engagement in WB-supported operations when there are constraints on conducting public meetings, issued on March 20, 2020

• Technical Note: Use of Military Forces to Assist in COVID-19 Operations, issued on March 25, 2020

• ESF/Safeguards Interim Note: COVID-19 Considerations in Construction/Civil Works Projects, issued on April 7, 2020

• Technical Note on SEA/H for HNP COVID Response Operations, issued in March 2020

• Interim Advice for IFC Clients on Preventing and Managing Health Risks of COVID-19 in the Workplace, issued on April 6, 2020

• Interim Advice for IFC Clients on Supporting Workers in the Context of COVID-19, issued on April 6, 2020

• IFC Tip Sheet for Company Leadership on Crisis Response: Facing the COVID-19 Pandemic, issued on April 6, 2020

• WBG EHS Guidelines for Healthcare Facilities, issued on April 30, 2007

ILO GUIDANCE

• ILO Standards and COVID-19 FAQ, issued on March 23, 2020 (provides a compilation of answers to most frequently asked questions related to international labor standards and COVID-19)
MFI GUIDANCE

- ADB Managing Infectious Medical Waste during the COVID-19 Pandemic
- IDB Invest Guidance for Infrastructure Projects on COVID-19: A Rapid Risk Profile and Decision Framework
- KfW DEG COVID-19 Guidance for employers, issued on March 31, 2020
- CDC Group COVID-19 Guidance for Employers, issued on March 23, 2020